
<html lang="en"     class="pb-page"  data-request-id="1ff4ed94-ef73-4c24-bbd0-4cc5e8a24c72"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.9b01136;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-5"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Selective Neuropeptide Y Conjugates with Maximized Carborane Loading as Promising Boron Delivery Agents for Boron Neutron Capture Therapy" /></meta><meta name="dc.Creator" content="Dennis J.  Worm" /></meta><meta name="dc.Creator" content="Paul  Hoppenz" /></meta><meta name="dc.Creator" content="Sylvia  Els-Heindl" /></meta><meta name="dc.Creator" content="Martin  Kellert" /></meta><meta name="dc.Creator" content="Robert  Kuhnert" /></meta><meta name="dc.Creator" content="Stefan  Saretz" /></meta><meta name="dc.Creator" content="Johannes  Köbberling" /></meta><meta name="dc.Creator" content="Bernd  Riedl" /></meta><meta name="dc.Creator" content="Evamarie  Hey-Hawkins" /></meta><meta name="dc.Creator" content="Annette G.  Beck-Sickinger" /></meta><meta name="dc.Description" content="G-protein-coupled receptors like the human Y1 receptor (hY1R) are promising targets in cancer therapy due to their high overexpression on cancer cells and their ability to internalize together with..." /></meta><meta name="Description" content="G-protein-coupled receptors like the human Y1 receptor (hY1R) are promising targets in cancer therapy due to their high overexpression on cancer cells and their ability to internalize together with..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 7, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b01136" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01136" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b01136" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01136" /></link>
        
    
    

<title>Selective Neuropeptide Y Conjugates with Maximized Carborane Loading as Promising Boron Delivery Agents for Boron Neutron Capture Therapy | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b01136" /></meta><meta property="og:title" content="Selective Neuropeptide Y Conjugates with Maximized Carborane Loading as Promising Boron Delivery Agents for Boron Neutron Capture Therapy" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/large/jm9b01136_0009.jpeg" /></meta><meta property="og:description" content="G-protein-coupled receptors like the human Y1 receptor (hY1R) are promising targets in cancer therapy due to their high overexpression on cancer cells and their ability to internalize together with the bound ligand. This mechanism was exploited to shuttle boron atoms into cancer cells for the application of boron neutron capture therapy (BNCT), a noninvasive approach to eliminate cancer cells. A maximized number of carboranes was introduced to the hY1R-preferring ligand [F7,P34]-NPY by solid phase peptide synthesis. Branched conjugates loaded with up to 80 boron atoms per peptide molecule exhibited a maintained receptor activation profile, and the selective uptake into hY1R-expressing cells was demonstrated by internalization studies. In order to ensure appropriate solubility in aqueous solution, we proved the need for eight hydroxyl groups per carborane. Thus, we suggest the utilization of bis-deoxygalactosyl-carborane building blocks in solid phase peptide synthesis to produce selective boron delivery agents for BNCT." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b01136"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01136">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b01136&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b01136&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b01136&amp;href=/doi/10.1021/acs.jmedchem.9b01136" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 2358-2371</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b01188" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b01287" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Selective Neuropeptide Y Conjugates with Maximized Carborane Loading as Promising Boron Delivery Agents for Boron Neutron Capture Therapy</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Dennis J. Worm</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dennis J. Worm</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biochemistry, Leipzig University, Brüderstrasse 34, 04103 Leipzig, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dennis+J.++Worm">Dennis J. Worm</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paul Hoppenz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paul Hoppenz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biochemistry, Leipzig University, Brüderstrasse 34, 04103 Leipzig, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paul++Hoppenz">Paul Hoppenz</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sylvia Els-Heindl</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sylvia Els-Heindl</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biochemistry, Leipzig University, Brüderstrasse 34, 04103 Leipzig, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sylvia++Els-Heindl">Sylvia Els-Heindl</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Martin Kellert</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Martin Kellert</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Inorganic Chemistry, Leipzig University, Johannisallee 29, 04103 Leipzig, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Martin++Kellert">Martin Kellert</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Robert Kuhnert</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Robert Kuhnert</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Inorganic Chemistry, Leipzig University, Johannisallee 29, 04103 Leipzig, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Robert++Kuhnert">Robert Kuhnert</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Stefan Saretz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stefan Saretz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Inorganic Chemistry, Leipzig University, Johannisallee 29, 04103 Leipzig, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stefan++Saretz">Stefan Saretz</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Johannes Köbberling</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Johannes Köbberling</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bayer AG, Aprather Weg 18A, 42113 Wuppertal, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Johannes++K%C3%B6bberling">Johannes Köbberling</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bernd Riedl</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bernd Riedl</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bayer AG, Aprather Weg 18A, 42113 Wuppertal, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bernd++Riedl">Bernd Riedl</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Evamarie Hey-Hawkins</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Evamarie Hey-Hawkins</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Inorganic Chemistry, Leipzig University, Johannisallee 29, 04103 Leipzig, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Evamarie++Hey-Hawkins">Evamarie Hey-Hawkins</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4267-0603" title="Orcid link">http://orcid.org/0000-0003-4267-0603</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Annette G. Beck-Sickinger</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Annette G. Beck-Sickinger</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biochemistry, Leipzig University, Brüderstrasse 34, 04103 Leipzig, Germany</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: 0049-341-9736900. Fax: 0049-341-9736909. E-mail: <a href="/cdn-cgi/l/email-protection#14757671777f39677d777f7d7a73716654617a7d3978717d646e7d733a7071"><span class="__cf_email__" data-cfemail="4f2e2d2a2c24623c262c242621282a3d0f3a212662232a263f352628612b2a">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Annette+G.++Beck-Sickinger">Annette G. Beck-Sickinger</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4560-8020" title="Orcid link">http://orcid.org/0000-0003-4560-8020</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01136&amp;href=/doi/10.1021%2Facs.jmedchem.9b01136" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 2358–2371</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 7, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>26 July 2019</li><li><span class="item_label"><b>Published</b> online</span>7 October 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 March 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b01136" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01136</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2358%26pageCount%3D14%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DDennis%2BJ.%2BWorm%252C%2BPaul%2BHoppenz%252C%2BSylvia%2BEls-Heindl%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D5%26contentID%3Dacs.jmedchem.9b01136%26title%3DSelective%2BNeuropeptide%2BY%2BConjugates%2Bwith%2BMaximized%2BCarborane%2BLoading%2Bas%2BPromising%2BBoron%2BDelivery%2BAgents%2Bfor%2BBoron%2BNeutron%2BCapture%2BTherapy%26numPages%3D14%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2371%26publicationDate%3DMarch%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b01136"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1059</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">16</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b01136" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Selective Neuropeptide Y Conjugates with Maximized Carborane Loading as Promising Boron Delivery Agents for Boron Neutron Capture Therapy&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Dennis&quot;,&quot;last_name&quot;:&quot;J. Worm&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;Hoppenz&quot;},{&quot;first_name&quot;:&quot;Sylvia&quot;,&quot;last_name&quot;:&quot;Els-Heindl&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;Kellert&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;Kuhnert&quot;},{&quot;first_name&quot;:&quot;Stefan&quot;,&quot;last_name&quot;:&quot;Saretz&quot;},{&quot;first_name&quot;:&quot;Johannes&quot;,&quot;last_name&quot;:&quot;Köbberling&quot;},{&quot;first_name&quot;:&quot;Bernd&quot;,&quot;last_name&quot;:&quot;Riedl&quot;},{&quot;first_name&quot;:&quot;Evamarie&quot;,&quot;last_name&quot;:&quot;Hey-Hawkins&quot;},{&quot;first_name&quot;:&quot;Annette&quot;,&quot;last_name&quot;:&quot;G. Beck-Sickinger&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;07&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;2358-2371&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b01136&quot;},&quot;abstract&quot;:&quot;G-protein-coupled receptors like the human Y1 receptor (hY1R) are promising targets in cancer therapy due to their high overexpression on cancer cells and their ability to internalize together with the bound ligand. This mechanism was exploited to shuttle boron atoms into cancer cells for the application of boron neutron capture therapy (BNCT), a noninvasive approach to eliminate cancer cells. A maximized number of carboranes was introduced to the hY1R-preferring ligand [F7,P34]-NPY by solid phase peptide synthesis. Branched conjugates loaded with up to 80 boron atoms per peptide molecule exhibited a maintained receptor activation profile, and the selective uptake into hY1R-expressing cells was demonstrated by internalization studies. In order to ensure appropriate solubility in aqueous solution, we proved the need for eight hydroxyl groups per carborane. Thus, we suggest the utilization of bis-deoxygalactosyl-carborane building blocks in solid phase peptide synthesis to produce selective boron delivery agent&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01136&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01136" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01136&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01136" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01136&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01136" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01136&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01136&amp;href=/doi/10.1021/acs.jmedchem.9b01136" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b01136" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b01136" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b01136%26sid%3Dliteratum%253Aachs%26pmid%3D31589041%26genre%3Darticle%26aulast%3DWorm%26date%3D2020%26atitle%3DSelective%2BNeuropeptide%2BY%2BConjugates%2Bwith%2BMaximized%2BCarborane%2BLoading%2Bas%2BPromising%2BBoron%2BDelivery%2BAgents%2Bfor%2BBoron%2BNeutron%2BCapture%2BTherapy%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D5%26spage%3D2358%26epage%3D2371%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291122" title="Boron">Boron</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a>,</li><li><a href="/action/doSearch?ConceptID=291290" title="Conjugate acid-base pairs">Conjugate acid-base pairs</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/jmcmar.2020.63.issue-5/20200312/jmcmar.2020.63.issue-5.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/medium/jm9b01136_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/large/jm9b01136_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01136&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">G-protein-coupled receptors like the human Y<sub>1</sub> receptor (hY<sub>1</sub>R) are promising targets in cancer therapy due to their high overexpression on cancer cells and their ability to internalize together with the bound ligand. This mechanism was exploited to shuttle boron atoms into cancer cells for the application of boron neutron capture therapy (BNCT), a noninvasive approach to eliminate cancer cells. A maximized number of carboranes was introduced to the hY<sub>1</sub>R-preferring ligand [F<sup>7</sup>,P<sup>34</sup>]-NPY by solid phase peptide synthesis. Branched conjugates loaded with up to 80 boron atoms per peptide molecule exhibited a maintained receptor activation profile, and the selective uptake into hY<sub>1</sub>R-expressing cells was demonstrated by internalization studies. In order to ensure appropriate solubility in aqueous solution, we proved the need for eight hydroxyl groups per carborane. Thus, we suggest the utilization of bis-deoxygalactosyl-carborane building blocks in solid phase peptide synthesis to produce selective boron delivery agents for BNCT.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="specialIssueNotice" class="extra-info-sec articleNote"><h4>SPECIAL ISSUE</h4><p class="last">This article is part of the <a href="/toc/jmcmar/63/5"><issue-title>Women in Medicinal Chemistry</issue-title></a> special issue.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75535" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75535" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Targeted delivery of anticancer drugs to tumor cells offers the possibility to enhance the therapeutic efficacy of the desired cancer treatment and to avoid severe side effects by sparing healthy tissue that surrounds the tumor. Conjugating therapeutically active molecules to a tumor-selective carrier system facilitates this approach.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Recently, peptide ligands have gained significant attention as carrier molecules, owing to their facile synthesis, low immunogenicity, and high target affinity and selectivity.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> Radiolabeled or toxophore-conjugated analogs of somatostatin, bombesin, and gonadotropin-releasing hormone are used to target their respective receptors on tumor cells.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a> Also neuropeptide Y (NPY), a 36-amino acid peptide of the three-membered NPY hormone family, has recently gained significant interest.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a> The NPY family binds to four G protein-coupled receptor (GPCR) subtypes in human with nanomolar affinity, namely, the human Y<sub>1</sub>, Y<sub>2</sub>, Y<sub>4</sub>, and Y<sub>5</sub> receptor (hY<sub>1</sub>R, hY<sub>2</sub>R, hY<sub>4</sub>R, and hY<sub>5</sub>R).<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> Specific binding of NPY ligands leads to activation, followed by internalization of the peptide–receptor complex into the cell by receptor-mediated endocytosis.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> The hY<sub>1</sub>R was found in very high density on breast tumor cells and breast tumor derived metastases, while in the surrounding non-neoplastic breast tissue, expression of the hY<sub>2</sub>R was predominantly observed.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a> By using the hY<sub>1</sub>R-preferring NPY analog [F<sup>7</sup>,P<sup>34</sup>]-NPY as a carrier peptide, a selective delivery of therapeutic agents into breast cancer cells has been achieved.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> The successful targeting of the hY<sub>1</sub>R in breast tumors in vivo has been already demonstrated with <sup>18</sup>F-labeled [F<sup>7</sup>,P<sup>34</sup>]-NPY by PET imaging in mice and with <sup>99m</sup>Tc-labeled [F<sup>7</sup>,P<sup>34</sup>]-NPY by whole-body scintimammography in tumor patients.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15,16)</a> Systems like [F<sup>7</sup>,P<sup>34</sup>]-NPY/hY<sub>1</sub>R are highly relevant for advanced cancer therapies that require selective delivery agents, such as the boron neutron capture therapy (BNCT). The principle of BNCT is the accumulation of boron in cancer cells followed by regional irradiation of the tumor site with (epi)thermal neutrons. Neutron capture by the <sup>10</sup>B isotope, which possesses a remarkably high neutron capture cross section, results in the fission reaction [<sup>10</sup>B(<sup>1</sup>n,α)<sup>7</sup>Li], generating α particles and <sup>7</sup>Li nuclei with a high linear energy transfer (LET).<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> These LET particles exhibit path lengths of 5–10 μm, which coincides with the diameter of a cell and therefore limits their destructive effects to boron-containing cells. For successful BNCT, high amounts of boron (at least 10<sup>9</sup> boron atoms per cell) have to be accumulated in the cancer cells to achieve an appropriate generation of radiation from the boron neutron capture reaction.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Selective tumor delivery of the required boron atoms in combination with the local neutron irradiation could allow the promising double-selective therapeutic effect of BNCT.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> However, suitable boron delivery agents with high tumor-to-normal cell distribution ratio are still missing.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21,22)</a> Currently, only <span class="smallcaps smallerCapital">l</span>-boronophenylalanine (BPA) and sodium mercaptoundecahydro-<i>closo</i>-dodecaborate (BSH) are used in clinical trials.<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23,24)</a> Both compounds exhibit a suboptimal BNCT efficacy, mostly due to their low tumor selectivity.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Boron-modified NPY analogs are therefore promising vehicles as breast cancer-targeted boron delivery agents for BNCT. We have previously demonstrated that the incorporation of boron-rich 1,2-dicarba-<i>closo</i>-dodecarborane (<i>ortho</i>-carborane) into [F<sup>7</sup>,P<sup>34</sup>]-NPY leads to conjugates with high activity and selectivity for the hY<sub>1</sub>R.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a> A triple <i>ortho</i>-carborane-modified [F<sup>7</sup>,P<sup>34</sup>]-NPY analog was able to shuttle sufficient amounts of boron for BNCT into receptor-expressing cells, but limited stability of the <i>ortho</i>-carborane prevented further application.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27,28)</a> Here, we describe the design and synthesis of hY<sub>1</sub>R-preferring [F<sup>7</sup>,P<sup>34</sup>]-NPY conjugates with a maximized <i>meta</i>-carborane loading. The use of deoxygalactopyranosyl-modified carborane building blocks ensured appropriate solubility in aqueous solution, allowing the incorporation of up to 80 boron atoms per peptide molecule and thereby boosting the selective boron delivery into cancer cells.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30426" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30426" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Synthesis of Carboranes</h3><div class="NLM_p">In this study, all carborane building blocks contain a carboxyl group to allow straightforward conjugation to peptides on solid support and the <i>meta</i>-isomeric form of the cluster was used in order to achieve appropriate chemical stability in aqueous solution. The <i>meta</i>-carborane <b>2</b> (Cb) was synthesized as described before.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a> It contains a mercaptoacetic acid linker for peptide coupling, which is connected to a boron atom of the carborane cluster. Since carboranes are highly hydrophobic molecules, monosaccharide units were chosen to increase the hydrophilicity of the building block. Therefore, either one or two α-<span class="smallcaps smallerCapital">d</span>-deoxygalactopyranosyl moieties were introduced at the carbon atoms of the <i>meta-</i>carborane, yielding <b>5</b> (Gal′-Cb) and <b>8</b> (Gal′<sub>2</sub>-Cb) (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Since both carbon atoms are chemically equally reactive, the introduction of one α-<span class="smallcaps smallerCapital">d</span>-deoxygalactosyl moiety results in the formation of a 1:1 isomeric mixture of 1-(1′,2′,3′,4′-di-O-isopropylidiene-6′-deoxy-α-<span class="smallcaps smallerCapital">d</span>-galactopyranos-6′-yl)-9-(carboxymethylthio)-1,7-dicarba-<i>closo</i>-dodecaborane(12) and 1-(1′,2′,3′,4′-di-O-isopropylidiene-6′-deoxy-α-<span class="smallcaps smallerCapital">d</span>-galactopyranos-6′-yl)-10-(carboxymethylthio)-1,7-dicarba-<i>closo</i>-dodecaborane(12). For the application as building block in peptide synthesis, the hydroxyl groups of the deoxygalactosyl moiety were protected as 1,2-acetonides, which were removed during final cleavage from the solid support.</div><figure id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/medium/jm9b01136_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/large/jm9b01136_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Chemical Structures and Synthesis of Carborane Building Blocks<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/large/jm9b01136_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01136&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) first 0.9 equiv <i>n</i>-butyllithium, THF, rt, 2 h; then 1.0 equiv 1,2:3,4-di-<i>O</i>-isopropylidene-α-<span class="smallcaps smallerCapital">d</span>-galactopyranosyltriflate, THF, rt, overnight, 60%; (b) 1.5 equiv of Hg(OAc)<sub>2</sub>, absolute acetic acid, 50 °C, 3 h, 96%; (c) 3.0 equiv of iodoacetic acid, 7.0 equiv of absolute Et<sub>3</sub>N, absolute DCM, rt, 3 days, 51%; (d) first 2.1 equiv of <i>n</i>-butyllithium, THF, rt, 2 h; then 2.1 equiv of 1,2:3,4-di-<i>O</i>-isopropylidene-α-<span class="smallcaps smallerCapital">d</span>-galactopyranosyltriflate, THF, rt, overnight, 54%; (e) as decribed under b yield: 97 %; (f) as decribed under c yield: 47 %; (g) as described previously.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a> THF: tetrahydrofuran, rt: room temperature, Et<sub>3</sub>N: triethylamine, DCM: dichloromethane.</p></p></figure><figure id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/medium/jm9b01136_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/large/jm9b01136_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Peptide sequence of pNPY (<b>10</b>) and [F<sup>7</sup>,P<sup>34</sup>]-NPY (<b>11</b>). Modification sites are indicated by arrows.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/large/jm9b01136_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01136&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Peptide Synthesis</h3><div class="NLM_p">Peptides were prepared by a combination of automated and manual solid phase peptide synthesis (SPPS). Full-length analogs of [F<sup>7</sup>,P<sup>34</sup>]-NPY, in which residue 18, residues 18 and 22, or residues 18, 22, and 26 were substituted with lysine <named-content content-type="anchor" rid="sch1" type="simple"></named-content>(<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), were synthesized by robot-assisted SPPS using the 9-fluorenylmethoxycarbonyl (Fmoc)/<i>tert</i>-butyl (<i>t</i>Bu) strategy. In previous experiments, replacement of these positions with lysine and modification of the resulting lysine side chains, also including the natural lysine at position 4 in the [F<sup>7</sup>,P<sup>34</sup>]-NPY sequence, was found to be tolerated with respect to the activity of the peptide analogs.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div><div class="NLM_p">For the generation of carborane-modified [F<sup>7</sup>,P<sup>34</sup>]-NPY analogs (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), the respective lysine side chains were orthogonally protected by 1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl (Dde) protecting groups. After selective removal of the Dde groups with hydrazine, multiple carborane building blocks (<b>2</b> or <b>5</b>) were simultaneously coupled to the unprotected lysine <i>N</i><sub>ε</sub>-amino groups, manually. Introduction of three carboranes <b>2</b> at positions 4, 18, and 22 in the peptide sequence yielded the triple-modified conjugate <b>13</b>. Attachment of <b>5</b> to these positions resulted in conjugate <b>14</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01136/suppl_file/jm9b01136_si_001.pdf" class="ext-link">Figure S9 and S10</a>). To obtain peptide conjugates with a high loading of deoxygalactosyl-carborane <b>5</b> (conjugates <b>15</b>–<b>19</b>), a branching approach was used. Therefore, a (2S)-2,3-diaminopropionic acid (Dap) group with doubly Fmoc-protected amino groups (Fmoc-<span class="smallcaps smallerCapital">l</span>-Dap(Fmoc)-OH) was coupled manually to the deprotected <i>N</i><sub>ε</sub>-amino groups of the lysine residues. Subsequent manual Fmoc cleavage yielded two free amino groups per one original lysine side chain. For conjugates <b>17</b> and <b>19</b>, a second branching step was performed (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Fmoc deprotection yielded four free amino groups per one original lysine side chain. Finally, multiple molecules of deoxygalactosyl-carborane <b>5</b> were attached simultaneously to the free amino functions of the Dap units by manual coupling. Single branching at positions 4 and 18, positions 4, 18, and 22, and positions 4, 18, 22, and 26 in [F<sup>7</sup>,P<sup>34</sup>]-NPY was used to generate conjugates <b>15</b>, <b>16</b>, and <b>18</b> carrying four, six, and eight deoxygalactosyl-carboranes <b>5</b>, respectively. Double branching at positions 4 and 18 and positions 4, 18, and 22 enabled the introduction of 8 and 12 deoxygalactosyl-carborane clusters <b>5</b> into [F<sup>7</sup>,P<sup>34</sup>]-NPY to yield conjugates <b>17</b> and <b>19</b>, which corresponded to a very high loading of 80 and 120 boron atoms per peptide, respectively (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01136/suppl_file/jm9b01136_si_001.pdf" class="ext-link">Figure S10</a>). Conjugate <b>20</b> was synthesized analogously to peptide <b>17</b>, but the bis-deoxygalactosyl-carborane <b>8</b> was incorporated, resulting in a conjugate with 8 carborane clusters and 16 deoxygalactosyl moieties (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01136/suppl_file/jm9b01136_si_001.pdf" class="ext-link">Figure S11</a>). Additionally, fluorescently labeled conjugates were synthesized to study blood plasma stability and cellular uptake by live cell fluorescence microscopy. Therefore, (6)-carboxytetramethylrhodamine (TAMRA, <b>9</b>) was introduced at position 18 after selective Dde cleavage, yielding conjugate [F<sup>7</sup>,K<sup>18</sup>(<b>9</b>),P<sup>34</sup>]-NPY (<b>21</b>) as control peptide. To gain a TAMRA and carborane-modified conjugate, a methoxytrityl (Mmt) group was chosen to protect the lysine side chain at position 22. After all carboranes were introduced analogously to conjugate <b>19</b>, Mmt was removed and TAMRA (<b>9</b>) was coupled manually, yielding conjugate <b>22</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01136/suppl_file/jm9b01136_si_001.pdf" class="ext-link">Figure S12</a>). Due to the isotopic distribution of 19.9% <sup>10</sup>B and 80.1% <sup>11</sup>B in naturally occurring boron, the successful introduction of the carboranes into the peptide sequence can be easily identified by mass spectrometry. This is exemplarily shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B for peptide conjugate <b>17</b>, which contains 80 boron atoms. The extrapolated single-charged ion species of <b>17</b> displays a broad isotopic distribution pattern with a multitude of signals, as determined by ESI-Orbitrap mass spectrometry. Reversed phase (RP)-HPLC analysis demonstrates that peptide conjugates with multiple incorporated carboranes were obtained in high purity (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A).</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/medium/jm9b01136_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/large/jm9b01136_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of the Branched NPY Conjugate <b>17</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/large/jm9b01136_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01136&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 3% hydrazine in DMF, 10 × 10 min; (b) 6 equiv of Fmoc-(<i>S</i>)-Dap(Fmoc)-OH, 6 equiv of HOBt and 6 equiv of DIC in DMF, 2 h; (c) 30% piperidine in DMF, 2 × 12 min; (d) 12 equiv of Fmoc-(<i>S</i>)-Dap(Fmoc)-OH, 12 equiv of HOBt and 12 equiv of DIC in DMF, 6 h; (e) 30% piperidine in DMF, 2 × 12 min; (f) 12 equiv of <b>5</b> (Gal′-Cb; 1.5 equiv per free amino group), 15 equiv of HOBt, and 15 equiv of DIC in DMF, overnight; (g) TFA/H<sub>2</sub>O (95:5, v/v), 2 h.</p></p></figure><figure id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/medium/jm9b01136_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/large/jm9b01136_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. RP-HPLC and ESI-MS analysis of conjugate <b>17</b>. (A) Reversed phase (RP)-HPLC analysis using a Phenomenex Jupiter Proteo C12 90 Å column and a linear gradient of 20–70% (v/v) eluent B (ACN + 0.08% TFA (v/v)) in eluent A (H<sub>2</sub>O + 0.1% TFA (v/v)) over 40 min. (B) ESI-Orbitrap mass spectrum showing the multiply charged ion species of <b>17</b> (top part). From the multiply charged signals in the original spectrum, the single charged signal [M + H]<sup>+</sup> with the corresponding isotopic distribution pattern can be convoluted (lower part). MW<sub>cal/mono</sub>: 7868.1 Da.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/large/jm9b01136_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01136&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Nomenclature and Receptor Activation Potencies of Synthesized Conjugates<a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="center" char="." /></col><col align="center" char="." /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" colspan="2" align="center">EC<sub>50</sub> [nM] (pEC<sub>50</sub> ± SEM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">peptide</th><th class="colsep0 rowsep0" align="center" char=".">clusters</th><th class="colsep0 rowsep0" align="center" char=".">Gal</th><th class="colsep0 rowsep0" align="center">hY<sub>1</sub>R</th><th class="colsep0 rowsep0" align="center">hY<sub>2</sub>R</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">NPY</td><td class="colsep0 rowsep0" align="center" char="."> </td><td class="colsep0 rowsep0" align="center" char="."> </td><td class="colsep0 rowsep0" align="center">3.8 (8.42 ± 0.02)</td><td class="colsep0 rowsep0" align="center">0.2 (9.64 ± 0.03)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">[F<sup>7</sup>,P<sup>34</sup>]-NPY</td><td class="colsep0 rowsep0" align="center" char="."> </td><td class="colsep0 rowsep0" align="center" char="."> </td><td class="colsep0 rowsep0" align="center">2.5 (8.61 ± 0.09)</td><td class="colsep0 rowsep0" align="center">78 (7.11 ± 0.06)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">hPP</td><td class="colsep0 rowsep0" align="center" char="."> </td><td class="colsep0 rowsep0" align="center" char="."> </td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">[K<sup>4,18,22</sup>(<b>2</b>),F<sup>7</sup>,P<sup>34</sup>]-NPY</td><td class="colsep0 rowsep0" align="center" char=".">3</td><td class="colsep0 rowsep0" align="center" char=".">0</td><td class="colsep0 rowsep0" align="center">9.2 (8.04 ± 0.06)</td><td class="colsep0 rowsep0" align="center">404 (6.39 ± 0.12)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">[K<sup>4,18,22</sup>(<b>5a</b>),F<sup>7</sup>,P<sup>34</sup>]-NPY</td><td class="colsep0 rowsep0" align="center" char=".">3</td><td class="colsep0 rowsep0" align="center" char=".">3</td><td class="colsep0 rowsep0" align="center">3.5 (8.46 ± 0.07)</td><td class="colsep0 rowsep0" align="center">416 (6.38 ± 0.04)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">[K<sup>4,18</sup>(Dap(<b>5a</b>)<sub>2</sub>),F<sup>7</sup>,P<sup>34</sup>]-NPY</td><td class="colsep0 rowsep0" align="center" char=".">4</td><td class="colsep0 rowsep0" align="center" char=".">4</td><td class="colsep0 rowsep0" align="center">2.6 (8.59 ± 0.06)</td><td class="colsep0 rowsep0" align="center">319 (6.50 ± 0.05)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">[K<sup>4,18,22</sup>(Dap(<b>5a</b>)<sub>2</sub>),F<sup>7</sup>,P<sup>34</sup>]-NPY</td><td class="colsep0 rowsep0" align="center" char=".">6</td><td class="colsep0 rowsep0" align="center" char=".">6</td><td class="colsep0 rowsep0" align="center">9.6 (8.02 ± 0.06)</td><td class="colsep0 rowsep0" align="center">722 (6.14 ± 0.05)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">[K<sup>4,18</sup>(Dap(Dap(<b>5a</b>)<sub>2</sub>)<sub>2</sub>),F<sup>7</sup>,P<sup>34</sup>]-NPY</td><td class="colsep0 rowsep0" align="center" char=".">8</td><td class="colsep0 rowsep0" align="center" char=".">8</td><td class="colsep0 rowsep0" align="center">7.8 (8.11 ± 0.07)</td><td class="colsep0 rowsep0" align="center">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="left">[K<sup>4,18,22,26</sup>(Dap(<b>5a</b>)<sub>2</sub>),F<sup>7</sup>,P<sup>34</sup>]-NPY</td><td class="colsep0 rowsep0" align="center" char=".">8</td><td class="colsep0 rowsep0" align="center" char=".">8</td><td class="colsep0 rowsep0" align="center">19 (7.72 ± 0.10)</td><td class="colsep0 rowsep0" align="center">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">[K<sup>4,18,22</sup>(Dap(Dap(<b>5a</b>)<sub>2</sub>)<sub>2</sub>),F<sup>7</sup>,P<sup>34</sup>]-NPY</td><td class="colsep0 rowsep0" align="center" char=".">12</td><td class="colsep0 rowsep0" align="center" char=".">12</td><td class="colsep0 rowsep0" align="center">50 (7.30 ± 0.04)</td><td class="colsep0 rowsep0" align="center">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">[K<sup>4,18</sup>(Dap(Dap(<b>8a</b>)<sub>2</sub>)<sub>2</sub>),F<sup>7</sup>,P<sup>34</sup>]-NPY</td><td class="colsep0 rowsep0" align="center" char=".">8</td><td class="colsep0 rowsep0" align="center" char=".">16</td><td class="colsep0 rowsep0" align="center">18 (7.76 ± 0.06)</td><td class="colsep0 rowsep0" align="center">>1000</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup><sup>a</sup></sup><p class="last">Receptor activation potencies were determined by inositol phosphate (IP) accumulation assay. nd: not determined.</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Utilization of a Deoxygalactosyl Moiety Reduces Hydrophobicity without Affecting Receptor Activity</h3><div class="NLM_p">The triple-modified [F<sup>7</sup>,P<sup>34</sup>]-NPY conjugate <b>13</b> was tested for receptor activation at the hY<sub>1</sub>R and hY<sub>2</sub>R by inositol phosphate accumulation assay. Conjugate <b>13</b> was found to be a highly potent, full agonist of the hY<sub>1</sub>R with an EC<sub>50</sub> of 9.2 nM, which is in a similar range as the control NPY (<b>10</b>) with 3.8 nM and unmodified [F<sup>7</sup>,P<sup>34</sup>]-NPY (<b>11</b>) with 2.5 nM (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.9b01136/suppl_file/jm9b01136_si_001.pdf" class="ext-link">Figure S15</a>). Recently published data emphasized the importance of hydrophilic carborane building blocks to facilitate a maximal boron loading per peptide molecule.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Therefore, <b>5</b> was utilized to gain conjugate <b>14</b>, leading to a more hydrophilic compound, recognizable by the lowered retention time in RP-HPLC (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01136/suppl_file/jm9b01136_si_001.pdf" class="ext-link">Table S1</a>), while the hY<sub>1</sub>R potency was not affected. With an EC<sub>50</sub> of 3.5 nM, conjugate <b>14</b> is slightly more active than the more hydrophobic derivative <b>13</b>. Furthermore, no difference has been observed between these two peptides with respect to selectivity. By featuring an EC<sub>50</sub> value of 404 nM (<b>13</b>) and 416 nM (<b>14</b>) at the hY<sub>2</sub>R, both peptides exhibit an even lower potency than the original [F<sup>7</sup>,P<sup>34</sup>]-NPY (<b>11</b>, EC<sub>50</sub> = 78 nM), thus increased selectivity.</div><div class="NLM_p last">In addition to receptor activation, peptide conjugates were investigated by fluorescence microscopy to visualize the hY<sub>1</sub>R and hY<sub>2</sub>R internalization after peptide stimulation. HEK293 cells stably expressing the hY<sub>1</sub>R or hY<sub>2</sub>R, C-terminally fused to the enhanced yellow fluorescent protein (eYFP), were used. Without peptide stimulation, the fluorescently labeled hY<sub>1</sub>R and hY<sub>2</sub>R (green) are predominantly localized in the cell membrane. Stimulation of hY<sub>1</sub>R- or hY<sub>2</sub>R-expressing cells with 100 nM or 1 μM of the native ligand NPY (<b>10</b>) for 1 h, respectively, led to internalization of both receptors into the cell, as observed by localization of the green fluorescence in intracellular vesicles. Incubation with the hY<sub>1</sub>R-preferring [F<sup>7</sup>,P<sup>34</sup>]-NPY (<b>11</b>) led to internalization of the hY<sub>1</sub>R comparable to NPY, but no internalization of the hY<sub>2</sub>R was observed in accordance with previous studies (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01136/suppl_file/jm9b01136_si_001.pdf" class="ext-link">Figure S15</a>).<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> The conjugates <b>13</b> and <b>14</b> led also to a strong internalization of the hY<sub>1</sub>R, while the hY<sub>2</sub>R remained at the cell membrane after 1 h of stimulation.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Maximizing Boron Loading per [F<sup>7</sup>,P<sup>34</sup>]-NPY</h3><div class="NLM_p">Next, [F<sup>7</sup>,P<sup>34</sup>]-NPY conjugates were generated using a branching strategy to increase the number of building blocks (5) per peptide molecule. Conjugate <b>15</b> bearing four carborane units was equipotent to NPY (<b>10</b>) with an EC<sub>50</sub> value of 2.6 nM. The 6-fold and 8-fold modified conjugates <b>16</b> and <b>17</b> exhibited a slightly reduced potency compared to NPY (<b>10</b>); however, the EC<sub>50</sub> values are still in the low nanomolar range (9.6 nM (<b>16</b>) and 7.8 nM (<b>17</b>)). For conjugate <b>18</b>, carrying eight clusters of <b>5</b> distributed widely over the peptide sequence, the potency was further reduced at the hY<sub>1</sub>R (EC<sub>50</sub> = 19 nM), and conjugate <b>19</b> with the highest carborane loading showed the lowest potency with an EC<sub>50</sub> of 50 nM. Modification of [F<sup>7</sup>,P<sup>34</sup>]-NPY with multiple deoxygalactosyl-carborane <b>5</b> units maintained the selectivity of the peptide conjugates against the hY<sub>2</sub>R, as seen by a clear shift of the concentration–response curves to the right compared to NPY. At a concentration of 10 μM, conjugates <b>15</b>–<b>19</b> were able to activate the hY<sub>2</sub>R up to 70–80% of the NPY response; however, the potency of the conjugates at the hY<sub>2</sub>R (EC<sub>50</sub> values of >300 nM) was further reduced compared to the unmodified [F<sup>7</sup>,P<sup>34</sup>]-NPY (<b>11</b>). Deoxygalactosyl-carborane conjugates <b>15</b>–<b>19</b> were also tested for their receptor internalization in fluorescence microscopy experiments. Peptides <b>15</b>–<b>18</b> were able to induce internalization of the hY<sub>1</sub>R comparable to the native ligand NPY (<b>10</b>), as seen by a predominant appearance of the hY<sub>1</sub>R-eYFP fluorescence in intracellular vesicles (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B). In contrast, after stimulation with conjugate <b>19</b>, most of the hY<sub>1</sub>R was still localized in the cell membrane and only slight receptor internalization was observed. Furthermore, no internalization of the hY<sub>2</sub>R was detected for all [F<sup>7</sup>,P<sup>34</sup>]-NPY conjugates <b>15</b>–<b>19</b>, confirming their hY<sub>1</sub>R selectivity. In summary, the deoxygalactosyl-carborane building block <b>5</b> enabled the generation of highly carborane-modified [F<sup>7</sup>,P<sup>34</sup>]-NPY conjugates with selective activity and internalization at the hY<sub>1</sub>R versus hY<sub>2</sub>R. Conjugate <b>17</b>, containing eight clusters of <b>5</b>, corresponding to 80 boron atoms per peptide, was determined as a promising compound with a maximized boron loading and high activity.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/medium/jm9b01136_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/large/jm9b01136_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Receptor activation and internalization properties of conjugates <b>15</b>–<b>19</b>. (A) hY<sub>1</sub>R and hY<sub>2</sub>R receptor activation of conjugates <b>15</b>–<b>19</b>, normalized to NPY (<b>10</b>). Curves represent mean values ± SEM of at least two independent experiments performed in duplicate. (B) Receptor internalization studies of conjugates <b>15</b>–<b>19</b> using HEK293 cells stably expressing the hY<sub>1</sub>R or hY<sub>2</sub>R fused to eYFP (green). Cells were stimulated with 100 nM peptide (hY<sub>1</sub>R) or 1 μM peptide (hY<sub>2</sub>R) for 1 h at 37 °C. Cell nuclei were stained with Hoechst 33342 (blue). Scale bar = 10 μm. Depicted images are representatives of at least two independent experiments performed in triplicate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/large/jm9b01136_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01136&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Utilizing Bis-deoxygalactosyl-carborane Prevents Aggregation</h3><div class="NLM_p">To rule out potential aggregation in aqueous solution, the highly carborane-loaded conjugate <b>17</b> was tested in comparison to the control peptide [F<sup>7</sup>,P<sup>34</sup>]-NPY (<b>11</b>) in a kinetic solubility assay.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> The HPLC analysis of the processed samples revealed that the peak area of the control peptide [F<sup>7</sup>,P<sup>34</sup>]-NPY (<b>11</b>) was similar in both solvent systems (Hank’s Balanced Salt Solution (HBSS) vs ACN/H<sub>2</sub>O) up to a concentration of 25 μM. This indicates no formation of aggregates in the aqueous buffer solution (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). For conjugate <b>17</b>, peaks were observed at all three tested concentrations (1, 10, and 25 μM) in the acetonitrile/water samples; however, no peaks were detectable at the same concentrations in the HBSS samples (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.9b01136/suppl_file/jm9b01136_si_001.pdf" class="ext-link">Figure S16</a>). This suggests that conjugate <b>17</b> forms aggregates in the aqueous buffer solution.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/medium/jm9b01136_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/large/jm9b01136_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Kinetic solubility assay for investigation of the potential aggregation of conjugates <b>8</b> and <b>11</b>. Depicted peak areas are representative for two independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/large/jm9b01136_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01136&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Therefore, the content of deoxygalactosyl moieties at the carborane clusters was doubled by conjugation of bis-deoxygalactosyl-carborane <b>8</b> to [F<sup>7</sup>,P<sup>34</sup>]-NPY in conjugate <b>20</b>. Compared to the structurally similar conjugate <b>17</b> (modified with eight deoxygalactosyl-carboranes <b>5</b>), conjugate <b>20</b> exhibited a significant increase in solubility in the kinetic solubility assay, similar to the control peptide <b>11</b>. The same peak areas for the peptide samples at 10 μM and 25 μM were obtained in both solvent systems, indicating that <b>20</b> is not aggregating in buffer solution. In receptor activation studies, conjugate <b>20</b> was found to exhibit a slight 2-fold loss in potency at the hY<sub>1</sub>R with an EC<sub>50</sub> value of 18 nM (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A). The selectivity against the hY<sub>2</sub>R was similar to <b>17</b>. Investigation of receptor internalization by fluorescence microscopy confirmed these results. Stimulation with conjugate <b>20</b> led to a slightly lower internalization of the hY<sub>1</sub>R in comparison to <b>17</b> at a concentration of 100 nM, while the hY<sub>2</sub>R showed no internalization at all (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B).</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/medium/jm9b01136_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/large/jm9b01136_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Biological characterization of conjugates <b>17</b> and <b>20</b>. (A) IP accumulation assay determining the receptor activation of conjugates <b>17</b> and <b>20</b> at the hY<sub>1</sub>R and hY<sub>2</sub>R normalized to NPY (<b>10</b>). Curves represent mean values ± SEM of at least two independent experiments performed in duplicate. (B) Receptor internalization studies of conjugates <b>17</b> and <b>20</b> using HEK293 cells stably expressing the hY<sub>1</sub>R or hY<sub>2</sub>R fused to eYFP (green). Cells were stimulated with 100 nM peptide (hY<sub>1</sub>R) or 1 μM peptide (hY<sub>2</sub>R) for 1 h at 37 °C. Cell nuclei were stained with Hoechst 33342 (blue). Scale bar = 10 μm. Depicted images are representatives of at least two independent experiments performed in triplicate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/large/jm9b01136_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01136&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Conjugate with 80 Boron Atoms Exhibits High Selectivity and Uptake into Cancer Cells</h3><div class="NLM_p">The hY<sub>1</sub>R-targeted [F<sup>7</sup>,P<sup>34</sup>]-NPY conjugate <b>20</b> was further investigated. At first, the selectivity of <b>20</b> against the two additional Y receptor subtypes in human, the hY<sub>4</sub>R and hY<sub>5</sub>R, was determined in internalization studies using HEK293 cells stably expressing these receptors, C-terminally fused to eYFP (green). In the unstimulated state, both receptors are predominantly localized in the cell membrane (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A). As controls, pancreatic polypeptide (hPP, <b>12</b>) was used for the hY<sub>4</sub>R and NPY (<b>10</b>) for the hY<sub>5</sub>R. Stimulation of cells with 100 nM of the respective natural ligand for 1 h induced partial internalization of both the hY<sub>4</sub>R and the hY<sub>5</sub>R into the cells, with a fraction of the receptors still being found in the membrane. Testing the selectivity of conjugate <b>20</b> was performed by facilitating the TAMRA-modified conjugate <b>22</b>, allowing the direct observation of the peptide uptake into the cells. To ensure comparability of derivatives <b>20</b> and <b>22</b>, the hY<sub>1</sub>R and hY<sub>2</sub>R receptor activation was tested in an IP-One assay, revealing no significant difference (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01136/suppl_file/jm9b01136_si_001.pdf" class="ext-link">Figure S17</a>). Stimulation of hY<sub>1</sub>R-expressing HEK293 cells with peptide <b>22</b> resulted in a distinct internalization of the hY<sub>1</sub>R together with the peptide (red) into vesicles, detectable by colocalization of both colors. In contrast, stimulation of the hY<sub>2</sub>R and hY<sub>4</sub>R showed no internalized receptor or peptide. Just the hY<sub>5</sub>R showed negligible uptake of the peptide, whereas no difference in the receptor localization was noticeable between the unstimulated and the stimulated hY<sub>5</sub>R. In addition, the uptake of <b>22</b> into endogenously hY<sub>1</sub>R-expressing MCF-7 cells was investigated. Stimulation with 100 nM for 1 h led to a significant uptake into MCF-7 cells detectable by red fluorescence in intracellular vesicles (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B).</div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/medium/jm9b01136_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/large/jm9b01136_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. In vitro characterization of fluorescently labeled analogs <b>21</b> and <b>22</b>. (A) Receptor internalization and conjugate uptake studies using HEK293 cells stably expressing the hY<sub>1</sub>R, hY<sub>2</sub>R, hY<sub>4</sub>R, or hY<sub>5</sub>R fused to eYFP (green). Cells were stimulated with 100 nM (hY<sub>1</sub>R, hY<sub>4</sub>R, and hY<sub>5</sub>R) and 1 μM (hY<sub>2</sub>R) peptide (red) for 1 h. Cell nuclei were stained with Hoechst 33342 (blue). 100 nM NPY (<b>10</b>) was used as control for hY<sub>1</sub>R, hY<sub>2</sub>R, and hY<sub>5</sub>R, while hPP (<b>12</b>) was used for hY<sub>4</sub>R. Scale bar = 10 μm. Depicted images are representatives of at least two independent experiments performed in triplicate. (B) Internalization of conjugate <b>22</b> into MCF-7 cells after 1 h stimulation with 1 μM peptide. Cell nuclei were stained with Hoechst 33342 (blue). Scale bar = 10 μm. Depicted images are representatives of at least two independent experiments performed in triplicate. (C) Cell viability assay on endogenously hY<sub>1</sub>R-expressing MCF-7 cells after 48 h of stimulation with conjugate <b>20</b> in comparison to [F<sup>7</sup>,P<sup>34</sup>]-NPY (<b>11</b>). Bars represent the mean value ± SEM of at least three independent experiments performed in duplicate. (D) Blood plasma stability of conjugate <b>22</b> in comparison to <b>21</b> of at least two independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/large/jm9b01136_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01136&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Bis-deoxygalactosyl-carborane Increases Conjugate Stability without Showing Cell Toxicity</h3><div class="NLM_p last">In addition to the uptake studies, the intrinsic cytotoxicity of the peptide conjugate <b>20</b> was also analyzed. MCF-7 cells were incubated with <b>20</b> in culture medium for 48 h, and subsequently cell viability was determined by a resazurin-based toxicity assay (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>C). Up to a concentration of 10 μM, no reduction in cell viability has been observed, neither for the control peptide <b>11</b> nor for conjugate <b>20</b>. This indicates that the 8-fold modification of the nontoxic peptide <b>11</b> with building block <b>8</b> is well tolerated and does not result in any intrinsic cytotoxicity. Furthermore, the highly carborane-loaded conjugate <b>22</b> was also investigated for its stability in blood plasma. The TAMRA-modified control peptide <b>21</b> was used as benchmark. Both conjugates show a decrease of the original peptide over time. While the control peptide <b>21</b> exhibited only a half-life of 3.6 h, the conjugate <b>22</b> showed a half-life of more than 100 h (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>D).</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01316" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01316" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">BNCT is a promising next-generation cancer therapy on the upward path as a result of the recent progress in the development of hospital-compatible linear accelerators for neutron beam generation.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> The development of novel boron delivery agents with increased selectivity and maximized boron loading enhances the therapeutic efficiency of BNCT and thereby prepares the ground for routine clinical application.<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33,34)</a> Higher selectivity for boron delivery has been achieved by using receptor-targeted peptide analogs such as the hY<sub>1</sub>R-preferring [F<sup>7</sup>,P<sup>34</sup>]-NPY as carrier system for boron compounds.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Besides the high overexpression on different cancer types, the internalization of the hY<sub>1</sub>R together with the bound ligand facilitates the intracellular localization of the boron compound, resulting in the delivery of a higher radiation dose to the DNA of the cancer cell in BNCT.<a onclick="showRef(event, 'ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref35 ref36">(35,36)</a> The concept of using internalizing, receptor-targeting peptide ligands as BNCT agents has already been proposed before. <i>closo</i>-Carborane or <i>closo</i>-borane conjugated [Tyr<sup>3</sup>]-octreotate analogs have been described by different groups for targeting the somatostatin receptor subtype-2 (SSTR2) in neuroendocrine tumors.<a onclick="showRef(event, 'ref37 ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref37 ref38 ref39">(37−39)</a> Another aspect, which has to be considered for successful BNCT despite the tumor selectivity, is the delivery of very high amounts of boron into the cancer cells. Computer simulations determined the need of approximately 10<sup>9</sup> boron atoms per cell to obtain a sufficient generation of destructive LET particles from the neutron capture fission reaction.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Loading of the delivery compound with a maximized number of boron atoms per molecule is therefore essential to yield a system with optimal boron shuttling efficiency. For a high boron modification of the peptide ligand [F<sup>7</sup>,P<sup>34</sup>]-NPY, carboranes were chosen as optimal building blocks. They comprise a high boron content with 10 boron atoms per molecule and suitable biological stability.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Furthermore, the vertexes of the carborane cluster can be readily chemically functionalized, which allows incorporation into peptides by peptide chemistry and further modulation of the physicochemical properties of the building block.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> As a first step in the development of boron-rich [F<sup>7</sup>,P<sup>34</sup>]-NPY conjugates, we evaluated the modification of the peptide with the <i>meta</i>-carborane <b>2</b>. We have recently described carborane <b>2</b> as suitable building block for modification of peptidic ghrelin receptor agonists.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> The carborane <b>2</b> is the <i>meta</i>-isomer of an <i>ortho</i>-carborane that has been previously used to generate a potent, multi-carborane [F<sup>7</sup>,P<sup>34</sup>]-NPY analog modified with three <i>ortho</i>-carboranes attached at positions 4, 18, and 22, which are well tolerated at the hY<sub>1</sub>R.<a onclick="showRef(event, 'ref27 ref42'); return false;" href="javascript:void(0);" class="ref ref27 ref42">(27,42)</a> The same positions were used in the present study yielding conjugate <b>13</b>, which displayed the desired hY<sub>1</sub>R activity, internalization, and selectivity against the hY<sub>2</sub>R. The use of <i>meta</i>-carborane, however, is highly preferred owing to the chemical stability of this isomer in aqueous basic solution in contrast to the less stable <i>ortho</i>-carborane.<a onclick="showRef(event, 'ref28 ref43'); return false;" href="javascript:void(0);" class="ref ref28 ref43">(28,43)</a> Further increase of the boron loading per peptide molecule could be achieved by incorporation of a 1,3,5-triazine-based biscluster building block.<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44,45)</a> Even though we reported the successful incorporation of up to six carborane clusters per [F<sup>7</sup>,P<sup>34</sup>]-NPY molecule, conjugates with more than two clusters exhibited a strong loss in receptor potency. We speculated that the hydrophobicity of the conjugate was too high and led to a hydrophobic collapse of the peptide.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> In order to counterbalance the hydrophobicity of the carborane clusters, we introduced a α-<span class="smallcaps smallerCapital">d</span>-deoxygalactopyranosyl moiety to the <i>meta</i>-carborane cluster yielding the building block <b>5</b>. The four hydroxy groups in the monosaccharide unit were expected to compensate the hydrophobic interactions of the carborane clusters and prevent the hydrophobic collapse. Direct functionalization of carboranes with hydrophilic residues such as alkylphosphonium groups, cascade-type polyols, and saccharide moieties as appropriate strategy to facilitate water solubility has been described before.<a onclick="showRef(event, 'ref46 ref47 ref48 ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref46 ref47 ref48 ref49 ref50">(46−50)</a> Additionally, the successful incorporation of a deoxygalactosyl-functionalized, charge-compensated cobalt bis(dicarbollide) building block into [F<sup>7</sup>,P<sup>34</sup>]-NPY has been previously reported.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Modification of [F<sup>7</sup>,P<sup>34</sup>]-NPY with deoxygalactosyl-carborane <b>5</b> by lysines at positions 4, 18, and 22 yielded the triple-modified conjugate <b>14</b> with high activity at the hY<sub>1</sub>R, demonstrating no influence of the galactose units on the biological activity. Further increase of the boron content was facilitated by incorporation of a single branching step or a progressive double branching with diaminopropionic acid at the lysine side chains. This led to conjugates with 4, 6, 8, and 12 deoxygalactosyl-carboranes <b>5</b>, respectively. Conjugates <b>15</b>–<b>17</b> with up to 8 incorporated deoxygalactosyl-carborane clusters exhibited high potency at the hY<sub>1</sub>R and internalization into hY<sub>1</sub>R-expressing cells comparable to the unmodified ligands NPY and [F<sup>7</sup>,P<sup>34</sup>]-NPY. Selectivity against the hY<sub>2</sub>R was fully maintained. Additionally, no hydrophobic shift in the RP-HPLC elution was observed when the number of incorporated carboranes <b>5</b> was increased. These results indicate that the concept of counterbalancing the hydrophobicity of the carborane clusters by direct functionalization with a deoxygalactosyl moiety allows a higher boron loading of [F<sup>7</sup>,P<sup>34</sup>]-NPY, while the biological activity in vitro was maintained. Conjugate <b>18</b>, however, with eight deoxygalactosyl-carborane clusters more widely distributed over the sequence of [F<sup>7</sup>,P<sup>34</sup>]-NPY displayed a slightly reduced activation potency at the hY<sub>1</sub>R. In accordance to the NPY binding site in the recently published crystal structure of the hY<sub>1</sub>R, it can be assumed that the modification at position 26 might lead to a sterical clash with the ECL3 of the hY<sub>1</sub>R.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> For conjugate <b>19</b>, containing 12 deoxygalactosyl-carboranes, a further loss in hY<sub>1</sub>R activity was observed, although <b>19</b> is still able to reach full agonism at the hY<sub>1</sub>R at high concentrations. The large sterical demand of the double-branched Dap-carborane dendron structure at amino acid position 22 in <b>19</b> might lead to a potential sterical clash with the flexible N-terminus of the hY<sub>1</sub>R.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Overall, the results demonstrate that very bulky carborane modifications are better tolerated at positions 4 and 18 in NPY, which are suggested to point more out of the binding pocket in the hY<sub>1</sub>R/NPY binding model. Regarding the hY<sub>2</sub>R, bulky carborane modifications at positions 18 and 22 in the helical part of NPY are suggested to lead to a sterical clash with the ECL2 of the hY<sub>2</sub>R during the binding event, a potential explanation for the increased selectivity of the highly modified conjugates over the hY<sub>2</sub>R.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Conjugate <b>17</b>, modified with eight clusters at positions 4 and 18, was found to be a promising compound owing to an optimal ratio of carborane loading to hY<sub>1</sub>R activity and selectivity. An extensive loading of 80 boron atoms per peptide molecule has been realized in this conjugate. In order to ensure a sufficient solubility for the desired BNCT application, we performed a HPLC-based kinetic solubility assay. In contrast to the control peptide [F<sup>7</sup>,P<sup>34</sup>]-NPY (<b>11</b>), the results for conjugate <b>17</b> indicated a strong aggregation in aqueous buffer solution, which is most likely due to the hydrophobic effect. In this context, the observed high activity of <b>17</b> at the hY<sub>1</sub>R might be explained by a sufficient amount of monomeric, receptor-active peptide in solution at the lower concentrations in the biological studies. However, aggregation has to be prevented not only to guarantee drug quality,but also to ensure a good safety profile,because drug aggregates can lead to immunogenic responses, which are highly unfavored. In addition, the applied conjugates should be non-aggregating in high concentrations, because the peptides have to be administered in high doses to facilitate sufficient effects at the tumor site and aggregates would reduce the compound concentration.</div><div class="NLM_p last">In order to improve the conjugate solubility while maintaining extensive boron loading, we synthesized the carborane building block <b>8</b> which comprises two α-<span class="smallcaps smallerCapital">d</span>-deoxygalactopyranosyl moieties attached to both carbon atoms of the <i>meta</i>-carborane cluster. This results in an 8:1 ratio of hydroxy groups per cluster. In the following, [F<sup>7</sup>,P<sup>34</sup>]-NPY conjugate <b>20</b> was prepared, which is structurally similar to <b>17</b>, but contains eight molecules of the bis-deoxygalactosyl-carborane <b>8</b> instead of the carborane <b>5</b>. Conjugate <b>20</b> displayed a small, 2-fold decrease in potency at the hY<sub>1</sub>R in comparison to <b>17</b> and a slightly lower internalization of this receptor. This can be explained by a larger sterical demand of the bis-deoxygalactosyl modifications in conjugate <b>20</b>, thereby slightly impairing the receptor binding. However, the activity of conjugate <b>20</b> at the hY<sub>1</sub>R is still in a good nanomolar range and selectivity against the hY<sub>2</sub>R was similar as for <b>17</b>. Importantly, testing in the kinetic solubility assay revealed that the use of the bis-deoxygalactosyl-carborane <b>8</b> in conjugate <b>20</b> prevented aggregation formation in HBSS. Peptide <b>20</b> therefore represents an active 80-boron-[F<sup>7</sup>,P<sup>34</sup>]-NPY derivative with adequate solubility in aqueous solution. Naturally, the influence on the selectivity of a targeted biomolecule carrier should be considered when such ample chemical conjugation is performed. Therefore, conjugate <b>20</b> was additionally modified at position 22 with TAMRA, resulting in <b>22</b> that allows the direct monitoring in live cell fluorescence microscopy. In addition to hY<sub>2</sub>R selectivity, conjugate <b>22</b> demonstrated no internalization at hY<sub>4</sub>R and just negligible uptake into hY<sub>5</sub>R-expressing cells, which is in agreement with previously reported carborane-[F<sup>7</sup>,P<sup>34</sup>]-NPY conjugates.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a> Since low intrinsic toxicity is a prerequisite for a BNCT agent, we additionally tested cytotoxicity of <b>20</b> and found none in hY<sub>1</sub>R-expressing MCF-7 cells. Next, we investigated the blood plasma stability to ensure a suitable half-life for the conjugate. The highly boron-loaded conjugate displayed an increased half-life of over 100 h compared to the unmodified peptide. This demonstrates the stabilizing effect of the building block <b>8</b>, which is most likely due to the sterically demanding saccharide units that shield the peptide from proteases and thereby lead to improved bioavailability.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Overall, the obtained results demonstrate the high potential of conjugate <b>20</b> as boron delivery agent for BNCT. The use of highly boron-loaded biomolecule carrier systems for BNCT has been only described in a few studies before. Conjugation of a heavily boronated polyamidoamine dendrimer to EGF or the monoclonal antibodies cetuximab and L8A4 for targeting the EGFR or its mutant isoform EGFRvIII on glioma cells was reported.<a onclick="showRef(event, 'ref55 ref56 ref57 ref58 ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref55 ref56 ref57 ref58 ref59 ref60">(55−60)</a> In this approach, a loading of the macromolecular carriers with around 1000 boron atoms was achieved, and first positive BNCT results in rats bearing EGFR/EGFRvIII-transfected F98 gliomas were obtained. However, preparation of these huge bioconjugates is rather laborious, and additionally, high expression heterogeneity of the targets EGFR and EGFRvIII in human gliomas stalled further clinical development.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Smaller biomolecules like polyarginine (11R) cell penetrating peptide (CPP) were modified with eight BSH molecules in a dendrimeric structure and also used as carrier systems.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> The resulting boron-rich CPP conjugate showed accumulation in glioma cells in mice with no uptake in the normal brain and a significant BNCT effect after neutron irradiation of glioma cells in vitro. However, despite the reported selective tumor delivery, the specificity of the cellular uptake of cationic CPPs is discussed controversially.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Thus, we propose the concept of using tumor-targeting peptides conjugated with carbohydrate-modified carborane clusters to counterbalance the hydrophobicity.<a onclick="showRef(event, 'ref64 ref65 ref66 ref67 ref68'); return false;" href="javascript:void(0);" class="ref ref64 ref65 ref66 ref67 ref68">(64−68)</a> The highly selective and nontoxic peptide conjugates are suggested to lead to high tumor selectivity with the additional potential to use a reduced dosage of these novel boron compounds compared to BSH and BPA.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87554" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87554" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">The use of bis-deoxygalactosyl-<i>meta</i>-carborane building blocks with enhanced hydrophilicity in combination with a branching approach enables the facile generation of hY<sub>1</sub>R-targeted [F<sup>7</sup>,P<sup>34</sup>]-NPY conjugates with a maximized carborane loading. A boron-rich peptide analog containing eight deoxygalactosyl-carborane clusters, i.e., 80 boron atoms per peptide molecule, exhibits high receptor activity and internalization at the hY<sub>1</sub>R, selectivity against other hYR subtypes and low intrinsic cytotoxicity. The concept of the hydrophilic bis-deoxygalactosyl-carborane unit is therefore excellent to also obtain a high boron conjugation of other biomolecule carriers. Notably, in the ongoing search for improved boron delivery agents, the highly carborane-loaded NPY conjugate can be considered as a promising, tumor-selective boron shuttle system for BNCT of breast cancer.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31556" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31556" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Carborane Synthesis. General</h3><div class="NLM_p last">Solvents were degassed, dried, and purified with the solvent purification system SPS-800 by MBraun. All reactions were carried out under nitrogen using standard Schlenk techniques. 1,7-Dicarba-<i>closo</i>-dodecaborane(12) is commercially available (Katchem, Prague, Czech Republic). NMR measurements were carried out on a Bruker Avance DRX 400 spectrometer (<sup>1</sup>H NMR 400.13 MHz, <sup>13</sup>C{<sup>1</sup>H} NMR 100.63 MHz, <sup>11</sup>B{<sup>1</sup>H} NMR 128.38 MHz, <sup>11</sup>B NMR 128.38 MHz) or an Ascend 400 spectrometer (<sup>1</sup>H NMR 400.16 MHz, <sup>13</sup>C{<sup>1</sup>H} NMR 100.63 MHz, <sup>11</sup>B{<sup>1</sup>H} NMR 128.38 MHz, <sup>11</sup>B NMR 128.38 MHz). Tetramethylsilane was used as internal standard, and <sup>11</sup>B NMR spectra were referenced to the Ξ-scale.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> All chemical shifts are reported in ppm. Assignment of the <sup>1</sup>H and <sup>13</sup>C signals was based on 2D NMR spectra (H,H-COSY, HMQC, HSQC, HMBC). The following pulse sequences were used: for COSY spectra the pulse sequence “cosygpqf”; for HSQC spectra the pulse sequence “hsqcedetgpsp” with <sup>1</sup><i>J</i><sub>CH</sub> = 145 Hz; for the HMQC spectra the pulse sequence “hmqcgpqf” with <sup>1</sup><i>J</i><sub>CH</sub> = 145 Hz; for HMBC spectra the pulse sequence “hmbcgpl2ndgf”. Identification of the boron atom attached to sulfur was possible by comparison of the proton-coupled and -decoupled <sup>11</sup>B NMR spectra. On the following pages, some NMR signals that appear as broad overlapping signals with the shape of a multiplet in either <sup>1</sup>H, <sup>11</sup>B{<sup>1</sup>H}, or <sup>11</sup>B NMR spectra are just described as “br” (broad). In this case, the superscript a is added (br<sup>a</sup>). IR data were obtained with a PerkinElmer FT-IR spectrometer Spectrum 2000 on KBr pellets or on a Thermo Scientific Nicolet iS5 with an ATR unit in the range from 4000 to 400 cm<sup>–1</sup>. All detected signals were interpreted as w, m, or s, which means weak, medium, or strong, respectively. Positive or negative low- and high-resolution electrospray ionization mass spectra were recorded with an ESI Esquire3000 PLUS spectrometer with an ion trap analyzer from Bruker Daltonics or on a MicroTOF spectrometer from Bruker Daltonics with a ToF analyzer. For these measurements, dichloromethane, acetonitrile, methanol, or a mixture of these solvents was used. The content of carbon, nitrogen, and hydrogen of the substances was determined with the elemental analyzer Vario EL from Heraeus. For column chromatography, silica gel (60 Å) with a particle diameter in the range of 0.035–0.070 mm purchased from ACROS, the Biotage Isolera 1 automatic purification system, or the Biotage Isolera 4 automatic purification system with SNAP (particle diameter 0.040–0.065 mm) and SNAP Ultra (spherical particle, diameter: 0.025 mm) cartridges was used. The carborane species were detected by an integrated UV/Vis detector or evaporative light scattering detector (ELSD-1080) from Biotage. Thin-layer chromatography (TLC) with silica gel 60 F<sub>254</sub> on glass support (Merck KGaA) was used for monitoring the reactions. Carborane-containing spots were visualized with a 1–10% solution of PdCl<sub>2</sub> in methanol.</div></div><div id="sec5_1_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> 9-(Carboxymethylthio)-1,7-dicarba-<i>closo</i>-dodecaborane(12) (<b>2</b>)</h3><div class="NLM_p last">The synthesis of carborane building block <b>2</b> was described before.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a></div></div><div id="sec5_1_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> 1-(1′,2′:3′,4′-Di-<i>O</i>-isopropylidene-6′-deoxy-α-<span class="smallcaps smallerCapital">d</span>-galactopyranos-6′-yl)-9/10-(<i>tert</i>-butylthio)-1,7-dicarba-<i>closo</i>-dodecaborane(12) (<b>3</b>)</h3><div class="NLM_p last">2.97 g (12.78 mmol, 1.0 equiv) of 9-(<i>tert</i>-butylthio)-1,7-dicarba-<i>closo</i>-dodecaborane(12) (<b>1</b>) is dissolved in 100 mL of diethyl ether and cooled to 0 °C, and 8.72 mL (1.45 M in <i>n</i>-hexane, 12.64 mmol, 0.9 equiv) of <i>n</i>-butyllithium is added dropwise. The reaction is allowed to warm up to room temperature over 2 h. The solution is cooled to 0 °C again, and 5.00 g (12.7 mmol, 1.0 equiv) of 1,2:3,4-di-<i>O</i>-isopropylidene-α-<span class="smallcaps smallerCapital">d</span>-galactopyranosyltriflate dissolved in diethyl ether (50 mL) are added dropwise. The reaction is allowed to warm up to ambient temperature and stirred overnight. Wet diethyl ether is added, and then the solvent is removed under reduced pressure. The residue is purified by column chromatography (ethyl acetate/<i>n</i>-hexane 1:3, v/v) yielding 3.62 g (7.67 mmol, 60% yield) of intermediate <b>3</b> as a colorless highly viscous oil. <i>R<sub>f</sub></i> = 0.50 (<i>n</i>-hexane/ethyl acetate 3:1, v/<i>v</i>). <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ = 1.30 (s, 3H), 1.34 (s, 3H), 1.41 (s, 3H), 1.43 (s, 9H), 1.50–3.50 (br<sup>a</sup>, 9H), 1.59 (s, 3H), 2.15 (virtual d, <sup>2</sup><i>J</i><sub>HH</sub> = 15.9 Hz, 1H), 2.34 (ddd, <sup>2</sup><i>J</i><sub>HH</sub> = 16.0 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 9.0 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 4.6 Hz, 1H), 2.96 (br s, 1H), 3.77 (ddt, <sup>3</sup><i>J</i><sub>HH</sub> = 8.9 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 4.4 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 2.2 Hz, 1H), 4.04 (virtual dd, <sup>3</sup><i>J</i><sub>HH</sub> = 7.8 Hz, <i>J</i><sub>HH</sub> = 1.6 Hz, 1H), 4.28 (virtual dd, <sup>3</sup><i>J</i><sub>HH</sub> = 5.1 Hz, <i>J</i><sub>HH</sub> = 2.4 Hz, 1H), 4.57 (virtual dd, <sup>3</sup><i>J</i><sub>HH</sub> = 7.9 Hz, <i>J</i><sub>HH</sub> = 2.2 Hz, 1H), 5.52 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 5.1 Hz, 1H) ppm. <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>): δ = 23.3 (s), 23.9 (s), 24.9 (s), 31.8 (s), 37.1 (s), 43.2 (s), 53.8 (s), 54.0 (s), 65.9 (s), 66.0 (s), 69.0 (s), 69.8 (s), 71.5 (s), 72.0 (s), 95.5 (s), 108.1 (s), 108.3 (s) ppm. <sup>11</sup>B{<sup>1</sup>H} NMR (CDCl<sub>3</sub>): δ = −1.4 (s, 1B), – 2.0 to −20.0 (br<sup>a</sup>, 9B) ppm. <sup>11</sup>B NMR (CDCl<sub>3</sub>): δ = −1.4 (s, 1B), – 2.0 to −20.0 (br<sup>a</sup>, 9B) ppm. IR (KBr): ν̃ = 2989 (s), 2601 (s, BH), 1457 (m), 1384 (s), 1258 (s), 1213 (s), 1166 (s), 1071 (s), 1003 (s), 899 (m), 858 (m), 738 (m), 510 (m) cm<sup>–1</sup>. MS (HR-ESI, positive mode): <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>38</sub>B<sub>10</sub>O<sub>5</sub>S<sub>1</sub>, 475.35254 (100%, [M + H]<sup>+</sup>); found, 475.35275 (100%, [M + H]<sup>+</sup>).</div></div><div id="sec5_1_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> 1-(1′,2′:3′,4′-Di-<i>O</i>-isopropylidene-6′-deoxy-α-<span class="smallcaps smallerCapital">d</span>-galactopyranos-6′-yl)-9/10-(mercapto)-1,7-dicarba-<i>closo</i>-dodecaborane(12) (<b>4</b>)</h3><div class="NLM_p last">The synthesis of intermediate <b>4</b> from precursor <b>3</b> is performed according to the procedure for a previously described <i>ortho</i>-carborane derivative.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> 0.36 g (0.76 mmol, 1.0 equiv) of intermediate <b>3</b> was used to prepare intermediate <b>4</b> in 96% yield (0.30 g, 0.73 mmol, <i>R</i><sub><i>f</i></sub> = 0.47 (<i>n</i>-hexane/ethyl acetate, 3:1, v/v)). <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ = 0.43 (m, 1H), 1.30 (s, 3H), 1.34 (s, 3H), 1.42 (s, 3H), 1.50–3.50 (br<sup>a</sup>, 9H), 1.59 and 1.60 (s, 3H), 2.15 (virtual dt, <sup>2</sup><i>J</i><sub>HH</sub> = 15.9 Hz, <i>J</i><sub>HH</sub> = 2.6 Hz, 1H), 2.34 (ddd, <sup>2</sup><i>J</i><sub>HH</sub> = 15.9 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 8.7 Hz, <i>J</i><sub>HH</sub> = 3.4 Hz, 1H), 2.97 (br, s, 1H), 3.75 (ddt, <sup>3</sup><i>J</i><sub>HH</sub> = 8.9 Hz, <i>J</i><sub>HH</sub> = 4.4 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 2.2 Hz, 1H), 4.03 (dd, <sup>3</sup><i>J</i><sub>HH</sub> = 7.9 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 2.0 Hz, 1H), 4.28 (ddd, <sup>3</sup><i>J</i><sub>HH</sub> = 5.1 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 2.5 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 0.8 Hz, 1H), 4.57 (ddd, <sup>3</sup><i>J</i><sub>HH</sub> = 7.8 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 2.5 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 1.0 Hz, 1H), 5.52 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 5.1 Hz, 1H) ppm. <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>): δ = 24.4, 24.9, 25.8, and 25.9 (s), 37.9 and 38.0 (s), 54.8 (br, s), 68.0 and 67.0 (s), 70.0 (s), 70.8 (s), 73.05 and 73.07 (s), 73.5 (br, s), 96.6 (s), 108.70 and 108.73 (s), 109.3 (s) ppm. <sup>11</sup>B{<sup>1</sup>H} NMR (CDCl<sub>3</sub>): δ = −2.6 (s, 1B), – 5.0 to −22.0 (br, 9B) ppm. <sup>11</sup>B NMR (CDCl<sub>3</sub>): δ = −2.6 (s, 1B), – 5.0 to −22.0 (br, 9B) ppm. IR (KBr): ν̃ = 3446 (br, m), 3051 (m), 2990 (s), 2937 (m), 2600 (s, BH), 1456 (w), 1428 (w), 1384 (s), 1257 (m), 1213 (m), 1166 (m), 1107 (m), 1070 (s), 1003 (m), 899 (m), 856 (m), 758 (m), 668 (w), 509 (w) cm<sup>–1</sup>. MS (HR-ESI, positive mode): <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>30</sub>B<sub>10</sub>O<sub>5</sub>S<sub>1</sub>, 419.28960 (100%, [M]<sup>+</sup>); found, 419.28976 (100%, [M]<sup>+</sup>). Elemental analysis, calcd (%) for C<sub>14</sub>H<sub>30</sub>B<sub>10</sub>O<sub>5</sub>S<sub>1</sub>: C 40.18, H 7.22. Found: C 39.35, H 7.40.</div></div><div id="sec5_1_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> 1-(1′,2′,3′,4′-Di-<i>O</i>-isopropylidene-6′-deoxy-α-<span class="smallcaps smallerCapital">d</span>-galactopyranos-6′-yl)-9/10-(carboxymethylthio)-1,7-dicarba-<i>closo</i>-dodecaborane(12) (<b>5</b>, Gal′-Cb)</h3><div class="NLM_p last">1.40 g (3.35 mmol, 1.0 equiv) of intermediate <b>4</b> and 3.11 g (16.75 mmol, 5.0 equiv) of iodoacetic acid are dissolved in 64 mL of dry DCM. With stirring, an amount of 2.76 mL (2.03 g, 20.10 mmol, 6.0 equiv) of dry triethylamine is added in one portion at ambient temperature. The mixture is stirred overnight at ambient temperature. Subsequently, the reaction mixture is diluted with 400 mL of technical DCM. The organic layer is washed two times with 100 mL of distilled water, respectively, and once with 100 mL of a saturated NaCl solution. The organic layer is dried over MgSO<sub>4</sub>, filtered, and the solution is dried under reduced pressure. The raw product is purified by column chromatography on silica using a <i>n</i>-hexane/ethyl acetate gradient mixture (v/v, 1/1 to 1/2) as eluent, yielding 0.82 g (1.71 mmol, 51%) of <b>5</b> as colorless highly viscous solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ = 1.30 (s, 3H), 1.34 (s, 3H), 1.42 (s, 3H), 1.50–3.50 (br<sup>a</sup>, 9H), 1.587 and 1.593 (s, 3H), 2.14 (virtual dt, <sup>2</sup><i>J</i><sub>HH</sub> = 15.9 Hz, <i>J</i><sub>HH</sub> = 2.5 Hz, 1H), 2.35 (ddd, <sup>2</sup><i>J</i><sub>HH</sub> = 16.1 Hz, <i>J</i><sub>HH</sub> = 9.2 Hz, <i>J</i><sub>HH</sub> = 2.0 Hz, 1H), 2.99 (br, s, 1H), 3.38 (d, <i>J</i><sub>HH</sub> = 6.0 Hz, 2H), 3.74 (m, 1H), 4.03 (m, 1H), 4.29 (virtual dd, <sup>3</sup><i>J</i><sub>HH</sub> = 5.1 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 2.5 Hz, 1H), 4.58 (virtual dd, <i>J</i><sub>HH</sub> = 7.9 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 2.4 Hz, 1H), 5.53 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 5.1 Hz, 1H) ppm. <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>): δ = 24.4 (s), 24.9 (s), 25.85 (s), 25.93 (s), 34.5 (s), 38.0 (s), 54.4 (s), 67.0 (s), 70.0 (s), 70.9 (s), 73.1 (s), 73.2 (s), 96.6 (s), 108.7 (s), 108.8 (s), 109.4 (s), 174.2 (s) ppm. <sup>11</sup>B{<sup>1</sup>H} NMR (CDCl<sub>3</sub>): δ = −0.8 (s, 1B), – 2.0 to −20.0 (br<sup>a</sup>, 9B) ppm. <sup>11</sup>B NMR (CDCl<sub>3</sub>): δ = −0.8 (s, 1B), – 2.0 to −20.0 (br<sup>a</sup>, 9B) ppm. IR (KBr): ν̃ = 3053 (s), 2990 (s), 2936 (s), 2602 (s, BH), 1712 (s), 1457 (m), 1428 (m), 1385 (s), 1303 (m), 1259 (s), 1213 (s), 1166 (s), 1142 (m), 1107 (s), 1069 (s), 1003 (s), 955 (m), 919 (m), 898 (m), 855 (m), 802 (m), 774 (m), 740 (m), 668 (w), 645 (w), 534 (w), 509 (m), 460 (w) cm<sup>–1</sup>. MS (HR-ESI, positive mode): <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>32</sub>B<sub>10</sub>Na<sub>1</sub>O<sub>7</sub>S<sub>1</sub>, 499.27728 (100%, [M + Na]<sup>+</sup>); found, 499.27684 (100%, [M + Na]<sup>+</sup>). Elemental analysis, calcd (%) for C<sub>16</sub>H<sub>32</sub>B<sub>10</sub>O<sub>7</sub>S<sub>1</sub>: C 40.30, H 6.77. Found: C 40.05, H 6.67.</div></div><div id="sec5_1_1_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 1,7-Bis(1′,2′:3′,4′-Di-<i>O</i>-isopropylidene-6′-deoxy-α-<span class="smallcaps smallerCapital">d</span>-galactopyranos-6′-yl)-9-(<i>tert</i>-butylthio)-1,7-dicarba-<i>closo</i>-dodecaborane(12) (<b>6</b>)</h3><div class="NLM_p last">3.00 g (12.91 mmol, 1.0 equiv) of 9-(<i>tert</i>-butylthio)-1,7-dicarba-<i>closo</i>-dodecaborane(12) (<b>1</b>) is dissolved in tetrahydrofuran (100 mL), cooled to 0 °C, and an amount of 18.70 mL (1.45 M in <i>n</i>-hexane, 27.11 mmol, 2.1 equiv) of <i>n</i>-butyllithium is added dropwise. The reaction is allowed to warm up to room temperature over 2 h. The solution is cooled to 0 °C again, and an amount of 10.66 g (27.11 mmol, 2.1 equiv) of 1,2:3,4-di-<i>O</i>-isopropylidene-α-<span class="smallcaps smallerCapital">d</span>-galactopyranosyltriflate dissolved in tetrahydrofuran (50 mL) is added dropwise. The reaction is allowed to warm up to ambient temperature and stirred overnight. Wet tetrahydrofuran is added, and then the solvent is removed under reduced pressure. The residue is purified by column chromatography (ethyl acetate/<i>n</i>-hexane 1:3 v/v) yielding 4.96 g (6.92 mmol, 54%) of intermediate <b>6</b> as colorless solid oil. <i>R<sub>f</sub></i> = 0.47 (<i>n-</i>hexane/ethyl acetate 3:1, v/v). <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ = 1.20–3.50 (br<sup>a</sup>, 9H), 1.32 (s, 6H), 1.35 (s, 6H), 1.43 (s, 9H), 1.59 and 1.60 (s, 6H), 2.21 (virtual dt, <sup>2</sup><i>J</i><sub>HH</sub> = 15.8 Hz, <i>J</i><sub>HH</sub> = 3.5 Hz, 2H), 2.31 (ddd, <sup>2</sup><i>J</i><sub>HH</sub> = 15.5 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 7.8 Hz, <i>J</i><sub>HH</sub> = 3.0 Hz, 2H), 3.75 (ddt, <sup>3</sup><i>J</i><sub>HH</sub> = 8.1 Hz, <i>J</i><sub>HH</sub> = 5.8 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 2.3 Hz, 2H), 4.12 (dt, <sup>3</sup><i>J</i><sub>HH</sub> = 7.8 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 2.6 Hz, 2H), 4.29 (dd, <sup>3</sup><i>J</i><sub>HH</sub> = 5.2 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 2.3 Hz, 2H), 4.57 (dd, <sup>3</sup><i>J</i><sub>HH</sub> = 8.1 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 2.3 Hz, 2H), 5.52 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 5.1 Hz, 2H) ppm. <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>): δ = 24.2 (s), 24.8 (s), 25.8 (s), 25.9 (s), 32.7 (s), 37.8 (s), 44.1 (s), 66.78 (s), 66.82 (s), 70.0 (s), 70.7 (s), 71.9 (s), 72.1 (s), 72.58 (s), 72.60 (s), 96.4 (s), 108.6 (s), 109.1 (s) ppm. <sup>11</sup>B{<sup>1</sup>H} NMR (CDCl<sub>3</sub>): δ = −1.0 (s, 1B), – 5.0 to −22.0 (br<sup>a</sup>, 9B) ppm. <sup>11</sup>B NMR (CDCl<sub>3</sub>): δ = −1.0 (s, 1B), − 5.0 to −22.0 (br<sup>a</sup>, 9B) ppm. IR (KBr): ν̃ = 3445 (s), 2964 (w), 2596 (m), 1635 (m), 1382 (m), 1258 (m), 1213 (m), 1167 (m), 1144 (m), 1070 (s), 1031 (m), 1003 (m), 857 (w), 802 (w), 642 (w) cm<sup>–1</sup>. MS (HR-ESI, positive mode): <i>m</i>/<i>z</i> calcd for C<sub>30</sub>H<sub>56</sub>B<sub>10</sub>O<sub>10</sub>SNa, 740.4459 (100%, [M + Na]<sup>+</sup>); found, 740.4460 (100%, [M + Na]<sup>+</sup>).</div></div><div id="sec5_1_1_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 1,7-Bis(1′,2′:3′,4′-Di-<i>O</i>-isopropylidene-6′-deoxy-α-<span class="smallcaps smallerCapital">d</span>-galactopyranos-6′-yl)-9-(mercapto)-1,7-dicarba-<i>closo</i>-dodecaborane(12) (<b>7</b>)</h3><div class="NLM_p last">4.92 g (6.90 mmol, 1.0 equiv) of intermediate <b>6</b> is dissolved in dry acetic acid (50 mL). 3.30 g (10.35 mmol, 1.5 equiv) of Hg(OAc)<sub>2</sub> is added in one portion, resulting in a pale yellow color of the reaction mixture. The reaction mixture is stirred at 50 °C for 3 h, during which the color turns intensely yellow. The reaction is cooled to room temperature, degassed ethyl acetate (100 mL) is added, and hydrogen sulfide is bubbled through the solution over 20 min resulting in a black precipitate. The suspension was filtered, nitrogen was bubbled through the filtrate to remove hydrogen sulfide, and the filtrate was washed two times with 5% NaHCO<sub>3</sub> solution (50 mL). The organic phase was dried over magnesium sulfate, and the solvent was removed under reduced pressure. The residue was purified by column chromatography on mercaptopropyl coated silica,<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> yielding 4.60 g (6.72 mmol, 97%) of <b>7</b> as a colorless highly viscous solid. <i>R<sub>f</sub></i> = 0.62 (<i>n-</i>hexane/ethyl acetate 2:1, v/v). <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ = 0.43 (m, 1H), 1.16–3.51 (br<sup>a</sup>, 9H), 1.33 (s, 6H), 1.35 (s, 6H), 1.43 (s, 6H), 1.60 and 1.61 (s, 6H), 2.22 (virtual dt, <sup>2</sup><i>J</i><sub>HH</sub> = 15.9 Hz, <i>J</i><sub>HH</sub> = 2.6 Hz, 2H), 2.32 (ddd, <sup>2</sup><i>J</i><sub>HH</sub> = 15.9 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 8.7 Hz, <i>J</i><sub>HH</sub> = 3.4 Hz, 2H), 3.75 (ddt, <sup>3</sup><i>J</i><sub>HH</sub> = 8.9 Hz, <i>J</i><sub>HH</sub> = 4.4 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 2.2 Hz, 2H), 4.10 (dd, <sup>3</sup><i>J</i><sub>HH</sub> = 7.9 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 2.0 Hz, 2H), 4.28 (ddd, <sup>3</sup><i>J</i><sub>HH</sub> = 5.1 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 2.5 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 0.8 Hz, 2H), 4.57 (ddd, <sup>3</sup><i>J</i><sub>HH</sub> = 7.8 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 2.5 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 1.0 Hz, 2H), 5.52 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 5.1 Hz, 2H) ppm. <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>): δ = 24.3 (s), 25.0 (s), 25.8 (s), 25.9 (s), 37.9 (s), 38.0 (s), 60.4 (br, s), 66.9 (s), 67.0 (s), 70.0 (s), 70.8 (s), 72.7 (s), 72.8 (s), 96.5 (s), 108.70 (s), 108.73 (s), 109.22 (s), 109.24 (s) ppm. <sup>11</sup>B{<sup>1</sup>H} NMR (CDCl<sub>3</sub>): δ = −2.8 (s, 1B), – 4.0 to −22.0 (br<sup>a</sup>, 9B) ppm. <sup>11</sup>B NMR (CDCl<sub>3</sub>): δ = −2.8 (s, 1B), − 4.0 to −22.0 (br<sup>a</sup>, 9B) ppm. IR (KBr): ν̃ = 3446 (br, m), 2989 (m), 2934 (s), 2606 (m), 1633 (w), 1457 (w), 1382 (s), 1257 (s), 1213 (s), 1169 (m), 1107 (m), 1070 (s), 918 (m), 900 (m), 884 (m), 862 (m), 804 (w), 756 (w), 648 (w), 553 (w), 511 (w) cm<sup>–1</sup>. MS (HR-ESI, positive mode): <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>48</sub>B<sub>10</sub>O<sub>10</sub>S<sub>1</sub>, 684.3833 (100%, [M + Na]<sup>+</sup>); found, 684.3820 (100%, [M + Na]<sup>+</sup>). Elemental analysis, calcd (%) for C<sub>26</sub>H<sub>48</sub>B<sub>10</sub>O<sub>10</sub>S<sub>1</sub>: C 47.26, H 7.32. Found: C 48.59, H 7.21.</div></div><div id="sec5_1_1_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 1,7-Bis(1′,2′,3′,4′-Di-<i>O</i>-isopropylidene-6′-deoxy-α-<span class="smallcaps smallerCapital">d</span>-galactopyranos-6′-yl)-9-(carboxymethylthio)-1,7-dicarba-<i>closo</i>-dodecaborane(12) (<b>8</b>, Gal′<sub>2</sub>-Cb)</h3><div class="NLM_p last">The synthesis of building block <b>8</b> from intermediate <b>7</b> is performed according to the procedure for building block <b>5</b>. Carborane <b>8</b> was obtained in a yield of 1.06 g (1.43 mmol, 47%). <i>R<sub>f</sub></i> = 0.38 (<i>n-</i>hexane/ethyl acetate 1:1, v/v). <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ = 1.31 (s, 6H), 1.33 (s, 6H), 1.41 (s, 6H), 1.57 and 1.58 (s, 6H), 1.59–3.47 (br<sup>a</sup>, 9H), 2.19 (ddd, <sup>2</sup><i>J</i><sub>HH</sub> = 15.8 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 5.8 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = −3.0 Hz 2H), 2.32 (virtual dd, <sup>2</sup><i>J</i><sub>HH</sub> = 15.8 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 8.4 Hz, 2H), 3.38 (δ, <sup>3</sup><i>J</i><sub>HH</sub> = 6.9 Hz, s, 2H), 3.71 (br d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.1 Hz, 2H), 4.07 (dt, <sup>3</sup><i>J</i><sub>HH</sub> = 7.9 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 1.9 Hz, 2H) 4.27 (dd, <sup>3</sup><i>J</i><sub>HH</sub> = 5.1 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 2.4 Hz, 2H), 4.57 (dd, <sup>3</sup><i>J</i><sub>HH</sub> = 7.9 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 2.4 Hz, 2H), 5.50 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 5.1 Hz, 2H) ppm; <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>): d = 24.4 (s), 25.1 (s), 26.0 (s), 26.1 (s), 34.8 (s), 33.0 (s), 67.0 (s), 70.2 (s), 71.0 (s), 72.92 and 72.94 (s), 73.2 (s), 96.6 (s), 108.87 and 108.89 (s), 109.4 (s), 171.2 (s) ppm; <sup>11</sup>B{<sup>1</sup>H} NMR (CDCl<sub>3</sub>): d = −1.1 (s, 1B), −2.0 to −20.0 (br<sup>a</sup>, 9B) ppm; <sup>11</sup>B NMR (CDCl<sub>3</sub>): δ = −1.3 (s, 1B), −5.0 to −16.0 (br<sup>a</sup>, 9B) ppm. IR (KBr): ν̃ = 3445 (br, m), 2989 (m), 2936 (m), 2596 (m), 1714 (m), 1636 (w), 1457 (w), 1426 (w), 1383 (m), 1257 (m), 1213 (s), 1168 (m), 1107 (m), 1070 (s), 1003 (m), 919 (w), 898 (m), 803 (w), 774 (m), 648 (w), 511 (w) cm<sup>–1</sup>. MS (HR-ESI, positive mode): <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>50</sub>B<sub>10</sub>O<sub>12</sub>SNa, 742.3888 (100% [M + Na]<sup>+</sup>); found, 742.3901 (100% [M + Na]<sup>+</sup>). Elemental analysis, calcd (%) for C<sub>28</sub>H<sub>50</sub>B<sub>10</sub>O<sub>12</sub>S<sub>1</sub>: C 46.78, H 7.01. Found: C 46.51, H 7.14.</div></div><div id="sec5_2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Peptide Synthesis. Materials</h3><div class="NLM_p last">9-Fluorenylmethoxycarbonyl (Fmoc)- and <i>tert</i>-butyloxycarbonyl (Boc)-protected amino acids were purchased from Orpegen OPC (Heidelberg, Germany), Iris Biotech (Marktredwitz, Germany), and Sigma-Aldrich (Taufkirchen, Germany). NovaSyn TGR R resin was from Novabiochem (Darmstadt, Germany), and 1-hydroxybenzotriazole (HOBt), <i>N</i>,<i>N</i>′-diisopropylcarbodiimide (DIC) and ethyl 2-cyano-2-(hydroxyimino)acetate (Oxyma) were obtained from Iris Biotech. Acetonitrile (ACN) was from VWR (Darmstadt, Germany), and dimethylformamide (DMF) and dichloromethane (DCM) were obtained from Biosolve (Valkenswaard, The Netherlands). Dimethylsulfoxide (DMSO), hydrazine, piperidine, thioanisole (TA), triisopropylsilane (TIS), and trifluoroacetic acid (TFA) were purchased from Sigma-Aldrich. Thiocresole (TC) was from Alfa Aesar (Ward Hill, MA, USA), and diethyl ether was from Merck (Darmstadt, Germany). Hank’s balanced salt solution (HBSS) was obtained from Lonza (Basel, Switzerland).</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Synthesis</h3><div class="NLM_p last">Synthesis of peptides was performed by a combination of automated solid phase peptide synthesis (SPPS) using a SYRO I peptide synthesizer (MultiSynTech, Bochum, Germany) and manual SPPS. The Fmoc/<i>tert</i>-butyl (<i>t</i>Bu) strategy was applied, and a NovaSyn TGR R resin (15 μmol scale, 0.19 mmol/g) was used to obtain peptides with C-terminal amidation. All amino acids were <i>N</i><sub>α</sub>-Fmoc-protected except for the N-terminal amino acid of the peptide conjugates, which was <i>N</i><sub>α</sub>-Boc-protected. Full-length peptide backbones Boc-[F<sup>7</sup><sub>,</sub>K<sup>18</sup>(Dde),P<sup>34</sup>]-NPY, Boc-[K<sup>4,(18),(22),(26)</sup>(Dde),F<sup>7</sup>,P<sup>34</sup>]-NPY, and Boc-[K<sup>4,18</sup>(Dde),F<sup>7</sup>,K<sup>22</sup>(Mmt),P<sup>34</sup>]-NPY were prepared by automated SPPS. In the automated synthesis, an 8-fold molar excess of amino acid was coupled with equimolar amounts of Oxyma and DIC (8 equiv, 120 μmol) in DMF for 2 × 40 min. Cleavage of the N-terminal Fmoc protecting group was performed with 40% (v/v) piperidine in DMF for 3 min and again 20% (v/v) piperidine in DMF for 10 min. The 4,4-dimethyl-2,6-dioxocyclohex-1-ylidenethyl (Dde) protecting group at the ε-amino group of lysine residues was removed with 3% (v/v) hydrazine in DMF for 12 × 10 min. The branching unit Fmoc-<span class="smallcaps smallerCapital">l</span>-Dap(Fmoc)-OH was coupled manually in 3-fold molar excess per free amino group with equimolar amounts of HOBt and DIC (3 equiv per free amino group) in DMF for at least 2 h. Manual Fmoc deprotection was accomplished with 30% piperidine in DMF twice for 12 min. <b>3</b> was coupled manually in 3-fold molar excess per free amino group with HOBt and DIC (5 equiv per free amino group) in DMF overnight at room temperature. Carborane synthons <b>5</b> and <b>8</b> were coupled manually in 1.5-fold molar excess per free amino group with HOBt and DIC (2 equiv per free amino group) in DMF overnight. To gain TAMRA-modified conjugates, selective Mmt cleavage was performed after successful carborane incorporation. The Mmt protecting group was removed by treating the resin 15 times for 1 min with the cleavage cocktail (3% TFA, 5% TIS in DCM, v/v/v). After the cleavage was complete, the resin was incubated for 10 min with 2.5% DIPEA in DCM (v/v) twice. Next, TAMRA was coupled to the free ε-amino group of the lysine by using 1.9 equiv of HATU and 2 equiv of TAMRA and DIPEA in DMF overnight. Finally, the cleavage from the resin and simultaneous side chain deprotection was accomplished using a mixture of TFA/TA/TC (90:5:5, v/v) for peptides <b>10</b>–<b>12</b>, TFA/H<sub>2</sub>O (95:5, v/v) for peptides <b>13</b>–<b>20</b>, and TFA/H<sub>2</sub>O/TIS (90:5:5, v/v/v) for conjugates <b>21</b> and <b>22.</b> After incubation for 2 h, the crude peptides were precipitated in ice-cold diethyl ether, washed, dissolved in ACN/H<sub>2</sub>O, and subsequently lyophilized. Purification of the crude peptides was achieved by preparative reversed-phase (RP)-HPLC using a Phenomenex Kinetex 5u XB-C18 (250 mm × 21.2 mm, 5 μm, 100 Å), a Phenomenex Kinetex 5u Biphenyl (250 mm × 21.2 mm, 5 μm, 100 Å), or a Phenomenex Aeris 3.6u PEPTIDE XB-C18 (250 mm × 21.2 mm, 3.6 μm, 100 Å) column with a flow rate of 15 mL/min, linear gradients of eluent B (0.08% (v/v) TFA in ACN) in eluent A (0.1% (v/v) TFA in water), and detection at λ = 220 nm. The purity of the peptides was determined by analytical RP-HPLC using a Phenomenex Jupiter 4u Proteo C12 90 Å (250 mm × 4.6 mm, 4 μm, 90 Å, 0.6 mL/min) and a Phenomenex Aeris Peptide 3.6u XB-C18 (250 mm × 4.6 mm, 3.6 μm, 100 Å, 1.55 mL/min) or Agilent VariTide RPC (250 mm × 4.6 mm, 6 μm, 200 Å, 1.0 mL/min) column. Different linear gradients of eluent B in eluent A over 40 min were applied (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01136/suppl_file/jm9b01136_si_001.pdf" class="ext-link">Supporting Information, Table S1</a>), and chromatograms were recorded at λ = 220 nm. MALDI-ToF mass spectrometry (UltraflexIII, Bruker, Bremen, Germany) and ESI ion-trap (HCT, Bruker Daltonics) or ESI Orbitrap (Orbitrap Elite, Thermo Scientific) mass spectrometry were used to verify the identity of the pure peptides (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01136/suppl_file/jm9b01136_si_001.pdf" class="ext-link">Supporting Information, Table S2</a>). The observed signals were in agreement with the calculated masses, and a purity of ≥95% was confirmed using two analytical RP-HPLC columns for all peptides. All assays were performed with lyophilized peptide aliquots, which were generated by weighing in at least 1 mg of peptide with a calibrated high precision scale. The amount of attached TFA salt was considered according to the quantity of net positive charges, and the peptides were dissolved to a concentration of 100 μM and distributed in accordance to the desired peptide amount.</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Kinetic Solubility Assay</h3><div class="NLM_p last">Kinetic solubility was determined in a HPLC-based UV detection assay. Peptide compounds (20 nmol) were dissolved in DMSO to concentrations of 1 mM, 100 μM, and 10 μM. The three DMSO stock solutions were then used to generate a dilution series in two different solvent systems for each peptide. HBSS was used as aqueous buffer solution, and 30% acetonitrile in H<sub>2</sub>O was used as reference solvent to ensure full solubilization. Peptides were diluted in both solvents to concentrations of 25 μM, 10 μM, 1 μM, and 100 nM in a sample volume of 200 μL each. Samples were incubated for 1 h at 37 °C in a dry block heater, subsequently transferred into Costar Spin-X centrifuge filter tubes (cellulose acetate, 0.22 μm pore size), and centrifuged. The flow-through of each sample was analyzed by analytical RP-HPLC using an Agilent Varitide RPC column (250 mm × 4.6 mm, 6 μm, 200 Å) with a flow rate of 1 mL/min and a linear gradient of 30–70% eluent B (0.08% (v/v) TFA in ACN) in eluent A (0.01% (v/v) TFA in water) over 30 min. Chromatograms were recorded at λ = 220 nm. For quantification, the area under the peaks in the chromatograms was determined by integration.</div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Blood Plasma Stability Assay</h3><div class="NLM_p last">Fluorescently labeled peptides were incubated at a concentration of 10<sup>–5</sup> M in human blood plasma under constant shaking at 37 °C. Samples (100 μL) were taken at the start and at additional time points during the incubation and precipitated for at least 1 h at −20 °C with 100 μL of ACN (5% TFA, v/v). After a first centrifugation step for 30 s at 14 000 rpm, the supernatant was diluted with 100 μL of H<sub>2</sub>O, and centrifuged again for 1 h at 12 000 rpm using Costar Spin-X centrifuge tube filters (0.22 μm). The fluorescence emission of the peptide solutions was detected by RP-HPLC at λ = 573 nm using linear gradients of eluent B in A (eluent A = 0.1% TFA in water; eluent B = 0.08% TFA in ACN) on a Agilent VariTide RPC column (250 mm × 4.6 mm, 6 μm, 200 Å, Agilent, Santa Clara, USA). Peak areas were normalized to the starting peak, and the half-life was calculated by one-phase decay analysis with GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA). The data points represent the mean ± SEM of at least two independent experiments.</div></div><div id="sec5_3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Biological Methods. Materials</h3><div class="NLM_p last">HEK293 cells were obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ) and authenticated by short tandem repeat-profiling. COS-7 cells were purchased from American Type Culture Collection (ATCC), and species specificity was verified by COI DNA barcoding. MCF-7 cells were obtained from DSMZ. Dulbecco’s modified Eagle’s medium (DMEM), Dulbecco’s phosphate buffered saline (DPBS), Ham’s F12, and trypsin/EDTA were purchased from Lonza. Fetal calf serum (FCS) was obtained from Biochrom (Berlin, Germany), hygromycin B was purchased from InvivoGen (San Diego, CA, USA), and G-418-sulfate was from Merck. Opti-MEM was purchased from Life Technologies (Carlsbad, CA, USA) and Hoechst 33342, and LiCl and resazurin (in vitro toxicology assay kit) were purchased from Sigma-Aldrich. [2-<sup>3</sup>H]-<i>myo</i>-Inositol was obtained from PerkinElmer (Waltham, MA, USA), and bovine serum albumin (BSA) was from Roth (Karlsruhe, Germany).</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Cell Culture</h3><div class="NLM_p last">All cell lines were maintained under humidified atmosphere at 37 °C and 5% CO<sub>2</sub> in 75 cm<sup>2</sup> cell culture flasks and routinely tested for mycoplasma contamination. HEK293 cells stably expressing the hY<sub>1</sub>R, hY<sub>2</sub>R, hY<sub>4</sub>R, or hY<sub>5</sub>R, C-terminally fused to the enhanced yellow fluorescent protein (eYFP), were cultured in DMEM/Ham’s F12 (1:1, v/v) supplemented with 15% (v/v) FCS and hygromycin (100 μg mL<sup>–1</sup>). Nontransfected HEK293 cells were cultured in DMEM/Ham’s F12 (1:1, v/v) supplemented with 15% (v/v) FCS. COS-7 cells, stably coexpressing either the hY<sub>1</sub>R or hY<sub>2</sub>R, C-terminally fused to eYFP, and the chimeric G protein Gα<sub>Δ6qi4myr</sub>, were cultured in DMEM high glucose supplemented with 10% (v/v) FCS, hygromycin B (133 μg mL<sup>–1</sup>), and G-418-sulfate (1.5 mg mL<sup>–1</sup>). MCF-7 cells were cultured in DMEM/Ham’s F12 (1:1, v/v) supplemented with 10% (v/v) FCS.</div></div><div id="sec5_3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Inositol Phosphate Accumulation Assay</h3><div class="NLM_p last">Inositol phosphate (IP) accumulation assay for the determination of receptor activation was carried out as described previously.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> Briefly, COS-7 cells stably co-transfected with the hY<sub>1</sub>R or hY<sub>2</sub>R and the chimeric G protein Gα<sub>Δ6qi4myr</sub> was seeded in 48-well plates (60 000 cells/well) and cultured overnight. Cells were labeled with [2-<sup>3</sup>H]-<i>myo</i>-inositol (2 μCi mL<sup>–1</sup>) in medium without penicillin and streptomycin overnight and stimulated with different peptide concentrations in DMEM supplemented with 10 mM LiCl and 0.1% (w/v) BSA for 1 h at 37 °C. Compounds were typically tested in a concentration range from 10<sup>–5</sup> M to 10<sup>–11</sup> M in duplicate. Radioactive IP species were isolated by anion-exchange chromatography and measured by scintillation counting. Data analysis was performed with GraphPad Prism 5.03. Obtained raw dpm values were normalized to NPY, and EC<sub>50</sub> and pEC<sub>50</sub> values were calculated from sigmoidal concentration–response curves. Each peptide was tested at least two times independently.</div></div><div id="sec5_3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Inositol Monophosphate Accumulation (IP-One) Assay</h3><div class="NLM_p last">The inositol phosphate (IP)-One assay was performed as described previously.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> In short, COS-7 cells, stably co-transfected with hY<sub>1</sub>R-eYFP or hY<sub>2</sub>R-eYFP and a chimeric G-protein (G<sub>αΔ6qi4myr</sub>), were seeded in a white 384-well plate (5000–7500 cells/well) and grown for 24 h under humidified atmosphere at 37 °C and 5% CO<sub>2</sub>. On the following day, the medium was removed by flipping the plate upside down and the cells were stimulated with increasing concentrations of peptide in HBSS supplemented with 20 mM LiCl for 1 h at 37 °C and 5% CO<sub>2</sub>. Peptides were tested in a concentration range from 10<sup>–5</sup> M to 10<sup>–13</sup> M in triplicate. Generated inositol monophosphate was subsequently quantified by using the Cisbio IP-One Gq HTRF assay kit (Cisbio, Codolet, France) according to the manufacturer’s instructions. For the assay read-out, a Tecan Spark microplate reader was used. Data analysis was performed with GraphPad Prism 5.03. Obtained HTRF values for the compounds were normalized to NPY, and EC<sub>50</sub> and pEC<sub>50</sub> values were calculated from sigmoidal concentration–response curves. Each peptide was tested at least two times independently.</div></div><div id="sec5_3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Internalization Studies</h3><div class="NLM_p last">HEK293 cells stably transfected with the hY<sub>1</sub>R, hY<sub>2</sub>R, hY<sub>4</sub>R, or hY<sub>5</sub>R, C-terminally fused to eYFP, were seeded into ibiTreat 8-well μ-slides (ibidi, Martinsried, Germany) at a density of 300 000 cells/well and cultured for 24 h until the cells reached confluency. MCF-7 cells were seeded accordingly at a density of 120 000 cells/well. The medium was aspirated, and the cells were starved in 200 μL of Opti-MEM with 1 μL of nuclear stain Hoechst 33342 (0.5 mg mL<sup>–1</sup>) for 30 min under standard incubation conditions. For nonstimulated cells, the solution was aspirated and 200 μL Opti-MEM was added. For testing the receptor internalization of the NPY analogs, the starving medium was aspirated and an amount of 200 μL of Opti-MEM containing 100 nM peptide (hY<sub>1</sub>R, hY<sub>4</sub>R, and hY<sub>5</sub>R) or 1 μM peptide (hY<sub>2</sub>R) was added to the cells. After 1 h of stimulation at 37 °C, the cells were washed once and maintained in Opti-MEM. A Zeiss Axio Observer microscope with an ApoTome.2 imaging system and a 63× immersion oil objective was used for fluorescence image acquisition. The nuclear stain Hoechst 33342 was visualized by the DAPI filter (excitation 335–383 nm; emission 420–470 nm) and the eYFP-tag on the receptor by the YFP filter (excitation 488–512 nm; emission 520–550 nm). Image processing was performed with Zeiss ZEN 2 software.</div></div><div id="sec5_3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Cytotoxicity Assay</h3><div class="NLM_p last">Cytotoxicity was evaluated by resazurin assay. MCF-7 (20 000 cells/well) cells were seeded in a 96-well plate and cultured overnight. Peptide dilutions were prepared in HBSS (max 0.5% DMSO, v/v) and added to the cells reaching final concentrations of 0.1 μM, 1 μM, or 10 μM in duplicate. As negative control, cells were treated with 0.5% (v/v) DMSO in HBSS only. After incubation for 48 h at 37 °C, stimulation medium was aspirated and cells were incubated with 10% (v/v) resazurin solution in HBSS for 1 h at 37 °C. As positive control, cells were treated with 70% (v/v) ethanol in water for 10 min prior to the resazurin incubation. A Tecan Infinite M200 plate reader (Tecan, Männedorf, Switzerland) was used for the detection of the fluorescence of the formed resorufin in vital cells (excitation, 550 nm; emission, 595 nm). Measurements were normalized to only medium-treated cells (100% cell viability) and cells treated with 70% (v/v) ethanol (0% cell viability). Experiments were performed three times independently.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35"><a href="/doi/suppl/10.1021/acs.jmedchem.9b01136" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21763" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21763" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b01136" class="ext-link">10.1021/acs.jmedchem.9b01136</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Structural Characterisation of synthesized building blocks; structures of synthesized peptide conjugates; RP-HPLC pure analytics of all synthesized peptide conjugates; biological characterization of conjugates <b>10</b>, <b>11</b>, <b>12</b>, and <b>14</b>; reversed phase chromatograms of the kinetic solubility assay; receptor activation properties of conjugate <b>22</b>; analytical characterization of synthesized peptides (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01136/suppl_file/jm9b01136_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01136/suppl_file/jm9b01136_si_001.pdf">jm9b01136_si_001.pdf (1.94 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b01136" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48201" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48201" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Annette G. Beck-Sickinger</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biochemistry, Leipzig University, Brüderstrasse 34, 04103 Leipzig, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4560-8020" title="Orcid link">http://orcid.org/0000-0003-4560-8020</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#31505354525a1c4258525a585f56544371445f581c5d5458414b58561f5554"><span class="__cf_email__" data-cfemail="75141710161e58061c161e1c1b12100735001b1c5819101c050f1c125b1110">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dennis J. Worm</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biochemistry, Leipzig University, Brüderstrasse 34, 04103 Leipzig, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul Hoppenz</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biochemistry, Leipzig University, Brüderstrasse 34, 04103 Leipzig, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sylvia Els-Heindl</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biochemistry, Leipzig University, Brüderstrasse 34, 04103 Leipzig, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin Kellert</span> - <span class="hlFld-Affiliation affiliation">Institute
of Inorganic Chemistry, Leipzig University, Johannisallee 29, 04103 Leipzig, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert Kuhnert</span> - <span class="hlFld-Affiliation affiliation">Institute
of Inorganic Chemistry, Leipzig University, Johannisallee 29, 04103 Leipzig, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stefan Saretz</span> - <span class="hlFld-Affiliation affiliation">Institute
of Inorganic Chemistry, Leipzig University, Johannisallee 29, 04103 Leipzig, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Johannes Köbberling</span> - <span class="hlFld-Affiliation affiliation">Bayer
AG, Aprather Weg 18A, 42113 Wuppertal, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bernd Riedl</span> - <span class="hlFld-Affiliation affiliation">Bayer
AG, Aprather Weg 18A, 42113 Wuppertal, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Evamarie Hey-Hawkins</span> - <span class="hlFld-Affiliation affiliation">Institute
of Inorganic Chemistry, Leipzig University, Johannisallee 29, 04103 Leipzig, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4267-0603" title="Orcid link">http://orcid.org/0000-0003-4267-0603</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>D.J.W. and P.H. contributed equally.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): The work was partly supported by Bayer AG. This work was further supported by the European Union, the Federal State of Saxony, and the European Regional Development Fund.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i37">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64311" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64311" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Ronny Müller, Christina Dammann, Kristin Löbner, and Regina Reppich-Sacher for expert technical assistance. Funding by the “Europäischer Fonds für Regionale Entwicklung (EFRE)”, the European Union, the Free State of Saxony (ESF), and the German Science Foundation SFB1052 as well as the Graduate School “Leipzig School of Natural Sciences—Building with Molecules and Nano-Objects” (BuildMoNa) is gratefully acknowledged.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ACN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">ATCC</td><td class="NLM_def"><p class="first last">American Type Culture Collection</p></td></tr><tr><td class="NLM_term">BNCT</td><td class="NLM_def"><p class="first last">boron neutron capture therapy</p></td></tr><tr><td class="NLM_term">Boc</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyloxycarbonyl</p></td></tr><tr><td class="NLM_term">BPA</td><td class="NLM_def"><p class="first last"><span class="smallcaps smallerCapital">l</span>-boronophenylalanine</p></td></tr><tr><td class="NLM_term">BSA</td><td class="NLM_def"><p class="first last">bovine serum albumin</p></td></tr><tr><td class="NLM_term">BSH</td><td class="NLM_def"><p class="first last">sodium mercaptoundecahydro-<i>closo</i>-dodecaborate</p></td></tr><tr><td class="NLM_term"><i>t</i>Bu</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyl</p></td></tr><tr><td class="NLM_term">calcd</td><td class="NLM_def"><p class="first last">calculated</p></td></tr><tr><td class="NLM_term">Cb</td><td class="NLM_def"><p class="first last">carborane</p></td></tr><tr><td class="NLM_term">COS-7</td><td class="NLM_def"><p class="first last">African green monkey kidney cell</p></td></tr><tr><td class="NLM_term">CPP</td><td class="NLM_def"><p class="first last">cell-penetrating peptide</p></td></tr><tr><td class="NLM_term">Dap</td><td class="NLM_def"><p class="first last">(2<i>S</i>)-2,3-diaminopropionic acid</p></td></tr><tr><td class="NLM_term">DAPI</td><td class="NLM_def"><p class="first last">4′,6-diamidino-2-phenylindole</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane, CH<sub>2</sub>Cl<sub>2</sub></p></td></tr><tr><td class="NLM_term">Dde</td><td class="NLM_def"><p class="first last">1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl</p></td></tr><tr><td class="NLM_term">DIC</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>′-diisopropylcarbodiimide</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DMEM</td><td class="NLM_def"><p class="first last">Dulbecco’s modified Eagle’s medium</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">DNA</td><td class="NLM_def"><p class="first last">deoxyribonucleic acid</p></td></tr><tr><td class="NLM_term">dpm</td><td class="NLM_def"><p class="first last">disintegrations per minute</p></td></tr><tr><td class="NLM_term">DPBS</td><td class="NLM_def"><p class="first last">Dulbecco’s phosphate-buffered saline</p></td></tr><tr><td class="NLM_term">DSMZ</td><td class="NLM_def"><p class="first last">collection of microorganisms and cell cultures</p></td></tr><tr><td class="NLM_term">EC<sub>50</sub></td><td class="NLM_def"><p class="first last">half-maximal effective concentration</p></td></tr><tr><td class="NLM_term">ECL</td><td class="NLM_def"><p class="first last">extracellular loop</p></td></tr><tr><td class="NLM_term">EDTA</td><td class="NLM_def"><p class="first last">ethylenediaminetetraacetic acid</p></td></tr><tr><td class="NLM_term">EGF</td><td class="NLM_def"><p class="first last">epidermal growth factor</p></td></tr><tr><td class="NLM_term">equiv</td><td class="NLM_def"><p class="first last">equivalent</p></td></tr><tr><td class="NLM_term">ESI</td><td class="NLM_def"><p class="first last">electrospray ionization</p></td></tr><tr><td class="NLM_term">Et<sub>2</sub>O</td><td class="NLM_def"><p class="first last">diethyl ether</p></td></tr><tr><td class="NLM_term">eYFP</td><td class="NLM_def"><p class="first last">enhanced yellow fluorescent protein</p></td></tr><tr><td class="NLM_term">FCS</td><td class="NLM_def"><p class="first last">fetal calf serum</p></td></tr><tr><td class="NLM_term">Fmoc</td><td class="NLM_def"><p class="first last"><i>N</i><sub>α</sub>-9-fluorenylmethoxycarbonyl</p></td></tr><tr><td class="NLM_term">Gal</td><td class="NLM_def"><p class="first last">deoxygalactosyl</p></td></tr><tr><td class="NLM_term">G protein</td><td class="NLM_def"><p class="first last">heterotrimeric guanosine triphosphate-binding protein</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G-protein-coupled receptor</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxide hexafluorophosphate</p></td></tr><tr><td class="NLM_term">HBSS</td><td class="NLM_def"><p class="first last">Hank’s balanced salt solution</p></td></tr><tr><td class="NLM_term">HEK293</td><td class="NLM_def"><p class="first last">human embryonic kidney cell line</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last">1-hydroxybenzotriazole</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">HTRF</td><td class="NLM_def"><p class="first last">homogeneous time-resolved fluorescence</p></td></tr><tr><td class="NLM_term">hY<sub><i>x</i></sub>R</td><td class="NLM_def"><p class="first last">human Y<sub><i>x</i></sub>-receptor</p></td></tr><tr><td class="NLM_term">MALDI</td><td class="NLM_def"><p class="first last">matrix-assisted laser desorption/ionization</p></td></tr><tr><td class="NLM_term">MCF-7</td><td class="NLM_def"><p class="first last">human-derived breast cancer cell line</p></td></tr><tr><td class="NLM_term"><i>M</i><sub>exact</sub></td><td class="NLM_def"><p class="first last">monoisotopic mass</p></td></tr><tr><td class="NLM_term">MS</td><td class="NLM_def"><p class="first last">mass spectrometry</p></td></tr><tr><td class="NLM_term"><i>m</i>/<i>z</i></td><td class="NLM_def"><p class="first last">mass-to-charge ratio</p></td></tr><tr><td class="NLM_term">nd</td><td class="NLM_def"><p class="first last">not determined</p></td></tr><tr><td class="NLM_term">NPY</td><td class="NLM_def"><p class="first last">neuropeptide Y</p></td></tr><tr><td class="NLM_term">PYY</td><td class="NLM_def"><p class="first last">peptide YY</p></td></tr><tr><td class="NLM_term">RP</td><td class="NLM_def"><p class="first last">reversed-phase</p></td></tr><tr><td class="NLM_term">SEM</td><td class="NLM_def"><p class="first last">standard error of the mean</p></td></tr><tr><td class="NLM_term">SPPS</td><td class="NLM_def"><p class="first last">solid phase peptide synthesis</p></td></tr><tr><td class="NLM_term">TA</td><td class="NLM_def"><p class="first last">thioanisole</p></td></tr><tr><td class="NLM_term">TAMRA</td><td class="NLM_def"><p class="first last">6-carboxytetramethylrhodamine</p></td></tr><tr><td class="NLM_term">TC</td><td class="NLM_def"><p class="first last">thiocresol</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">TGR</td><td class="NLM_def"><p class="first last">TentaGel resin</p></td></tr><tr><td class="NLM_term">TIS</td><td class="NLM_def"><p class="first last">triisopropylsilane</p></td></tr><tr><td class="NLM_term">ToF</td><td class="NLM_def"><p class="first last">time-of-flight</p></td></tr><tr><td class="NLM_term"><i>t</i><sub>R</sub></td><td class="NLM_def"><p class="first last">retention time</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i39">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17834" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17834" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 73 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kratz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryppa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warnecke, A.</span></span> <span> </span><span class="NLM_article-title">Prodrug strategies in anticancer chemotherapy</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200700159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1002%2Fcmdc.200700159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=17963208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlt1KqsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=20-53&author=F.+Kratzauthor=I.+A.+M%C3%BCllerauthor=C.+Ryppaauthor=A.+Warnecke&title=Prodrug+strategies+in+anticancer+chemotherapy&doi=10.1002%2Fcmdc.200700159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Prodrug strategies in anticancer chemotherapy</span></div><div class="casAuthors">Kratz, Felix; Mueller, Ivonne A.; Ryppa, Claudia; Warnecke, Andre</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-53</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The majority of clin. approved anticancer drugs are characterized by a narrow therapeutic window that results mainly from a high systemic toxicity of the drugs in combination with an evident lack of tumor selectivity.  Besides the development of suitable galenic formulations such as liposomes or micelles, several promising prodrug approaches have been followed in the last decades with the aim of improving chemotherapy.  In this review we elucidate the two main concepts that underlie the design of most anticancer prodrugs: drug targeting and controlled release of the drug at the tumor site.  Consequently, active and passive targeting using tumor-specific ligands or macromol. carriers are discussed as well as release strategies that are based on tumor-specific characteristics such as low pH or the expression of tumor-assocd. enzymes.  Furthermore, other strategies such as ADEPT (antibody-directed enzyme prodrug therapy) and the design of self-eliminating structures are introduced.  Chem. realization of prodrug approaches is illustrated by drug candidates that have or may have clin. importance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7KWHTS-qaUbVg90H21EOLACvtfcHk0liKUuntXFgtPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlt1KqsrY%253D&md5=1f43c66a71a6291f392f01cc73380479</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200700159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200700159%26sid%3Dliteratum%253Aachs%26aulast%3DKratz%26aufirst%3DF.%26aulast%3DM%25C3%25BCller%26aufirst%3DI.%2BA.%26aulast%3DRyppa%26aufirst%3DC.%26aulast%3DWarnecke%26aufirst%3DA.%26atitle%3DProdrug%2520strategies%2520in%2520anticancer%2520chemotherapy%26jtitle%3DChemMedChem%26date%3D2008%26volume%3D3%26spage%3D20%26epage%3D53%26doi%3D10.1002%2Fcmdc.200700159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahrens, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellmann-Sickert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span></span> <span> </span><span class="NLM_article-title">Peptides and peptide conjugates: therapeutics on the upward path</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1567</span>– <span class="NLM_lpage">1586</span>, <span class="refDoi"> DOI: 10.4155/fmc.12.76</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.4155%2Ffmc.12.76" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=22917246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Gjtb3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=1567-1586&author=V.+M.+Ahrensauthor=K.+Bellmann-Sickertauthor=A.+G.+Beck-Sickinger&title=Peptides+and+peptide+conjugates%3A+therapeutics+on+the+upward+path&doi=10.4155%2Ffmc.12.76"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Peptides and peptide conjugates: therapeutics on the upward path</span></div><div class="casAuthors">Ahrens, Verena M.; Bellmann-Sickert, Kathrin; Beck-Sickinger, Annette G.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1567-1586</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The main benefit of natural peptides, peptide analogs and newly designed peptides as therapeutics, lies in their high selectivity and affinity, which are frequently in the nanomolar range.  New drugs targeting protein-protein interactions often require larger interaction sites than small mols. can offer.  Thus, many peptidic drugs are already applied in therapy at the current state.  The next generation of peptide-based therapeutic agents is currently on its way from basic research to clin. studies and eventually to the pharmaceutical market.  Development of more robust and long-lasting drugs owing to well-known and new stabilization strategies is yielding novel and continuously improving peptide drugs.  The introduction of smart linkers that exhibit stability towards blood plasma but intracellular lability will lead to target-oriented activity, which might successfully decrease side effects.  In this review, peptidic therapeutics on the market, in clin. studies and some of those in basic research are characterized.  Stabilization strategies and intelligent linkers are discussed with respect to their use in peptide drug therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaBOLVVLuwhLVg90H21EOLACvtfcHk0liB4KHqEjr5wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Gjtb3P&md5=1b7acc892ab2ee8a7473fac86d93c141</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.4155%2Ffmc.12.76&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.12.76%26sid%3Dliteratum%253Aachs%26aulast%3DAhrens%26aufirst%3DV.%2BM.%26aulast%3DBellmann-Sickert%26aufirst%3DK.%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26atitle%3DPeptides%2520and%2520peptide%2520conjugates%253A%2520therapeutics%2520on%2520the%2520upward%2520path%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2012%26volume%3D4%26spage%3D1567%26epage%3D1586%26doi%3D10.4155%2Ffmc.12.76" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mäde, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Els-Heindl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span></span> <span> </span><span class="NLM_article-title">Automated solid-phase peptide synthesis to obtain therapeutic peptides</span>. <i>Beilstein J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1197</span>– <span class="NLM_lpage">1212</span>, <span class="refDoi"> DOI: 10.3762/bjoc.10.118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.3762%2Fbjoc.10.118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=24991269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A280%3ADC%252BC2cfovFCnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=1197-1212&author=V.+M%C3%A4deauthor=S.+Els-Heindlauthor=A.+G.+Beck-Sickinger&title=Automated+solid-phase+peptide+synthesis+to+obtain+therapeutic+peptides&doi=10.3762%2Fbjoc.10.118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Automated solid-phase peptide synthesis to obtain therapeutic peptides</span></div><div class="casAuthors">Made Veronika; Els-Heindl Sylvia; Beck-Sickinger Annette G</div><div class="citationInfo"><span class="NLM_cas:title">Beilstein journal of organic chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1197-212</span>
        ISSN:<span class="NLM_cas:issn">1860-5397</span>.
    </div><div class="casAbstract">The great versatility and the inherent high affinities of peptides for their respective targets have led to tremendous progress for therapeutic applications in the last years.  In order to increase the drugability of these frequently unstable and rapidly cleared molecules, chemical modifications are of great interest.  Automated solid-phase peptide synthesis (SPPS) offers a suitable technology to produce chemically engineered peptides.  This review concentrates on the application of SPPS by Fmoc/t-Bu protecting-group strategy, which is most commonly used.  Critical issues and suggestions for the synthesis are covered.  The development of automated methods from conventional to essentially improved microwave-assisted instruments is discussed.  In order to improve pharmacokinetic properties of peptides, lipidation and PEGylation are described as covalent conjugation methods, which can be applied by a combination of automated and manual synthesis approaches.  The synthesis and application of SPPS is described for neuropeptide Y receptor analogs as an example for bioactive hormones.  The applied strategies represent innovative and potent methods for the development of novel peptide drug candidates that can be manufactured with optimized automated synthesis technologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQDzQldX7Z4YinGiHuhFGv8fW6udTcc2eYrpw46FKAGU7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfovFCnsA%253D%253D&md5=2cc3d20221e88f69c35f3ec1713f3d92</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.3762%2Fbjoc.10.118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3762%252Fbjoc.10.118%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25A4de%26aufirst%3DV.%26aulast%3DEls-Heindl%26aufirst%3DS.%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26atitle%3DAutomated%2520solid-phase%2520peptide%2520synthesis%2520to%2520obtain%2520therapeutic%2520peptides%26jtitle%3DBeilstein%2520J.%2520Org.%2520Chem.%26date%3D2014%26volume%3D10%26spage%3D1197%26epage%3D1212%26doi%3D10.3762%2Fbjoc.10.118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engel, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schally, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rieger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hönig, A.</span></span> <span> </span><span class="NLM_article-title">Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">652</span>– <span class="NLM_lpage">658</span>, <span class="refDoi"> DOI: 10.1021/mp0700514</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp0700514" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpt1GitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2007&pages=652-658&author=J.+B.+Engelauthor=A.+V.+Schallyauthor=J.+Dietlauthor=L.+Riegerauthor=A.+H%C3%B6nig&title=Targeted+therapy+of+breast+and+gynecological+cancers+with+cytotoxic+analogues+of+peptide+hormones&doi=10.1021%2Fmp0700514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Therapy of Breast and Gynecological Cancers with Cytotoxic Analogues of Peptide Hormones</span></div><div class="casAuthors">Engel, Joerg B.; Schally, Andrew V.; Dietl, Johannes; Rieger, Lorenz; Hoenig, Arnd</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">652-658</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review and discussion.  Gynecol. cancers such as breast, ovarian, and endometrial carcinoma express receptors for LH-releasing hormone (LHRH), bombesin/gastrin-releasing peptide (BN/GRP), and somatostatin (SST).  These tumors are therefore suitable candidates for targeted therapy with cytotoxic hybrid mols. consisting of a cytotoxic radical and a peptide hormone analog as a carrier.  These compds. have been shown to be more active and less toxic in vivo than nontargeted chemotherapy in models of various human cancers which express the resp. receptors.  The current review summarizes exptl. and clin. findings with cytotoxic peptide hormone analogs of LHRH (AN-152 [AEZS 108], AN-207), BN/GRP (AN-215), and SST (AN-238) in breast, ovarian, and endometrial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAD9SM0sGXh7Vg90H21EOLACvtfcHk0liB4KHqEjr5wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpt1GitL4%253D&md5=c1bcab69c621c220bd473316ec09d95a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fmp0700514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp0700514%26sid%3Dliteratum%253Aachs%26aulast%3DEngel%26aufirst%3DJ.%2BB.%26aulast%3DSchally%26aufirst%3DA.%2BV.%26aulast%3DDietl%26aufirst%3DJ.%26aulast%3DRieger%26aufirst%3DL.%26aulast%3DH%25C3%25B6nig%26aufirst%3DA.%26atitle%3DTargeted%2520therapy%2520of%2520breast%2520and%2520gynecological%2520cancers%2520with%2520cytotoxic%2520analogues%2520of%2520peptide%2520hormones%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2007%26volume%3D4%26spage%3D652%26epage%3D658%26doi%3D10.1021%2Fmp0700514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okarvi, S. M.</span></span> <span> </span><span class="NLM_article-title">Peptide-based radiopharmaceuticals and cytotoxic conjugates: potential tools against cancer</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1016/j.ctrv.2007.07.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1016%2Fj.ctrv.2007.07.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=17870245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVKht7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2008&pages=13-26&author=S.+M.+Okarvi&title=Peptide-based+radiopharmaceuticals+and+cytotoxic+conjugates%3A+potential+tools+against+cancer&doi=10.1016%2Fj.ctrv.2007.07.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide-based radiopharmaceuticals and cytotoxic conjugates: Potential tools against cancer</span></div><div class="casAuthors">Okarvi, S. M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-26</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Summary: A hope for the diagnosis and treatment of cancer is the development of new tumor-specific peptide-based radiopharmaceuticals.  The overexpression of many peptide receptors on human tumors makes such receptors an attractive potential target for diagnostic imaging and radiotherapy with specifically designed radiolabeled peptides.  The use of solid-phase peptide synthesis, and the availability of a wide range of bifunctional chelating agents for the convenient radiolabeling of bioactive peptides with different radionuclides have produced a wide variety of medicinally useful peptide radiopharmaceuticals.  A few of these peptides, such as somatostatin, bombesin, cholecystokinin/gastrin, neurotensin and vasoactive intestinal peptide are currently under investigation for their possible clin. applications in nuclear oncol.  This article presents the recent development in radiolabeled small peptides, with major emphasis on somatostatin and bombesin analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnoWW9VaE3gbVg90H21EOLACvtfcHk0ljTVSfpVe_ADA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVKht7Y%253D&md5=f6c0694ef7afcf01fd010705928fedec</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2007.07.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2007.07.017%26sid%3Dliteratum%253Aachs%26aulast%3DOkarvi%26aufirst%3DS.%2BM.%26atitle%3DPeptide-based%2520radiopharmaceuticals%2520and%2520cytotoxic%2520conjugates%253A%2520potential%2520tools%2520against%2520cancer%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2008%26volume%3D34%26spage%3D13%26epage%3D26%26doi%3D10.1016%2Fj.ctrv.2007.07.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tatemoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlquist, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutt, V.</span></span> <span> </span><span class="NLM_article-title">Neuropeptide Y--a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>296</i></span>,  <span class="NLM_fpage">659</span>– <span class="NLM_lpage">660</span>, <span class="refDoi"> DOI: 10.1038/296659a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1038%2F296659a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=6896083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADyaL38XlsFKlt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=296&publication_year=1982&pages=659-660&author=K.+Tatemotoauthor=M.+Carlquistauthor=V.+Mutt&title=Neuropeptide+Y%2D%2Da+novel+brain+peptide+with+structural+similarities+to+peptide+YY+and+pancreatic+polypeptide&doi=10.1038%2F296659a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Neuropeptide Y.  A novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide</span></div><div class="casAuthors">Tatemoto, Kazuhiko; Carlquist, Mats; Mutt, Viktor</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">296</span>
        (<span class="NLM_cas:issue">5858</span>),
    <span class="NLM_cas:pages">659-61</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">A peptide amide thought to be peptide YY was isolated from exts. of porcine brain.  However, the peptide, although having distinct structural and biol. similarities to both peptide YY and pancreatic polypeptide, was shown to be a novel peptide which was designated neuropeptide Y.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUAmzxRfV_5rVg90H21EOLACvtfcHk0ljTVSfpVe_ADA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XlsFKlt78%253D&md5=a012588ed43cc6a6de7afb974b703e4b</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2F296659a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F296659a0%26sid%3Dliteratum%253Aachs%26aulast%3DTatemoto%26aufirst%3DK.%26aulast%3DCarlquist%26aufirst%3DM.%26aulast%3DMutt%26aufirst%3DV.%26atitle%3DNeuropeptide%2520Y--a%2520novel%2520brain%2520peptide%2520with%2520structural%2520similarities%2520to%2520peptide%2520YY%2520and%2520pancreatic%2520polypeptide%26jtitle%3DNature%26date%3D1982%26volume%3D296%26spage%3D659%26epage%3D660%26doi%3D10.1038%2F296659a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larhammar, D.</span></span> <span> </span><span class="NLM_article-title">Evolution of neuropeptide Y, peptide YY and pancreatic polypeptide</span>. <i>Regul. Pept.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1016/0167-0115(95)00169-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1016%2F0167-0115%2895%2900169-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=8738876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADyaK28XjtFWit7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=1996&pages=1-11&author=D.+Larhammar&title=Evolution+of+neuropeptide+Y%2C+peptide+YY+and+pancreatic+polypeptide&doi=10.1016%2F0167-0115%2895%2900169-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Evolution of neuropeptide Y, peptide YY and pancreatic polypeptide</span></div><div class="casAuthors">Larhammar, Dan</div><div class="citationInfo"><span class="NLM_cas:title">Regulatory Peptides</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-11</span>CODEN:
                <span class="NLM_cas:coden">REPPDY</span>;
        ISSN:<span class="NLM_cas:issn">0167-0115</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review, with 104 refs., on the evolution of the title peptides in vertebrates and invertebrates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOOam8F5YOF7Vg90H21EOLACvtfcHk0ljTVSfpVe_ADA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjtFWit7g%253D&md5=39c1e52b9dc19fbfaea51904839f1228</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2F0167-0115%2895%2900169-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0167-0115%252895%252900169-7%26sid%3Dliteratum%253Aachs%26aulast%3DLarhammar%26aufirst%3DD.%26atitle%3DEvolution%2520of%2520neuropeptide%2520Y%252C%2520peptide%2520YY%2520and%2520pancreatic%2520polypeptide%26jtitle%3DRegul.%2520Pept.%26date%3D1996%26volume%3D62%26spage%3D1%26epage%3D11%26doi%3D10.1016%2F0167-0115%2895%2900169-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michel, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doods, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herzog, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larhammar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quirion, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westfall, T.</span></span> <span> </span><span class="NLM_article-title">XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">143</span>– <span class="NLM_lpage">150</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=9549761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADyaK1cXitlylsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1998&pages=143-150&author=M.+C.+Michelauthor=A.+G.+Beck-Sickingerauthor=H.+Coxauthor=H.+N.+Doodsauthor=H.+Herzogauthor=D.+Larhammarauthor=R.+Quirionauthor=T.+Schwartzauthor=T.+Westfall&title=XVI.+International+Union+of+Pharmacology+recommendations+for+the+nomenclature+of+neuropeptide+Y%2C+peptide+YY%2C+and+pancreatic+polypeptide+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">XVI. International union of pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors</span></div><div class="casAuthors">Michel, Martin C.; Beck-Sickinger, Annette; Cox, Helen; Doods, Henri N.; Herzog, Herbert; Larhammar, Dan; Quirion, Remi; Schwartz, Thue; Westfall, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">143-150</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">A review with ∼80 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_xqi5KSXmjLVg90H21EOLACvtfcHk0lj3Cy9fZhr8Dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXitlylsrc%253D&md5=a7fef0f0217b7cef340130fb94989b7a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMichel%26aufirst%3DM.%2BC.%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26aulast%3DCox%26aufirst%3DH.%26aulast%3DDoods%26aufirst%3DH.%2BN.%26aulast%3DHerzog%26aufirst%3DH.%26aulast%3DLarhammar%26aufirst%3DD.%26aulast%3DQuirion%26aufirst%3DR.%26aulast%3DSchwartz%26aufirst%3DT.%26aulast%3DWestfall%26aufirst%3DT.%26atitle%3DXVI.%2520International%2520Union%2520of%2520Pharmacology%2520recommendations%2520for%2520the%2520nomenclature%2520of%2520neuropeptide%2520Y%252C%2520peptide%2520YY%252C%2520and%2520pancreatic%2520polypeptide%2520receptors%26jtitle%3DPharmacol.%2520Rev.%26date%3D1998%26volume%3D50%26spage%3D143%26epage%3D150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stichel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span></span> <span> </span><span class="NLM_article-title">Molecular recognition of the NPY hormone family by their receptors</span>. <i>Nutrition</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">907</span>– <span class="NLM_lpage">917</span>, <span class="refDoi"> DOI: 10.1016/j.nut.2008.06.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1016%2Fj.nut.2008.06.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=18725086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVent7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2008&pages=907-917&author=D.+Lindnerauthor=J.+Stichelauthor=A.+G.+Beck-Sickinger&title=Molecular+recognition+of+the+NPY+hormone+family+by+their+receptors&doi=10.1016%2Fj.nut.2008.06.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular recognition of the NPY hormone family by their receptors</span></div><div class="casAuthors">Lindner, Diana; Stichel, Jan; Beck-Sickinger, Annette G.</div><div class="citationInfo"><span class="NLM_cas:title">Nutrition (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">907-917</span>CODEN:
                <span class="NLM_cas:coden">NUTRER</span>;
        ISSN:<span class="NLM_cas:issn">0899-9007</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Many G-protein-coupled receptors belong to families of different receptor subtypes, which are recognized by a variety of distinct ligands.  We summarize the current state of the art of the multireceptor/multiligand system of the so-called Y-receptor family.  This family consists of four G-protein-coupled Y receptors in humans (hY1, hY2, hY4, and hY5) and is activated by the so-called neuropeptide Y hormone family, which consists of three native peptide ligands named neuropeptide Y, pancreatic polypeptide, and peptide YY.  We recently reported that one conserved aspartate residue in the third extracellular loop is essential for ligand binding in all four Y receptors, but binds the endogenous ligands in a different mode by interacting with different ligand arginine residues.  By combining peptide synthesis to obtain chem. modified neuropeptide Y, peptide YY, and pancreatic polypeptide analogs, receptor mutagenesis, and receptor chimeras, we could trace binding and signaling to a mol. level.  The data on the variation of the ligands and an overview of the currently known mutagenesis data are summarized and specific models for the binding mode of the three ligands in all four receptors are provided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXmabT3Bi7p7Vg90H21EOLACvtfcHk0lj3Cy9fZhr8Dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVent7vM&md5=f4a221a59d63a3d5ffaea5e3ece25d89</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.nut.2008.06.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nut.2008.06.025%26sid%3Dliteratum%253Aachs%26aulast%3DLindner%26aufirst%3DD.%26aulast%3DStichel%26aufirst%3DJ.%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26atitle%3DMolecular%2520recognition%2520of%2520the%2520NPY%2520hormone%2520family%2520by%2520their%2520receptors%26jtitle%3DNutrition%26date%3D2008%26volume%3D24%26spage%3D907%26epage%3D917%26doi%3D10.1016%2Fj.nut.2008.06.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Böhme, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stichel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walther, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mörl, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span></span> <span> </span><span class="NLM_article-title">Agonist induced receptor internalization of neuropeptide Y receptor subtypes depends on third intracellular loop and C-terminus</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1740</span>– <span class="NLM_lpage">1749</span>, <span class="refDoi"> DOI: 10.1016/j.cellsig.2008.05.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1016%2Fj.cellsig.2008.05.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=18598760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A280%3ADC%252BD1crjtFSltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2008&pages=1740-1749&author=I.+B%C3%B6hmeauthor=J.+Stichelauthor=C.+Waltherauthor=K.+M%C3%B6rlauthor=A.+G.+Beck-Sickinger&title=Agonist+induced+receptor+internalization+of+neuropeptide+Y+receptor+subtypes+depends+on+third+intracellular+loop+and+C-terminus&doi=10.1016%2Fj.cellsig.2008.05.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Agonist induced receptor internalization of neuropeptide Y receptor subtypes depends on third intracellular loop and C-terminus</span></div><div class="casAuthors">Bohme Ilka; Stichel Jan; Walther Cornelia; Morl Karin; Beck-Sickinger Annette G</div><div class="citationInfo"><span class="NLM_cas:title">Cellular signalling</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1740-9</span>
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    </div><div class="casAbstract">Agonist stimulation of G-protein coupled receptors (GPCRs) results in the redistribution of the receptor from the cell surface into intracellular compartments through the process of endocytosis.  Monitoring ligand-mediated internalization of GPCRs in living cells has become experimentally accessible by applying fluorescent reagents and fluorescence microscopy.  By using cell lines that transiently, stably or endogenously express the human Y receptor (hYR) subtypes hY(1)R, hY(2)R, hY(4)R and hY(5)R and differently fluorescently tagged receptor proteins we were able to unravel further details concerning the internalization behavior of this multi-receptor/multi-ligand system.  For the first time we could show that also the hY(2)R is internalized with a rate which is comparable to the hY(1)R and the hY(4)R.  In contrast, the hY(5)R was internalized much slower and the rate remained unaffected by co-expression with other hYR subtypes.  Furthermore receptor subtype co-expressing cells and selectively binding peptides revealed a receptor subtype selective internalization.  By using novel hY(5)/hY(2) receptor chimera the receptor subtype dependent differences in hY receptor internalization could be identified on a molecular level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS1_oavs96kyXO4gDb7JggCfW6udTcc2eZjrVTyShLuerntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1crjtFSltQ%253D%253D&md5=5eb7dfb86e75c35b92b95b5ee3775f39</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2008.05.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2008.05.017%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25B6hme%26aufirst%3DI.%26aulast%3DStichel%26aufirst%3DJ.%26aulast%3DWalther%26aufirst%3DC.%26aulast%3DM%25C3%25B6rl%26aufirst%3DK.%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26atitle%3DAgonist%2520induced%2520receptor%2520internalization%2520of%2520neuropeptide%2520Y%2520receptor%2520subtypes%2520depends%2520on%2520third%2520intracellular%2520loop%2520and%2520C-terminus%26jtitle%3DCell.%2520Signalling%26date%3D2008%26volume%3D20%26spage%3D1740%26epage%3D1749%26doi%3D10.1016%2Fj.cellsig.2008.05.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reubi, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gugger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waser, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaer, J. C. Y.</span></span> <span> </span><span class="NLM_article-title">Y(1)-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4636</span>– <span class="NLM_lpage">4641</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=11389101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD3MXktlWjsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=4636-4641&author=J.+C.+Reubiauthor=M.+Guggerauthor=B.+Waserauthor=J.+C.+Y.+Schaer&title=Y%281%29-mediated+effect+of+neuropeptide+Y+in+cancer%3A+breast+carcinomas+as+targets"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Y1-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets</span></div><div class="casAuthors">Reubi, Jean Claude; Gugger, Mathias; Waser, Beatrice; Schaer, Jean-Claude</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4636-4641</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Overexpression of selected peptide receptors in human tumors has been shown to represent clin. relevant targets for cancer diagnosis and therapy.  Neuropeptide Y (NPY) is a peptide neurotransmitter mediating feeding behavior and vasoconstriction.  It has never been shown to be involved in human cancer.  The authors show here, using in vitro receptor autoradiog., a NPY receptor incidence of 85% in primary human breast carcinomas and of 100% in lymph node metastases of receptor-pos. primaries, predominantly as Y1 subtype, whereas non-neoplastic human breast expressed Y2 preferentially.  Y1 mRNA was detected in Y1-expressing tumors by in situ hybridization, whereas Y2 mRNA was found in normal breast tissue.  The strong predominance of Y1 in breast carcinomas compared with Y2 in normal breast suggests that neoplastic transformation can switch the NPY receptor expression from Y2 to Y1 subtype.  Moreover, in Y1-expressing human SK-N-MC tumor cells, an NPY-induced, dose-dependent inhibition of tumor cell growth of >40% was obsd., suggesting a functional role of NPY in cancer, mediated by Y1.  NPY should therefore be added to the list of small regulatory peptides related to cancer.  The high incidence of Y1 in in situ, invasive, and metastatic breast cancers allows for the possibility to target them for diagnosis and therapy with NPY analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNp9iNJjyGQrVg90H21EOLACvtfcHk0lj3Cy9fZhr8Dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXktlWjsbo%253D&md5=cef7c485884a8e9c937aade3cfd45567</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DReubi%26aufirst%3DJ.%2BC.%26aulast%3DGugger%26aufirst%3DM.%26aulast%3DWaser%26aufirst%3DB.%26aulast%3DSchaer%26aufirst%3DJ.%2BC.%2BY.%26atitle%3DY%25281%2529-mediated%2520effect%2520of%2520neuropeptide%2520Y%2520in%2520cancer%253A%2520breast%2520carcinomas%2520as%2520targets%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D4636%26epage%3D4641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Körner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reubi, J. C.</span></span> <span> </span><span class="NLM_article-title">NPY receptors in human cancer</span>. <i>Peptides</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">419</span>– <span class="NLM_lpage">425</span>, <span class="refDoi"> DOI: 10.1016/j.peptides.2006.08.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1016%2Fj.peptides.2006.08.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=17223228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252FnsFyjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2007&pages=419-425&author=M.+K%C3%B6rnerauthor=J.+C.+Reubi&title=NPY+receptors+in+human+cancer&doi=10.1016%2Fj.peptides.2006.08.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">NPY receptors in human cancer: a review of current knowledge</span></div><div class="casAuthors">Korner Meike; Reubi Jean Claude</div><div class="citationInfo"><span class="NLM_cas:title">Peptides</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">419-25</span>
        ISSN:<span class="NLM_cas:issn">0196-9781</span>.
    </div><div class="casAbstract">Many peptide hormone receptors are over-expressed in human cancer, permitting an in vivo targeting of tumors for diagnostic and therapeutic purposes.  NPY receptors are novel and promising candidates in this field.  Using in vitro receptor autoradiography, Y1 and Y2 receptors have been found to be expressed in breast carcinomas, adrenal gland and related tumors, renal cell carcinomas, and ovarian cancers in both tumor cells and tumor-associated blood vessels.  Pathophysiologically, tumoral NPY receptors may be activated by endogenous NPY released from intratumoral nerve fibers or tumor cells themselves, and mediate NPY effects on tumor cell proliferation and tumoral blood supply.  Clinically, tumoral NPY receptors may be targeted with NPY analogs coupled with adequate radionuclides or cytotoxic agents for a scintigraphic tumor imaging and/or tumor therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQKRlaq_gfxtNyzdcP07UmufW6udTcc2eZJudi2prbRmrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252FnsFyjtA%253D%253D&md5=c9ee2ef8072c56a93aa0336d7826733f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.peptides.2006.08.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.peptides.2006.08.037%26sid%3Dliteratum%253Aachs%26aulast%3DK%25C3%25B6rner%26aufirst%3DM.%26aulast%3DReubi%26aufirst%3DJ.%2BC.%26atitle%3DNPY%2520receptors%2520in%2520human%2520cancer%26jtitle%3DPeptides%26date%3D2007%26volume%3D28%26spage%3D419%26epage%3D425%26doi%3D10.1016%2Fj.peptides.2006.08.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Söll, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinger, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundell, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larhammer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span></span> <span> </span><span class="NLM_article-title">Novel analogues of neuropeptide Y with a preference for the Y1-receptor</span>. <i>Eur. J. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>268</i></span>,  <span class="NLM_fpage">2828</span>– <span class="NLM_lpage">2837</span>, <span class="refDoi"> DOI: 10.1046/j.1432-1327.2001.02161.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1046%2Fj.1432-1327.2001.02161.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=11358498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD3MXktVSktrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=2001&pages=2828-2837&author=R.+M.+S%C3%B6llauthor=M.+C.+Dingerauthor=I.+Lundellauthor=D.+Larhammerauthor=A.+G.+Beck-Sickinger&title=Novel+analogues+of+neuropeptide+Y+with+a+preference+for+the+Y1-receptor&doi=10.1046%2Fj.1432-1327.2001.02161.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Novel analogues of neuropeptide Y with a preference for the Y1-receptor</span></div><div class="casAuthors">Soll, Richard M.; Dinger, Michaela C.; Lundell, Ingrid; Larhammer, Dan; Beck-Sickinger, Annette G.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">268</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2828-2837</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">Neuropeptide Y (NPY) is one of the most abundant neuropeptides in the mammalian brain and acts in humans via at least three receptor subtypes: Y1, Y2, and Y5.  Whereas selective agonists and antagonists are known for the Y2- and Y5-receptors, the Y1-receptor still lacks a highly selective agonist.  This work presents the first NPY-based analogs with Y1-receptor preference and agonistic properties.  Furthermore, the importance of specific amino acids of NPY for binding to the Y-receptor subtypes is presented.  Amongst the analogs tested, [Phe 7,Pro 34]pNPY (where pNPY is porcine neuropeptide Y) showed the most significant Y1-receptor preference (> 1: 3000-fold), with subnanomolar affinity to the Y1-receptor, and Ki values of ≈ 30 nM for the Y2- and Y5-subtype, resp.  Variations of position 6, esp. [Arg 6,Pro 34]pNPY and variations within positions 20-23 of NPY were found to result in further analogs with significant Y1-receptor preference (1: 400-1: 2000).  In contrast, cyclo S-S [Cys 20,Cys 24]pNPY was found to be a highly selective ligand at the Y2-receptor, binding only threefold less efficiently than NPY.  Analogs contg. variations of positions 31 and 32 showed highly reduced affinity to the Y1-receptor, while binding to the Y5-receptor was affected less.  Inhibition of cAMP-accumulation of selected peptides with replacements within position 20-23 of NPY showed preserved agonistic properties.  The NPY analogs tested give insights into ligand-receptor interaction of NPY at the Y1-, Y2- and Y5-receptor and contribute to the authors' understanding of subtype selectivity.  Furthermore, the Y1-receptor-preferring peptides are novel tools that will provide insight into the physiol. role of the Y1-receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtVDMFg8Gy5bVg90H21EOLACvtfcHk0lhu6oc-OmI50w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXktVSktrc%253D&md5=f1f262c1527c76ba3f43a7b8d84a2b41</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1046%2Fj.1432-1327.2001.02161.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1432-1327.2001.02161.x%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25B6ll%26aufirst%3DR.%2BM.%26aulast%3DDinger%26aufirst%3DM.%2BC.%26aulast%3DLundell%26aufirst%3DI.%26aulast%3DLarhammer%26aufirst%3DD.%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26atitle%3DNovel%2520analogues%2520of%2520neuropeptide%2520Y%2520with%2520a%2520preference%2520for%2520the%2520Y1-receptor%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D2001%26volume%3D268%26spage%3D2828%26epage%3D2837%26doi%3D10.1046%2Fj.1432-1327.2001.02161.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Böhme, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span></span> <span> </span><span class="NLM_article-title">Controlling toxicity of Peptide-drug conjugates by different chemical linker structures</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">804</span>– <span class="NLM_lpage">814</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201402514</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1002%2Fcmdc.201402514" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=25914147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A280%3ADC%252BC2MjnvFartA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=804-814&author=D.+B%C3%B6hmeauthor=A.+G.+Beck-Sickinger&title=Controlling+toxicity+of+Peptide-drug+conjugates+by+different+chemical+linker+structures&doi=10.1002%2Fcmdc.201402514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Controlling toxicity of Peptide-drug conjugates by different chemical linker structures</span></div><div class="casAuthors">Bohme David; Beck-Sickinger Annette G</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">804-14</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The side effects of chemotherapy can be overcome by linking toxic agents to tumor-targeting peptides with cleavable linkers.  Herein, this concept is demonstrated by addressing the human Y1 receptor (hY1 R), overexpressed in breast tumors, with analogues of the hY1 R-preferring [F(7) ,P(34) ]NPY.  First, carboxytetramethylrhodamine was connected to [F(7) ,P(34) ]NPY by an amide, ester, disulfide, or enzymatic linkage.  Live imaging revealed hY1 R-mediated delivery and allowed visualization of time-dependent intracellular release.  Next, the fluorophore was replaced by the toxic agent methotrexate (MTX).  In addition to linkage through the amide, ester, disulfide bond, or enzymatic cleavage site, a novel disulfide/ester linker was designed and coupled to [F(7) ,P(34) ]NPY by solid-phase peptide synthesis.  Internalization studies showed hY1 R subtype selective uptake, and cell viability experiments demonstrated hY1 R-mediated toxicity that was clearly dependent on the linkage type.  Fast release profiles for fluorophore-[F(7) ,P(34) ]NPY analogues correlated with high toxicities of MTX conjugates carrying the same linker types and emphasize the relevance of new structures connecting the toxophore and the carrier.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT2bukcAgyF4-RS7coPn-RtfW6udTcc2eZJudi2prbRmrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjnvFartA%253D%253D&md5=f2a894f2cd215e9bc28c7bda041e03ae</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201402514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201402514%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25B6hme%26aufirst%3DD.%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26atitle%3DControlling%2520toxicity%2520of%2520Peptide-drug%2520conjugates%2520by%2520different%2520chemical%2520linker%2520structures%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D804%26epage%3D814%26doi%3D10.1002%2Fcmdc.201402514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maschauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwert, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prante, O.</span></span> <span> </span><span class="NLM_article-title">Synthesis and in vitro and in vivo evaluation of an (18)F-labeled neuropeptide Y analogue for imaging of breast cancer by PET</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1121</span>– <span class="NLM_lpage">1130</span>, <span class="refDoi"> DOI: 10.1021/mp500601z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp500601z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFensLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=1121-1130&author=S.+Hofmannauthor=S.+Maschauerauthor=T.+Kuwertauthor=A.+G.+Beck-Sickingerauthor=O.+Prante&title=Synthesis+and+in+vitro+and+in+vivo+evaluation+of+an+%2818%29F-labeled+neuropeptide+Y+analogue+for+imaging+of+breast+cancer+by+PET&doi=10.1021%2Fmp500601z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and in Vitro and in Vivo Evaluation of an 18F-Labeled Neuropeptide Y Analogue for Imaging of Breast Cancer by PET</span></div><div class="casAuthors">Hofmann, Sven; Maschauer, Simone; Kuwert, Torsten; Beck-Sickinger, Annette G.; Prante, Olaf</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1121-1130</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Imaging of Y1R expression in breast cancer is still a challenging task.  Herein, we report a suitable 18F-labeled high-mol.-wt. glycopeptide for imaging of peripheral neuropeptide Y (NPY) Y1 receptor (Y1R)-pos. tumors by preclin. small-animal positron emission tomog. (PET).  The Y1R-preferring NPY [F7,P34]NPY analog was functionalized with an alkyne-bearing propargylglycine (Pra) in position 4.  The corresponding fluoroglycosylated (FGlc) peptide analog [Pra4(FGlc),F7,P34]NPY and its 18F-labeled analog were synthesized by click chem.-based fluoroglycosylation.  The radiosynthesis was performed by 18F-fluoroglycosylation starting from the 2-triflate of the β-mannosylazide and the alkyne peptide [Pra4,F7,P34]NPY.  The radiosynthesis of the18F-labeled analog was optimized using a min. amt. of peptide precursor (40 nmol), proceeding with an overall radiochem. yield of 20-25% (nondecay cor.) in a total synthesis time of 75 min with specific activities of 40-70 GBq/μmol.  In comparison to NPY and [F7,P34]NPY, in vitro Y1R and Y2R activation studies with the cold [Pra4(FGlc),F7,P34]NPY on stably transfected COS-7 cells displayed a high potency for the induction of Y1R-specific inositol accumulation (pEC50 = 8.5 ± 0.1), whereas the potency at Y2R was significantly decreased.  Internalization studies on stably transfected HEK293 cells confirmed a strong glycopeptide-mediated Y1R internalization and a substantial Y1R subtype selectivity over Y2R.  In vitro autoradiog. with Y1R-pos. MCF-7 tumor tissue slices indicated high specific binding of the 18F-labeled glycopeptide, when binding was reduced by 95% ([Pra4,F7,P34]NPY) and by 86% (BIBP3226 Y1R antagonist) in competition studies.  Biodistribution and small-animal PET studies on MCF-7 breast tumor-bearing nude mice revealed radiotracer uptake in the MCF-7 tumor of 1.8%ID/g at 20 min p.i. and 0.7%ID/g at 120 min p.i. (n = 3-4), increasing tumor-to-blood ratios from 1.2 to 2.4, and a tumor retention of 76 ± 4% (n = 4; 45-90 min p.i.).  PET imaging studies with MCF-7 tumor-bearing nude mice demonstrated uptake of the 18F-labeled glycopeptide in the tumor region at 60 min p.i., whereas only negligible tumor uptake was obsd. in animals injected with a nonbinding 18F-labeled glycopeptide pendant as a measure of nonspecific binding.  In conclusion, PET imaging expts. with the 18F-labeled NPY glycopeptide revealed Y1R-specific binding uptake in MCF-7 tumors in vivo together with decreased kidney uptake compared to DOTA-derivs. of this peptide.  We consider this glycopeptide to be a potent lead peptide for the design of improved 18F-glycopeptides with shorter amino acid sequences that would further facilitate PET imaging studies of Y1R-pos. breast tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCDblWANo0ZLVg90H21EOLACvtfcHk0lg9MiYZgYSp5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFensLs%253D&md5=51b3662355d59694cb4b09a3cfb9653e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fmp500601z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp500601z%26sid%3Dliteratum%253Aachs%26aulast%3DHofmann%26aufirst%3DS.%26aulast%3DMaschauer%26aufirst%3DS.%26aulast%3DKuwert%26aufirst%3DT.%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26aulast%3DPrante%26aufirst%3DO.%26atitle%3DSynthesis%2520and%2520in%2520vitro%2520and%2520in%2520vivo%2520evaluation%2520of%2520an%2520%252818%2529F-labeled%2520neuropeptide%2520Y%2520analogue%2520for%2520imaging%2520of%2520breast%2520cancer%2520by%2520PET%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2015%26volume%3D12%26spage%3D1121%26epage%3D1130%26doi%3D10.1021%2Fmp500601z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, I. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwanziger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böhme, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naseer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyder, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span></span> <span> </span><span class="NLM_article-title">Breast-cancer diagnosis by neuropeptide Y analogues: from synthesis to clinical application</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">1155</span>– <span class="NLM_lpage">1158</span>, <span class="refDoi"> DOI: 10.1002/anie.200905008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1002%2Fanie.200905008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVGktLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=1155-1158&author=I.+U.+Khanauthor=D.+Zwanzigerauthor=I.+B%C3%B6hmeauthor=M.+Javedauthor=H.+Naseerauthor=S.+W.+Hyderauthor=A.+G.+Beck-Sickinger&title=Breast-cancer+diagnosis+by+neuropeptide+Y+analogues%3A+from+synthesis+to+clinical+application&doi=10.1002%2Fanie.200905008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Breast Cancer Diagnosis by Neuropeptide Y Analogues: From Synthesis to Clinical Application</span></div><div class="casAuthors">Khan, Irfan U.; Zwanziger, Denise; Boehme, Ilka; Javed, Muhammad; Naseer, Hamid; Hyder, Syed W.; Beck-Sickinger, Annette G.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1155-1158, S1155/1-S1155/6</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Synthesis and clin. application of radiolabeled neuropeptide Y analogs for breast cancer imaging and diagnosis are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovlr3pffrSGrVg90H21EOLACvtfcHk0lg9MiYZgYSp5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVGktLk%253D&md5=2770c359dbab5b8680520fa0f9a75009</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fanie.200905008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200905008%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DI.%2BU.%26aulast%3DZwanziger%26aufirst%3DD.%26aulast%3DB%25C3%25B6hme%26aufirst%3DI.%26aulast%3DJaved%26aufirst%3DM.%26aulast%3DNaseer%26aufirst%3DH.%26aulast%3DHyder%26aufirst%3DS.%2BW.%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26atitle%3DBreast-cancer%2520diagnosis%2520by%2520neuropeptide%2520Y%2520analogues%253A%2520from%2520synthesis%2520to%2520clinical%2520application%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2010%26volume%3D49%26spage%3D1155%26epage%3D1158%26doi%3D10.1002%2Fanie.200905008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hawthorne, M. F.</span></span> <span> </span><span class="NLM_article-title">The role of chemistry in the development of boron neutron capture therapy of cancer</span>. <i>Angew. Chem., Int. Ed. Engl.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">950</span>– <span class="NLM_lpage">984</span>, <span class="refDoi"> DOI: 10.1002/anie.199309501</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1002%2Fanie.199309501" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1993&pages=950-984&author=M.+F.+Hawthorne&title=The+role+of+chemistry+in+the+development+of+boron+neutron+capture+therapy+of+cancer&doi=10.1002%2Fanie.199309501"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2Fanie.199309501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.199309501%26sid%3Dliteratum%253Aachs%26aulast%3DHawthorne%26aufirst%3DM.%2BF.%26atitle%3DThe%2520role%2520of%2520chemistry%2520in%2520the%2520development%2520of%2520boron%2520neutron%2520capture%2520therapy%2520of%2520cancer%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%2520Engl.%26date%3D1993%26volume%3D32%26spage%3D950%26epage%3D984%26doi%3D10.1002%2Fanie.199309501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soloway, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tjarks, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnum, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, F.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Codogni, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J. G.</span></span> <span> </span><span class="NLM_article-title">The chemistry of neutron capture therapy</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">1515</span>– <span class="NLM_lpage">1562</span>, <span class="refDoi"> DOI: 10.1021/cr941195u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr941195u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADyaK1cXjtlygtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=1998&pages=1515-1562&author=A.+H.+Solowayauthor=W.+Tjarksauthor=B.+A.+Barnumauthor=F.-G.+Rongauthor=R.+F.+Barthauthor=I.+M.+Codogniauthor=J.+G.+Wilson&title=The+chemistry+of+neutron+capture+therapy&doi=10.1021%2Fcr941195u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The Chemistry of Neutron Capture Therapy</span></div><div class="casAuthors">Soloway, Albert H.; Tjarks, Werner; Barnum, Beverly A.; Rong, Feng-Guang; Barth, Rolf F.; Codogni, Iwona M.; Wilson, J. Gerald</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1515-1562</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with 633 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQlar2oXrwMrVg90H21EOLACvtfcHk0lg9MiYZgYSp5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjtlygtL8%253D&md5=52bcd4d4e2f37833d76092e9a1867b3c</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fcr941195u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr941195u%26sid%3Dliteratum%253Aachs%26aulast%3DSoloway%26aufirst%3DA.%2BH.%26aulast%3DTjarks%26aufirst%3DW.%26aulast%3DBarnum%26aufirst%3DB.%2BA.%26aulast%3DRong%26aufirst%3DF.-G.%26aulast%3DBarth%26aufirst%3DR.%2BF.%26aulast%3DCodogni%26aufirst%3DI.%2BM.%26aulast%3DWilson%26aufirst%3DJ.%2BG.%26atitle%3DThe%2520chemistry%2520of%2520neutron%2520capture%2520therapy%26jtitle%3DChem.%2520Rev.%26date%3D1998%26volume%3D98%26spage%3D1515%26epage%3D1562%26doi%3D10.1021%2Fcr941195u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlsson, J.</span></span> <span> </span><span class="NLM_article-title">Radiation dose heterogeneity in receptor and antigen mediated boron neutron capture therapy</span>. <i>Radiother. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">75</span>, <span class="refDoi"> DOI: 10.1016/0167-8140(94)90414-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1016%2F0167-8140%2894%2990414-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=8041899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADyaK2cXlsFahtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1994&pages=61-75&author=T.+Hartmanauthor=J.+Carlsson&title=Radiation+dose+heterogeneity+in+receptor+and+antigen+mediated+boron+neutron+capture+therapy&doi=10.1016%2F0167-8140%2894%2990414-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Radiation dose heterogeneity in receptor and antigen mediated boron neutron capture therapy</span></div><div class="casAuthors">Hartman, Torjoern; Carlsson, Joergen</div><div class="citationInfo"><span class="NLM_cas:title">Radiotherapy and Oncology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">61-75</span>CODEN:
                <span class="NLM_cas:coden">RAONDT</span>;
        ISSN:<span class="NLM_cas:issn">0167-8140</span>.
    </div><div class="casAbstract">Boron neutron capture therapy, BNCT, might be a valuable tumor therapeutical modality for the treatment of cells that are difficult to handle with conventional methods such as surgery or external radiotherapy.  The principle is that tumor assocd. 10B atoms capture thermal neutrons and thereby forms high-LET helium and lithium ions as reaction products.  An interesting development is to conjugate 10B atoms to macromols. that bind to tumor cells with over-expressed receptors or specific antigens.  The targeting macromols. might be receptor-ligands, antibodies or antibody-fragments contg. 10B.  The present study deals with the limitations of such an approach.  One problem is the background dose from capture of neutrons in physiol. occurring elements, esp. nitrogen.  The authors showed, with computer simulations, that the background specific energy (the stochastic analogy of dose) in the cell nuclei, due to captures in nitrogen, had a wide spread and could be rather high, up to 3 Gy in some cells, when relevant neutron fluences were applied.  The maximal amt. of 10B that can be delivered to single tumor cells due to receptor-ligand, receptor-antibody or antigen-antibody mediated binding is probably in the range 108-1010 atoms/cell.  The authors' calcns. showed that the tumor cells had to contain about 109 10B/cell to give a therapeutically interesting dose to the nuclei of the targeted cells.  The doses were highest when the boron was in the cell nucleus.  There was also a wide spread of specific energy absorbed by the nuclei after neutron capture in 10B.  When, for example, 108 10B/nucleus were applied the specific energy to the analyzed nuclei varied from 0 Gy up to about 7 Gy.  These variations were due to the stochastic nature of the capture processes.  Some helium or lithium ion tracks passed through the center of the cell nuclei delivering a lot of energy, some passed through only a smaller part delivering small amts. of energy and sometimes the nuclei escaped without any hits at all.  The results were obtained when relevant neutron fluences (2-5 × 1012 n/cm2) were applied.  Increased neutron fluences gave higher doses both due to capture in boron and in nitrogen but in order to improve the ratio between the dose to targeted tumor cells and the dose to normal cells, the no. of 10B atoms in the targeted cells had to be increased and/or the boron placed in the cell nuclei.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe3TsTs0ii1LVg90H21EOLACvtfcHk0ljgE0kxIluzgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlsFahtLg%253D&md5=230b2bbb5e63ac80548443023944812f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2F0167-8140%2894%2990414-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0167-8140%252894%252990414-6%26sid%3Dliteratum%253Aachs%26aulast%3DHartman%26aufirst%3DT.%26aulast%3DCarlsson%26aufirst%3DJ.%26atitle%3DRadiation%2520dose%2520heterogeneity%2520in%2520receptor%2520and%2520antigen%2520mediated%2520boron%2520neutron%2520capture%2520therapy%26jtitle%3DRadiother.%2520Oncol.%26date%3D1994%26volume%3D31%26spage%3D61%26epage%3D75%26doi%3D10.1016%2F0167-8140%2894%2990414-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barth, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coderre, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vicente, M. G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blue, T. E.</span></span> <span> </span><span class="NLM_article-title">Boron neutron capture therapy of cancer: current status and future prospects</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">3987</span>– <span class="NLM_lpage">4002</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-05-0035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1158%2F1078-0432.CCR-05-0035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=15930333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Gksr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=3987-4002&author=R.+F.+Barthauthor=J.+A.+Coderreauthor=M.+G.+H.+Vicenteauthor=T.+E.+Blue&title=Boron+neutron+capture+therapy+of+cancer%3A+current+status+and+future+prospects&doi=10.1158%2F1078-0432.CCR-05-0035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Boron Neutron Capture Therapy of Cancer: Current Status and Future Prospects</span></div><div class="casAuthors">Barth, Rolf F.; Coderre, Jeffrey A.; Vicente, M. Graca H.; Blue, Thomas E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3987-4002</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Background: Boron neutron capture therapy (BNCT) is based on the nuclear reaction that occurs when boron-10 is irradiated with low-energy thermal neutrons to yield high linear energy transfer α particles and recoiling lithium-7 nuclei.  Clin. interest in BNCT has focused primarily on the treatment of high-grade gliomas and either cutaneous primaries or cerebral metastases of melanoma, most recently, head and neck and liver cancer.  Neutron sources for BNCT currently are limited to nuclear reactors and these are available in the United States, Japan, several European countries, and Argentina.  Accelerators also can be used to produce epithermal neutrons and these are being developed in several countries, but none are currently being used for BNCT.  Boron Delivery Agents: Two boron drugs have been used clin., sodium borocaptate (Na2B12H11SH) and a dihydroxyboryl deriv. of phenylalanine called boronophenylalanine.  The major challenge in the development of boron delivery agents has been the requirement for selective tumor targeting to achieve boron concns. (∼20 μg/g tumor) sufficient to deliver therapeutic doses of radiation to the tumor with minimal normal tissue toxicity.  Over the past 20 years, other classes of boron-contg. compds. have been designed and synthesized that include boron-contg. amino acids, biochem. precursors of nucleic acids, DNA-binding mols., and porphyrin derivs.  High mol. wt. delivery agents include monoclonal antibodies and their fragments, which can recognize a tumor-assocd. epitope, such as epidermal growth factor, and liposomes.  However, it is unlikely that any single agent will target all or even most of the tumor cells, and most likely, combinations of agents will be required and their delivery will have to be optimized.  Clin. Trials: Current or recently completed clin. trials have been carried out in Japan, Europe, and the United States.  The vast majority of patients have had high-grade gliomas.  Treatment has consisted first of "debulking" surgery to remove as much of the tumor as possible, followed by BNCT at varying times after surgery.  Sodium borocaptate and boronophenylalanine administered i.v. have been used as the boron delivery agents.  The best survival data from these studies are at least comparable with those obtained by current std. therapy for glioblastoma multiforme, and the safety of the procedure has been established.  Conclusions: Crit. issues that must be addressed include the need for more selective and effective boron delivery agents, the development of methods to provide semiquant. ests. of tumor boron content before treatment, improvements in clin. implementation of BNCT, and a need for randomized clin. trials with an unequivocal demonstration of therapeutic efficacy.  If these issues are adequately addressed, then BNCT could move forward as a treatment modality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6ZX4_Ygd317Vg90H21EOLACvtfcHk0ljgE0kxIluzgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Gksr4%253D&md5=377a149d1c9c994ebe7b9655e18726b2</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-0035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-0035%26sid%3Dliteratum%253Aachs%26aulast%3DBarth%26aufirst%3DR.%2BF.%26aulast%3DCoderre%26aufirst%3DJ.%2BA.%26aulast%3DVicente%26aufirst%3DM.%2BG.%2BH.%26aulast%3DBlue%26aufirst%3DT.%2BE.%26atitle%3DBoron%2520neutron%2520capture%2520therapy%2520of%2520cancer%253A%2520current%2520status%2520and%2520future%2520prospects%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D3987%26epage%3D4002%26doi%3D10.1158%2F1078-0432.CCR-05-0035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barth, R. F.</span></span> <span> </span><span class="NLM_article-title">Boron neutron capture therapy at the crossroads: challenges and opportunities</span>. <i>Appl. Radiat. Isot.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">S3</span>– <span class="NLM_lpage">S6</span>, <span class="refDoi"> DOI: 10.1016/j.apradiso.2009.03.102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1016%2Fj.apradiso.2009.03.102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=19467879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnt1Wqurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2009&pages=S3-S6&author=R.+F.+Barth&title=Boron+neutron+capture+therapy+at+the+crossroads%3A+challenges+and+opportunities&doi=10.1016%2Fj.apradiso.2009.03.102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Boron neutron capture therapy at the crossroads: Challenges and opportunities</span></div><div class="casAuthors">Barth, Rolf F.</div><div class="citationInfo"><span class="NLM_cas:title">Applied Radiation and Isotopes</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">7-8S</span>),
    <span class="NLM_cas:pages">S3-S6</span>CODEN:
                <span class="NLM_cas:coden">ARISEF</span>;
        ISSN:<span class="NLM_cas:issn">0969-8043</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Over the past 25 years research on boron neutron capture therapy (BNCT) has progressed relatively slowly but steadily with the greatest progress in the field of clin. studies.  These specifically have included the use of BNCT to treat a variety of malignancies other than high grade gliomas and melanomas.  However, there are a no. of key areas where little, if any, significant progress has been made.  First and foremost among these has been the lack of new boron delivery agents.  Improvement in drug delivery and the development of the best dosing paradigms for both boronophenylalanine (BPA) and sodium borocaptate (BSH) are of major importance and these still have not been optimized.  Dosimetry for BNCT is still imprecise and is based on treating to normal tissue tolerance, based on blood boron values, rather than any real-time information on the boron content of the residual tumor that is to be irradiated.  Another major problem has been the total dependence on nuclear reactors as neutron sources for BNCT.  However, this will change in the near future when a clin. useful accelerator comes into use in 2009.  Like it or not, in order to gain the credibility of a broad community of physicians who treat brain tumor patients, there will have to be a randomized clin. trial.  Finally, BNCT will have to compete with new therapeutic approaches that are less costly and more effective for the treatment of brain tumors.  These challenges notwithstanding, BNCT can fill an important niche for those malignancies, whether primary or recurrent, for which there is currently no effective therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9aFSQ_rvvkbVg90H21EOLACvtfcHk0ljgE0kxIluzgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnt1Wqurw%253D&md5=9d2a2e07cb0af5bf8e91fbf42b9eea51</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.apradiso.2009.03.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apradiso.2009.03.102%26sid%3Dliteratum%253Aachs%26aulast%3DBarth%26aufirst%3DR.%2BF.%26atitle%3DBoron%2520neutron%2520capture%2520therapy%2520at%2520the%2520crossroads%253A%2520challenges%2520and%2520opportunities%26jtitle%3DAppl.%2520Radiat.%2520Isot.%26date%3D2009%26volume%3D67%26spage%3DS3%26epage%3DS6%26doi%3D10.1016%2Fj.apradiso.2009.03.102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barth, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vicente, M. G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harling, O. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiger, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binns, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aihara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawabata, S.</span></span> <span> </span><span class="NLM_article-title">Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer</span>. <i>Radiat. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">146</span>, <span class="refDoi"> DOI: 10.1186/1748-717X-7-146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1186%2F1748-717X-7-146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=22929110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A280%3ADC%252BC38bhvFyntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=146&author=R.+F.+Barthauthor=M.+G.+H.+Vicenteauthor=O.+K.+Harlingauthor=W.+S.+Kigerauthor=K.+J.+Rileyauthor=P.+J.+Binnsauthor=F.+M.+Wagnerauthor=M.+Suzukiauthor=T.+Aiharaauthor=I.+Katoauthor=S.+Kawabata&title=Current+status+of+boron+neutron+capture+therapy+of+high+grade+gliomas+and+recurrent+head+and+neck+cancer&doi=10.1186%2F1748-717X-7-146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer</span></div><div class="casAuthors">Barth Rolf F; Vicente M Graca H; Harling Otto K; Kiger W S 3rd; Riley Kent J; Binns Peter J; Wagner Franz M; Suzuki Minoru; Aihara Teruhito; Kato Itsuro; Kawabata Shinji</div><div class="citationInfo"><span class="NLM_cas:title">Radiation oncology (London, England)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">146</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Boron neutron capture therapy (BNCT) is a biochemically targeted radiotherapy based on the nuclear capture and fission reactions that occur when non-radioactive boron-10, which is a constituent of natural elemental boron, is irradiated with low energy thermal neutrons to yield high linear energy transfer alpha particles and recoiling lithium-7 nuclei.  Clinical interest in BNCT has focused primarily on the treatment of high grade gliomas, recurrent cancers of the head and neck region and either primary or metastatic melanoma.  Neutron sources for BNCT currently have been limited to specially modified nuclear reactors, which are or until the recent Japanese natural disaster, were available in Japan, United States, Finland and several other European countries, Argentina and Taiwan.  Accelerators producing epithermal neutron beams also could be used for BNCT and these are being developed in several countries.  It is anticipated that the first Japanese accelerator will be available for therapeutic use in 2013.  The major hurdle for the design and synthesis of boron delivery agents has been the requirement for selective tumor targeting to achieve boron concentrations in the range of 20 μg/g.  This would be sufficient to deliver therapeutic doses of radiation with minimal normal tissue toxicity.  Two boron drugs have been used clinically, a dihydroxyboryl derivative of phenylalanine, referred to as boronophenylalanine or "BPA", and sodium borocaptate or "BSH" (Na2B12H11SH).  In this report we will provide an overview of other boron delivery agents that currently are under evaluation, neutron sources in use or under development for BNCT, clinical dosimetry, treatment planning, and finally a summary of previous and on-going clinical studies for high grade gliomas and recurrent tumors of the head and neck region.  Promising results have been obtained with both groups of patients but these outcomes must be more rigorously evaluated in larger, possibly randomized clinical trials.  Finally, we will summarize the critical issues that must be addressed if BNCT is to become a more widely established clinical modality for the treatment of those malignancies for which there currently are no good treatment options.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSmgtNvZmceJgxyojvcjibhfW6udTcc2eYQTCOdvzxQebntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38bhvFyntw%253D%253D&md5=67fe6387a90e9ec7aa293340f54e92fa</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1186%2F1748-717X-7-146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1748-717X-7-146%26sid%3Dliteratum%253Aachs%26aulast%3DBarth%26aufirst%3DR.%2BF.%26aulast%3DVicente%26aufirst%3DM.%2BG.%2BH.%26aulast%3DHarling%26aufirst%3DO.%2BK.%26aulast%3DKiger%26aufirst%3DW.%2BS.%26aulast%3DRiley%26aufirst%3DK.%2BJ.%26aulast%3DBinns%26aufirst%3DP.%2BJ.%26aulast%3DWagner%26aufirst%3DF.%2BM.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DAihara%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DI.%26aulast%3DKawabata%26aufirst%3DS.%26atitle%3DCurrent%2520status%2520of%2520boron%2520neutron%2520capture%2520therapy%2520of%2520high%2520grade%2520gliomas%2520and%2520recurrent%2520head%2520and%2520neck%2520cancer%26jtitle%3DRadiat.%2520Oncol.%26date%3D2012%26volume%3D7%26spage%3D146%26doi%3D10.1186%2F1748-717X-7-146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reedy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lennarz, W. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis of aromatic boronic acids. Aldehydo boronic acids and a boronic acid analog of tyrosine 1</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1958</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">835</span>– <span class="NLM_lpage">838</span>, <span class="refDoi"> DOI: 10.1021/ja01537a021</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja01537a021" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADyaG1cXmtV2lsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=1958&pages=835-838&author=H.+R.+Snyderauthor=A.+J.+Reedyauthor=W.+J.+Lennarz&title=Synthesis+of+aromatic+boronic+acids.+Aldehydo+boronic+acids+and+a+boronic+acid+analog+of+tyrosine+1&doi=10.1021%2Fja01537a021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of aromatic boronic acids. Aldehydo boronic acids and a boronic acid analog of tyrosine</span></div><div class="casAuthors">Snyder, H. R.; Reedy, Albert J.; Lennarz, Wm. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1958</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">835-8</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">ο-MeC6H4B(OH)2 (I) (5 g.) and 100 cc. CCl4 treated with stirring with about 5 cc. soln. of 6 g. dry Br in 50 cc. CCl4 while being illuminated with a 200-w. light bulb, the mixt. treated after an induction period of 5-15 min. with the remainder of the Br soln. in portions of about 5 cc. during about 15 min. and evapd., and the residue recrystd. from CHCl3 yielded 7.4 g. ο-BrCH2C6H4B(OH)2 (II), m. 139-46°.  p-MeC6H4B(OH)2 (III) (5 g.) gave similarly 7.2 g. p-BrCH2C6H4B(OH)2 (IV), m. 138-44°.  III (5 g.), 150 cc. dry CHCl3, 650 mg. Bz2O2, and 6.5 g. N-bromosuccinimide (V) refluxed 3 hrs. while being illuminated with a 200-w. light bulb, the mixt. refluxed 1 hr. with 7 g. hexamethylenetetramine in 75 cc. dry CHCl3, the hot soln. decanted, the residue extd. with 40 cc. HCl of pH 4, the aq. soln. freed of a few drops CHCl3, refluxed 1 hr., poured into a beaker, treated immediately with 10 cc. concd. HCl, and cooled, and the cryst. product recrystd. from H2O yielded 1.5 g. p-OHCC6H4B(OH)2 (VI).0.5H2O, m. 230-40°, which dried 24 hrs. at room temp. and 1 mm. gave VI; a sample dried 1 hr. at 80°/1 mm. gave the anhydride.  I (1 g.), 40 cc. dry CCl4, 2.6 g. V, and 260 mg. Bz2O2 refluxed 2.5 hrs. while being illuminated by a 200-w. bulb, filtered, and extd. with 15% aq. KOH, the alk. ext. acidified after 15 min., kept 2 hrs., and extd. with Et2O, and the ext. evapd. gave 370 mg. ο-OHCC6H4B(OH)2 (VII), m. 118-20°.  VI (500 mg.), 200 mg. MeNO2, and 4 cc. EtOH treated slowly below 10° with 274 mg. NaOH in 4 cc. H2O, stirred 15 min. at 10°, clarified with aq. NaOH, cooled to 5°, and added to 2 cc. concd. HCl in 3 cc. H2O at 0° yielded 455 mg. p-O2NCH:CHC6H4B(OH)2, light yellow, m. 289-90° (decompn.) (33% EtOH).  VII was recovered unchanged from a similar run.  VI (1 g.), 15 cc. Me2CO, 5 cc. H2O, and 5 cc. 10% aq. NaOH kept below 30° by cooling with tap water and then 4 hrs. at room temp. and filtered, the residue dissolved in 10 cc. H2O and acidified, the ppt. filtered, and the residues recrystd. from aq. EtOH gave 1.05 g. p-AcCH:CHC6H4B(OH)2, m. 205-12°.  VII was recovered unchanged from a similar run.  VI (1 g.), 3.5 g. KCN, and 7 cc. H2O treated slowly at 10° with 0.57 cc. concd. H2SO4 in 1.73 cc. H2O, filtered, acidified with 10% HCl, kept 10 min. at 10°, and the product isolated with Et2O gave p-NC(HO)CHC6H4B(OH)2, which softened at about 65° and appeared to undergo several changes before completely m. 104°.  VI treated with N2H4.H2O gave the azine of VI, m. 295° (aq. HCONMe2).  VI oxidized with KMnO4 at room temp. yielded 86% p-HO2CC6H4B(OH)2, m. 219-20°.  VI in EtOH hydrogenated over PtO2 gave a gelatinous solid which could not be purified.  VI treated with 10 or 20% aq. NaOH at room temp. to reflux temp. from 45 min. to 12 hrs. was recovered unchanged; similar results were obtained in the attempted benzoin condensation during 40-90 min. and in the attempted condensations with BzH, p-Me2NC6H4CHO, and p-O2NC6H4CHO.  VII (600 mg.) refluxed 2 hrs. with 5 cc. deoxygenated 20% aq. NaOH under N yielded 300 mg. BzOH.  VII (500 mg.) and 360 mg. NH2OH.HCl in 20 cc. hot H2O adjusted with NaOH to pH 7, refluxed 15 min., cooled, acidified with concd. HCl, and refrigerated 2 days gave 420 mg. p-HON:CHC6H4B(OH)2, m. 150-5°.  I (5 g.) treated in CCl4 in the usual manner with 6 g. Br and extd. with 15% aq. KOH, the ext. kept 1 hr. at room temp., acidified with 15% HCl, and filtered, the filtrate concd. to 50 cc., and the product isolated with Et2O gave 3.5 g. ο-C6H4.CH2.O.BOH (VIII), m. 96-8° (H2O).  I (25 g.), 32.5 g. V, 3.25 g. Bz2O2, and 350 cc. dry CHCl3 refluxed 3 hrs., treated with 30 g. hexamethylenetetramine in 200 cc. CHCl3, refluxed 15 min., and decanted, the residue dissolved in 100 cc. aq. HCl of pH 4, and the aq. soln. refluxed 1 hr. gave 5.2 g. IX, m. 308-9° (HCONMe2).  IX in 10% HCl treated with NaNO2 effervesced and gave VIII.  AcNHCH(CO2Et)2 (28.8 g.) added to 3.16 g. Na in 300 cc. abs. EtOH with stirring, the mixt. treated with stirring with 19.7 g. VI, refluxed 11 hrs. with stirring, cooled to room temp., treated with 12 cc. 3N HCl, and filtered, the filtrate evapd., and the residual semisolid crystd. from about 600 cc. 33% EtOH yielded 21.7 g. p-(EtO2C)2C(NHAc)CH2C6H4B(OH)2 (X), m. 220-3°.  X (21.7 g.) and 180 cc. 5% aq. NaOH refluxed 3.75 hrs. with stirring, cooled, treated slowly with 90 cc. 3NN HCl, refluxed 1 hr., and evapd. in vacuo, and the residue crystd. from the min. amt. of H2O yielded 13.5 g. p-HO2CCH(NHAc)C6H4B(OH)2 (XI), m. 168-70°.  XI (13.5 g.) and 16 g. NaOH in 250 cc. H2O refluxed 9 hrs. with stirring, acidified with 25 cc. concd. HCl, adjusted to pH 6.2 with NH4OH, concd. to 100 cc. in vacuo, and refrigerated overnight yielded 8.3 g. p-HO2CCH(NH2)CH2C6H4B(OH)2 (XII), m. 285-90° (decompn.).  XII (0.1-0.2 g.) treated with 3 cc. N HCl and slowly evapd. to dryness yielded XII.HCl, m. 200-3°.  XII (0.5 g.) in 20 cc. 5% aq. NaOH refluxed 48 hrs. in a Cu flask, filtered hot, adjusted to pH 3 with HCl and then to pH 5.7 with NH4OH, and filtered, the filtrate evapd. to near dryness in vacuo, the residue treated with 10 cc. H2O, and the remaining solid filtered off gave a mixt., m. 235-40°, of XII and PhCH2CH(NH2)CO2H which chromatographed with 4:1:5 BuOH-AcOH-H2O (descending) showed the Rf values 0.46 and 0.69, resp.  XII in excess aq. NaOH titrated with 0.1N HCl gave a titration curve similar in shape to that of a normal amino acid.  The boronic acid function has a pKa of the same magnitude as the ammonium ion; on the basic side of the titration curve 2 equivs. acid were required for neutralization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo50pif1I7F2bVg90H21EOLACvtfcHk0lgqNFcP65vEnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaG1cXmtV2lsw%253D%253D&md5=95318dbe3031236608bed3b91c3bdf2a</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fja01537a021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja01537a021%26sid%3Dliteratum%253Aachs%26aulast%3DSnyder%26aufirst%3DH.%2BR.%26aulast%3DReedy%26aufirst%3DA.%2BJ.%26aulast%3DLennarz%26aufirst%3DW.%2BJ.%26atitle%3DSynthesis%2520of%2520aromatic%2520boronic%2520acids.%2520Aldehydo%2520boronic%2520acids%2520and%2520a%2520boronic%2520acid%2520analog%2520of%2520tyrosine%25201%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1958%26volume%3D80%26spage%3D835%26epage%3D838%26doi%3D10.1021%2Fja01537a021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soloway, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. A.</span></span> <span> </span><span class="NLM_article-title">Penetration of brain and brain tumor. VII. Tumor-binding sulfhydryl boron compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1967</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">714</span>– <span class="NLM_lpage">717</span>, <span class="refDoi"> DOI: 10.1021/jm00316a042</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00316a042" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADyaF2sXksFalurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1967&pages=714-717&author=A.+H.+Solowayauthor=H.+Hatanakaauthor=M.+A.+Davis&title=Penetration+of+brain+and+brain+tumor.+VII.+Tumor-binding+sulfhydryl+boron+compounds&doi=10.1021%2Fjm00316a042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Penetration of brain and brain tumor.  VII.  Tumor-binding sulfhydryl boron compounds</span></div><div class="casAuthors">Soloway, Albert H.; Hatanaka, Hiroshi; Davis, Michael Allan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1967</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">714-17</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">cf. CA 62: 10964d.  The discovery of a class of B compds. contg. the sulfhydryl group, which become fixed to tumor tissue and to serum proteins, is presented.  A comparison is made between the toxicity and tissue-binding properties of B12H122- and B12H11SH2-.  There are definite indications that SH groups on such anions are potent nucleophils.  Toxicity studies of this latter anion in rabbits are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1onOfKKUZ-LVg90H21EOLACvtfcHk0lgqNFcP65vEnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2sXksFalurY%253D&md5=ab337fa146d6a39900e661c2edbf6ce5</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm00316a042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00316a042%26sid%3Dliteratum%253Aachs%26aulast%3DSoloway%26aufirst%3DA.%2BH.%26aulast%3DHatanaka%26aufirst%3DH.%26aulast%3DDavis%26aufirst%3DM.%2BA.%26atitle%3DPenetration%2520of%2520brain%2520and%2520brain%2520tumor.%2520VII.%2520Tumor-binding%2520sulfhydryl%2520boron%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1967%26volume%3D10%26spage%3D714%26epage%3D717%26doi%3D10.1021%2Fjm00316a042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luderer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Puente, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azab, A. K.</span></span> <span> </span><span class="NLM_article-title">Advancements in tumor targeting strategies for boron neutron capture therapy</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">2824</span>– <span class="NLM_lpage">2836</span>, <span class="refDoi"> DOI: 10.1007/s11095-015-1718-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1007%2Fs11095-015-1718-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=26033767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsVyktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2015&pages=2824-2836&author=M.+J.+Ludererauthor=P.+de+la+Puenteauthor=A.+K.+Azab&title=Advancements+in+tumor+targeting+strategies+for+boron+neutron+capture+therapy&doi=10.1007%2Fs11095-015-1718-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Advancements in Tumor Targeting Strategies for Boron Neutron Capture Therapy</span></div><div class="casAuthors">Luderer, Micah John; de la Puente, Pilar; Azab, Abdel Kareem</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2824-2836</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Boron neutron capture therapy (BNCT) is a promising cancer therapy modality that utilizes the nuclear capture reaction of epithermal neutrons by boron-10 resulting in a localized nuclear fission reaction and subsequent cell death.  Since cellular destruction is limited to approx. the diam. of a single cell, primarily only cells in the neutron field with significant boron accumulation will be damaged.  However, the emergence of BNCT as a prominent therapy has in large part been hindered by a paucity of tumor selective boron contg. agents.  While L-boronophenylalanine and sodium borocaptate are the most commonly investigated clin. agents, new agents are desperately needed due to their suboptimal tumor selectivity.  This review will highlight the various strategies to improve tumor boron delivery including: nucleoside and carbohydrate analogs, unnatural amino acids, porphyrins, antibody-dendrimer conjugates, cationic polymers, cell-membrane penetrating peptides, liposomes and nanoparticles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR6dU5mkUizrVg90H21EOLACvtfcHk0ljA9IT_BPWBNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsVyktb8%253D&md5=32c8e328650a1147d2535204bc64af5b</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs11095-015-1718-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-015-1718-y%26sid%3Dliteratum%253Aachs%26aulast%3DLuderer%26aufirst%3DM.%2BJ.%26aulast%3Dde%2Bla%2BPuente%26aufirst%3DP.%26aulast%3DAzab%26aufirst%3DA.%2BK.%26atitle%3DAdvancements%2520in%2520tumor%2520targeting%2520strategies%2520for%2520boron%2520neutron%2520capture%2520therapy%26jtitle%3DPharm.%2520Res.%26date%3D2015%26volume%3D32%26spage%3D2824%26epage%3D2836%26doi%3D10.1007%2Fs11095-015-1718-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahrens, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadlbauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hey-Hawkins, E.</span></span> <span> </span><span class="NLM_article-title">Incorporation of ortho-carbaboranyl-Nε-modified L-lysine into neuropeptide Y receptor Y1- and Y2-selective analogues</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2368</span>– <span class="NLM_lpage">2377</span>, <span class="refDoi"> DOI: 10.1021/jm101514m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101514m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtFeksLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2368-2377&author=V.+M.+Ahrensauthor=R.+Frankauthor=S.+Stadlbauerauthor=A.+G.+Beck-Sickingerauthor=E.+Hey-Hawkins&title=Incorporation+of+ortho-carbaboranyl-N%CE%B5-modified+L-lysine+into+neuropeptide+Y+receptor+Y1-+and+Y2-selective+analogues&doi=10.1021%2Fjm101514m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Incorporation of ortho-Carbaboranyl-Nε-Modified L-Lysine into Neuropeptide Y Receptor Y1- and Y2-Selective Analogues</span></div><div class="casAuthors">Ahrens, Verena M.; Frank, Rene; Stadlbauer, Sven; Beck-Sickinger, Annette G.; Hey-Hawkins, Evamarie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2368-2377</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nontoxic ortho-carbaborane is one of the most promising structure for boron neutron capture therapy (BNCT).  For directed uptake of ortho-carbaborane by tumor cells, receptor-subtype selective neuropeptide Y (NPY) and its derivs. were modified with ortho-carbaborane.  The deriv. [F7, P34]-NPY has been shown to be a breast cancer selective ligand that binds to the Y1-receptor subtype, whereas [Ahx(5-24)]-NPY selectively addresses Y2-receptor subtypes that are found in neuroblastoma cells.  Ortho-carbaboranylpropionic acid was synthesized and linked to the ε-amino group of Nα-Fmoc protected L-lysine.  The characterization of the compds. was performed by NMR, IR, and MS studies.  The carbaborane-modified amino acid was incorporated into NPY, [F7, P34]-NPY, and [Ahx(5-24)]-NPY by an optimized solid-phase peptide synthesis using Fmoc protection.  Binding studies and IP accumulation assays confirmed nanomolar affinity and activity of the modified analogs despite of the large carbaborane cluster.  Internalization studies revealed excellent and receptor subtype specific uptake of the conjugates into resp. cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLcru9u9v-B7Vg90H21EOLACvtfcHk0ljA9IT_BPWBNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtFeksLY%253D&md5=383ef862554b036f8289144487d0eda3</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm101514m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101514m%26sid%3Dliteratum%253Aachs%26aulast%3DAhrens%26aufirst%3DV.%2BM.%26aulast%3DFrank%26aufirst%3DR.%26aulast%3DStadlbauer%26aufirst%3DS.%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26aulast%3DHey-Hawkins%26aufirst%3DE.%26atitle%3DIncorporation%2520of%2520ortho-carbaboranyl-N%25CE%25B5-modified%2520L-lysine%2520into%2520neuropeptide%2520Y%2520receptor%2520Y1-%2520and%2520Y2-selective%2520analogues%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2368%26epage%3D2377%26doi%3D10.1021%2Fjm101514m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahrens, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehnke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schütz, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hampel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iffland, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bings, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hey-Hawkins, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span></span> <span> </span><span class="NLM_article-title">Receptor-mediated uptake of boron-rich neuropeptide y analogues for boron neutron capture therapy</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">164</span>– <span class="NLM_lpage">172</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201402368</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1002%2Fcmdc.201402368" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=25338544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFamtr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=164-172&author=V.+M.+Ahrensauthor=R.+Frankauthor=S.+Boehnkeauthor=C.+L.+Sch%C3%BCtzauthor=G.+Hampelauthor=D.+S.+Ifflandauthor=N.+H.+Bingsauthor=E.+Hey-Hawkinsauthor=A.+G.+Beck-Sickinger&title=Receptor-mediated+uptake+of+boron-rich+neuropeptide+y+analogues+for+boron+neutron+capture+therapy&doi=10.1002%2Fcmdc.201402368"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor-Mediated Uptake of Boron-Rich Neuropeptide Y Analogues for Boron Neutron Capture Therapy</span></div><div class="casAuthors">Ahrens, Verena M.; Frank, Rene; Boehnke, Solveig; Schuetz, Christian L.; Hampel, Gabriele; Iffland, Dorothee S.; Bings, Nicolas H.; Hey-Hawkins, Evamarie; Beck-Sickinger, Annette G.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">164-172</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Peptidic ligands selectively targeting distinct G protein-coupled receptors that are highly expressed in tumor tissue represent a promising approach in drug delivery.  Receptor-preferring analogs of neuropeptide Y (NPY) bind and activate the human Y1 receptor subtype (hY1 receptor), which is found in 90 % of breast cancer tissue and in all breast-cancer-derived metastases.  Herein, novel highly boron-loaded Y1-receptor-preferring peptide analogs are described as smart shuttle systems for carbaboranes as 10B-contg. moieties.  Various positions in the peptide were screened for their susceptibility to carbaborane modification, and the most promising positions were chosen to create a multi-carbaborane peptide contg. 30 boron atoms per peptide with excellent activation and internalization patterns at the hY1 receptor.  Boron uptake studies by inductively coupled plasma mass spectrometry revealed successful uptake of the multi-carbaborane peptide into hY1-receptor-expressing cells, exceeding the required amt. of 109 boron atoms per cell.  This result demonstrates that the NPY/hY receptor system can act as an effective transport system for boron-contg. moieties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjhrquUuNmmrVg90H21EOLACvtfcHk0ljA9IT_BPWBNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFamtr3I&md5=01ba090bce18667db1893b3be84399a8</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201402368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201402368%26sid%3Dliteratum%253Aachs%26aulast%3DAhrens%26aufirst%3DV.%2BM.%26aulast%3DFrank%26aufirst%3DR.%26aulast%3DBoehnke%26aufirst%3DS.%26aulast%3DSch%25C3%25BCtz%26aufirst%3DC.%2BL.%26aulast%3DHampel%26aufirst%3DG.%26aulast%3DIffland%26aufirst%3DD.%2BS.%26aulast%3DBings%26aufirst%3DN.%2BH.%26aulast%3DHey-Hawkins%26aufirst%3DE.%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26atitle%3DReceptor-mediated%2520uptake%2520of%2520boron-rich%2520neuropeptide%2520y%2520analogues%2520for%2520boron%2520neutron%2520capture%2520therapy%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D164%26epage%3D172%26doi%3D10.1002%2Fcmdc.201402368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Worm, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Els-Heindl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kellert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhnert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saretz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koebberling, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riedl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hey-Hawkins, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span></span> <span> </span><span class="NLM_article-title">A stable meta-carborane enables the generation of boron-rich peptide agonists targeting the ghrelin receptor</span>. <i>J. Pept. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>, <span class="NLM_elocation-id">e3119</span> <span class="refDoi"> DOI: 10.1002/psc.3119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1002%2Fpsc.3119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=30168238" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&author=D.+J.+Wormauthor=S.+Els-Heindlauthor=M.+Kellertauthor=R.+Kuhnertauthor=S.+Saretzauthor=J.+Koebberlingauthor=B.+Riedlauthor=E.+Hey-Hawkinsauthor=A.+G.+Beck-Sickinger&title=A+stable+meta-carborane+enables+the+generation+of+boron-rich+peptide+agonists+targeting+the+ghrelin+receptor&doi=10.1002%2Fpsc.3119"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fpsc.3119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsc.3119%26sid%3Dliteratum%253Aachs%26aulast%3DWorm%26aufirst%3DD.%2BJ.%26aulast%3DEls-Heindl%26aufirst%3DS.%26aulast%3DKellert%26aufirst%3DM.%26aulast%3DKuhnert%26aufirst%3DR.%26aulast%3DSaretz%26aufirst%3DS.%26aulast%3DKoebberling%26aufirst%3DJ.%26aulast%3DRiedl%26aufirst%3DB.%26aulast%3DHey-Hawkins%26aufirst%3DE.%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26atitle%3DA%2520stable%2520meta-carborane%2520enables%2520the%2520generation%2520of%2520boron-rich%2520peptide%2520agonists%2520targeting%2520the%2520ghrelin%2520receptor%26jtitle%3DJ.%2520Pept.%2520Sci.%26date%3D2018%26volume%3D24%26doi%3D10.1002%2Fpsc.3119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Plešek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heřmánek, S.</span></span> <span> </span><span class="NLM_article-title">Experimental evaluation of charge distribution on particular skeletal atoms in icosahedral carboranes by means of HS-derivatives</span>. <i>Collect. Czech. Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">24</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1135/cccc19790024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1135%2Fcccc19790024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADyaE1MXhs1OrsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1979&pages=24-33&author=J.+Ple%C5%A1ekauthor=S.+He%C5%99m%C3%A1nek&title=Experimental+evaluation+of+charge+distribution+on+particular+skeletal+atoms+in+icosahedral+carboranes+by+means+of+HS-derivatives&doi=10.1135%2Fcccc19790024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental evaluation of charge distribution on particular skeletal atoms in icosahedral carboranes by means of mercapto derivatives</span></div><div class="casAuthors">Plesek, Jaromir; Hermanek, Stanislav</div><div class="citationInfo"><span class="NLM_cas:title">Collection of Czechoslovak Chemical Communications</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">24-33</span>CODEN:
                <span class="NLM_cas:coden">CCCCAK</span>;
        ISSN:<span class="NLM_cas:issn">0366-547X</span>.
    </div><div class="casAbstract">The icosahedral skeleton is capable of conjugative interactions with HS groups and all groups of +M character.  The M interaction with the HS is approx. the same in all positions and is similar to that in PhSH.  The LFER for the pKa of the HS-isomer with the group charge (ε) on BH or CH is obsd.  The ε ranges between -0.10 (9-o) and +0.156 (1-o) and is correlated with dipole moment and chem. reactivity.  The pKa of 8 mercaptodicarba-closo-dodecaboranes (1-o, 8-o, 9-o, 1-m, 4-m, 9-m, 1-p, 2-p) and pKa values of 5 of their -SCH2CO2H derivs. are detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfgnoTaAZmg7Vg90H21EOLACvtfcHk0lijaj5-qDc-Ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXhs1OrsLg%253D&md5=62b133600c9ab222476aa52dd3e46d53</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1135%2Fcccc19790024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1135%252Fcccc19790024%26sid%3Dliteratum%253Aachs%26aulast%3DPle%25C5%25A1ek%26aufirst%3DJ.%26aulast%3DHe%25C5%2599m%25C3%25A1nek%26aufirst%3DS.%26atitle%3DExperimental%2520evaluation%2520of%2520charge%2520distribution%2520on%2520particular%2520skeletal%2520atoms%2520in%2520icosahedral%2520carboranes%2520by%2520means%2520of%2520HS-derivatives%26jtitle%3DCollect.%2520Czech.%2520Chem.%2520Commun.%26date%3D1979%26volume%3D44%26spage%3D24%26epage%3D33%26doi%3D10.1135%2Fcccc19790024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kellert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Worm, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoppenz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sárosi, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lönnecke, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riedl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koebberling, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hey-Hawkins, E.</span></span> <span> </span><span class="NLM_article-title">Modular triazine-based carborane-containing carboxylic acids - synthesis and characterisation of potential boron neutron capture therapy agents made of readily accessible building blocks</span>. <i>Dalton Trans</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">10834</span>– <span class="NLM_lpage">10844</span>, <span class="refDoi"> DOI: 10.1039/C9DT02130B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1039%2FC9DT02130B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=31246208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFyisL7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2019&pages=10834-10844&author=M.+Kellertauthor=D.+J.+Wormauthor=P.+Hoppenzauthor=M.+B.+S%C3%A1rosiauthor=P.+L%C3%B6nneckeauthor=B.+Riedlauthor=J.+Koebberlingauthor=A.+G.+Beck-Sickingerauthor=E.+Hey-Hawkins&title=Modular+triazine-based+carborane-containing+carboxylic+acids+-+synthesis+and+characterisation+of+potential+boron+neutron+capture+therapy+agents+made+of+readily+accessible+building+blocks&doi=10.1039%2FC9DT02130B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Modular triazine-based carborane-containing carboxylic acids - synthesis and characterisation of potential boron neutron capture therapy agents made of readily accessible building blocks</span></div><div class="casAuthors">Kellert, Martin; Worm, Dennis J.; Hoppenz, Paul; Sarosi, Menyhart B.; Loennecke, Peter; Riedl, Bernd; Koebberling, Johannes; Beck-Sickinger, Annette G.; Hey-Hawkins, Evamarie</div><div class="citationInfo"><span class="NLM_cas:title">Dalton Transactions</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">10834-10844</span>CODEN:
                <span class="NLM_cas:coden">DTARAF</span>;
        ISSN:<span class="NLM_cas:issn">1477-9226</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Triazine-bridged carborane-aminocarboxylate and peptide conjugates were prepd. as prospective BNCT agents.  Based on a modular combination of s-triazine, the well-known 9-mercapto-1,7-dicarba-closo-dodecaborane(12) and com. available carboxylic acids, namely thioglycolic acid, glycine, and Nα-Boc-L-lysine, several carboxylic acid derivs. were synthesized and fully characterized.  The thioglycolic acid deriv. was introduced into a peptide hormone by solid phase peptide synthesis.  High activity and selective internalization into peptide receptor-expressing cells was obsd.  With a very high boron content of twenty boron atoms, these derivs. are interesting as selective Boron Neutron Capture Therapy (BNCT) agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0sjdC_QKaw7Vg90H21EOLACvtfcHk0lijaj5-qDc-Ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFyisL7P&md5=0c14505635d92b01f8d4f3e24e3c0692</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1039%2FC9DT02130B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9DT02130B%26sid%3Dliteratum%253Aachs%26aulast%3DKellert%26aufirst%3DM.%26aulast%3DWorm%26aufirst%3DD.%2BJ.%26aulast%3DHoppenz%26aufirst%3DP.%26aulast%3DS%25C3%25A1rosi%26aufirst%3DM.%2BB.%26aulast%3DL%25C3%25B6nnecke%26aufirst%3DP.%26aulast%3DRiedl%26aufirst%3DB.%26aulast%3DKoebberling%26aufirst%3DJ.%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26aulast%3DHey-Hawkins%26aufirst%3DE.%26atitle%3DModular%2520triazine-based%2520carborane-containing%2520carboxylic%2520acids%2520-%2520synthesis%2520and%2520characterisation%2520of%2520potential%2520boron%2520neutron%2520capture%2520therapy%2520agents%2520made%2520of%2520readily%2520accessible%2520building%2520blocks%26jtitle%3DDalton%2520Trans%26date%3D2019%26volume%3D48%26spage%3D10834%26epage%3D10844%26doi%3D10.1039%2FC9DT02130B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kerns, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, G. T.</span></span> <span> </span><span class="NLM_article-title">In vitro solubility assays in drug discovery</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">879</span>– <span class="NLM_lpage">885</span>, <span class="refDoi"> DOI: 10.2174/138920008786485100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.2174%2F138920008786485100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=18991584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivF2nsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=879-885&author=E.+H.+Kernsauthor=L.+Diauthor=G.+T.+Carter&title=In+vitro+solubility+assays+in+drug+discovery&doi=10.2174%2F138920008786485100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro solubility assays in drug discovery</span></div><div class="casAuthors">Kerns, Edward H.; Di, Li; Carter, Guy T.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">879-885</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The soly. of a compd. depends on its structure and soln. conditions.  Structure dets. the lipophilicity, hydrogen bonding, mol. vol., crystal energy and ionizability, which det. soly.  Soln. conditions are affected by pH, cosolvents, additives, ionic strength, time and temp.  Many drug discovery expts. are conducted under "kinetic" soly. conditions.  In drug discovery, soly. has a major impact on bioassays, formulation for in vivo dosing, and intestinal absorption.  A good goal for the soly. of drug discovery compds. is >60 ug/mL.  Equil. soly. assays can be conducted in moderate throughput, by incubating excess solid with buffer and agitating for several days, prior to filtration and HPLC quantitation.  Kinetic soly. assays are performed in high throughput with shorter incubation times and high throughput analyses using plate readers.  The most frequently used of these are the nephelometric assay and direct UV assay, which begin by adding a small vol. of DMSO stock soln. of each test compd. to buffer.  In nephelometry, this soln. is serially dild. across a microtiter plate and undissolved particles are detected via light scattering.  In direct UV, undissolved particles are sepd. by filtration, after which the dissolved material is quantitated using UV absorption.  Equil. soly. is useful for preformulation.  Kinetic soly. is useful for rapid compd. assessment, guiding optimization via structure modification, and diagnosing bioassays.  It is often useful to customize soly. expts. using conditions that answer specific research questions of drug discovery teams, such as compd. selection and vehicle development for pharmacol. and PK studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1Pe5z4JU_6LVg90H21EOLACvtfcHk0lh1Jz__HR0vjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivF2nsb8%253D&md5=416cf5bfde2278eac1ba2c67feb1f62e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.2174%2F138920008786485100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920008786485100%26sid%3Dliteratum%253Aachs%26aulast%3DKerns%26aufirst%3DE.%2BH.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DCarter%26aufirst%3DG.%2BT.%26atitle%3DIn%2520vitro%2520solubility%2520assays%2520in%2520drug%2520discovery%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2008%26volume%3D9%26spage%3D879%26epage%3D885%26doi%3D10.2174%2F138920008786485100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kreiner, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergueiro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cartelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castell, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asoia, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padulo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suárez Sandín, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igarzabal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erhardt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercuri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valda, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minsky, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debray, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somacal, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capoulat, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrera, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Grosso, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagetti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anzorena, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canepa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Real, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tacca, H.</span></span> <span> </span><span class="NLM_article-title">Present status of accelerator-based BNCT</span>. <i>Rep. Pract. Oncol. Radiother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">101</span>, <span class="refDoi"> DOI: 10.1016/j.rpor.2014.11.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1016%2Fj.rpor.2014.11.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=26933390" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A280%3ADC%252BC28jmtFOrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=95-101&author=A.+J.+Kreinerauthor=J.+Bergueiroauthor=D.+Cartelliauthor=M.+Baldoauthor=W.+Castellauthor=J.+G.+Asoiaauthor=J.+Paduloauthor=J.+C.+Su%C3%A1rez+Sand%C3%ADnauthor=M.+Igarzabalauthor=J.+Erhardtauthor=D.+Mercuriauthor=A.+A.+Valdaauthor=D.+M.+Minskyauthor=M.+E.+Debrayauthor=H.+R.+Somacalauthor=M.+E.+Capoulatauthor=M.+S.+Herreraauthor=M.+F.+Del+Grossoauthor=L.+Gagettiauthor=M.+S.+Anzorenaauthor=N.+Canepaauthor=N.+Realauthor=M.+Gunauthor=H.+Tacca&title=Present+status+of+accelerator-based+BNCT&doi=10.1016%2Fj.rpor.2014.11.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Present status of Accelerator-Based BNCT</span></div><div class="casAuthors">Kreiner Andres Juan; Cartelli Daniel; Minsky Daniel M; Capoulat Maria Eugenia; Herrera Maria S; Gagetti Leonardo; Bergueiro Javier; Baldo Matias; Castell Walter; Asoia Javier Gomez; Padulo Javier; Suarez Sandin Juan Carlos; Igarzabal Marcelo; Erhardt Julian; Mercuri Daniel; Anzorena Manuel Suarez; Canepa Nicolas; Real Nicolas; Valda Alejandro A; Debray Mario E; Somacal Hector R; Del Grosso Mariela F; Gun Marcelo; Tacca Hernan</div><div class="citationInfo"><span class="NLM_cas:title">Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">95-101</span>
        ISSN:<span class="NLM_cas:issn">1507-1367</span>.
    </div><div class="casAbstract">AIM:  This work aims at giving an updated report of the worldwide status of Accelerator-Based BNCT (AB-BNCT).  BACKGROUND:  There is a generalized perception that the availability of accelerators installed in hospitals, as neutron sources, may be crucial for the advancement of BNCT.  Accordingly, in recent years a significant effort has started to develop such machines.  MATERIALS AND METHODS:  A variety of possible charged-particle induced nuclear reactions and the characteristics of the resulting neutron spectra are discussed along with the worldwide activity in suitable accelerator development.  RESULTS:  Endothermic (7)Li(p,n)(7)Be and (9)Be(p,n)(9)B and exothermic (9)Be(d,n)(10)B are compared.  In addition to having much better thermo-mechanical properties than Li, Be as a target leads to stable products.  This is a significant advantage for a hospital-based facility. (9)Be(p,n)(9)B needs at least 4-5 MeV bombarding energy to have a sufficient yield, while (9)Be(d,n)(10)B can be utilized at about 1.4 MeV, implying the smallest possible accelerator.  This reaction operating with a thin target can produce a sufficiently soft spectrum to be viable for AB-BNCT.  The machines considered are electrostatic single ended or tandem accelerators or radiofrequency quadrupoles plus drift tube Linacs.  CONCLUSIONS:  (7)Li(p,n)(7)Be provides one of the best solutions for the production of epithermal neutron beams for deep-seated tumors.  However, a Li-based target poses significant technological challenges.  Hence, Be has been considered as an alternative target, both in combination with (p,n) and (d,n) reactions. (9)Be(d,n)(10)B at 1.4 MeV, with a thin target has been shown to be a realistic option for the treatment of deep-seated lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSiRzYlOIIH2Ny3lHz94U-GfW6udTcc2eZ1j721PSu5Vrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jmtFOrsQ%253D%253D&md5=e934e8e2a0d54a06bee775cf8de1e880</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.rpor.2014.11.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rpor.2014.11.004%26sid%3Dliteratum%253Aachs%26aulast%3DKreiner%26aufirst%3DA.%2BJ.%26aulast%3DBergueiro%26aufirst%3DJ.%26aulast%3DCartelli%26aufirst%3DD.%26aulast%3DBaldo%26aufirst%3DM.%26aulast%3DCastell%26aufirst%3DW.%26aulast%3DAsoia%26aufirst%3DJ.%2BG.%26aulast%3DPadulo%26aufirst%3DJ.%26aulast%3DSu%25C3%25A1rez%2BSand%25C3%25ADn%26aufirst%3DJ.%2BC.%26aulast%3DIgarzabal%26aufirst%3DM.%26aulast%3DErhardt%26aufirst%3DJ.%26aulast%3DMercuri%26aufirst%3DD.%26aulast%3DValda%26aufirst%3DA.%2BA.%26aulast%3DMinsky%26aufirst%3DD.%2BM.%26aulast%3DDebray%26aufirst%3DM.%2BE.%26aulast%3DSomacal%26aufirst%3DH.%2BR.%26aulast%3DCapoulat%26aufirst%3DM.%2BE.%26aulast%3DHerrera%26aufirst%3DM.%2BS.%26aulast%3DDel%2BGrosso%26aufirst%3DM.%2BF.%26aulast%3DGagetti%26aufirst%3DL.%26aulast%3DAnzorena%26aufirst%3DM.%2BS.%26aulast%3DCanepa%26aufirst%3DN.%26aulast%3DReal%26aufirst%3DN.%26aulast%3DGun%26aufirst%3DM.%26aulast%3DTacca%26aufirst%3DH.%26atitle%3DPresent%2520status%2520of%2520accelerator-based%2520BNCT%26jtitle%3DRep.%2520Pract.%2520Oncol.%2520Radiother.%26date%3D2016%26volume%3D21%26spage%3D95%26epage%3D101%26doi%3D10.1016%2Fj.rpor.2014.11.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barth, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span> <span> </span><span class="NLM_article-title">A realistic appraisal of boron neutron capture therapy as a cancer treatment modality</span>. <i>Cancer Commun. (Lond).</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1186/s40880-018-0280-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1186%2Fs40880-018-0280-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=29914575" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A280%3ADC%252BC1MbosFamuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=36-43&author=R.+F.+Barthauthor=Z.+Zhangauthor=T.+Liu&title=A+realistic+appraisal+of+boron+neutron+capture+therapy+as+a+cancer+treatment+modality&doi=10.1186%2Fs40880-018-0280-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">A realistic appraisal of boron neutron capture therapy as a cancer treatment modality</span></div><div class="casAuthors">Barth Rolf F; Zhang Zizhu; Liu Tong</div><div class="citationInfo"><span class="NLM_cas:title">Cancer communications (London, England)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Boron neutron capture therapy (BNCT) is a binary therapeutic modality based on the nuclear capture and fission reactions that occur when the stable isotope boron-10 is irradiated with neutrons to produce high-energy alpha particles and recoiling lithium-7 nuclei.  In this Commentary we will focus on a number of papers that were presented at a Symposium entitled "Current Clinical Status of Boron Neutron Capture Therapy and Paths to the Future", which was held in September 2017 at the China National Convention Center in Beijing.  Results were presented by clinicians from Japan, Finland, the United States, the China mainland and Taiwan, China who have been working in the multiple disciplines that are required for carrying out clinical BNCT.  The main focus was on the treatment of patients with malignant brain tumors, recurrent tumors of the head and neck region, and cutaneous melanomas.  The results obtained in treating these patients were reported in detail and, although most of the patients with brain tumors and head and neck cancer were not cured, there was evidence of some clinical efficacy.  Although there are a number of problems that must be addressed, further clinical studies to evaluate the efficacy of BNCT are warranted.  First, despite considerable effort by numerous investigators over the past 40 years, there still are only two boron-containing drugs in clinical use, L-boronophenylalanine (BPA) and sodium borocaptate (BSH).  Therefore, until new and more effective boron delivery agents are developed, efforts should be directed to improving the dosing and delivery of BPA and BSH.  Second, due to a variety of reasons, nuclear reactor-based BNCT has ended except for its use in the China mainland and Taiwan.  Therefore, the future of BNCT depends upon the results of the ongoing Phase II clinical trials that are being carried out in Japan and the soon to be initiated trials that will be carried out in Finland.  If the results obtained from these clinical trials are sufficiently promising, then BNCT will have a clear path to the future, especially for patients with the therapeutically challenging malignancies that in the past have been treated with reactor-based BNCT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR-_cHN3uno-8K3uFsUIZtkfW6udTcc2eZ1j721PSu5Vrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MbosFamuw%253D%253D&md5=aaf7960e10efcae0cbdcaa5113ba2bda</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1186%2Fs40880-018-0280-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40880-018-0280-5%26sid%3Dliteratum%253Aachs%26aulast%3DBarth%26aufirst%3DR.%2BF.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DT.%26atitle%3DA%2520realistic%2520appraisal%2520of%2520boron%2520neutron%2520capture%2520therapy%2520as%2520a%2520cancer%2520treatment%2520modality%26jtitle%3DCancer%2520Commun.%2520%2528Lond%2529.%26date%3D2018%26volume%3D38%26spage%3D36%26epage%3D43%26doi%3D10.1186%2Fs40880-018-0280-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barth, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span> <span> </span><span class="NLM_article-title">Boron delivery agents for neutron capture therapy of cancer</span>. <i>Cancer Commun. (Lond).</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">35</span>, <span class="refDoi"> DOI: 10.1186/s40880-018-0299-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1186%2Fs40880-018-0299-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=29914561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A280%3ADC%252BC1MbosFantw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=35&author=R.+F.+Barthauthor=P.+Miauthor=W.+Yang&title=Boron+delivery+agents+for+neutron+capture+therapy+of+cancer&doi=10.1186%2Fs40880-018-0299-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Boron delivery agents for neutron capture therapy of cancer</span></div><div class="casAuthors">Barth Rolf F; Yang Weilian; Mi Peng; Yang Weilian</div><div class="citationInfo"><span class="NLM_cas:title">Cancer communications (London, England)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">35</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Boron neutron capture therapy (BNCT) is a binary radiotherapeutic modality based on the nuclear capture and fission reactions that occur when the stable isotope, boron-10, is irradiated with neutrons to produce high energy alpha particles.  This review will focus on tumor-targeting boron delivery agents that are an essential component of this binary system.  Two low molecular weight boron-containing drugs currently are being used clinically, boronophenylalanine (BPA) and sodium borocaptate (BSH).  Although they are far from being ideal, their therapeutic efficacy has been demonstrated in patients with high grade gliomas, recurrent tumors of the head and neck region, and a much smaller number with cutaneous and extra-cutaneous melanomas.  Because of their limitations, great effort has been expended over the past 40 years to develop new boron delivery agents that have more favorable biodistribution and uptake for clinical use.  These include boron-containing porphyrins, amino acids, polyamines, nucleosides, peptides, monoclonal antibodies, liposomes, nanoparticles of various types, boron cluster compounds and co-polymers.  Currently, however, none of these have reached the stage where there is enough convincing data to warrant clinical biodistribution studies.  Therefore, at present the best way to further improve the clinical efficacy of BNCT would be to optimize the dosing paradigms and delivery of BPA and BSH, either alone or in combination, with the hope that future research will identify new and better boron delivery agents for clinical use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR-_cHN3uno-8NIRw0GKUoEfW6udTcc2eZagxI0Bzrelrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MbosFantw%253D%253D&md5=4580caac6fbe21e1487ca8bb897f96ed</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1186%2Fs40880-018-0299-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40880-018-0299-7%26sid%3Dliteratum%253Aachs%26aulast%3DBarth%26aufirst%3DR.%2BF.%26aulast%3DMi%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DW.%26atitle%3DBoron%2520delivery%2520agents%2520for%2520neutron%2520capture%2520therapy%2520of%2520cancer%26jtitle%3DCancer%2520Commun.%2520%2528Lond%2529.%26date%3D2018%26volume%3D38%26spage%3D35%26doi%3D10.1186%2Fs40880-018-0299-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Körner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waser, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reubi, J. C.</span></span> <span> </span><span class="NLM_article-title">High expression of neuropeptide Y1 receptors in ewing sarcoma tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">5043</span>– <span class="NLM_lpage">5049</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-4551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1158%2F1078-0432.CCR-07-4551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=18698022" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A280%3ADC%252BD1crhsVyhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=5043-5049&author=M.+K%C3%B6rnerauthor=B.+Waserauthor=J.+C.+Reubi&title=High+expression+of+neuropeptide+Y1+receptors+in+ewing+sarcoma+tumors&doi=10.1158%2F1078-0432.CCR-07-4551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">High expression of neuropeptide Y1 receptors in ewing sarcoma tumors</span></div><div class="casAuthors">Korner Meike; Waser Beatrice; Reubi Jean Claude</div><div class="citationInfo"><span class="NLM_cas:title">Clinical cancer research : an official journal of the American Association for Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5043-9</span>
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    </div><div class="casAbstract">PURPOSE:  Peptide receptors are frequently overexpressed in human tumors, allowing receptor-targeted scintigraphic imaging and therapy with radiolabeled peptide analogues.  Neuropeptide Y (NPY) receptors are new candidates for these applications, based on their high expression in specific cancers.  Because NPY receptors are expressed in selected sarcoma cell lines and because novel treatment options are needed for sarcomas, this study assessed the NPY receptor in primary human sarcomas.  EXPERIMENTAL DESIGN:  Tumor tissues of 88 cases, including Ewing sarcoma family of tumors (ESFT), synovial sarcomas, osteosarcomas, chondrosarcomas, liposarcomas, angiosarcomas, rhabdomyosarcomas, leiomyosarcomas, and desmoid tumors, were investigated for NPY receptor protein with in vitro receptor autoradiography using (125)I-labeled NPY receptor ligands and for NPY receptor mRNA expression with in situ hybridization.  RESULTS:  ESFT expressed the NPY receptor subtype Y1 on tumor cells in remarkably high incidence (84%) and density (mean, 5,314 dpm/mg tissue).  Likewise, synovial sarcomas expressed Y1 on tumor cells in high density (mean, 7,497 dpm/mg; incidence, 40%).  The remaining tumors expressed NPY receptor subtypes Y1 or Y2 at lower levels.  Moreover, many of the sarcomas showed Y1 expression on intratumoral blood vessels.  In situ hybridization for Y1 mRNA confirmed the autoradiography results.  CONCLUSIONS:  NPY receptors are novel molecular markers for human sarcomas.  Y1 may inhibit growth of specific sarcomas, as previously shown in an in vivo mouse model of human ESFT.  The high Y1 expression on tumor cells of ESFT and synovial sarcomas and on blood vessels in many other sarcomas represents an attractive basis for an in vivo tumor targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTuDvMZ7pFzitLIORRPd5lbfW6udTcc2eZagxI0Bzrelrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1crhsVyhuw%253D%253D&md5=969fda27f4733e5d578f339933be4c74</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-4551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-4551%26sid%3Dliteratum%253Aachs%26aulast%3DK%25C3%25B6rner%26aufirst%3DM.%26aulast%3DWaser%26aufirst%3DB.%26aulast%3DReubi%26aufirst%3DJ.%2BC.%26atitle%3DHigh%2520expression%2520of%2520neuropeptide%2520Y1%2520receptors%2520in%2520ewing%2520sarcoma%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D5043%26epage%3D5049%26doi%3D10.1158%2F1078-0432.CCR-07-4551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gabel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairchild, R. G.</span></span> <span> </span><span class="NLM_article-title">The Monte Carlo simulation of the biological effect of the 10B(n, alpha)7Li reaction in cells and tissue and its implication for boron neutron capture therapy</span>. <i>Radiat. Res.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">14</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.2307/3577018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.2307%2F3577018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=3602351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADyaL2sXkslenur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=1987&pages=14-25&author=D.+Gabelauthor=S.+Fosterauthor=R.+G.+Fairchild&title=The+Monte+Carlo+simulation+of+the+biological+effect+of+the+10B%28n%2C+alpha%297Li+reaction+in+cells+and+tissue+and+its+implication+for+boron+neutron+capture+therapy&doi=10.2307%2F3577018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">The Monte Carlo simulation of the biological effect on the 10B(n,α)7Li reaction in cells and tissue and its implication for boron neutron capture therapy</span></div><div class="casAuthors">Gabel, Detlef; Foster, Sheila; Fairchild, Ralph G.</div><div class="citationInfo"><span class="NLM_cas:title">Radiation Research</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">14-25</span>CODEN:
                <span class="NLM_cas:coden">RAREAE</span>;
        ISSN:<span class="NLM_cas:issn">0033-7587</span>.
    </div><div class="casAbstract">The energy deposition in the nucleus of cells exposed to the 10B(n,α)7Li neutron capture reaction has been calcd. and compared to the measured biol. effect of this reaction.  It was found that a considerable distribution of hit sizes to the nucleus occurs.  The comparison of hit size frequency with the obsd. survival indicates that not every hit, independent of its size, can lead to cell death.  This implies the existence of a hit size effectiveness function.  The anal. shows that the location of B relative to the radiation-sensitive vol. of the cell is of great importance and that av. dose values alone are of limited use for predicting the biol. effect of this reaction.  B accumulating in the cell nucleus is much more efficient in cell killing than the same amt. of B uniformly distributed; its presence in one cell, however, has little effect on its neighboring cells in a tissue.  When B is present on the cell surface of a tissue (as presumably delivered by antibodies), its cell-killing effect is greatly reduced compared to that in uniform distribution.  However, in this case much of the dose to one cell comes from neutron capture reactions occurring on the surface of its neighbor cells.  These data have implications for the choice of B carriers in neutron capture therapy.  The math. anal. carried out here is similar to that proposed recently for low-level exposure effects of radiation, taking mutation and/or carcinogenesis as biol. effects.  The results here show that high-level exposure to high linear energy transfer particles (resulting in cell killing) should be treated in an analogous manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwl3Ha5xw3WrVg90H21EOLACvtfcHk0lj_3lTKVHWL3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXkslenur4%253D&md5=eab28332c0b0ae59f05978c0c9cbf740</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.2307%2F3577018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2307%252F3577018%26sid%3Dliteratum%253Aachs%26aulast%3DGabel%26aufirst%3DD.%26aulast%3DFoster%26aufirst%3DS.%26aulast%3DFairchild%26aufirst%3DR.%2BG.%26atitle%3DThe%2520Monte%2520Carlo%2520simulation%2520of%2520the%2520biological%2520effect%2520of%2520the%252010B%2528n%252C%2520alpha%25297Li%2520reaction%2520in%2520cells%2520and%2520tissue%2520and%2520its%2520implication%2520for%2520boron%2520neutron%2520capture%2520therapy%26jtitle%3DRadiat.%2520Res.%26date%3D1987%26volume%3D111%26spage%3D14%26epage%3D25%26doi%3D10.2307%2F3577018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schirrmacher, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirrmacher, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trautman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rösch, F.</span></span> <span> </span><span class="NLM_article-title">Synthesis of a Tyr3-octreotate conjugated closo-carborane [HC<sub>2</sub>B<sub>10</sub>H<sub>10</sub>]</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">9143</span>– <span class="NLM_lpage">9145</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2003.10.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1016%2Fj.tetlet.2003.10.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovF2ltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2003&pages=9143-9145&author=E.+Schirrmacherauthor=R.+Schirrmacherauthor=C.+Beckauthor=W.+Mierauthor=N.+Trautmanauthor=F.+R%C3%B6sch&title=Synthesis+of+a+Tyr3-octreotate+conjugated+closo-carborane+%5BHC2B10H10%5D&doi=10.1016%2Fj.tetlet.2003.10.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of a Tyr3-octreotate conjugated closo-carborane [HC2B10H10]: a potential compound for boron neutron capture therapy</span></div><div class="casAuthors">Schirrmacher, Esther; Schirrmacher, Ralf; Beck, Carmen; Mier, Walter; Trautman, Norbert; Rosch, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">9143-9145</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A novel Tyr3-octreotate conjugated closo-carborane as a potential compd. for boron neutron capture therapy was obtained via Fmoc (Fmoc = 9-fluorenylmethyloxycarbonyl) solid phase peptide synthesis.  The boron cluster [C2B10H11] was introduced through the reaction of 6,9-bis(acetonitrile)decaborane and 5-hexynoic acid yielding a new closo-carborane conjugated carboxylic acid which was coupled subsequently with solid phase conjugated Tyr3-octreotate.  The final boron-contg. peptide was purified by preparative reverse phase HPLC and structural identity was proved applying MALDI-TOF mass spectrometry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDfu1KH0IpB7Vg90H21EOLACvtfcHk0lj_3lTKVHWL3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovF2ltL8%253D&md5=9d175eab88f70e88d89bfe9ed622283c</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2003.10.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2003.10.048%26sid%3Dliteratum%253Aachs%26aulast%3DSchirrmacher%26aufirst%3DE.%26aulast%3DSchirrmacher%26aufirst%3DR.%26aulast%3DBeck%26aufirst%3DC.%26aulast%3DMier%26aufirst%3DW.%26aulast%3DTrautman%26aufirst%3DN.%26aulast%3DR%25C3%25B6sch%26aufirst%3DF.%26atitle%3DSynthesis%2520of%2520a%2520Tyr3-octreotate%2520conjugated%2520closo-carborane%2520%255BHC2B10H10%255D%26jtitle%3DTetrahedron%2520Lett.%26date%3D2003%26volume%3D44%26spage%3D9143%26epage%3D9145%26doi%3D10.1016%2Fj.tetlet.2003.10.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberkorn, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenhut, M.</span></span> <span> </span><span class="NLM_article-title">Conjugation of the closo-borane mercaptoundecahydrododecaborate (BSH) to a tumour selective peptide</span>. <i>Z. Anorg. Allg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>630</i></span>,  <span class="NLM_fpage">1258</span>– <span class="NLM_lpage">1262</span>, <span class="refDoi"> DOI: 10.1002/zaac.200400064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1002%2Fzaac.200400064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmsFSntLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=630&publication_year=2004&pages=1258-1262&author=W.+Mierauthor=D.+Gabelauthor=U.+Haberkornauthor=M.+Eisenhut&title=Conjugation+of+the+closo-borane+mercaptoundecahydrododecaborate+%28BSH%29+to+a+tumour+selective+peptide&doi=10.1002%2Fzaac.200400064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Conjugation of the closo-borane mercaptoundecahydrododecaborate (BSH) to a tumor selective peptide</span></div><div class="casAuthors">Mier, Walter; Gabel, Detlef; Haberkorn, Uwe; Eisenhut, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Zeitschrift fuer Anorganische und Allgemeine Chemie</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">630</span>
        (<span class="NLM_cas:issue">8-9</span>),
    <span class="NLM_cas:pages">1258-1262</span>CODEN:
                <span class="NLM_cas:coden">ZAACAB</span>;
        ISSN:<span class="NLM_cas:issn">0044-2313</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The non-toxic disodium mercaptoundecahydrododecaborate (BSH) is one of the most promising agents known for boron-neutron-capture therapy (BNCT).  In order to enhance the intratumoral concn. of the boron cluster by receptor mediated endocytosis, a synthetic method for the conjugation of borane clusters to peptides was developed.  A Michael addn. was performed to link BSH to the thiol reactive maleimido modified Tyr3-octreotate.  Tyr3-octreotate, synthesized by Fmoc-solid phase peptide synthesis, is a selective ligand for somatostatin receptors.  The modified boron cluster was obtained in 68% yield after purifn.  Characterization of the BSH conjugate was performed with HPLC, MALDI-TOF and electrospray mass spectrometry.  The BSH-Tyr3-octreotate conjugate is considered to target receptor-pos. tumors which might further improve the potential of BNCT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAA1G3yAX4-LVg90H21EOLACvtfcHk0liRAPtS2CcT6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmsFSntLc%253D&md5=5c264f0453cbdcbcc757fa5450dcfb09</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1002%2Fzaac.200400064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fzaac.200400064%26sid%3Dliteratum%253Aachs%26aulast%3DMier%26aufirst%3DW.%26aulast%3DGabel%26aufirst%3DD.%26aulast%3DHaberkorn%26aufirst%3DU.%26aulast%3DEisenhut%26aufirst%3DM.%26atitle%3DConjugation%2520of%2520the%2520closo-borane%2520mercaptoundecahydrododecaborate%2520%2528BSH%2529%2520to%2520a%2520tumour%2520selective%2520peptide%26jtitle%3DZ.%2520Anorg.%2520Allg.%2520Chem.%26date%3D2004%26volume%3D630%26spage%3D1258%26epage%3D1262%26doi%3D10.1002%2Fzaac.200400064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Betzel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waser, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reubi, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roesch, F.</span></span> <span> </span><span class="NLM_article-title">closo-borane conjugated regulatory peptides retain high biological affinity: synthesis of closo-borane conjugated Tyr(3)-octreotate derivatives for BNCT</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1796</span>– <span class="NLM_lpage">1802</span>, <span class="refDoi"> DOI: 10.1021/bc800101h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc800101h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVShtLjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2008&pages=1796-1802&author=T.+Betzelauthor=T.+Hessauthor=B.+Waserauthor=J.+C.+Reubiauthor=F.+Roesch&title=closo-borane+conjugated+regulatory+peptides+retain+high+biological+affinity%3A+synthesis+of+closo-borane+conjugated+Tyr%283%29-octreotate+derivatives+for+BNCT&doi=10.1021%2Fbc800101h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">closo-Borane Conjugated Regulatory Peptides Retain High Biological Affinity: Synthesis of closo-Borane Conjugated Tyr3-Octreotate Derivatives for BNCT</span></div><div class="casAuthors">Betzel, Thomas; Hess, Tobias; Waser, Beatrice; Reubi, Jean-C.; Roesch, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1796-1802</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Despite the improvements in cancer therapy during the past years, high-grade gliomas and many other types of cancer are still extremely resistant to current forms of therapy.  Boron neutron capture therapy (BNCT) provides a promising way to destroy cancer cells without damaging healthy tissue.  However, BNCT in practice is still limited due to the lack of boron-contg. compds. that selectively deliver boron to cancer cells.  Since many neuroendocrine tumors show an overexpression of the somatostatin receptor, it was our aim to synthesize compds. that contain a large no. of boron atoms and still show high affinity toward this transmembrane receptor.  The synthetic peptide Tyr3-octreotate (TATE) was chosen as a high-affinity and internalizing tumor targeting vector (TTV).  Novel boron cluster compds., contg. 10 or 20 boron atoms, were coupled to the N-terminus of TATE.  The obtained affinity data demonstrate that the use of a spacer between TATE and the closo-borane moiety is the option to avoid a loss of biol. affinity of closo-borane conjugated TATE.  For the first time, it was shown that closo-borane conjugated regulatory peptides retain high biol. affinity and selectivity toward their transmembrane tumor receptors.  The results obtained and the improvement of spacer and boron building block chem. may stimulate new directions for BNCT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrB-TrLFb3XmbVg90H21EOLACvtfcHk0liRAPtS2CcT6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVShtLjL&md5=91b9559936a84427015dad982c2276c1</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fbc800101h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc800101h%26sid%3Dliteratum%253Aachs%26aulast%3DBetzel%26aufirst%3DT.%26aulast%3DHess%26aufirst%3DT.%26aulast%3DWaser%26aufirst%3DB.%26aulast%3DReubi%26aufirst%3DJ.%2BC.%26aulast%3DRoesch%26aufirst%3DF.%26atitle%3Dcloso-borane%2520conjugated%2520regulatory%2520peptides%2520retain%2520high%2520biological%2520affinity%253A%2520synthesis%2520of%2520closo-borane%2520conjugated%2520Tyr%25283%2529-octreotate%2520derivatives%2520for%2520BNCT%26jtitle%3DBioconjugate%2520Chem.%26date%3D2008%26volume%3D19%26spage%3D1796%26epage%3D1802%26doi%3D10.1021%2Fbc800101h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Valliant, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guenther, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaffer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sogbein, O. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephenson, K. A.</span></span> <span> </span><span class="NLM_article-title">The medicinal chemistry of carboranes</span>. <i>Coord. Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>232</i></span>,  <span class="NLM_fpage">173</span>– <span class="NLM_lpage">230</span>, <span class="refDoi"> DOI: 10.1016/S0010-8545(02)00087-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1016%2FS0010-8545%2802%2900087-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD38XntF2kur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=232&publication_year=2002&pages=173-230&author=J.+F.+Valliantauthor=K.+J.+Guentherauthor=A.+S.+Kingauthor=P.+Morelauthor=P.+Schafferauthor=O.+O.+Sogbeinauthor=K.+A.+Stephenson&title=The+medicinal+chemistry+of+carboranes&doi=10.1016%2FS0010-8545%2802%2900087-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The medicinal chemistry of carboranes</span></div><div class="casAuthors">Valliant, John F.; Guenther, Katharina J.; King, Arienne S.; Morel, Pierre; Schaffer, Paul; Sogbein, Oyebola O.; Stephenson, Karin A.</div><div class="citationInfo"><span class="NLM_cas:title">Coordination Chemistry Reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">232</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">173-230</span>CODEN:
                <span class="NLM_cas:coden">CCHRAM</span>;
        ISSN:<span class="NLM_cas:issn">0010-8545</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  The medicinal chem. of dicarba-closo-dodecaboranes (otherwise referred to as carboranes) has traditionally centered on their use in B neutron capture therapy (BNCT).  More recently, work has begun to exploit the unique chem. and phys. properties of carboranes for the prepn. of novel inorg. pharmaceuticals and biol. probes.  This review is designed to highlight some of the recent work concerning medicinal carborane chem. including the synthesis and testing of new BNCT agents, use of carboranes in medical imaging, and use of carboranes as pharmacophores.  Following this review, as an appendix, is an illustrated summary of reactions involving carboranes reported in literature since 1992.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNW7Buyv6o17Vg90H21EOLACvtfcHk0liRAPtS2CcT6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntF2kur8%253D&md5=52e3a1bb3de706088f181207d6a3e377</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2FS0010-8545%2802%2900087-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0010-8545%252802%252900087-5%26sid%3Dliteratum%253Aachs%26aulast%3DValliant%26aufirst%3DJ.%2BF.%26aulast%3DGuenther%26aufirst%3DK.%2BJ.%26aulast%3DKing%26aufirst%3DA.%2BS.%26aulast%3DMorel%26aufirst%3DP.%26aulast%3DSchaffer%26aufirst%3DP.%26aulast%3DSogbein%26aufirst%3DO.%2BO.%26aulast%3DStephenson%26aufirst%3DK.%2BA.%26atitle%3DThe%2520medicinal%2520chemistry%2520of%2520carboranes%26jtitle%3DCoord.%2520Chem.%2520Rev.%26date%3D2002%26volume%3D232%26spage%3D173%26epage%3D230%26doi%3D10.1016%2FS0010-8545%2802%2900087-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scholz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hey-Hawkins, E.</span></span> <span> </span><span class="NLM_article-title">Carbaboranes as pharmacophores: properties, synthesis, and application strategies</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">7035</span>– <span class="NLM_lpage">7062</span>, <span class="refDoi"> DOI: 10.1021/cr200038x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr200038x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptlSltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2011&pages=7035-7062&author=M.+Scholzauthor=E.+Hey-Hawkins&title=Carbaboranes+as+pharmacophores%3A+properties%2C+synthesis%2C+and+application+strategies&doi=10.1021%2Fcr200038x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Carbaboranes as Pharmacophores: Properties, Synthesis, and Application Strategies</span></div><div class="casAuthors">Scholz, Matthias; Hey-Hawkins, Evamarie</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">7035-7062</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Geometry and electronic structure make carbaboranes unique artificial pharmacophores that are inert to catabolism, because corresponding enzymes are not known.  Most frequently, carbaboranes are used as hydrophobic pharmacophores to address hydrophobic binding sites of biol. targets.  The icosahedral cluster with its very versatile chem. allows attachment of all org. substituents that are necessary in drug design in mostly high-yielding syntheses.  The orthogonality of the reactions at the carbonatoms to those at the boron atoms renders regioselective substitutions easily possible.  The extraordinary electronic structure makes the carbaboranes yet more than just scaffolds.  This is expressed byhydrogen and dihydrogen bonds with CH or BH vertices and by the influence on adjacent substituents.  The inductive effects at different cluster positions fine-tune adjacent functionalities, which is particularly useful to adjust a pharmacophoric entity to a biol. target.  The option to increase the size by modifying multiple boron vertices makes the cluster addnl. superior to classical org. fragments such as benzene and adamantane.  The deboronation reaction allows formation of charged cluster species and thus modification of the soly.  This option is very pronounced for ortho-carbaborane, which also clearly differs from the other two isomers in pharmacol. behavior and should therefore be regarded as functional group.  The carbaboranyl-Ph arrangement in general turned out to be a very good scaffold to address different targets by addn. of particular substituents.  All these aspects make carbaboranes unique and yet underrepresented pharmacophores, which will hopefully change in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqngRuxXCYl9LVg90H21EOLACvtfcHk0lgSLljbUFKxHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptlSltb8%253D&md5=46592230e62a115fb669620da5540bab</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fcr200038x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr200038x%26sid%3Dliteratum%253Aachs%26aulast%3DScholz%26aufirst%3DM.%26aulast%3DHey-Hawkins%26aufirst%3DE.%26atitle%3DCarbaboranes%2520as%2520pharmacophores%253A%2520properties%252C%2520synthesis%252C%2520and%2520application%2520strategies%26jtitle%3DChem.%2520Rev.%26date%3D2011%26volume%3D111%26spage%3D7035%26epage%3D7062%26doi%3D10.1021%2Fcr200038x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieland, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittneben, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willim, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolf, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, G.</span></span> <span> </span><span class="NLM_article-title">Complete L-alanine scan of neuropeptide Y reveals ligands binding to Y1 and Y2 receptors with distinguished conformations</span>. <i>Eur. J. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>225</i></span>,  <span class="NLM_fpage">947</span>– <span class="NLM_lpage">958</span>, <span class="refDoi"> DOI: 10.1111/j.1432-1033.1994.0947b.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1111%2Fj.1432-1033.1994.0947b.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=7957231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADyaK2cXmsVKmtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=225&publication_year=1994&pages=947-958&author=A.+G.+Beck-Sickingerauthor=H.+A.+Wielandauthor=H.+Wittnebenauthor=K.+D.+Willimauthor=K.+Rudolfauthor=G.+Jung&title=Complete+L-alanine+scan+of+neuropeptide+Y+reveals+ligands+binding+to+Y1+and+Y2+receptors+with+distinguished+conformations&doi=10.1111%2Fj.1432-1033.1994.0947b.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Complete L-alanine scan of neuropeptide Y reveals ligands binding to Y1 and Y2 receptors with distinguished conformations</span></div><div class="casAuthors">Beck-Sickinger, Annette G.; Wieland, Heike A.; Wittneben, Helmut; Willim, Klaus-Dieter; Rudolf, Klaus; Jung, Guenther</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">225</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">947-58</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    </div><div class="casAbstract">The synthesis of more than fifty 36-residue oligopeptide analogs of neuropeptide Y (NPY) and their affinity to human Y1 and Y2 receptors is described.  Each amino acid of the natural sequence was replaced by L-alanine, the four alanine residues at position 12, 14, 18 and 23 were replaced by glycine.  Addnl. residues were exchanged to closely related ones to characterize the prerequisites for binding.  A combination of automated single and multiple peptide synthesis using fluoren-9-ylmethoxycarbonyl/tert-butoxy strategy was applied.  The purified peptides were characterized by electrospray mass spectrometry, anal. HPLC and amino acid anal.  Binding was investigated by displacement of 125I-labeled neuropeptide Y from human neuroblastoma cell lines SK-N-MC and SMS-KAN. PhenylalanineABS: whereas Pro2 and the integrity of the neuropeptide Y loop is important for the binding to the Y1 receptor, exchanges within the C-terminal helix affect the affinity to the Y2 receptor.  The C-terminal pentapeptide amide is important for both receptors and probably represents the binding site.  However, Arg33 and Arg35 may not be exchanged by L-alanine in the Y1 system, whereas Arg35 and Tyr36 are the most susceptible residues in the Y2 system.  To distinguish between conformational effects and direct hormone/receptor interaction via the side chains of neuropeptide Y, circular dichroic studies of the alanine-contg. peptides were performed and structure affinity relationships are discussed.  Comparing the affinities of the neuropeptide Y analogs to Y1 and Y2 receptors significant differences were found for the two binding sites, which suggests a different active conformation of neuropeptide Y at the two subtypes of receptors.  Using mol. dynamics calcns., two distinct conformations were identified which are in good agreement with the data obtained by structure/affinity investigations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCypHQPmEPgLVg90H21EOLACvtfcHk0lgSLljbUFKxHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmsVKmtbk%253D&md5=617d86a9c13fdca96b2e38d87d94705d</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1111%2Fj.1432-1033.1994.0947b.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1432-1033.1994.0947b.x%26sid%3Dliteratum%253Aachs%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26aulast%3DWieland%26aufirst%3DH.%2BA.%26aulast%3DWittneben%26aufirst%3DH.%26aulast%3DWillim%26aufirst%3DK.%2BD.%26aulast%3DRudolf%26aufirst%3DK.%26aulast%3DJung%26aufirst%3DG.%26atitle%3DComplete%2520L-alanine%2520scan%2520of%2520neuropeptide%2520Y%2520reveals%2520ligands%2520binding%2520to%2520Y1%2520and%2520Y2%2520receptors%2520with%2520distinguished%2520conformations%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D1994%26volume%3D225%26spage%3D947%26epage%3D958%26doi%3D10.1111%2Fj.1432-1033.1994.0947b.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Svantesson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettersson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olin, Å.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markides, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjöberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallec, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shono, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toftlund, H.</span></span> <span> </span><span class="NLM_article-title">A kinetic study of the self-degradation of o-carboranylalanine to nido-carboranylalanine in solution</span>. <i>Acta Chem. Scand.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">731</span>– <span class="NLM_lpage">736</span>, <span class="refDoi"> DOI: 10.3891/acta.chem.scand.53-0731</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.3891%2Facta.chem.scand.53-0731" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADyaK1MXmtVaqt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1999&pages=731-736&author=E.+Svantessonauthor=J.+Petterssonauthor=%C3%85.+Olinauthor=K.+Markidesauthor=S.+Sj%C3%B6bergauthor=A.+Tallecauthor=T.+Shonoauthor=H.+Toftlund&title=A+kinetic+study+of+the+self-degradation+of+o-carboranylalanine+to+nido-carboranylalanine+in+solution&doi=10.3891%2Facta.chem.scand.53-0731"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">A kinetic study of the self-degradation of o-carboranylalanine to nido-carboranylalanine in solution</span></div><div class="casAuthors">Svantesson, Eva; Pettersson, Jean; Olin, Ake; Markides, Karin; Sjoberg, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Acta Chemica Scandinavica</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">731-736</span>CODEN:
                <span class="NLM_cas:coden">ACHSE7</span>;
        ISSN:<span class="NLM_cas:issn">0904-213X</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard International Publishers Ltd.</span>)
        </div><div class="casAbstract">The spontaneous degrdn. of racemic o-carboranylalanine [3-(1,2-dicarba-closo-dodecaboran(12)-1-yl)-2-aminopropanoic acid], a carborane analog of the amino acid phenylalanine, to the corresponding diastereomeric, racemic pairs of nido-carboranylalanine [contg. the dodecahydro-7,8-dicarba-nido-undecaborate(1-) cage] was studied in buffered water-MeOH soln. at three temps.  The parent compd. and the two diastereomeric reaction products were sepd. off-line by liq. chromatog.  The reaction is 1st order with respect to o-carboranylalanine.  The rate is pH dependent with a broad max. around pH 5, where the zwitterion form predominates.  Rate consts. and activation parameters for the formation of the two nido-compds. were detd.  The activation entropies close to zero (0 and 3 J K-1 mol-1, resp.) show that the loss of one B atom from o-carboranylalanine is a unimol. process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot9g5Jr-ONhbVg90H21EOLACvtfcHk0lgSLljbUFKxHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmtVaqt7Y%253D&md5=749ca5620e7c62e9459e6db0f2b5bc54</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.3891%2Facta.chem.scand.53-0731&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3891%252Facta.chem.scand.53-0731%26sid%3Dliteratum%253Aachs%26aulast%3DSvantesson%26aufirst%3DE.%26aulast%3DPettersson%26aufirst%3DJ.%26aulast%3DOlin%26aufirst%3D%25C3%2585.%26aulast%3DMarkides%26aufirst%3DK.%26aulast%3DSj%25C3%25B6berg%26aufirst%3DS.%26aulast%3DTallec%26aufirst%3DA.%26aulast%3DShono%26aufirst%3DT.%26aulast%3DToftlund%26aufirst%3DH.%26atitle%3DA%2520kinetic%2520study%2520of%2520the%2520self-degradation%2520of%2520o-carboranylalanine%2520to%2520nido-carboranylalanine%2520in%2520solution%26jtitle%3DActa%2520Chem.%2520Scand.%26date%3D1999%26volume%3D53%26spage%3D731%26epage%3D736%26doi%3D10.3891%2Facta.chem.scand.53-0731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Azev, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slepukhina, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabel, D.</span></span> <span> </span><span class="NLM_article-title">Synthesis of boron-containing heterocyclic compounds</span>. <i>Appl. Radiat. Isot.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1107</span>– <span class="NLM_lpage">1110</span>, <span class="refDoi"> DOI: 10.1016/j.apradiso.2004.05.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1016%2Fj.apradiso.2004.05.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=15308200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD2cXms1yhur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2004&pages=1107-1110&author=Y.+Azevauthor=I.+Slepukhinaauthor=D.+Gabel&title=Synthesis+of+boron-containing+heterocyclic+compounds&doi=10.1016%2Fj.apradiso.2004.05.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of boron-containing heterocyclic compounds</span></div><div class="casAuthors">Azev, Yuri; Slepukhina, Irina; Gabel, Detlef</div><div class="citationInfo"><span class="NLM_cas:title">Applied Radiation and Isotopes</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1107-1110</span>CODEN:
                <span class="NLM_cas:coden">ARISEF</span>;
        ISSN:<span class="NLM_cas:issn">0969-8043</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The synthesis of B-contg. 1,3,5-triazines and 1,2,4-triazines is described.  Derivs. of 1,3,5-triazine contg. the o-carborane cluster were obtained by reacting the corresponding propargyl derivs. with B10H14.  Derivs. of 1,2,4-triazine contg. the B12H122- cluster were obtained by nucleophilic substitution of alkylsulfone derivs. with B12H11SH2-.  They were isolated in their ring-protonated form.  Reaction of RNH2-B8H11NH-R with sterically demanding heterocycles failed, either for steric or for soly. reasons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMcG86aY1aArVg90H21EOLACvtfcHk0li53SIvfuqDmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXms1yhur8%253D&md5=b60a4fa42a4bab37ec9e388dac1c8050</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.apradiso.2004.05.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apradiso.2004.05.002%26sid%3Dliteratum%253Aachs%26aulast%3DAzev%26aufirst%3DY.%26aulast%3DSlepukhina%26aufirst%3DI.%26aulast%3DGabel%26aufirst%3DD.%26atitle%3DSynthesis%2520of%2520boron-containing%2520heterocyclic%2520compounds%26jtitle%3DAppl.%2520Radiat.%2520Isot.%26date%3D2004%26volume%3D61%26spage%3D1107%26epage%3D1110%26doi%3D10.1016%2Fj.apradiso.2004.05.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.-D.</span></span> <span> </span><span class="NLM_article-title">Synthesis and characterization of o-carboranylthiolate substituted 1,3,5-triazines</span>. <i>Bull. Korean Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">697</span>– <span class="NLM_lpage">700</span>, <span class="refDoi"> DOI: 10.5012/bkcs.2008.29.3.697</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.5012%2Fbkcs.2008.29.3.697" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlt1Ois74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2008&pages=697-700&author=C.-H.+Leeauthor=G.+F.+Jinauthor=H.-S.+Kimauthor=H.+Nakamuraauthor=J.-D.+Lee&title=Synthesis+and+characterization+of+o-carboranylthiolate+substituted+1%2C3%2C5-triazines&doi=10.5012%2Fbkcs.2008.29.3.697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and characterization of o-carboranylthiolate substituted 1,3,5-triazines</span></div><div class="casAuthors">Lee, Chai-Ho; Jin, Guo Fan; Kim, Hyo-Suk; Nakamura, Hiroyuki; Lee, Jong-Dae</div><div class="citationInfo"><span class="NLM_cas:title">Bulletin of the Korean Chemical Society</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">697-700</span>CODEN:
                <span class="NLM_cas:coden">BKCSDE</span>;
        ISSN:<span class="NLM_cas:issn">0253-2964</span>.
    
            (<span class="NLM_cas:orgname">Korean Chemical Society</span>)
        </div><div class="casAbstract">Ortho-carboranyl 1,3,5-triazin-2-yl thioethers were prepd. from appropriate Li thiolates and chlorotriazines.  The products are moderately stable in air and decomp. slowly on contact with light and moisture.  Unexpectedly, toxicity was not improved, but boron uptake in B-16 melanoma cells increased.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCH4WeCcw_IbVg90H21EOLACvtfcHk0li53SIvfuqDmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlt1Ois74%253D&md5=babd13772edafbb38cd676e4bb7eb8e0</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.5012%2Fbkcs.2008.29.3.697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5012%252Fbkcs.2008.29.3.697%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.-H.%26aulast%3DJin%26aufirst%3DG.%2BF.%26aulast%3DKim%26aufirst%3DH.-S.%26aulast%3DNakamura%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DJ.-D.%26atitle%3DSynthesis%2520and%2520characterization%2520of%2520o-carboranylthiolate%2520substituted%25201%252C3%252C5-triazines%26jtitle%3DBull.%2520Korean%2520Chem.%2520Soc.%26date%3D2008%26volume%3D29%26spage%3D697%26epage%3D700%26doi%3D10.5012%2Fbkcs.2008.29.3.697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockwell, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knobler, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawthorne, M. F.</span></span> <span> </span><span class="NLM_article-title">Synthesis and characterization of water-soluble boron-substituted ortho-carborane derivatives</span>. <i>C. R. Acad. Sci., Ser. IIc: Chim.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">223</span>– <span class="NLM_lpage">229</span>, <span class="refDoi"> DOI: 10.1016/S1387-1609(00)00132-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1016%2FS1387-1609%2800%2900132-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlvFOqsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2000&pages=223-229&author=W.+Chenauthor=M.+Diazauthor=J.+J.+Rockwellauthor=C.+B.+Knoblerauthor=M.+F.+Hawthorne&title=Synthesis+and+characterization+of+water-soluble+boron-substituted+ortho-carborane+derivatives&doi=10.1016%2FS1387-1609%2800%2900132-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and characterization of water-soluble boron-substituted ortho-carborane derivatives</span></div><div class="casAuthors">Chen, Weilin; Diaz, Martin; Rockwell, Juston J.; Knobler, Carolyn B.; Hawthorne, M. Frederick</div><div class="citationInfo"><span class="NLM_cas:title">Comptes Rendus de l'Academie des Sciences, Serie IIc: Chimie</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">223-229</span>CODEN:
                <span class="NLM_cas:coden">CASCFN</span>;
        ISSN:<span class="NLM_cas:issn">1387-1609</span>.
    
            (<span class="NLM_cas:orgname">Editions Scientifiques et Medicales Elsevier</span>)
        </div><div class="casAbstract">The synthesis of water-sol., boron-substituted carborane derivs. was achieved by treatment of boron-substituted bromoalkyl carborane derivs. with trimethylphosphine to yield the corresponding phosphonium salts.  These new carborane salts exhibit soly. in both aq. and polar org. media.  The synthesis and characterization of the first water-sol., boron-substituted carborane species, closo-9,12-(CH2CH2CH2P(CH3)3+Br-)2-1,2-C2B10H10, 4, and closo-3-[CH2CH2CH2P(CH3)3+B r-]-1,2-C2B10H11, 5 is reported.  The crystal structure of 5 is reported.  Addnl., another method of prepg. mono- and difunctionalized water-sol. phosphonium salts of B3-substituted carborane derivs. was developed.  This method produces both the monophosphonium salt, closo-3-[CH2CH(CH2I)CH2P(CH3)3+ I-]-1,2-C2B10H11 and the diphosphonium salt, closo-3-[CH2CH(CH2P(CH3)3+I-)2]-1,2-C2B10H11.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlQBRd4fWiobVg90H21EOLACvtfcHk0li53SIvfuqDmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlvFOqsbg%253D&md5=f94414345d6496a2326937c8848e06c1</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2FS1387-1609%2800%2900132-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1387-1609%252800%252900132-8%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DW.%26aulast%3DDiaz%26aufirst%3DM.%26aulast%3DRockwell%26aufirst%3DJ.%2BJ.%26aulast%3DKnobler%26aufirst%3DC.%2BB.%26aulast%3DHawthorne%26aufirst%3DM.%2BF.%26atitle%3DSynthesis%2520and%2520characterization%2520of%2520water-soluble%2520boron-substituted%2520ortho-carborane%2520derivatives%26jtitle%3DC.%2520R.%2520Acad.%2520Sci.%252C%2520Ser.%2520IIc%253A%2520Chim.%26date%3D2000%26volume%3D3%26spage%3D223%26epage%3D229%26doi%3D10.1016%2FS1387-1609%2800%2900132-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nemoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, Y.</span></span> <span> </span><span class="NLM_article-title">Polyols of a cascade type as a water-solubilizing element of carborane derivatives for boron neutron capture therapy</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">435</span>– <span class="NLM_lpage">435</span>, <span class="refDoi"> DOI: 10.1021/jo00028a010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00028a010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADyaK38XktVylsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1992&pages=435-435&author=H.+Nemotoauthor=J.+G.+Wilsonauthor=H.+Nakamuraauthor=Y.+Yamamoto&title=Polyols+of+a+cascade+type+as+a+water-solubilizing+element+of+carborane+derivatives+for+boron+neutron+capture+therapy&doi=10.1021%2Fjo00028a010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Polyols of a cascade type as a water-solubilizing element of carborane derivatives for boron neutron capture therapy</span></div><div class="casAuthors">Nemoto, Hisao; Wilson, J. Gerald; Nakamura, Hiroyuki; Yamamoto, Yoshinori</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">435</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">The reaction of epichlorohydrin with benzyl alc. in the presence of Bu4NI, KOH, and water gave 88% 1,3-dibenzyloxy-2-propanol.  The reaction of this alc. with epichlorohydrin under the same conditions produced 88% 1,3-bis[2-(1,3-dibenzylglyceryl]glycerol (I).  Debenzylation of I in the presence of Pd(OH)2 gave the corresponding tetraol (II).  Accordingly, the repeated use of this reaction sequence affords polyols of a cascade type in high yield.  A carborane attached to tetraol (II) was dissolved in water in a concn. of 5.44 M.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpomkj-CROvrbVg90H21EOLACvtfcHk0ljyX-dUNlpPQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XktVylsQ%253D%253D&md5=ebaa346621d961409a73b79f1da8a391</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjo00028a010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00028a010%26sid%3Dliteratum%253Aachs%26aulast%3DNemoto%26aufirst%3DH.%26aulast%3DWilson%26aufirst%3DJ.%2BG.%26aulast%3DNakamura%26aufirst%3DH.%26aulast%3DYamamoto%26aufirst%3DY.%26atitle%3DPolyols%2520of%2520a%2520cascade%2520type%2520as%2520a%2520water-solubilizing%2520element%2520of%2520carborane%2520derivatives%2520for%2520boron%2520neutron%2520capture%2520therapy%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1992%26volume%3D57%26spage%3D435%26epage%3D435%26doi%3D10.1021%2Fjo00028a010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serino, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawthorne, M. F.</span></span> <span> </span><span class="NLM_article-title">Hydrophilically augmented glycosyl carborane derivatives for incorporation in antibody conjugation reagents</span>. <i>Organometallics</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2519</span>– <span class="NLM_lpage">2524</span>, <span class="refDoi"> DOI: 10.1021/om00102a015</span> </span><div class="citationLinks">[<a href="/doi/10.1021/om00102a015" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADyaL1cXmtlWnsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1988&pages=2519-2524&author=J.+L.+Maurerauthor=A.+J.+Serinoauthor=M.+F.+Hawthorne&title=Hydrophilically+augmented+glycosyl+carborane+derivatives+for+incorporation+in+antibody+conjugation+reagents&doi=10.1021%2Fom00102a015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Hydrophilically augmented glycosyl carborane derivatives for incorporation in antibody conjugation reagents</span></div><div class="casAuthors">Maurer, Julie L.; Serino, Anthony J.; Hawthrone, M. Frederick</div><div class="citationInfo"><span class="NLM_cas:title">Organometallics</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2519-24</span>CODEN:
                <span class="NLM_cas:coden">ORGND7</span>;
        ISSN:<span class="NLM_cas:issn">0276-7333</span>.
    </div><div class="casAbstract">The synthesis of a series of O-glycosyl carboranes is described.  The reactions of hydroxyalkyl carboranes and esterified carbohydrates, in the presence of a Lesis acid catalyst, proved to be stereoselective.  Reactions of these carboranes with tri-O-acetyl-D-glucal or di-O-acetyl-D-xylal and a catalytic amt. of BF3.OEt2 favored the formation of α anomers, while the β anomer was the major product of the SnCl4-catalyzed reaction involving hydroxymethyl carborane and 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose.  The 1H and 13C NMR spectra of 1-[(4,6-di-O-acetyl-2,3-dideoxy-α-D-erythro-hex-2-enopyranosyl)methyl]-1,2-dicarba-closo-dodecaborane (I) were analyzed by using several one-dimensional and two-dimensional techniques; the chem. shifts and coupling interactions of all atoms were unequivocally assigned.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdlArPJCvjobVg90H21EOLACvtfcHk0ljyX-dUNlpPQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXmtlWnsrc%253D&md5=1ccbf34904faf2e5242aeb45befb64fc</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fom00102a015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fom00102a015%26sid%3Dliteratum%253Aachs%26aulast%3DMaurer%26aufirst%3DJ.%2BL.%26aulast%3DSerino%26aufirst%3DA.%2BJ.%26aulast%3DHawthorne%26aufirst%3DM.%2BF.%26atitle%3DHydrophilically%2520augmented%2520glycosyl%2520carborane%2520derivatives%2520for%2520incorporation%2520in%2520antibody%2520conjugation%2520reagents%26jtitle%3DOrganometallics%26date%3D1988%26volume%3D7%26spage%3D2519%26epage%3D2524%26doi%3D10.1021%2Fom00102a015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tietze, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bothe, U.</span></span> <span> </span><span class="NLM_article-title">Ortho-carboranyl glycosides of glucose, mannose, maltose and lactose for cancer treatment by boron neutron-capture therapy</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1179</span>– <span class="NLM_lpage">1183</span>, <span class="refDoi"> DOI: 10.1002/(SICI)1521-3765(19980710)4:7<1179::AID-CHEM1179>3.0.CO;2-F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1002%2F%28SICI%291521-3765%2819980710%294%3A7%3C1179%3A%3AAID-CHEM1179%3E3.0.CO%3B2-F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADyaK1cXkvVamu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1998&pages=1179-1183&author=L.+F.+Tietzeauthor=U.+Bothe&title=Ortho-carboranyl+glycosides+of+glucose%2C+mannose%2C+maltose+and+lactose+for+cancer+treatment+by+boron+neutron-capture+therapy&doi=10.1002%2F%28SICI%291521-3765%2819980710%294%3A7%3C1179%3A%3AAID-CHEM1179%3E3.0.CO%3B2-F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Ortho-carboranyl glycosides of glucose, mannose, maltose and lactose for cancer treatment by boron neutron-capture therapy</span></div><div class="casAuthors">Tietze, Lutz F.; Bothe, Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1179-1183</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH</span>)
        </div><div class="casAbstract">Glycosidation of alkynols HO (CH2)n C≡CH using the trichloroacetimidate method led to the alkynyl glycosides (I; R = Ac, R1 = CH2C≡CH), I [R = Ac, (CH2)4C≡CH], (II; R = Ac, R1 = CH2CH2C≡CH), (III; R = Ac, R1 = CH2C≡CH), and IV (R = Ac, R1 = CH2C≡CH) in 53-68% yield, which by reaction with decaborane (B10H14) afforded the protected peracetylated ortho-carboranyl glycosides I (R = Ac, R1 = Q, n = 2), I (R = Ac, R1 = Q1, n = 4), II (R = Ac, R1 = Q, n = 2), III (R = Ac, R1 = Q, n = 1), and IV (R = Ac, R1 = Q, n = 1) in 43-61% yield.  Base-catalyzed solvolysis gave the unprotected glycosides I (R = H, R1 = Q, n = 2), I (R = H, R1 = Q1, n = 4), II (R = H, R1 = Q, n = 2), III (R = H, R1 = Q, n = 1), and IV (R = H, R1 = Q, n = 1) in 71-97% yield.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQvmRlCEiIV7Vg90H21EOLACvtfcHk0ljyX-dUNlpPQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXkvVamu70%253D&md5=b08ed4f66379a95fe43ecac22df77f0e</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291521-3765%2819980710%294%3A7%3C1179%3A%3AAID-CHEM1179%3E3.0.CO%3B2-F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291521-3765%252819980710%25294%253A7%253C1179%253A%253AAID-CHEM1179%253E3.0.CO%253B2-F%26sid%3Dliteratum%253Aachs%26aulast%3DTietze%26aufirst%3DL.%2BF.%26aulast%3DBothe%26aufirst%3DU.%26atitle%3DOrtho-carboranyl%2520glycosides%2520of%2520glucose%252C%2520mannose%252C%2520maltose%2520and%2520lactose%2520for%2520cancer%2520treatment%2520by%2520boron%2520neutron-capture%2520therapy%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D1998%26volume%3D4%26spage%3D1179%26epage%3D1183%26doi%3D10.1002%2F%28SICI%291521-3765%2819980710%294%3A7%3C1179%3A%3AAID-CHEM1179%3E3.0.CO%3B2-F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frank, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hey-Hawkins, E.</span></span> <span> </span><span class="NLM_article-title">A convenient route towards deoxygalactosyl-functionalised <i>ortho</i>-carbaborane</span>. <i>J. Organomet. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>798</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1016/j.jorganchem.2015.08.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1016%2Fj.jorganchem.2015.08.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCnu7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=798&publication_year=2015&pages=46-50&author=R.+Frankauthor=E.+Hey-Hawkins&title=A+convenient+route+towards+deoxygalactosyl-functionalised+ortho-carbaborane&doi=10.1016%2Fj.jorganchem.2015.08.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">A convenient route towards deoxygalactosyl-functionalised ortho-carbaborane: Synthesis of a building block for peptide conjugation</span></div><div class="casAuthors">Frank, Rene; Hey-Hawkins, Evamarie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organometallic Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">798</span>
        (<span class="NLM_cas:issue">Part_1</span>),
    <span class="NLM_cas:pages">46-50</span>CODEN:
                <span class="NLM_cas:coden">JORCAI</span>;
        ISSN:<span class="NLM_cas:issn">0022-328X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In the treatment of cancer, boron neutron capture therapy (BNCT) is a mild and promising alternative to established harsh therapeutic methods such as chemo- and radiation therapy.  However, successful BNCT procedures strongly depend on efficient, tumor-selective boron-delivery systems, and recently we have demonstrated that the breast tumor-selective peptide [F7,P34]-NPY is a promising boron-shuttle system after conjugation with three ortho-carbaborane clusters (1,2-closo-C2B10H10).  The extreme hydrophobicity of the latter, however, causes problems in medicinal applications in vivo.  Therefore, we have elaborated a synthetic protocol towards a deoxygalactosyl-modified (and thus more hydrophilic) building block that can readily be conjugated with the shuttle peptide.  A key intermediate, i.e., ortho-carbaborane functionalised with a bis-isopropylidene-protected deoxygalactosyl moiety, was synthesized by both a silyl protection strategy (which is generally recommended for monosubstitution) and direct reaction of metalated ortho-carbaborane in acceptable yield.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOwwzC6b-GD7Vg90H21EOLACvtfcHk0li0SmV5lp6yOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCnu7jP&md5=4d73743345c43564c7c4703e2c8ea7ad</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.jorganchem.2015.08.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jorganchem.2015.08.011%26sid%3Dliteratum%253Aachs%26aulast%3DFrank%26aufirst%3DR.%26aulast%3DHey-Hawkins%26aufirst%3DE.%26atitle%3DA%2520convenient%2520route%2520towards%2520deoxygalactosyl-functionalised%2520ortho-carbaborane%26jtitle%3DJ.%2520Organomet.%2520Chem.%26date%3D2015%26volume%3D798%26spage%3D46%26epage%3D50%26doi%3D10.1016%2Fj.jorganchem.2015.08.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frank, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahrens, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehnke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hey-Hawkins, E.</span></span> <span> </span><span class="NLM_article-title">Charge-compensated metallacarborane building blocks for conjugation with peptides</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">308</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1002/cbic.201500569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1002%2Fcbic.201500569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=26662708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BC28Xoslaluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=308-317&author=R.+Frankauthor=V.+M.+Ahrensauthor=S.+Boehnkeauthor=A.+G.+Beck-Sickingerauthor=E.+Hey-Hawkins&title=Charge-compensated+metallacarborane+building+blocks+for+conjugation+with+peptides&doi=10.1002%2Fcbic.201500569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Charge-Compensated Metallacarborane Building Blocks for Conjugation with Peptides</span></div><div class="casAuthors">Frank, Rene; Ahrens, Verena M.; Boehnke, Solveig; Beck-Sickinger, Annette G.; Hey-Hawkins, Evamarie</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">308-317</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The cobalt bis(dicarbollide) complex [commo-3,3'-Co(1,2-C2B9H11)2]- has captured much attention in biochem. and medical contexts, in particular for the treatment of tumors by boron neutron capture therapy (BNCT).  Derivs. of cobalt bis(dicarbollide) are commonly prepd. through ring-opening reactions of cyclic oxonium ions, so the corresponding products are usually charged.  Furthermore, attempts to incorporate cobalt bis(dicarbollide) into peptides are rare, despite obvious potential advantages.  Here the synthesis of an imidazolium-based charge-compensated cobalt bis(dicarbollide) building block, which allows addnl. modifications with moieties of biochem. relevance, such as monosaccharides, is reported.  Furthermore, conjugates of these building blocks with the Y1-receptor-selective deriv. of neuropeptide Y ([F7,P34]-NPY) retained excellent response to hY1 receptors found to be overexpressed in breast tumors and metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_KAeTOOESOrVg90H21EOLACvtfcHk0li0SmV5lp6yOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xoslaluw%253D%253D&md5=40a3b207f40db23164ae8bdc9e7c37ea</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201500569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201500569%26sid%3Dliteratum%253Aachs%26aulast%3DFrank%26aufirst%3DR.%26aulast%3DAhrens%26aufirst%3DV.%2BM.%26aulast%3DBoehnke%26aufirst%3DS.%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26aulast%3DHey-Hawkins%26aufirst%3DE.%26atitle%3DCharge-compensated%2520metallacarborane%2520building%2520blocks%2520for%2520conjugation%2520with%2520peptides%26jtitle%3DChemBioChem%26date%3D2016%26volume%3D17%26spage%3D308%26epage%3D317%26doi%3D10.1002%2Fcbic.201500569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kögler, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wifling, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernhardt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plank, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Littmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larhammar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huster, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meiler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buschauer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span> <span> </span><span class="NLM_article-title">Structural basis of ligand binding modes at the neuropeptide Y Y1 receptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>556</i></span>,  <span class="NLM_fpage">520</span>– <span class="NLM_lpage">524</span>, <span class="refDoi"> DOI: 10.1038/s41586-018-0046-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1038%2Fs41586-018-0046-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=29670288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosVCgur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=556&publication_year=2018&pages=520-524&author=Z.+Yangauthor=S.+Hanauthor=M.+Kellerauthor=A.+Kaiserauthor=B.+J.+Benderauthor=M.+Bosseauthor=K.+Burkertauthor=L.+M.+K%C3%B6glerauthor=D.+Wiflingauthor=G.+Bernhardtauthor=N.+Plankauthor=T.+Littmannauthor=P.+Schmidtauthor=C.+Yiauthor=B.+Liauthor=S.+Yeauthor=R.+Zhangauthor=B.+Xuauthor=D.+Larhammarauthor=R.+C.+Stevensauthor=D.+Husterauthor=J.+Meilerauthor=Q.+Zhaoauthor=A.+G.+Beck-Sickingerauthor=A.+Buschauerauthor=B.+Wu&title=Structural+basis+of+ligand+binding+modes+at+the+neuropeptide+Y+Y1+receptor&doi=10.1038%2Fs41586-018-0046-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of ligand binding modes at the neuropeptide Y Y1 receptor</span></div><div class="casAuthors">Yang, Zhenlin; Han, Shuo; Keller, Max; Kaiser, Anette; Bender, Brian J.; Bosse, Mathias; Burkert, Kerstin; Kogler, Lisa M.; Wifling, David; Bernhardt, Guenther; Plank, Nicole; Littmann, Timo; Schmidt, Peter; Yi, Cuiying; Li, Beibei; Ye, Sheng; Zhang, Rongguang; Xu, Bo; Larhammar, Dan; Stevens, Raymond C.; Huster, Daniel; Meiler, Jens; Zhao, Qiang; Beck-Sickinger, Annette G.; Buschauer, Armin; Wu, Beili</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">556</span>
        (<span class="NLM_cas:issue">7702</span>),
    <span class="NLM_cas:pages">520-524</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Neuropeptide Y (NPY) receptors belong to the G-protein-coupled receptor superfamily and have important roles in food intake, anxiety and cancer biol.1,2.  The NPY-Y receptor system has emerged as one of the most complex networks with three peptide ligands (NPY, peptide YY and pancreatic polypeptide) binding to four receptors in most mammals, namely the Y1, Y2, Y4 and Y5 receptors, with different affinity and selectivity3.  NPY is the most powerful stimulant of food intake and this effect is primarily mediated by the Y1 receptor (Y1R)4.  A no. of peptides and small-mol. compds. have been characterized as Y1R antagonists and have shown clin. potential in the treatment of obesity4, tumor1 and bone loss5.  However, their clin. usage has been hampered by low potency and selectivity, poor brain penetration ability or lack of oral bioavailability6.  Here we report crystal structures of the human Y1R bound to the two selective antagonists UR-MK299 and BMS-193885 at 2.7 and 3.0 Å resoln., resp.  The structures combined with mutagenesis studies reveal the binding modes of Y1R to several structurally diverse antagonists and the determinants of ligand selectivity.  The Y1R structure and mol. docking of the endogenous agonist NPY, together with NMR, photo-crosslinking and functional studies, provide insights into the binding behavior of the agonist and for the first time, to our knowledge, det. the interaction of its N terminus with the receptor.  These insights into Y1R can enable structure-based drug discovery that targets NPY receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr584bBD3wdnbVg90H21EOLACvtfcHk0li0SmV5lp6yOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosVCgur8%253D&md5=79289fb85d5f65b94fbf873ec4ea31f3</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fs41586-018-0046-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-018-0046-x%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DKeller%26aufirst%3DM.%26aulast%3DKaiser%26aufirst%3DA.%26aulast%3DBender%26aufirst%3DB.%2BJ.%26aulast%3DBosse%26aufirst%3DM.%26aulast%3DBurkert%26aufirst%3DK.%26aulast%3DK%25C3%25B6gler%26aufirst%3DL.%2BM.%26aulast%3DWifling%26aufirst%3DD.%26aulast%3DBernhardt%26aufirst%3DG.%26aulast%3DPlank%26aufirst%3DN.%26aulast%3DLittmann%26aufirst%3DT.%26aulast%3DSchmidt%26aufirst%3DP.%26aulast%3DYi%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DYe%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DLarhammar%26aufirst%3DD.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DHuster%26aufirst%3DD.%26aulast%3DMeiler%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26aulast%3DBuschauer%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DB.%26atitle%3DStructural%2520basis%2520of%2520ligand%2520binding%2520modes%2520at%2520the%2520neuropeptide%2520Y%2520Y1%2520receptor%26jtitle%3DNature%26date%3D2018%26volume%3D556%26spage%3D520%26epage%3D524%26doi%3D10.1038%2Fs41586-018-0046-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zellmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheidt, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meiler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huster, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, P.</span></span> <span> </span><span class="NLM_article-title">Unwinding of the C-terminal residues of neuropeptide Y is critical for Y<sub>2</sub> receptor binding and activation</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7446</span>– <span class="NLM_lpage">7449</span>, <span class="refDoi"> DOI: 10.1002/anie.201411688</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1002%2Fanie.201411688" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnsFCmtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=7446-7449&author=A.+Kaiserauthor=P.+M%C3%BCllerauthor=T.+Zellmannauthor=H.+A.+Scheidtauthor=L.+Thomasauthor=M.+Bosseauthor=R.+Meierauthor=J.+Meilerauthor=D.+Husterauthor=A.+G.+Beck-Sickingerauthor=P.+Schmidt&title=Unwinding+of+the+C-terminal+residues+of+neuropeptide+Y+is+critical+for+Y2+receptor+binding+and+activation&doi=10.1002%2Fanie.201411688"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Unwinding of the C-Terminal Residues of Neuropeptide Y is critical for Y2 Receptor Binding and Activation</span></div><div class="casAuthors">Kaiser, Anette; Mueller, Paul; Zellmann, Tristan; Scheidt, Holger A.; Thomas, Lars; Bosse, Mathias; Meier, Rene; Meiler, Jens; Huster, Daniel; Beck-Sickinger, Annette G.; Schmidt, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">7446-7449</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Despite recent breakthroughs in the structural characterization of G-protein-coupled receptors (GPCRs), there is only sparse data on how GPCRs recognize larger peptide ligands.  NMR spectroscopy, mol. modeling, and double-cycle mutagenesis studies were integrated to obtain a structural model of the peptide hormone neuropeptide Y (NPY) bound to its human G-protein-coupled Y2 receptor (Y2R).  Solid-state NMR measurements of specific isotope-labeled NPY in complex with in vitro folded Y2R reconstituted into phospholipid bicelles provided the bioactive structure of the peptide.  Guided by soln. NMR expts., it could be shown that the ligand is tethered to the second extracellular loop by hydrophobic contacts.  The C-terminal α-helix of NPY, which is formed in a membrane environment in the absence of the receptor, is unwound starting at T32 to provide optimal contacts in a deep binding pocket within the transmembrane bundle of the Y2R.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLkPseIiGmvrVg90H21EOLACvtfcHk0lhul0uf9H4aug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnsFCmtrY%253D&md5=327c142cca18a18959057f45dc3b2f96</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1002%2Fanie.201411688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201411688%26sid%3Dliteratum%253Aachs%26aulast%3DKaiser%26aufirst%3DA.%26aulast%3DM%25C3%25BCller%26aufirst%3DP.%26aulast%3DZellmann%26aufirst%3DT.%26aulast%3DScheidt%26aufirst%3DH.%2BA.%26aulast%3DThomas%26aufirst%3DL.%26aulast%3DBosse%26aufirst%3DM.%26aulast%3DMeier%26aufirst%3DR.%26aulast%3DMeiler%26aufirst%3DJ.%26aulast%3DHuster%26aufirst%3DD.%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26aulast%3DSchmidt%26aufirst%3DP.%26atitle%3DUnwinding%2520of%2520the%2520C-terminal%2520residues%2520of%2520neuropeptide%2520Y%2520is%2520critical%2520for%2520Y2%2520receptor%2520binding%2520and%2520activation%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D7446%26epage%3D7449%26doi%3D10.1002%2Fanie.201411688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moradi, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussein, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varamini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simerska, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toth, I.</span></span> <span> </span><span class="NLM_article-title">Glycosylation, an effective synthetic strategy to improve the bioavailability of therapeutic peptides</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2492</span>– <span class="NLM_lpage">2500</span>, <span class="refDoi"> DOI: 10.1039/C5SC04392A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1039%2FC5SC04392A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=28660018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1Krsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=2492-2500&author=S.+V.+Moradiauthor=W.+M.+Husseinauthor=P.+Varaminiauthor=P.+Simerskaauthor=I.+Toth&title=Glycosylation%2C+an+effective+synthetic+strategy+to+improve+the+bioavailability+of+therapeutic+peptides&doi=10.1039%2FC5SC04392A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Glycosylation, an effective synthetic strategy to improve the bioavailability of therapeutic peptides</span></div><div class="casAuthors">Moradi, Shayli Varasteh; Hussein, Waleed M.; Varamini, Pegah; Simerska, Pavla; Toth, Istvan</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2492-2500</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Glycosylation of peptides is a promising strategy for modulating the physicochem. properties of peptide drugs and for improving their absorption through biol. membranes.  This review highlights various methods for the synthesis of glycoconjugates and recent progress in the development of glycosylated peptide therapeutics.  Furthermore, the impacts of glycosylation in overcoming the existing barriers that restrict oral and brain delivery of peptides are described herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3OH1jtMuZibVg90H21EOLACvtfcHk0lhul0uf9H4aug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1Krsb0%253D&md5=4b48b4aaf751cfc2dda015123aa3aad3</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1039%2FC5SC04392A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5SC04392A%26sid%3Dliteratum%253Aachs%26aulast%3DMoradi%26aufirst%3DS.%2BV.%26aulast%3DHussein%26aufirst%3DW.%2BM.%26aulast%3DVaramini%26aufirst%3DP.%26aulast%3DSimerska%26aufirst%3DP.%26aulast%3DToth%26aufirst%3DI.%26atitle%3DGlycosylation%252C%2520an%2520effective%2520synthetic%2520strategy%2520to%2520improve%2520the%2520bioavailability%2520of%2520therapeutic%2520peptides%26jtitle%3DChem.%2520Sci.%26date%3D2016%26volume%3D7%26spage%3D2492%26epage%3D2500%26doi%3D10.1039%2FC5SC04392A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Capala, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendayan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauzon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soloway, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenstermaker, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlsson, J.</span></span> <span> </span><span class="NLM_article-title">Boronated epidermal growth factor as a potential targeting agent for boron neutron capture therapy of brain tumors</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1021/bc950077q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc950077q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADyaK28XivVartA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1996&pages=7-15&author=J.+Capalaauthor=R.+F.+Barthauthor=M.+Bendayanauthor=M.+Lauzonauthor=D.+M.+Adamsauthor=A.+H.+Solowayauthor=R.+A.+Fenstermakerauthor=J.+Carlsson&title=Boronated+epidermal+growth+factor+as+a+potential+targeting+agent+for+boron+neutron+capture+therapy+of+brain+tumors&doi=10.1021%2Fbc950077q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Boronated Epidermal Growth Factor as a Potential Targeting Agent for Boron Neutron Capture Therapy of Brain Tumors</span></div><div class="casAuthors">Capala, Jacek; Barth, Rolf F.; Bendayan, Moise; Lauzon, Michel; Adams, Dianne M.; Soloway, Albert H.; Fenstermaker, Robert A.; Carlsson, Jorgen</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-15</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">For boron neutron capture therapy (BNCT) to be successful, a large no. (∼109) of 10B atoms must be delivered to each cancer cell to sustain a lethal 10B(n, α)7Li reaction.  The majority of high grade gliomas express an amplified epidermal growth factor receptor (EGFR) gene, and increased nos. of EGFR are found on the cell surface.  If a sufficiently large no. of 10B atoms could be attached to EGF, the resulting bioconjugates might be useful for targeting brain tumors.  To accomplish this, we have boronated a fourth-generation starburst dendrimer (SD) using an isocyanato polyhedral borane, Na(CH3)3NB10H8NCO.  For conjugation, reactive thiol groups were introduced into the boronated SD using N-succinimidyl 3-(2-pyridyldithio)propionate (SPDP), and EGF was derivatized with m-maleimidobenzoyl-N-hydroxysulfosuccinimide ester (sMBS).  Subsequent reaction of thiol groups of derivatized BSD with maleimide groups of derivatized EGF produced stable BSD-EGF bioconjugates contg. ∼960 atoms of boron per mol. of EGF with KA of 8.55 × 107 M-1 compared to 9.1 × 108 M-1 for native EGF.  As detd. by electron spectroscopic imaging, the BSD-EGF initially was bound to the cell surface membrane and then was endocytosed, which resulted in accumulation of boron in lysosomes.  The favorable in vitro properties of these bioconjugates suggest that they may be useful for the in vivo targeting of EGFR pos. brain tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGri6nQyYtW3mrVg90H21EOLACvtfcHk0lhul0uf9H4aug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XivVartA%253D%253D&md5=664262af1d849d8580bc006070a05812</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fbc950077q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc950077q%26sid%3Dliteratum%253Aachs%26aulast%3DCapala%26aufirst%3DJ.%26aulast%3DBarth%26aufirst%3DR.%2BF.%26aulast%3DBendayan%26aufirst%3DM.%26aulast%3DLauzon%26aufirst%3DM.%26aulast%3DAdams%26aufirst%3DD.%2BM.%26aulast%3DSoloway%26aufirst%3DA.%2BH.%26aulast%3DFenstermaker%26aufirst%3DR.%2BA.%26aulast%3DCarlsson%26aufirst%3DJ.%26atitle%3DBoronated%2520epidermal%2520growth%2520factor%2520as%2520a%2520potential%2520targeting%2520agent%2520for%2520boron%2520neutron%2520capture%2520therapy%2520of%2520brain%2520tumors%26jtitle%3DBioconjugate%2520Chem.%26date%3D1996%26volume%3D7%26spage%3D7%26epage%3D15%26doi%3D10.1021%2Fbc950077q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tjarks, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciesielski, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenstermaker, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wikstrand, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binns, P. J.</span></span> <span> </span><span class="NLM_article-title">Convection enhanced delivery of boronated EGF as a molecular targeting agent for neutron capture therapy of brain tumors</span>. <i>J. Neuro-Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">355</span>– <span class="NLM_lpage">365</span>, <span class="refDoi"> DOI: 10.1007/s11060-009-9945-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1007%2Fs11060-009-9945-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=19588228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlKitbvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2009&pages=355-365&author=W.+Yangauthor=R.+F.+Barthauthor=G.+Wuauthor=T.+Huoauthor=W.+Tjarksauthor=M.+J.+Ciesielskiauthor=R.+A.+Fenstermakerauthor=B.+D.+Rossauthor=C.+J.+Wikstrandauthor=K.+J.+Rileyauthor=P.+J.+Binns&title=Convection+enhanced+delivery+of+boronated+EGF+as+a+molecular+targeting+agent+for+neutron+capture+therapy+of+brain+tumors&doi=10.1007%2Fs11060-009-9945-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Convection enhanced delivery of boronated EGF as a molecular targeting agent for neutron capture therapy of brain tumors</span></div><div class="casAuthors">Yang, Weilian; Barth, Rolf F.; Wu, Gong; Huo, Tian-Yao; Tjarks, Werner; Ciesielski, Michael; Fenstermaker, Robert A.; Ross, Brain D.; Wikstrand, Carol J.; Riley, Kent J.; Binns, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuro-Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">355-365</span>CODEN:
                <span class="NLM_cas:coden">JNODD2</span>;
        ISSN:<span class="NLM_cas:issn">0167-594X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">In the present study, we have evaluated a boronated dendrimer-epidermal growth factor (BD-EGF) bioconjugate as a mol. targeting agent for boron neutron capture therapy (BNCT) of the human EGFR gene-transfected F98 rat glioma, designated F98EGFR.  EGF was chem. linked to a heavily boronated polyamidoamine dendrimer (BD) by means of the heterobifunctional reagent, mMBS.  Biodistribution studies were carried out at 6 h and 24 h following intratumoral (i.t.) injection or intracerebral (i.c.) convection enhanced delivery (CED) of 125I-labeled or unlabeled BD-EGF (40 μg 10B/10 μg EGF) to F98 glioma bearing rats.  At 24 h. there was 43% more radioactivity in EGFR(+) tumors following CED compared to i.t. injection, and a doubling of the tumor boron concn. (22.3 μg/g vs. 11.7 μg/g).  CED of BD-EGF resulted in a 7.2× increase in the vol. of distribution within the infused cerebral hemisphere and a 1.9× increase in tumor uptake of BD-EGF compared with i.t. injection.  Based on these favorable biodistribution data, BNCT was carried out at the Massachusetts Institute of Technol. nuclear reactor 14 days following i.c. tumor implantation and 24 h. after CED of BD-EGF.  These animals had a MST of 54.1 ± 4.7 days compared to 43.0 ± 2.8 days following i.t. injection.  Rats that received BD-EGF by CED in combination with i.v. boronophenylalanine (BPA), which has been used in both exptl. and clin. studies, had a MST of 86.0 ± 28.1 days compared to 39.8 ± 1.6 days for i.v.  BPA alone (P < 0.01), 30.9 ± 1.4 days for irradiated controls and 25.1 ± 1.0 days for untreated controls (overall P < 0.0001).  These data have demonstrated that the efficacy of BNCT was significantly increased (P < 0.006), following i.c CED of BD-EGF compared to i.t injection, and that the survival data were equiv. to those previously reported by us using the boronated anti-human-EGF mAb, C225 (cetuximab).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNNOK5mLSWf7Vg90H21EOLACvtfcHk0lgYg8tDzGZevg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlKitbvP&md5=c02d1b5492bf577a8820837589f887ff</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1007%2Fs11060-009-9945-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11060-009-9945-x%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DW.%26aulast%3DBarth%26aufirst%3DR.%2BF.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DHuo%26aufirst%3DT.%26aulast%3DTjarks%26aufirst%3DW.%26aulast%3DCiesielski%26aufirst%3DM.%2BJ.%26aulast%3DFenstermaker%26aufirst%3DR.%2BA.%26aulast%3DRoss%26aufirst%3DB.%2BD.%26aulast%3DWikstrand%26aufirst%3DC.%2BJ.%26aulast%3DRiley%26aufirst%3DK.%2BJ.%26aulast%3DBinns%26aufirst%3DP.%2BJ.%26atitle%3DConvection%2520enhanced%2520delivery%2520of%2520boronated%2520EGF%2520as%2520a%2520molecular%2520targeting%2520agent%2520for%2520neutron%2520capture%2520therapy%2520of%2520brain%2520tumors%26jtitle%3DJ.%2520Neuro-Oncol.%26date%3D2009%26volume%3D95%26spage%3D355%26epage%3D365%26doi%3D10.1007%2Fs11060-009-9945-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tjarks, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciesielski, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenstermaker, R. A.</span></span> <span> </span><span class="NLM_article-title">Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab (IMC-C225) and its evaluation as a potential delivery agent for neutron capture therapy</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">194</span>, <span class="refDoi"> DOI: 10.1021/bc0341674</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc0341674" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD3sXps1WgtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2004&pages=185-194&author=G.+Wuauthor=R.+F.+Barthauthor=W.+Yangauthor=M.+Chatterjeeauthor=W.+Tjarksauthor=M.+J.+Ciesielskiauthor=R.+A.+Fenstermaker&title=Site-specific+conjugation+of+boron-containing+dendrimers+to+anti-EGF+receptor+monoclonal+antibody+cetuximab+%28IMC-C225%29+and+its+evaluation+as+a+potential+delivery+agent+for+neutron+capture+therapy&doi=10.1021%2Fbc0341674"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Site-Specific Conjugation of Boron-Containing Dendrimers to Anti-EGF Receptor Monoclonal Antibody Cetuximab (IMC-C225) and Its Evaluation as a Potential Delivery Agent for Neutron Capture Therapy</span></div><div class="casAuthors">Wu, Gong; Barth, Rolf F.; Yang, Weilian; Chatterjee, Madhumita; Tjarks, Werner; Ciesielski, Michael J.; Fenstermaker, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">185-194</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The gene encoding EGFR often is amplified in human gliomas, and the receptor itself has been considered as a potential target for the specific delivery of therapeutic agents to brain tumors.  The purpose of the present study was to investigate the use of the chimeric MoAb cetuximab (IMC-C225), which is directed against EGFR and EGFRvIII, as a boron delivery agent for neutron capture therapy (NCT) of brain tumors.  As detd. by 125I-cetuximab radioligand binding assays, F98 rat glioma cells, which had been transfected with the gene encoding EGFR (F98EGFR), expressed 1.60 ± 0.13 × 105 receptor sites/cell with a Ka = 1.64 ± 0.32 × 108 M-1.  F98 cells transfected with the gene encoding a mutant form of EGFR, designated the F98EGFRvIII glioma, expressed 1.07 ± 0.10 × 105 receptor sites/cell with a Ka = 2.18 ± 0.54 × 109 M-1 compared to background levels expressed on F98 wild-type cells (F98WT).  A heavily boronated, fifth generation polyamidoamine (PAMAM or "starburst") dendrimer, G5-B1100, was linked to oligosaccharide moieties, which were distant from antigen binding sites of cetuximab, by means of the heterobifunctional reagents N-succinimidyl 3-(2-pyridyldithio)propionate (SPDP) and N-(k-maleimidoundecanoic acid) hydrazide (KMUH).  The resulting bioconjugate, designated C225-G5-B1100, was sepd. from the unconjugated dendrimer using a Sephacryl S-300 column.  On the basis of the relative concn. ratios of boron and protein, there were ∼1100 boron atoms per mol. of cetuximab with only a slight redn. of Ka.  The localization of C225-G5-B1100 or G5-B1100 in rats bearing intracerebral implants of either F98EGFR or F98WT gliomas was detd. 24 h following direct intratumoral (i.t.) injection at which time 92.3 ± 23.3 μg B/g tumor was localized in F98EGFR gliomas vs. 36.5 ± 18.8 μg B/g tumor in F98WT gliomas and 13.4 ± 6.1 μg in normal brain.  In contrast, only 6.7 ± 3.6 μg B/g tumor of G5-B1100 was localized in F98EGFR gliomas following i.t.  Injection, thereby demonstrating specific mol. targeting of EGFR.  Based on these data, BNCT studies will be initiated in F98EGFR glioma bearing rats to evaluate C225-G5-B1100 for the treatment of intracerebral brain tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt3633MwPsB7Vg90H21EOLACvtfcHk0lgYg8tDzGZevg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXps1WgtLg%253D&md5=d1de41c2c82d0a2e0179394b0c6ce758</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Fbc0341674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc0341674%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DG.%26aulast%3DBarth%26aufirst%3DR.%2BF.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DChatterjee%26aufirst%3DM.%26aulast%3DTjarks%26aufirst%3DW.%26aulast%3DCiesielski%26aufirst%3DM.%2BJ.%26aulast%3DFenstermaker%26aufirst%3DR.%2BA.%26atitle%3DSite-specific%2520conjugation%2520of%2520boron-containing%2520dendrimers%2520to%2520anti-EGF%2520receptor%2520monoclonal%2520antibody%2520cetuximab%2520%2528IMC-C225%2529%2520and%2520its%2520evaluation%2520as%2520a%2520potential%2520delivery%2520agent%2520for%2520neutron%2520capture%2520therapy%26jtitle%3DBioconjugate%2520Chem.%26date%3D2004%26volume%3D15%26spage%3D185%26epage%3D194%26doi%3D10.1021%2Fbc0341674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawabata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sferra, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandyopadhyaya, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tjarks, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferketich, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moeschberger, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binns, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coderre, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciesielski, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenstermaker, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wikstrand, C. J.</span></span> <span> </span><span class="NLM_article-title">Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">3792</span>– <span class="NLM_lpage">3802</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-06-0141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1158%2F1078-0432.CCR-06-0141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=16778107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvVSltrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=3792-3802&author=W.+Yangauthor=R.+F.+Barthauthor=G.+Wuauthor=S.+Kawabataauthor=T.+J.+Sferraauthor=A.+K.+Bandyopadhyayaauthor=W.+Tjarksauthor=A.+K.+Ferketichauthor=M.+L.+Moeschbergerauthor=P.+J.+Binnsauthor=K.+J.+Rileyauthor=J.+A.+Coderreauthor=M.+J.+Ciesielskiauthor=R.+A.+Fenstermakerauthor=C.+J.+Wikstrand&title=Molecular+targeting+and+treatment+of+EGFRvIII-positive+gliomas+using+boronated+monoclonal+antibody+L8A4&doi=10.1158%2F1078-0432.CCR-06-0141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Targeting and Treatment of EGFRvIII-Positive Gliomas Using Boronated Monoclonal Antibody L8A4</span></div><div class="casAuthors">Yang, Weilian; Barth, Rolf F.; Wu, Gong; Kawabata, Shinji; Sferra, Thomas J.; Bandyopadhyaya, Achintya K.; Tjarks, Werner; Ferketich, Amy K.; Moeschberger, Melvin L.; Binns, Peter J.; Riley, Kent J.; Coderre, Jeffrey A.; Ciesielski, Michael J.; Fenstermaker, Robert A.; Wikstrand, Carol J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3792-3802</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: The purpose of the present study was to evaluate a boronated EGFRvIII-specific monoclonal antibody, L8A4, for boron neutron capture therapy (BNCT) of the receptor-pos. rat glioma, F98npEGFRvIII.  Exptl. Design: A heavily boronated polyamido amine (PAMAM) dendrimer (BD) was chem. linked to L8A4 by two heterobifunctional reagents, N-succinimidyl 3-(2-pyridyldithio)propionate and N-(k-maleimidoundecanoic acid)hydrazide.  For in vivo studies, F98 wild-type receptor-neg. or EGFRvIII human gene-transfected receptor-pos. F98npEGFRvIII glioma cells were implanted i.c. into the brains of Fischer rats.  Biodistribution studies were initiated 14 days later.  Animals received [125I]BD-L8A4 by either convection enhanced delivery (CED) or direct i.t. injection and were euthanized 6, 12, 24, or 48 h later.  RESULTS: At 6 h, equiv. amts. of the bioconjugate were detected in receptor-pos. and receptor-neg. tumors, but by 24 h the amts. retained by receptor-pos. gliomas were 60.1% following CED and 43.7% following i.t. injection compared with 14.6% ID/g by receptor-neg. tumors.  Boron concns. in normal brain, blood, liver, kidneys, and spleen all were at nondetectable levels (<0.5 μg/g) at the corresponding times.  Based on these favorable biodistribution data, BNCT studies were initiated at the Massachusetts Institute of Technol. Research Reactor-II.  Rats received BD-L8A4 (∼40 μg 10B/∼750 μg protein) by CED either alone or in combination with i.v. boronophenylalanine (BPA; 500 mg/kg).  BNCT was carried out 24 h after administration of the bioconjugate and 2.5 h after i.v. injection of BPA for those animals that received both agents.  Rats that received BD-L8A4 by CED in combination with i.v.  BPA had a mean ± SE survival time of 85.5 ± 15.5 days with 20% long-term survivors (>6 mo) and those that received BD-L8A4 alone had a mean ± SE survival time of 70.4 ± 11.1 days with 10% long-term survivors compared with 40.1 ± 2.2 days for i.v.  BPA and 30.3 ± 1.6 and 26.3 ± 1.1 days for irradiated and untreated controls, resp.  CONCLUSIONS: These data convincingly show the therapeutic efficacy of mol. targeting of EGFRvIII using either boronated monoclonal antibody L8A4 alone or in combination with BPA and should provide a platform for the future development of combinations of high and low mol. wt. delivery agents for BNCT of brain tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtL7HONgZyY7Vg90H21EOLACvtfcHk0lgYg8tDzGZevg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvVSltrc%253D&md5=8162846f8b388e7a56c74747546be928</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-0141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-0141%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DW.%26aulast%3DBarth%26aufirst%3DR.%2BF.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DKawabata%26aufirst%3DS.%26aulast%3DSferra%26aufirst%3DT.%2BJ.%26aulast%3DBandyopadhyaya%26aufirst%3DA.%2BK.%26aulast%3DTjarks%26aufirst%3DW.%26aulast%3DFerketich%26aufirst%3DA.%2BK.%26aulast%3DMoeschberger%26aufirst%3DM.%2BL.%26aulast%3DBinns%26aufirst%3DP.%2BJ.%26aulast%3DRiley%26aufirst%3DK.%2BJ.%26aulast%3DCoderre%26aufirst%3DJ.%2BA.%26aulast%3DCiesielski%26aufirst%3DM.%2BJ.%26aulast%3DFenstermaker%26aufirst%3DR.%2BA.%26aulast%3DWikstrand%26aufirst%3DC.%2BJ.%26atitle%3DMolecular%2520targeting%2520and%2520treatment%2520of%2520EGFRvIII-positive%2520gliomas%2520using%2520boronated%2520monoclonal%2520antibody%2520L8A4%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D3792%26epage%3D3802%26doi%3D10.1158%2F1078-0432.CCR-06-0141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawabata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swindall, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandyopadhyaya, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tjarks, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khorsandi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blue, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferketich, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christoforidis, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sferra, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binns, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciesielski, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenstermaker, R. A.</span></span> <span> </span><span class="NLM_article-title">Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1260</span>– <span class="NLM_lpage">1268</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-06-2399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1158%2F1078-0432.CCR-06-2399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=17317838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvF2htrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=1260-1268&author=G.+Wuauthor=W.+Yangauthor=R.+F.+Barthauthor=S.+Kawabataauthor=M.+R.+Swindallauthor=A.+K.+Bandyopadhyayaauthor=W.+Tjarksauthor=B.+Khorsandiauthor=T.+E.+Blueauthor=A.+K.+Ferketichauthor=M.+Yangauthor=G.+A.+Christoforidisauthor=T.+J.+Sferraauthor=P.+J.+Binnsauthor=K.+J.+Rileyauthor=M.+J.+Ciesielskiauthor=R.+A.+Fenstermaker&title=Molecular+targeting+and+treatment+of+an+epidermal+growth+factor+receptor-positive+glioma+using+boronated+cetuximab&doi=10.1158%2F1078-0432.CCR-06-2399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Targeting and Treatment of an Epidermal Growth Factor Receptor-Positive Glioma Using Boronated Cetuximab</span></div><div class="casAuthors">Wu, Gong; Yang, Weilian; Barth, Rolf F.; Kawabata, Shinji; Swindall, Michele; Bandyopadhyaya, Achintya K.; Tjarks, Werner; Khorsandi, Behrooz; Blue, Thomas E.; Ferketich, Amy K.; Yang, Ming; Christoforidis, Gregory A.; Sferra, Thomas J.; Binns, Peter J.; Riley, Kent J.; Ciesielski, Michael J.; Fenstermaker, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1260-1268</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The purpose of the present study was to evaluate the anti-epidermal growth factor monoclonal antibody (mAb) cetuximab (IMC-C225) as a delivery agent for boron neutron capture therapy (BNCT) of a human epidermal growth factor receptor (EGFR) gene-transfected rat glioma, designated as F98EGFR.  Exptl. Design: A heavily boronated polyamidoamine dendrimer was chem. linked to cetuximab by means of the heterobifunctional reagents N-succinimidyl 3-(2-pyridyldithio)-propionate and N-(k-maleimido undecanoic acid)-hydrazide.  The bioconjugate, designated as BD-C225, was specifically taken up by F98EGFR glioma cells in vitro compared with receptor-neg. F98 wild-type cells (41.8 vs. 9.1 μg/g).  For in vivo biodistribution studies, F98EGFR cells were implanted stereotactically into the brains of Fischer rats, and 14 days later, BD-C225 was given intracerebrally by either convection enhanced delivery (CED) or direct intratumoral (i.t.) injection.  Results: The amt. of boron retained by F98EGFR gliomas 24 h following CED or i.t. injection was 77.2 and 50.8 μg/g, resp., with normal brain and blood boron values <0.05 μg/g.  Boron neutron capture therapy was carried out at the Massachusetts Institute of Technol. Research Reactor 24 h after CED of BD-C225, either alone or in combination with i.v. boronophenylalanine (BPA).  The corresponding mean survival times (MST) were 54.5 and 70.9 days (P = 0.017), resp., with one long-term survivor (more than 180 days).  In contrast, the MSTs of irradiated and untreated controls, resp., were 30.3 and 26.3 days.  In a second study, the combination of BD-C225 and BPA plus sodium borocaptate, given by either i.v. or intracarotid injection, was evaluated and the MSTs were equiv. to that obtained with BD-C225 plus i.v. BPA.  Conclusions: The survival data obtained with BD-C225 are comparable with those recently reported by us using boronated mAb L8A4 as the delivery agent.  This mAb recognizes the mutant receptor, EGFRvIII.  Taken together, these data convincingly show the therapeutic efficacy of mol. targeting of EGFR using a boronated mAb either alone or in combination with BPA and provide a platform for the future development of combinations of high and low mol. wt. delivery agents for BNCT of brain tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotddR9_NdN-bVg90H21EOLACvtfcHk0lhbVescBMgEdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvF2htrw%253D&md5=0a032c37c254ec3a650466df33b3c7a9</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-2399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-2399%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DBarth%26aufirst%3DR.%2BF.%26aulast%3DKawabata%26aufirst%3DS.%26aulast%3DSwindall%26aufirst%3DM.%2BR.%26aulast%3DBandyopadhyaya%26aufirst%3DA.%2BK.%26aulast%3DTjarks%26aufirst%3DW.%26aulast%3DKhorsandi%26aufirst%3DB.%26aulast%3DBlue%26aufirst%3DT.%2BE.%26aulast%3DFerketich%26aufirst%3DA.%2BK.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DChristoforidis%26aufirst%3DG.%2BA.%26aulast%3DSferra%26aufirst%3DT.%2BJ.%26aulast%3DBinns%26aufirst%3DP.%2BJ.%26aulast%3DRiley%26aufirst%3DK.%2BJ.%26aulast%3DCiesielski%26aufirst%3DM.%2BJ.%26aulast%3DFenstermaker%26aufirst%3DR.%2BA.%26atitle%3DMolecular%2520targeting%2520and%2520treatment%2520of%2520an%2520epidermal%2520growth%2520factor%2520receptor-positive%2520glioma%2520using%2520boronated%2520cetuximab%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D1260%26epage%3D1268%26doi%3D10.1158%2F1078-0432.CCR-06-2399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swindall, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandyopadhyaya, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tjarks, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tordoff, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moeschberger, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sferra, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binns, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciesielski, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenstermaker, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wikstrand, C. J.</span></span> <span> </span><span class="NLM_article-title">Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">883</span>– <span class="NLM_lpage">891</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-1968</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1158%2F1078-0432.CCR-07-1968" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=18245552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFyktLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=883-891&author=W.+Yangauthor=G.+Wuauthor=R.+F.+Barthauthor=M.+R.+Swindallauthor=A.+K.+Bandyopadhyayaauthor=W.+Tjarksauthor=K.+Tordoffauthor=M.+L.+Moeschbergerauthor=T.+J.+Sferraauthor=P.+J.+Binnsauthor=K.+J.+Rileyauthor=M.+J.+Ciesielskiauthor=R.+A.+Fenstermakerauthor=C.+J.+Wikstrand&title=Molecular+targeting+and+treatment+of+composite+EGFR+and+EGFRvIII-positive+gliomas+using+boronated+monoclonal+antibodies&doi=10.1158%2F1078-0432.CCR-07-1968"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Targeting and Treatment of Composite EGFR and EGFRvIII-Positive Gliomas Using Boronated Monoclonal Antibodies</span></div><div class="casAuthors">Yang, Weilian; Wu, Gong; Barth, Rolf F.; Swindall, Michele R.; Bandyopadhyaya, Achintya K.; Tjarks, Werner; Tordoff, Kevin; Moeschberger, Melvin; Sferra, Thomas J.; Binns, Peter J.; Riley, Kent J.; Ciesielski, Michael J.; Fenstermaker, Robert A.; Wikstrand, Carol J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">883-891</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: The purpose of the present study was to evaluate the anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb), cetuximab, (IMC-C225) and the anti-EGFRvIII mAb, L8A4, used in combination as delivery agents for boron neutron capture therapy (BNCT) of a rat glioma composed of a mixt. of cells expressing either wild-type (F98EGFR) or mutant receptors(F98npEGFRvIII).  Exptl. Design: A heavily boronated polyamidoamine dendrimer (BD) was linked by heterobifunctional reagents to produce the boronated mAbs, BD-C225 and BD-L8A4.  For in vivo biodistribution and therapy studies, a mixt. of tumor cells were implanted intracerebrally into Fischer rats.  Biodistribution studies were carried out by administering 125I-labeled bioconjugates via convection-enhanced delivery (CED), and for therapy studies, nonradiolabeled bioconjugates were used for BNCT.  This was carried out 14 days after tumor implantation and 24 h after CED at the Massachusetts Institute of Technol. nuclear reactor.  RESULTS: Following CED of a mixt. of 125I-BD-C225 and 125I-BD-L8A4 to rats bearing composite tumors, 61.4% of the injected dose per g (ID/g) was localized in the tumor compared with 30.8% ID/g for 125I-BD-L8A4 and 34.7% ID/g for 125I-BD-C225 alone.  The corresponding calcd. tumor boron values were 24.4 μg/g for rats that received both mAbs, and 12.3 and 13.8 μg/g, resp., for BD-L8A4 or BD-C225 alone.  The mean survival time of animals bearing composite tumors, which received both mAbs, was 55 days (P < 0.0001) compared with 36 days for BD-L8A4 and 38 days for BD-C225 alone, which were not significantly different from irradiated controls.  CONCLUSIONS: Both EGFRvIII and wild-type EGFR tumor cell populations must be targeted using a combination of BD-cetuximab and BD-L8A4.  Although in vitro C225 recognized both receptors, in vivo it was incapable of delivering the requisite amt. of 10B for BNCT of EGFRvIII-expressing gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrARkzcnXBdabVg90H21EOLACvtfcHk0lhbVescBMgEdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFyktLs%253D&md5=7ba4e2739edba61248b514b16be23822</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-1968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-1968%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DBarth%26aufirst%3DR.%2BF.%26aulast%3DSwindall%26aufirst%3DM.%2BR.%26aulast%3DBandyopadhyaya%26aufirst%3DA.%2BK.%26aulast%3DTjarks%26aufirst%3DW.%26aulast%3DTordoff%26aufirst%3DK.%26aulast%3DMoeschberger%26aufirst%3DM.%2BL.%26aulast%3DSferra%26aufirst%3DT.%2BJ.%26aulast%3DBinns%26aufirst%3DP.%2BJ.%26aulast%3DRiley%26aufirst%3DK.%2BJ.%26aulast%3DCiesielski%26aufirst%3DM.%2BJ.%26aulast%3DFenstermaker%26aufirst%3DR.%2BA.%26aulast%3DWikstrand%26aufirst%3DC.%2BJ.%26atitle%3DMolecular%2520targeting%2520and%2520treatment%2520of%2520composite%2520EGFR%2520and%2520EGFRvIII-positive%2520gliomas%2520using%2520boronated%2520monoclonal%2520antibodies%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D883%26epage%3D891%26doi%3D10.1158%2F1078-0432.CCR-07-1968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tjarks, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binns, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, K.</span></span> <span> </span><span class="NLM_article-title">Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents</span>. <i>Appl. Radiat. Isot.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">S328</span>– <span class="NLM_lpage">S331</span>, <span class="refDoi"> DOI: 10.1016/j.apradiso.2009.03.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1016%2Fj.apradiso.2009.03.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=19467880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnt1Wqu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2009&pages=S328-S331&author=W.+Yangauthor=R.+F.+Barthauthor=G.+Wuauthor=W.+Tjarksauthor=P.+Binnsauthor=K.+Riley&title=Boron+neutron+capture+therapy+of+EGFR+or+EGFRvIII+positive+gliomas+using+either+boronated+monoclonal+antibodies+or+epidermal+growth+factor+as+molecular+targeting+agents&doi=10.1016%2Fj.apradiso.2009.03.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents</span></div><div class="casAuthors">Yang, W.; Barth, R. F.; Wu, G.; Tjarks, W.; Binns, P.; Riley, K.</div><div class="citationInfo"><span class="NLM_cas:title">Applied Radiation and Isotopes</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">7-8S</span>),
    <span class="NLM_cas:pages">S328-S331</span>CODEN:
                <span class="NLM_cas:coden">ARISEF</span>;
        ISSN:<span class="NLM_cas:issn">0969-8043</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In the present report we have summarized studies carried out over the past five years on mol. targeting of the epidermal growth factor receptor (EGFR) and its mutant isoform, EFGRvIII, for BNCT of genetically engineered F98 rat gliomas, expressing either wildtype (F98EGFR) or mutant receptors (F98npEGFRvIII).  EGF or the monoclonal antibodies (mAbs), cetuximab (IMC-C225) and L8A4, which recognize wildtype EGFR and EGFRvIII, resp., were heavily boronated using polyamidoamine (PAMAM) dendrimers (BD) linked to the targeting vehicles by means of heterobifunctional reagents.  Boronated EGF or mAbs, alone or in combination with i.v. boronophenylalanine (BPA), were administered intracerebrally (i.c.) by either intratumoral (i.t.) injection or convection enhanced delivery (CED) to rats bearing F98 gliomas following which BNCT was initiated.  The best survival data were obtained in rats bearing F98npEGFRvIII gliomas that had received CED of BD-L8A4 either alone or in combination with i.v. boronophenylalanine (BPA).  Studies carried out in rats bearing composite tumors (F98EGFR/F98npEGFRvIII) demonstrated that it was essential to target both tumor cell populations in order to obtain an optimal therapeutic effect.  Based on these observations, we have concluded that EGFR targeting vehicles are useful, but not stand-alone boron delivery agents due to the heterogeneity of receptor expression in brain tumors.  They could, however, be quite useful in combination with the two drugs that currently are being used clin., BPA and sodium borocaptate (BSH) for BNCT of either brain tumors or head and neck cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeZD6OF-L4-rVg90H21EOLACvtfcHk0lhbVescBMgEdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnt1Wqu78%253D&md5=c50903c1448205084a83521a84772cad</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.apradiso.2009.03.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apradiso.2009.03.030%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DW.%26aulast%3DBarth%26aufirst%3DR.%2BF.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DTjarks%26aufirst%3DW.%26aulast%3DBinns%26aufirst%3DP.%26aulast%3DRiley%26aufirst%3DK.%26atitle%3DBoron%2520neutron%2520capture%2520therapy%2520of%2520EGFR%2520or%2520EGFRvIII%2520positive%2520gliomas%2520using%2520either%2520boronated%2520monoclonal%2520antibodies%2520or%2520epidermal%2520growth%2520factor%2520as%2520molecular%2520targeting%2520agents%26jtitle%3DAppl.%2520Radiat.%2520Isot.%26date%3D2009%26volume%3D67%26spage%3DS328%26epage%3DS331%26doi%3D10.1016%2Fj.apradiso.2009.03.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michiue, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakurai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitamatsu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirota, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawabata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiki, T.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohmori, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomizawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyatake, S.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ono, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsui, H.</span></span> <span> </span><span class="NLM_article-title">The acceleration of boron neutron capture therapy using multi-linked mercaptoundecahydrododecaborate (BSH) fused cell-penetrating peptide</span>. <i>Biomaterials</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">3396</span>– <span class="NLM_lpage">3405</span>, <span class="refDoi"> DOI: 10.1016/j.biomaterials.2013.12.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1016%2Fj.biomaterials.2013.12.055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=24452095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVyjs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=3396-3405&author=H.+Michiueauthor=Y.+Sakuraiauthor=N.+Kondoauthor=M.+Kitamatsuauthor=F.+Binauthor=K.+Nakajimaauthor=Y.+Hirotaauthor=S.+Kawabataauthor=T.-i.+Nishikiauthor=I.+Ohmoriauthor=K.+Tomizawaauthor=S.-i.+Miyatakeauthor=K.+Onoauthor=H.+Matsui&title=The+acceleration+of+boron+neutron+capture+therapy+using+multi-linked+mercaptoundecahydrododecaborate+%28BSH%29+fused+cell-penetrating+peptide&doi=10.1016%2Fj.biomaterials.2013.12.055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">The acceleration of boron neutron capture therapy using multi-linked mercaptoundecahydrododecaborate (BSH) fused cell-penetrating peptide</span></div><div class="casAuthors">Michiue, Hiroyuki; Sakurai, Yoshinori; Kondo, Natsuko; Kitamatsu, Mizuki; Bin, Feng; Nakajima, Kiichiro; Hirota, Yuki; Kawabata, Shinji; Nishiki, Tei-ichi; Ohmori, Iori; Tomizawa, Kazuhito; Miyatake, Shin-ichi; Ono, Koji; Matsui, Hideki</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3396-3405</span>CODEN:
                <span class="NLM_cas:coden">BIMADU</span>;
        ISSN:<span class="NLM_cas:issn">0142-9612</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">New anti-cancer therapy with boron neutron capture therapy (BNCT) is based on the nuclear reaction of boron-10 with neutron irradn.  The median survival of BNCT patients with glioblastoma was almost twice as long as those receiving std. therapy in a Japanese BNCT clin. trial.  In this clin. trial, two boron compds., BPA (boronophenylalanine) and BSH (sodium borocaptate), were used for BNCT.  BPA is taken up into cells through amino acid transporters that are expressed highly in almost all malignant cells, but BSH cannot pass through the cell membrane and remains outside the cell.  We simulated the energy transfer against the nucleus at different locations of boron from outside the cell to the nuclear region with neutron irradn. and concluded that there was a marked difference between inside and outside the cell in boron localization.  To overcome this disadvantage of BSH in BNCT, we used a cell-penetrating peptide system for transduction of BSH.  CPP (cell-membrane penetrating peptide) is very common peptide domains that transduce many physiol. active substances into cells in vitro and in vivo.  BSH-fused CPPs can penetrate the cell membrane and localize inside a cell.  To increase the boron ratio in one BSH-peptide mol., 8BSH fused to 11R with a dendritic lysine structure was synthesized and administrated to malignant glioma cells and a brain tumor mouse model.  8BSH-11R localized at the cell nucleus and showed a very high boron value in ICP results.  With neutron irradn., the 8BSH-11R administrated group showed a significant cancer killing effect compared to the 100 times higher concn. of BSH-administrated group.  We concluded that BSH-fused CPPs were one of the most improved and potential boron compds. in the next-stage BNCT trial and 8BSH-11R may be applied in the clin. setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtp_1ZZM5M8bVg90H21EOLACvtfcHk0lgjglMu5BHJSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVyjs74%253D&md5=cd2c4799cd7e8ba8806cdbafaf7f482b</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.biomaterials.2013.12.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biomaterials.2013.12.055%26sid%3Dliteratum%253Aachs%26aulast%3DMichiue%26aufirst%3DH.%26aulast%3DSakurai%26aufirst%3DY.%26aulast%3DKondo%26aufirst%3DN.%26aulast%3DKitamatsu%26aufirst%3DM.%26aulast%3DBin%26aufirst%3DF.%26aulast%3DNakajima%26aufirst%3DK.%26aulast%3DHirota%26aufirst%3DY.%26aulast%3DKawabata%26aufirst%3DS.%26aulast%3DNishiki%26aufirst%3DT.-i.%26aulast%3DOhmori%26aufirst%3DI.%26aulast%3DTomizawa%26aufirst%3DK.%26aulast%3DMiyatake%26aufirst%3DS.-i.%26aulast%3DOno%26aufirst%3DK.%26aulast%3DMatsui%26aufirst%3DH.%26atitle%3DThe%2520acceleration%2520of%2520boron%2520neutron%2520capture%2520therapy%2520using%2520multi-linked%2520mercaptoundecahydrododecaborate%2520%2528BSH%2529%2520fused%2520cell-penetrating%2520peptide%26jtitle%3DBiomaterials%26date%3D2014%26volume%3D35%26spage%3D3396%26epage%3D3405%26doi%3D10.1016%2Fj.biomaterials.2013.12.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, N.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, X.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">A survey on “Trojan Horse” peptides: opportunities, issues and controlled entry to “Troy”</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>194</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1016/j.jconrel.2014.08.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1016%2Fj.jconrel.2014.08.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=25151981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVCisr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=2014&pages=53-70&author=N.-Q.+Shiauthor=X.-R.+Qiauthor=B.+Xiangauthor=Y.+Zhang&title=A+survey+on+%E2%80%9CTrojan+Horse%E2%80%9D+peptides%3A+opportunities%2C+issues+and+controlled+entry+to+%E2%80%9CTroy%E2%80%9D&doi=10.1016%2Fj.jconrel.2014.08.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">A survey on "Trojan Horse" peptides: Opportunities, issues and controlled entry to "Troy"</span></div><div class="casAuthors">Shi, Nian-Qiu; Qi, Xian-Rong; Xiang, Bai; Zhang, Yong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">194</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">53-70</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Cell-penetrating peptides (CPPs), often vividly termed as the "Trojan Horse" peptides, have attracted considerable interest for the intracellular delivery of a wide range of cargoes, such as small mols., peptides, proteins, nucleic acids, contrast agents, nanocarriers and so on.  Some preclin. and clin. developments of CPP conjugates demonstrate their promise as therapeutic agents for drug discovery.  There is increasing evidence to suggest that CPPs have the potential to cross several bio-barriers (e.g., blood-brain barriers, intestinal mucosa, nasal mucosa and skin barriers).  Despite revolutionary process in many aspects, there are a lot of basic issues unclear for these entities, such as internalization mechanisms, translocation efficiency, translocation kinetics, metabolic degrdn., toxicity, side effect, distribution and non-specificity.  Among them, non-specificity remains a major drawback for the in vivo application of CPPs in the targeted delivery of cargoes.  So far, diverse organelle-specific CPPs or controlled delivery strategies have emerged and improved their specificity.  In this review, we will look at the opportunities of CPPs in clin. development, bio-barriers penetration and nanocarriers delivery.  Then, a series of basic problems of CPPs will be discussed.  Finally, this paper will highlight the use of various controlled strategies in the organelle-specific delivery and targeted delivery of CPPs.  The purpose of this review will be to emphasize most influential advance in this field and present a fundamental understanding for challenges and utilizations of CPPs.  This will accelerate their translation as efficient vectors from the in vitro setting into the clinic arena, and retrieve the entry art to "Troy".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokzu6wAt-y2rVg90H21EOLACvtfcHk0lgjglMu5BHJSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVCisr7O&md5=149b9e4bfc80e0eb9a19b0531bc32d62</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2014.08.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2014.08.014%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DN.-Q.%26aulast%3DQi%26aufirst%3DX.-R.%26aulast%3DXiang%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DA%2520survey%2520on%2520%25E2%2580%259CTrojan%2520Horse%25E2%2580%259D%2520peptides%253A%2520opportunities%252C%2520issues%2520and%2520controlled%2520entry%2520to%2520%25E2%2580%259CTroy%25E2%2580%259D%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2014%26volume%3D194%26spage%3D53%26epage%3D70%26doi%3D10.1016%2Fj.jconrel.2014.08.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span>; <span class="NLM_string-name">Els-Heindl, S.</span>; <span class="NLM_string-name">Worm, D. J.</span>; <span class="NLM_string-name">Hey-Hawkins, E.</span>; <span class="NLM_string-name">Kellert, M.</span>; <span class="NLM_string-name">Kuhnert, R.</span>; <span class="NLM_string-name">Saretz, S.</span>; <span class="NLM_string-name">Riedl, B.</span>; <span class="NLM_string-name">Bierer, D.</span>; <span class="NLM_string-name">Koebberling, J.</span>; <span class="NLM_string-name">Griebenow, N.</span></span> <span> </span><span class="NLM_article-title">Saccharide Functionalised Carborane Conjugates of Human Peptide Y</span>. Patent 	<span class="NLM_patent">WO 2019/115609</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=A.+G.+Beck-Sickinger&author=S.+Els-Heindl&author=D.+J.+Worm&author=E.+Hey-Hawkins&author=M.+Kellert&author=R.+Kuhnert&author=S.+Saretz&author=B.+Riedl&author=D.+Bierer&author=J.+Koebberling&author=N.+Griebenow&title=Saccharide+Functionalised+Carborane+Conjugates+of+Human+Peptide+Y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26atitle%3DSaccharide%2520Functionalised%2520Carborane%2520Conjugates%2520of%2520Human%2520Peptide%2520Y%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span>; <span class="NLM_string-name">Els-Heindl, S.</span>; <span class="NLM_string-name">Wolf, P.</span>; <span class="NLM_string-name">Hey-Hawkins, E.</span>; <span class="NLM_string-name">Kellert, M.</span>; <span class="NLM_string-name">Kuhnert, R.</span>; <span class="NLM_string-name">Saretz, S.</span>; <span class="NLM_string-name">Riedl, B.</span>; <span class="NLM_string-name">Bierer, D.</span>; <span class="NLM_string-name">Koebberling, J.</span>; <span class="NLM_string-name">Griebenow, N.</span></span> <span> </span><span class="NLM_article-title">Peptidic Melanocortin 1 Receptor Agonist - Saccharirde Functionalised Carbaborane Conjugates</span>. Patent <span class="NLM_patent">WO 2019/115614 A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=A.+G.+Beck-Sickinger&author=S.+Els-Heindl&author=P.+Wolf&author=E.+Hey-Hawkins&author=M.+Kellert&author=R.+Kuhnert&author=S.+Saretz&author=B.+Riedl&author=D.+Bierer&author=J.+Koebberling&author=N.+Griebenow&title=Peptidic+Melanocortin+1+Receptor+Agonist+-+Saccharirde+Functionalised+Carbaborane+Conjugates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26atitle%3DPeptidic%2520Melanocortin%25201%2520Receptor%2520Agonist%2520-%2520Saccharirde%2520Functionalised%2520Carbaborane%2520Conjugates%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span>; <span class="NLM_string-name">Els-Heindl, S.</span>; <span class="NLM_string-name">Hoppenz, P.</span>; <span class="NLM_string-name">Hey-Hawkins, E.</span>; <span class="NLM_string-name">Kellert, M.</span>; <span class="NLM_string-name">Kuhnert, R.</span>; <span class="NLM_string-name">Saretz, S.</span>; <span class="NLM_string-name">Riedl, B.</span>; <span class="NLM_string-name">Bierer, D.</span>; <span class="NLM_string-name">Koebberling, J.</span>; <span class="NLM_string-name">Griebenow, N.</span></span> <span> </span><span class="NLM_article-title">Peptidic BB2 Receptor Agonist - Saccharirde Functionalised Carbaborane Conjugates</span>. Patent <span class="NLM_patent">WO 2019/115611</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=A.+G.+Beck-Sickinger&author=S.+Els-Heindl&author=P.+Hoppenz&author=E.+Hey-Hawkins&author=M.+Kellert&author=R.+Kuhnert&author=S.+Saretz&author=B.+Riedl&author=D.+Bierer&author=J.+Koebberling&author=N.+Griebenow&title=Peptidic+BB2+Receptor+Agonist+-+Saccharirde+Functionalised+Carbaborane+Conjugates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26atitle%3DPeptidic%2520BB2%2520Receptor%2520Agonist%2520-%2520Saccharirde%2520Functionalised%2520Carbaborane%2520Conjugates%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span>; <span class="NLM_string-name">Els-Heindl, S.</span>; <span class="NLM_string-name">Worm, D. J.</span>; <span class="NLM_string-name">Hey-Hawkins, E.</span>; <span class="NLM_string-name">Kellert, M.</span>; <span class="NLM_string-name">Kuhnert, R.</span>; <span class="NLM_string-name">Saretz, S.</span>; <span class="NLM_string-name">Riedl, B.</span>; <span class="NLM_string-name">Bierer, D.</span>; <span class="NLM_string-name">Koebberling, J.</span>; <span class="NLM_string-name">Griebenow, N.</span></span> <span> </span><span class="NLM_article-title">Carborane-Modified Ghrelin Receptor Agonists for BNCT</span>. <span class="NLM_patent">WO 2019/115624</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=A.+G.+Beck-Sickinger&author=S.+Els-Heindl&author=D.+J.+Worm&author=E.+Hey-Hawkins&author=M.+Kellert&author=R.+Kuhnert&author=S.+Saretz&author=B.+Riedl&author=D.+Bierer&author=J.+Koebberling&author=N.+Griebenow&title=Carborane-Modified+Ghrelin+Receptor+Agonists+for+BNCT"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26atitle%3DCarborane-Modified%2520Ghrelin%2520Receptor%2520Agonists%2520for%2520BNCT%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hey-Hawkins, E.</span>; <span class="NLM_string-name">Beck-Sickinger, A. G.</span>; <span class="NLM_string-name">Kellert, M.</span>; <span class="NLM_string-name">Kuhnert, R.</span>; <span class="NLM_string-name">Saretz, S.</span>; <span class="NLM_string-name">Riedl, B.</span>; <span class="NLM_string-name">Bierer, D.</span>; <span class="NLM_string-name">Koebberling, J.</span>; <span class="NLM_string-name">Griebenow, N.</span></span> <span> </span><span class="NLM_article-title">Novel 1,7-Dicarba-Closo-Dodecarborane(12) (Meta-Carbaborane)-derived Carboxylic Acids Suitable for Peptide Modification for Application in Boron Neutron Capture Therapy (BNCT)</span>. Patent 	<span class="NLM_patent">WO 2019/115616</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=E.+Hey-Hawkins&author=A.+G.+Beck-Sickinger&author=M.+Kellert&author=R.+Kuhnert&author=S.+Saretz&author=B.+Riedl&author=D.+Bierer&author=J.+Koebberling&author=N.+Griebenow&title=Novel+1%2C7-Dicarba-Closo-Dodecarborane%2812%29+%28Meta-Carbaborane%29-derived+Carboxylic+Acids+Suitable+for+Peptide+Modification+for+Application+in+Boron+Neutron+Capture+Therapy+%28BNCT%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHey-Hawkins%26aufirst%3DE.%26atitle%3DNovel%25201%252C7-Dicarba-Closo-Dodecarborane%252812%2529%2520%2528Meta-Carbaborane%2529-derived%2520Carboxylic%2520Acids%2520Suitable%2520for%2520Peptide%2520Modification%2520for%2520Application%2520in%2520Boron%2520Neutron%2520Capture%2520Therapy%2520%2528BNCT%2529%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harris, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabral de Menezes, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodfellow, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granger, P.</span></span> <span> </span><span class="NLM_article-title">NMR nomenclature: nuclear spin properties and conventions for chemical shifts. IUPAC recommendations 2001</span>. <i>Solid State Nucl. Magn. Reson.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">458</span>– <span class="NLM_lpage">483</span>, <span class="refDoi"> DOI: 10.1006/snmr.2002.0063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1006%2Fsnmr.2002.0063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=12637147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD38XpslWltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2002&pages=458-483&author=R.+K.+Harrisauthor=E.+D.+Beckerauthor=S.+M.+Cabral+de+Menezesauthor=R.+Goodfellowauthor=P.+Granger&title=NMR+nomenclature%3A+nuclear+spin+properties+and+conventions+for+chemical+shifts.+IUPAC+recommendations+2001&doi=10.1006%2Fsnmr.2002.0063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">NMR nomenclature: Nuclear spin properties and conventions for chemical shifts. IUPAC recommendations 2001</span></div><div class="casAuthors">Harris, Robin K.; Becker, Edwin D.; Cabral de Menezes, Sonia M.; Goodfellow, Robin; Granger, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Solid State Nuclear Magnetic Resonance</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">458-483</span>CODEN:
                <span class="NLM_cas:coden">SSNRE4</span>;
        ISSN:<span class="NLM_cas:issn">0926-2040</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">A unified scale is recommended for reporting the NMR chem. shifts of all nuclei relative to the 1H resonance of tetramethylsilane.  The unified scale is designed to provide a precise ratio, Ξ, of the resonance frequency of a given nuclide to that of the primary ref., the 1H resonance of tetramethylsilane (TMS) in dil. soln. (vol. fraction, φ<1%) in CHCl3.  Referencing procedures are discussed, including matters of practical application of the unified scale.  Special attention is paid to recommended ref. samples, and values of Ξ for secondary refs. on the unified scale are listed, many of which are the results of new measurements.  Some earlier recommendations relating to the reporting of chem. shifts are endorsed.  The chem. shift, δ, is redefined to avoid previous ambiguities but to leave practical usage unchanged.  Relations between the unified scale and recently published recommendations for referencing in aq. solns. (for specific use in biochem. work) are discussed, as well as the special effects of working in the solid state with magic-angle spinning.  In all, nine new recommendations relating to chem. shifts are made.  Standardized nuclear spin data are also presented in tabular form for the stable (and some unstable) isotopes of all elements with nonzero quantum nos.  The information given includes quantum nos., isotopic abundances, magnetic moments, magnetogyric ratios, and receptivities, together with quadrupole moments and line-width factors (appropriate).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp7V_2u85ZU7Vg90H21EOLACvtfcHk0lgeiYCCzZ0qNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpslWltrw%253D&md5=0bf22f16d4c932a54075c9619edca00c</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1006%2Fsnmr.2002.0063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fsnmr.2002.0063%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DR.%2BK.%26aulast%3DBecker%26aufirst%3DE.%2BD.%26aulast%3DCabral%2Bde%2BMenezes%26aufirst%3DS.%2BM.%26aulast%3DGoodfellow%26aufirst%3DR.%26aulast%3DGranger%26aufirst%3DP.%26atitle%3DNMR%2520nomenclature%253A%2520nuclear%2520spin%2520properties%2520and%2520conventions%2520for%2520chemical%2520shifts.%2520IUPAC%2520recommendations%25202001%26jtitle%3DSolid%2520State%2520Nucl.%2520Magn.%2520Reson.%26date%3D2002%26volume%3D22%26spage%3D458%26epage%3D483%26doi%3D10.1006%2Fsnmr.2002.0063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frank, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehnke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hey-Hawkins, E.</span></span> <span> </span><span class="NLM_article-title">From ortho-carbaborane-9-thiol towards new building blocks</span>. <i>Polyhedron</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.1016/j.poly.2012.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1016%2Fj.poly.2012.03.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BC38Xls1ens7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2012&pages=9-13&author=R.+Frankauthor=S.+Boehnkeauthor=A.+Alievauthor=E.+Hey-Hawkins&title=From+ortho-carbaborane-9-thiol+towards+new+building+blocks&doi=10.1016%2Fj.poly.2012.03.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">From ortho-carbaborane-9-thiol towards new building blocks</span></div><div class="casAuthors">Frank, Rene; Boehnke, Solveig; Aliev, Almaz; Hey-Hawkins, Evamarie</div><div class="citationInfo"><span class="NLM_cas:title">Polyhedron</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-13</span>CODEN:
                <span class="NLM_cas:coden">PLYHDE</span>;
        ISSN:<span class="NLM_cas:issn">0277-5387</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The potential of 1,2-dicarba-closo-dodecaborane(12)-9-thiol, 9-HS-1,2-closo-C2B10H11, for the design of novel building blocks is highlighted by two examples envisioned for incorporation into tumor-selective peptides for B neutron capture therapy (BNCT).  By employing a t-Bu protection strategy the synthesis of a bis-galactosyl-substituted ortho-carbaborane carboxylic acid was elaborated, and the procedure is suggested as a general approach towards carbaboranes with three substituents.  Also, a simple route to a tris(ortho-carbaborane) building block starting from pentaerythritol is illustrated.  All compds. were synthesized in moderate to high yields and identified by 1H, 11B, and 13C NMR spectroscopy, IR spectroscopy, mass spectrometry, and in one case by x-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpas1kN2Q88C7Vg90H21EOLACvtfcHk0lgeiYCCzZ0qNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xls1ens7s%253D&md5=6537ba24c3ab602771c943e9a9af159e</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.poly.2012.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.poly.2012.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DFrank%26aufirst%3DR.%26aulast%3DBoehnke%26aufirst%3DS.%26aulast%3DAliev%26aufirst%3DA.%26aulast%3DHey-Hawkins%26aufirst%3DE.%26atitle%3DFrom%2520ortho-carbaborane-9-thiol%2520towards%2520new%2520building%2520blocks%26jtitle%3DPolyhedron%26date%3D2012%26volume%3D39%26spage%3D9%26epage%3D13%26doi%3D10.1016%2Fj.poly.2012.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crudden, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sateesh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, R.</span></span> <span> </span><span class="NLM_article-title">Mercaptopropyl-modified mesoporous silica: a remarkable support for the preparation of a reusable, heterogeneous palladium catalyst for coupling reactions</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">10045</span>– <span class="NLM_lpage">10050</span>, <span class="refDoi"> DOI: 10.1021/ja0430954</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja0430954" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltlyrtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2005&pages=10045-10050&author=C.+M.+Cruddenauthor=M.+Sateeshauthor=R.+Lewis&title=Mercaptopropyl-modified+mesoporous+silica%3A+a+remarkable+support+for+the+preparation+of+a+reusable%2C+heterogeneous+palladium+catalyst+for+coupling+reactions&doi=10.1021%2Fja0430954"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Mercaptopropyl-Modified Mesoporous Silica: A Remarkable Support for the Preparation of a Reusable, Heterogeneous Palladium Catalyst for Coupling Reactions</span></div><div class="casAuthors">Crudden, Cathleen M.; Sateesh, Mutyala; Lewis, Roxanne</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">10045-10050</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The functionalization of SBA-15 with mercaptopropyl trimethoxysilane leads to a material capable of absorbing Pd from org. and aq. solns.  The resulting Pd-loaded material acts as a catalyst for the Suzuki-Miyaura and Mizoroki-Heck coupling reactions.  Leaching studies show that the filtrate contains as little as 3 ppb Pd after reaction.  (Amino)propyl-modified silica is an effective scavenger, and catalyst for the Mizoroki-Heck reaction, but leaching is significant (35 ppm), illustrating the importance of the thiol ligand to retain Pd on the surface.  Heterogeneity tests such as hot filtration expts. and three-phase tests show that the reaction is occurring predominantly via surface-bound Pd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCU0hOOyLilbVg90H21EOLACvtfcHk0lhXyNWMaDnqvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltlyrtrc%253D&md5=8cf722caf4d68a99633bf560794579bd</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Fja0430954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja0430954%26sid%3Dliteratum%253Aachs%26aulast%3DCrudden%26aufirst%3DC.%2BM.%26aulast%3DSateesh%26aufirst%3DM.%26aulast%3DLewis%26aufirst%3DR.%26atitle%3DMercaptopropyl-modified%2520mesoporous%2520silica%253A%2520a%2520remarkable%2520support%2520for%2520the%2520preparation%2520of%2520a%2520reusable%252C%2520heterogeneous%2520palladium%2520catalyst%2520for%2520coupling%2520reactions%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2005%26volume%3D127%26spage%3D10045%26epage%3D10050%26doi%3D10.1021%2Fja0430954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hey-Hawkins, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, P.</span></span> <span> </span><span class="NLM_article-title">Manipulating Y receptor subtype activation of short neuropeptide Y analogs by introducing carbaboranes</span>. <i>Neuropeptides</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1016/j.npep.2012.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1016%2Fj.npep.2012.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=23352609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFCqsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2013&pages=59-66&author=S.+Hofmannauthor=R.+Frankauthor=E.+Hey-Hawkinsauthor=A.+G.+Beck-Sickingerauthor=P.+Schmidt&title=Manipulating+Y+receptor+subtype+activation+of+short+neuropeptide+Y+analogs+by+introducing+carbaboranes&doi=10.1016%2Fj.npep.2012.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Manipulating Y receptor subtype activation of short neuropeptide Y analogs by introducing carbaboranes</span></div><div class="casAuthors">Hofmann, S.; Frank, R.; Hey-Hawkins, E.; Beck-Sickinger, A. G.; Schmidt, P.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropeptides (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">59-66</span>CODEN:
                <span class="NLM_cas:coden">NRPPDD</span>;
        ISSN:<span class="NLM_cas:issn">0143-4179</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Short selective neuropeptide Y (NPY) analogs are highly attractive because of their facile synthesis.  Based on the reduced-size NPY analog [Pro30, Nle31, Bpa32, Leu34]NPY 28-36 position 32 was identified as a key position to alter the preferential activation pattern of the human neuropeptide Y receptors (hYRs).  By replacing benzoylphenylalanine (Bpa) by a biphenylalanine (Bip) the photostability was first improved while the biol. activity was maintained.  SAR-studies showed that both arom. rings have a high influence on the preferential hYR subtype activation.  Interestingly, replacement of Bpa32 by a strongly hydrophobic moiety changed the hYR subtype preference of the analog.  Whereas the parent compd. is able to activate the human neuropeptide Y1 receptor (hY1R) subtype, the introduction of an Nε-ortho-carbaboranyl propionic acid modified lysine resulted in a loss of activity at the hY1R but in an increased activity at both the hY2R and the hY4R.  However, subsequent receptor internalization studies with this novel analog revealed that receptor internalization can neither be triggered at the hY2R nor at the hY4R suggesting a biased ligand.  Surprisingly, investigations by 1H NMR spectroscopy revealed structural changes in the side chains of residues Pro30 and Leu34 which nicely correlates with the shift from hY1R/hY4R to hY2R/hY4R activation preference.  Thus, position 32 has been identified to switch the bioactive conformation and subsequently influences receptor subtype activation behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvP9VxxSzNyrVg90H21EOLACvtfcHk0lhXyNWMaDnqvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFCqsbw%253D&md5=bc298e83582804b6cad8c2000a99b172</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.npep.2012.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.npep.2012.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DHofmann%26aufirst%3DS.%26aulast%3DFrank%26aufirst%3DR.%26aulast%3DHey-Hawkins%26aufirst%3DE.%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26aulast%3DSchmidt%26aufirst%3DP.%26atitle%3DManipulating%2520Y%2520receptor%2520subtype%2520activation%2520of%2520short%2520neuropeptide%2520Y%2520analogs%2520by%2520introducing%2520carbaboranes%26jtitle%3DNeuropeptides%26date%3D2013%26volume%3D47%26spage%3D59%26epage%3D66%26doi%3D10.1016%2Fj.npep.2012.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wanka, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babilon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mörl, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span></span> <span> </span><span class="NLM_article-title">Different mode of arrestin-3 binding at the human Y1 and Y2 receptor</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.1016/j.cellsig.2018.06.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1016%2Fj.cellsig.2018.06.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=29944985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht12mu77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2018&pages=58-71&author=L.+Wankaauthor=S.+Babilonauthor=A.+Kaiserauthor=K.+M%C3%B6rlauthor=A.+G.+Beck-Sickinger&title=Different+mode+of+arrestin-3+binding+at+the+human+Y1+and+Y2+receptor&doi=10.1016%2Fj.cellsig.2018.06.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Different mode of arrestin-3 binding at the human Y1 and Y2 receptor</span></div><div class="casAuthors">Wanka, Lizzy; Babilon, Stefanie; Kaiser, Anette; Moerl, Karin; Beck-Sickinger, Annette G.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">58-71</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">GPCR internalization, which is induced by arrestin recruitment, is an important mechanism for the regulation of signaling and receptor quantity at the cell surface.  In this study, differences in the mechanism of arrestin-3 (arr-3) recruitment to the neuropeptide Y1 and Y2 receptor were identified.  These receptors play an essential role in the regulation of feeding, energy homeostasis and cancer.  The Y1R displays high affinity to arr-3, which induces rapid internalization of the arrestin/receptor complex.  In contrast, the Y2R has a lower affinity for arr-3.  Internalization is induced by arrestin binding, but arr-3 is released from the receptor and remains at the membrane while the receptor internalizes.  Moreover, the deletion of the finger loop region of arr-3 reduces its agonist-dependent recruitment to the Y2R significantly, but not to the Y1R suggesting different binding conformations.  For the first time, the formation of a supercomplex consisting of Y receptor, Gα0 protein and arrestin was studied by BRET-assay.  We demonstrated that the Y1R is able to bind Gα0 protein as well as arr-3 simultaneously and internalizes as a supercomplex.  For the Y2R no supercomplex formation was obsd.  By substituting the C-terminus or specific residues within the intracellular loop 1 and 2 of the receptors, the arr-3 recruitment of the Y1R and Y2R can be switched.  Thus, we shed light on the specific spatio-temporal distribution of Gα0 protein and arrestin in response to Y1 vs. Y2 receptor activation and identified the mol. determinants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYuyxWeG-A7bVg90H21EOLACvtfcHk0lhXyNWMaDnqvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht12mu77N&md5=b52c1ea5cb54ae0d8fe0d4840e4ac4c3</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2018.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2018.06.010%26sid%3Dliteratum%253Aachs%26aulast%3DWanka%26aufirst%3DL.%26aulast%3DBabilon%26aufirst%3DS.%26aulast%3DKaiser%26aufirst%3DA.%26aulast%3DM%25C3%25B6rl%26aufirst%3DK.%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26atitle%3DDifferent%2520mode%2520of%2520arrestin-3%2520binding%2520at%2520the%2520human%2520Y1%2520and%2520Y2%2520receptor%26jtitle%3DCell.%2520Signalling%26date%3D2018%26volume%3D50%26spage%3D58%26epage%3D71%26doi%3D10.1016%2Fj.cellsig.2018.06.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 16 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Tobias F. Fischer, Clara T. Schoeder, Tristan Zellmann, Jan Stichel, Jens Meiler, <span class="NLM_string-name hlFld-ContribAuthor">Annette G. Beck-Sickinger</span>. </span><span class="cited-content_cbyCitation_article-title">Cyclic Analogues of the Chemerin C-Terminus Mimic a Loop Conformation Essential for Activating the Chemokine-like Receptor 1. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (6)
                                     , 3048-3058. <a href="https://doi.org/10.1021/acs.jmedchem.0c01804" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01804</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01804&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01804%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCyclic%252BAnalogues%252Bof%252Bthe%252BChemerin%252BC-Terminus%252BMimic%252Ba%252BLoop%252BConformation%252BEssential%252Bfor%252BActivating%252Bthe%252BChemokine-like%252BReceptor%252B1%26aulast%3DFischer%26aufirst%3DTobias%2BF.%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D15102020%26date%3D11032021%26volume%3D64%26issue%3D6%26spage%3D3048%26epage%3D3058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jelena Matović, Juulia Järvinen, Iris K. Sokka, Surachet Imlimthan, Jan-Erik Raitanen, Ahmed Montaser, Hannu Maaheimo, Kristiina M. Huttunen, Sirpa Peräniemi, Anu J. Airaksinen, Mirkka Sarparanta, Mikael P. Johansson, Jarkko Rautio, <span class="NLM_string-name hlFld-ContribAuthor">Filip S. Ekholm</span>. </span><span class="cited-content_cbyCitation_article-title">Exploring the Biochemical Foundations of a Successful GLUT1-Targeting Strategy to BNCT: Chemical Synthesis and In Vitro Evaluation of the Entire Positional Isomer Library of ortho-Carboranylmethyl-Bearing Glucoconjugates. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2021,</strong> <em>18 </em>
                                    (1)
                                     , 285-304. <a href="https://doi.org/10.1021/acs.molpharmaceut.0c00917" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.0c00917</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.0c00917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.0c00917%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DExploring%252Bthe%252BBiochemical%252BFoundations%252Bof%252Ba%252BSuccessful%252BGLUT1-Targeting%252BStrategy%252Bto%252BBNCT%25253A%252BChemical%252BSynthesis%252Band%252BIn%252BVitro%252BEvaluation%252Bof%252Bthe%252BEntire%252BPositional%252BIsomer%252BLibrary%252Bof%252Bortho-Carboranylmethyl-Bearing%252BGlucoconjugates%26aulast%3DMatovi%25C4%2587%26aufirst%3DJelena%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D10092020%26date%3D18112020%26date%3D17112020%26date%3D02122020%26volume%3D18%26issue%3D1%26spage%3D285%26epage%3D304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Paul Hoppenz, Sylvia Els-Heindl, Martin Kellert, Robert Kuhnert, Stefan Saretz, Hans-Georg Lerchen, Johannes Köbberling, Bernd Riedl, Evamarie Hey-Hawkins, <span class="NLM_string-name hlFld-ContribAuthor">Annette G. Beck-Sickinger</span>. </span><span class="cited-content_cbyCitation_article-title">A Selective Carborane-Functionalized Gastrin-Releasing Peptide Receptor Agonist as Boron Delivery Agent for Boron Neutron Capture Therapy. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (3)
                                     , 1446-1457. <a href="https://doi.org/10.1021/acs.joc.9b02406" title="DOI URL">https://doi.org/10.1021/acs.joc.9b02406</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.9b02406&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.9b02406%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DA%252BSelective%252BCarborane-Functionalized%252BGastrin-Releasing%252BPeptide%252BReceptor%252BAgonist%252Bas%252BBoron%252BDelivery%252BAgent%252Bfor%252BBoron%252BNeutron%252BCapture%252BTherapy%26aulast%3DHoppenz%26aufirst%3DPaul%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D03092019%26date%3D23122019%26date%3D09122019%26volume%3D85%26issue%3D3%26spage%3D1446%26epage%3D1457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fabian  Heide</span>, <span class="hlFld-ContribAuthor ">Matthew  McDougall</span>, <span class="hlFld-ContribAuthor ">Candice  Harder-Viddal</span>, <span class="hlFld-ContribAuthor ">Roy  Roshko</span>, <span class="hlFld-ContribAuthor ">David  Davidson</span>, <span class="hlFld-ContribAuthor ">Jiandong  Wu</span>, <span class="hlFld-ContribAuthor ">Camila  Aprosoff</span>, <span class="hlFld-ContribAuthor ">Aniel  Moya-Torres</span>, <span class="hlFld-ContribAuthor ">Francis  Lin</span>, <span class="hlFld-ContribAuthor ">Jörg  Stetefeld</span>. </span><span class="cited-content_cbyCitation_article-title">Boron rich nanotube drug carrier system is suited for boron neutron capture therapy. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2021,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-021-95044-0" title="DOI URL">https://doi.org/10.1038/s41598-021-95044-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-021-95044-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-021-95044-0%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DBoron%252Brich%252Bnanotube%252Bdrug%252Bcarrier%252Bsystem%252Bis%252Bsuited%252Bfor%252Bboron%252Bneutron%252Bcapture%252Btherapy%26aulast%3DHeide%26aufirst%3DFabian%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chiara  Bellomo</span>, <span class="hlFld-ContribAuthor ">Davide  Zanetti</span>, <span class="hlFld-ContribAuthor ">Francesca  Cardano</span>, <span class="hlFld-ContribAuthor ">Sohini  Sinha</span>, <span class="hlFld-ContribAuthor ">Mahdi  Chaari</span>, <span class="hlFld-ContribAuthor ">Andrea  Fin</span>, <span class="hlFld-ContribAuthor ">Andrea  Maranzana</span>, <span class="hlFld-ContribAuthor ">Rosario  Núñez</span>, <span class="hlFld-ContribAuthor ">Marco  Blangetti</span>, <span class="hlFld-ContribAuthor ">Cristina  Prandi</span>. </span><span class="cited-content_cbyCitation_article-title">Red light-emitting Carborane-BODIPY dyes: Synthesis and properties of visible-light tuned fluorophores with enhanced boron content. </span><span class="cited-content_cbyCitation_journal-name">Dyes and Pigments</span><span> <strong>2021,</strong> <em>194 </em>, 109644. <a href="https://doi.org/10.1016/j.dyepig.2021.109644" title="DOI URL">https://doi.org/10.1016/j.dyepig.2021.109644</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.dyepig.2021.109644&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.dyepig.2021.109644%26sid%3Dliteratum%253Aachs%26jtitle%3DDyes%2520and%2520Pigments%26atitle%3DRed%252Blight-emitting%252BCarborane-BODIPY%252Bdyes%25253A%252BSynthesis%252Band%252Bproperties%252Bof%252Bvisible-light%252Btuned%252Bfluorophores%252Bwith%252Benhanced%252Bboron%252Bcontent%26aulast%3DBellomo%26aufirst%3DChiara%26date%3D2021%26volume%3D194%26spage%3D109644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tobias F.  Fischer</span>, <span class="hlFld-ContribAuthor ">Anne S.  Czerniak</span>, <span class="hlFld-ContribAuthor ">Tina  Weiß</span>, <span class="hlFld-ContribAuthor ">Tristan  Zellmann</span>, <span class="hlFld-ContribAuthor ">Lina  Zielke</span>, <span class="hlFld-ContribAuthor ">Sylvia  Els-Heindl</span>, <span class="hlFld-ContribAuthor ">Annette G.  Beck-Sickinger</span>. </span><span class="cited-content_cbyCitation_article-title">Cyclic Derivatives of the Chemerin C-Terminus as Metabolically Stable Agonists at the Chemokine-like Receptor 1 for Cancer Treatment. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (15)
                                     , 3788. <a href="https://doi.org/10.3390/cancers13153788" title="DOI URL">https://doi.org/10.3390/cancers13153788</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13153788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13153788%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DCyclic%252BDerivatives%252Bof%252Bthe%252BChemerin%252BC-Terminus%252Bas%252BMetabolically%252BStable%252BAgonists%252Bat%252Bthe%252BChemokine-like%252BReceptor%252B1%252Bfor%252BCancer%252BTreatment%26aulast%3DFischer%26aufirst%3DTobias%2BF.%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D15%26spage%3D3788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Philipp  Wolf</span>, <span class="hlFld-ContribAuthor ">Annette G.  Beck‐Sickinger</span>. </span><span class="cited-content_cbyCitation_article-title">The ring size of monocyclic ET‐1 controls selectivity and signaling efficiency at both endothelin receptor subtypes. </span><span class="cited-content_cbyCitation_journal-name">Journal of Peptide Science</span><span> <strong>2021,</strong> <em>27 </em>
                                    (7)
                                     <a href="https://doi.org/10.1002/psc.3325" title="DOI URL">https://doi.org/10.1002/psc.3325</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/psc.3325&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fpsc.3325%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Peptide%2520Science%26atitle%3DThe%252Bring%252Bsize%252Bof%252Bmonocyclic%252BET%2525E2%252580%2525901%252Bcontrols%252Bselectivity%252Band%252Bsignaling%252Befficiency%252Bat%252Bboth%252Bendothelin%252Breceptor%252Bsubtypes%26aulast%3DWolf%26aufirst%3DPhilipp%26date%3D2021%26date%3D2021%26volume%3D27%26issue%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anaïs  Pitto-Barry</span>. </span><span class="cited-content_cbyCitation_article-title">Polymers and boron neutron capture therapy (BNCT): a potent combination. </span><span class="cited-content_cbyCitation_journal-name">Polymer Chemistry</span><span> <strong>2021,</strong> <em>12 </em>
                                    (14)
                                     , 2035-2044. <a href="https://doi.org/10.1039/D0PY01392G" title="DOI URL">https://doi.org/10.1039/D0PY01392G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0PY01392G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0PY01392G%26sid%3Dliteratum%253Aachs%26jtitle%3DPolymer%2520Chemistry%26atitle%3DPolymers%252Band%252Bboron%252Bneutron%252Bcapture%252Btherapy%252B%252528BNCT%252529%25253A%252Ba%252Bpotent%252Bcombination%26aulast%3DPitto-Barry%26aufirst%3DAna%25C3%25AFs%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D14%26spage%3D2035%26epage%3D2044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dmitry A.  Gruzdev</span>, <span class="hlFld-ContribAuthor ">Galina L.  Levit</span>, <span class="hlFld-ContribAuthor ">Victor P.  Krasnov</span>, <span class="hlFld-ContribAuthor ">Valery N.  Charushin</span>. </span><span class="cited-content_cbyCitation_article-title">Carborane-containing amino acids and peptides: Synthesis, properties and applications. </span><span class="cited-content_cbyCitation_journal-name">Coordination Chemistry Reviews</span><span> <strong>2021,</strong> <em>433 </em>, 213753. <a href="https://doi.org/10.1016/j.ccr.2020.213753" title="DOI URL">https://doi.org/10.1016/j.ccr.2020.213753</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ccr.2020.213753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ccr.2020.213753%26sid%3Dliteratum%253Aachs%26jtitle%3DCoordination%2520Chemistry%2520Reviews%26atitle%3DCarborane-containing%252Bamino%252Bacids%252Band%252Bpeptides%25253A%252BSynthesis%25252C%252Bproperties%252Band%252Bapplications%26aulast%3DGruzdev%26aufirst%3DDmitry%2BA.%26date%3D2021%26volume%3D433%26spage%3D213753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Martin  Kellert</span>, <span class="hlFld-ContribAuthor ">Jan-Simon Jeshua  Friedrichs</span>, <span class="hlFld-ContribAuthor ">Nadine Anke  Ullrich</span>, <span class="hlFld-ContribAuthor ">Alexander  Feinhals</span>, <span class="hlFld-ContribAuthor ">Jonas  Tepper</span>, <span class="hlFld-ContribAuthor ">Peter  Lönnecke</span>, <span class="hlFld-ContribAuthor ">Evamarie  Hey-Hawkins</span>. </span><span class="cited-content_cbyCitation_article-title">Modular Synthetic Approach to Carboranyl‒Biomolecules Conjugates. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (7)
                                     , 2057. <a href="https://doi.org/10.3390/molecules26072057" title="DOI URL">https://doi.org/10.3390/molecules26072057</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26072057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26072057%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DModular%252BSynthetic%252BApproach%252Bto%252BCarboranyl%2525E2%252580%252592Biomolecules%252BConjugates%26aulast%3DKellert%26aufirst%3DMartin%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D7%26spage%3D2057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna N.  Tevyashova</span>, <span class="hlFld-ContribAuthor ">Mikhail V.  Chudinov</span>. </span><span class="cited-content_cbyCitation_article-title">Progress in the medicinal chemistry of organoboron compounds. </span><span class="cited-content_cbyCitation_journal-name">Russian Chemical Reviews</span><span> <strong>2021,</strong> <em>90 </em>
                                    (4)
                                     , 451-487. <a href="https://doi.org/10.1070/RCR4977" title="DOI URL">https://doi.org/10.1070/RCR4977</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1070/RCR4977&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1070%2FRCR4977%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Chemical%2520Reviews%26atitle%3DProgress%252Bin%252Bthe%252Bmedicinal%252Bchemistry%252Bof%252Borganoboron%252Bcompounds%26aulast%3DTevyashova%26aufirst%3DAnna%2BN.%26date%3D2021%26volume%3D90%26issue%3D4%26spage%3D451%26epage%3D487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adrien  Chastel</span>, <span class="hlFld-ContribAuthor ">Dennis J.  Worm</span>, <span class="hlFld-ContribAuthor ">Isabel D.  Alves</span>, <span class="hlFld-ContribAuthor ">Delphine  Vimont</span>, <span class="hlFld-ContribAuthor ">Melina  Petrel</span>, <span class="hlFld-ContribAuthor ">Samantha  Fernandez</span>, <span class="hlFld-ContribAuthor ">Philippe  Garrigue</span>, <span class="hlFld-ContribAuthor ">Philippe  Fernandez</span>, <span class="hlFld-ContribAuthor ">Elif  Hindié</span>, <span class="hlFld-ContribAuthor ">Annette G.  Beck-Sickinger</span>, <span class="hlFld-ContribAuthor ">Clément  Morgat</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological evaluation of a multifunctional neuropeptide-Y conjugate for selective nuclear delivery of radiolanthanides. </span><span class="cited-content_cbyCitation_journal-name">EJNMMI Research</span><span> <strong>2020,</strong> <em>10 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13550-020-0612-8" title="DOI URL">https://doi.org/10.1186/s13550-020-0612-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13550-020-0612-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13550-020-0612-8%26sid%3Dliteratum%253Aachs%26jtitle%3DEJNMMI%2520Research%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252Ba%252Bmultifunctional%252Bneuropeptide-Y%252Bconjugate%252Bfor%252Bselective%252Bnuclear%252Bdelivery%252Bof%252Bradiolanthanides%26aulast%3DChastel%26aufirst%3DAdrien%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paul  Hoppenz</span>, <span class="hlFld-ContribAuthor ">Sylvia  Els-Heindl</span>, <span class="hlFld-ContribAuthor ">Annette G.  Beck-Sickinger</span>. </span><span class="cited-content_cbyCitation_article-title">Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Chemistry</span><span> <strong>2020,</strong> <em>8 </em><a href="https://doi.org/10.3389/fchem.2020.00571" title="DOI URL">https://doi.org/10.3389/fchem.2020.00571</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fchem.2020.00571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffchem.2020.00571%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Chemistry%26atitle%3DPeptide-Drug%252BConjugates%252Band%252BTheir%252BTargets%252Bin%252BAdvanced%252BCancer%252BTherapies%26aulast%3DHoppenz%26aufirst%3DPaul%26date%3D2020%26date%3D2020%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chuyi  Zhang</span>, <span class="hlFld-ContribAuthor ">Qian  Wang</span>, <span class="hlFld-ContribAuthor ">Song  Tian</span>, <span class="hlFld-ContribAuthor ">Jianwei  Zhang</span>, <span class="hlFld-ContribAuthor ">Jiaoyi  Li</span>, <span class="hlFld-ContribAuthor ">Ling  Zhou</span>, <span class="hlFld-ContribAuthor ">Jian  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Palladium-catalyzed regioselective synthesis of B(4,5)- or B(4)-substituted
              o
              -carboranes containing α,β-unsaturated carbonyls. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2020,</strong> <em>18 </em>
                                    (25)
                                     , 4723-4727. <a href="https://doi.org/10.1039/D0OB00698J" title="DOI URL">https://doi.org/10.1039/D0OB00698J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0OB00698J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0OB00698J%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DPalladium-catalyzed%252Bregioselective%252Bsynthesis%252Bof%252BB%2525284%25252C5%252529-%252Bor%252BB%2525284%252529-substituted%252Bo%252B-carboranes%252Bcontaining%252B%2525CE%2525B1%25252C%2525CE%2525B2-unsaturated%252Bcarbonyls%26aulast%3DZhang%26aufirst%3DChuyi%26date%3D2020%26date%3D2020%26volume%3D18%26issue%3D25%26spage%3D4723%26epage%3D4727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dennis J.  Worm</span>, <span class="hlFld-ContribAuthor ">Sylvia  Els‐Heindl</span>, <span class="hlFld-ContribAuthor ">Annette G.  Beck‐Sickinger</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting of peptide‐binding receptors on cancer cells with peptide‐drug conjugates. </span><span class="cited-content_cbyCitation_journal-name">Peptide Science</span><span> <strong>2020,</strong> <em>112 </em>
                                    (3)
                                     <a href="https://doi.org/10.1002/pep2.24171" title="DOI URL">https://doi.org/10.1002/pep2.24171</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/pep2.24171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fpep2.24171%26sid%3Dliteratum%253Aachs%26jtitle%3DPeptide%2520Science%26atitle%3DTargeting%252Bof%252Bpeptide%2525E2%252580%252590binding%252Breceptors%252Bon%252Bcancer%252Bcells%252Bwith%252Bpeptide%2525E2%252580%252590drug%252Bconjugates%26aulast%3DWorm%26aufirst%3DDennis%2BJ.%26date%3D2020%26date%3D2020%26volume%3D112%26issue%3D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Martin  Kellert</span>, <span class="hlFld-ContribAuthor ">Paul  Hoppenz</span>, <span class="hlFld-ContribAuthor ">Peter  Lönnecke</span>, <span class="hlFld-ContribAuthor ">Dennis J.  Worm</span>, <span class="hlFld-ContribAuthor ">Bernd  Riedl</span>, <span class="hlFld-ContribAuthor ">Johannes  Koebberling</span>, <span class="hlFld-ContribAuthor ">Annette G.  Beck-Sickinger</span>, <span class="hlFld-ContribAuthor ">Evamarie  Hey-Hawkins</span>. </span><span class="cited-content_cbyCitation_article-title">Tuning a modular system – synthesis and characterisation of a boron-rich
              s
              -triazine-based carboxylic acid and amine bearing a galactopyranosyl moiety. </span><span class="cited-content_cbyCitation_journal-name">Dalton Transactions</span><span> <strong>2020,</strong> <em>49 </em>
                                    (1)
                                     , 57-69. <a href="https://doi.org/10.1039/C9DT04031E" title="DOI URL">https://doi.org/10.1039/C9DT04031E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9DT04031E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9DT04031E%26sid%3Dliteratum%253Aachs%26jtitle%3DDalton%2520Transactions%26atitle%3DTuning%252Ba%252Bmodular%252Bsystem%252B%2525E2%252580%252593%252Bsynthesis%252Band%252Bcharacterisation%252Bof%252Ba%252Bboron-rich%252Bs%252B-triazine-based%252Bcarboxylic%252Bacid%252Band%252Bamine%252Bbearing%252Ba%252Bgalactopyranosyl%252Bmoiety%26aulast%3DKellert%26aufirst%3DMartin%26date%3D2020%26date%3D2020%26volume%3D49%26issue%3D1%26spage%3D57%26epage%3D69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/medium/jm9b01136_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/large/jm9b01136_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01136&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/medium/jm9b01136_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/large/jm9b01136_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Chemical Structures and Synthesis of Carborane Building Blocks<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/large/jm9b01136_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01136&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) first 0.9 equiv <i>n</i>-butyllithium, THF, rt, 2 h; then 1.0 equiv 1,2:3,4-di-<i>O</i>-isopropylidene-α-<span class="smallcaps smallerCapital">d</span>-galactopyranosyltriflate, THF, rt, overnight, 60%; (b) 1.5 equiv of Hg(OAc)<sub>2</sub>, absolute acetic acid, 50 °C, 3 h, 96%; (c) 3.0 equiv of iodoacetic acid, 7.0 equiv of absolute Et<sub>3</sub>N, absolute DCM, rt, 3 days, 51%; (d) first 2.1 equiv of <i>n</i>-butyllithium, THF, rt, 2 h; then 2.1 equiv of 1,2:3,4-di-<i>O</i>-isopropylidene-α-<span class="smallcaps smallerCapital">d</span>-galactopyranosyltriflate, THF, rt, overnight, 54%; (e) as decribed under b yield: 97 %; (f) as decribed under c yield: 47 %; (g) as described previously.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a> THF: tetrahydrofuran, rt: room temperature, Et<sub>3</sub>N: triethylamine, DCM: dichloromethane.</p></p></figure><figure data-id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/medium/jm9b01136_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/large/jm9b01136_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Peptide sequence of pNPY (<b>10</b>) and [F<sup>7</sup>,P<sup>34</sup>]-NPY (<b>11</b>). Modification sites are indicated by arrows.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/large/jm9b01136_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01136&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/medium/jm9b01136_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/large/jm9b01136_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of the Branched NPY Conjugate <b>17</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/large/jm9b01136_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01136&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 3% hydrazine in DMF, 10 × 10 min; (b) 6 equiv of Fmoc-(<i>S</i>)-Dap(Fmoc)-OH, 6 equiv of HOBt and 6 equiv of DIC in DMF, 2 h; (c) 30% piperidine in DMF, 2 × 12 min; (d) 12 equiv of Fmoc-(<i>S</i>)-Dap(Fmoc)-OH, 12 equiv of HOBt and 12 equiv of DIC in DMF, 6 h; (e) 30% piperidine in DMF, 2 × 12 min; (f) 12 equiv of <b>5</b> (Gal′-Cb; 1.5 equiv per free amino group), 15 equiv of HOBt, and 15 equiv of DIC in DMF, overnight; (g) TFA/H<sub>2</sub>O (95:5, v/v), 2 h.</p></p></figure><figure data-id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/medium/jm9b01136_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/large/jm9b01136_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. RP-HPLC and ESI-MS analysis of conjugate <b>17</b>. (A) Reversed phase (RP)-HPLC analysis using a Phenomenex Jupiter Proteo C12 90 Å column and a linear gradient of 20–70% (v/v) eluent B (ACN + 0.08% TFA (v/v)) in eluent A (H<sub>2</sub>O + 0.1% TFA (v/v)) over 40 min. (B) ESI-Orbitrap mass spectrum showing the multiply charged ion species of <b>17</b> (top part). From the multiply charged signals in the original spectrum, the single charged signal [M + H]<sup>+</sup> with the corresponding isotopic distribution pattern can be convoluted (lower part). MW<sub>cal/mono</sub>: 7868.1 Da.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/large/jm9b01136_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01136&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/medium/jm9b01136_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/large/jm9b01136_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Receptor activation and internalization properties of conjugates <b>15</b>–<b>19</b>. (A) hY<sub>1</sub>R and hY<sub>2</sub>R receptor activation of conjugates <b>15</b>–<b>19</b>, normalized to NPY (<b>10</b>). Curves represent mean values ± SEM of at least two independent experiments performed in duplicate. (B) Receptor internalization studies of conjugates <b>15</b>–<b>19</b> using HEK293 cells stably expressing the hY<sub>1</sub>R or hY<sub>2</sub>R fused to eYFP (green). Cells were stimulated with 100 nM peptide (hY<sub>1</sub>R) or 1 μM peptide (hY<sub>2</sub>R) for 1 h at 37 °C. Cell nuclei were stained with Hoechst 33342 (blue). Scale bar = 10 μm. Depicted images are representatives of at least two independent experiments performed in triplicate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/large/jm9b01136_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01136&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/medium/jm9b01136_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/large/jm9b01136_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Kinetic solubility assay for investigation of the potential aggregation of conjugates <b>8</b> and <b>11</b>. Depicted peak areas are representative for two independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/large/jm9b01136_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01136&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/medium/jm9b01136_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/large/jm9b01136_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Biological characterization of conjugates <b>17</b> and <b>20</b>. (A) IP accumulation assay determining the receptor activation of conjugates <b>17</b> and <b>20</b> at the hY<sub>1</sub>R and hY<sub>2</sub>R normalized to NPY (<b>10</b>). Curves represent mean values ± SEM of at least two independent experiments performed in duplicate. (B) Receptor internalization studies of conjugates <b>17</b> and <b>20</b> using HEK293 cells stably expressing the hY<sub>1</sub>R or hY<sub>2</sub>R fused to eYFP (green). Cells were stimulated with 100 nM peptide (hY<sub>1</sub>R) or 1 μM peptide (hY<sub>2</sub>R) for 1 h at 37 °C. Cell nuclei were stained with Hoechst 33342 (blue). Scale bar = 10 μm. Depicted images are representatives of at least two independent experiments performed in triplicate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/large/jm9b01136_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01136&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/medium/jm9b01136_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/large/jm9b01136_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. In vitro characterization of fluorescently labeled analogs <b>21</b> and <b>22</b>. (A) Receptor internalization and conjugate uptake studies using HEK293 cells stably expressing the hY<sub>1</sub>R, hY<sub>2</sub>R, hY<sub>4</sub>R, or hY<sub>5</sub>R fused to eYFP (green). Cells were stimulated with 100 nM (hY<sub>1</sub>R, hY<sub>4</sub>R, and hY<sub>5</sub>R) and 1 μM (hY<sub>2</sub>R) peptide (red) for 1 h. Cell nuclei were stained with Hoechst 33342 (blue). 100 nM NPY (<b>10</b>) was used as control for hY<sub>1</sub>R, hY<sub>2</sub>R, and hY<sub>5</sub>R, while hPP (<b>12</b>) was used for hY<sub>4</sub>R. Scale bar = 10 μm. Depicted images are representatives of at least two independent experiments performed in triplicate. (B) Internalization of conjugate <b>22</b> into MCF-7 cells after 1 h stimulation with 1 μM peptide. Cell nuclei were stained with Hoechst 33342 (blue). Scale bar = 10 μm. Depicted images are representatives of at least two independent experiments performed in triplicate. (C) Cell viability assay on endogenously hY<sub>1</sub>R-expressing MCF-7 cells after 48 h of stimulation with conjugate <b>20</b> in comparison to [F<sup>7</sup>,P<sup>34</sup>]-NPY (<b>11</b>). Bars represent the mean value ± SEM of at least three independent experiments performed in duplicate. (D) Blood plasma stability of conjugate <b>22</b> in comparison to <b>21</b> of at least two independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01136/20210317/images/large/jm9b01136_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01136&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i39">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03254" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03254" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 73 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kratz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryppa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warnecke, A.</span></span> <span> </span><span class="NLM_article-title">Prodrug strategies in anticancer chemotherapy</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200700159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1002%2Fcmdc.200700159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=17963208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlt1KqsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=20-53&author=F.+Kratzauthor=I.+A.+M%C3%BCllerauthor=C.+Ryppaauthor=A.+Warnecke&title=Prodrug+strategies+in+anticancer+chemotherapy&doi=10.1002%2Fcmdc.200700159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Prodrug strategies in anticancer chemotherapy</span></div><div class="casAuthors">Kratz, Felix; Mueller, Ivonne A.; Ryppa, Claudia; Warnecke, Andre</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-53</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The majority of clin. approved anticancer drugs are characterized by a narrow therapeutic window that results mainly from a high systemic toxicity of the drugs in combination with an evident lack of tumor selectivity.  Besides the development of suitable galenic formulations such as liposomes or micelles, several promising prodrug approaches have been followed in the last decades with the aim of improving chemotherapy.  In this review we elucidate the two main concepts that underlie the design of most anticancer prodrugs: drug targeting and controlled release of the drug at the tumor site.  Consequently, active and passive targeting using tumor-specific ligands or macromol. carriers are discussed as well as release strategies that are based on tumor-specific characteristics such as low pH or the expression of tumor-assocd. enzymes.  Furthermore, other strategies such as ADEPT (antibody-directed enzyme prodrug therapy) and the design of self-eliminating structures are introduced.  Chem. realization of prodrug approaches is illustrated by drug candidates that have or may have clin. importance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7KWHTS-qaUbVg90H21EOLACvtfcHk0lg8aR_5-S5rVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlt1KqsrY%253D&md5=1f43c66a71a6291f392f01cc73380479</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200700159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200700159%26sid%3Dliteratum%253Aachs%26aulast%3DKratz%26aufirst%3DF.%26aulast%3DM%25C3%25BCller%26aufirst%3DI.%2BA.%26aulast%3DRyppa%26aufirst%3DC.%26aulast%3DWarnecke%26aufirst%3DA.%26atitle%3DProdrug%2520strategies%2520in%2520anticancer%2520chemotherapy%26jtitle%3DChemMedChem%26date%3D2008%26volume%3D3%26spage%3D20%26epage%3D53%26doi%3D10.1002%2Fcmdc.200700159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahrens, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellmann-Sickert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span></span> <span> </span><span class="NLM_article-title">Peptides and peptide conjugates: therapeutics on the upward path</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1567</span>– <span class="NLM_lpage">1586</span>, <span class="refDoi"> DOI: 10.4155/fmc.12.76</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.4155%2Ffmc.12.76" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=22917246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Gjtb3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=1567-1586&author=V.+M.+Ahrensauthor=K.+Bellmann-Sickertauthor=A.+G.+Beck-Sickinger&title=Peptides+and+peptide+conjugates%3A+therapeutics+on+the+upward+path&doi=10.4155%2Ffmc.12.76"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Peptides and peptide conjugates: therapeutics on the upward path</span></div><div class="casAuthors">Ahrens, Verena M.; Bellmann-Sickert, Kathrin; Beck-Sickinger, Annette G.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1567-1586</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The main benefit of natural peptides, peptide analogs and newly designed peptides as therapeutics, lies in their high selectivity and affinity, which are frequently in the nanomolar range.  New drugs targeting protein-protein interactions often require larger interaction sites than small mols. can offer.  Thus, many peptidic drugs are already applied in therapy at the current state.  The next generation of peptide-based therapeutic agents is currently on its way from basic research to clin. studies and eventually to the pharmaceutical market.  Development of more robust and long-lasting drugs owing to well-known and new stabilization strategies is yielding novel and continuously improving peptide drugs.  The introduction of smart linkers that exhibit stability towards blood plasma but intracellular lability will lead to target-oriented activity, which might successfully decrease side effects.  In this review, peptidic therapeutics on the market, in clin. studies and some of those in basic research are characterized.  Stabilization strategies and intelligent linkers are discussed with respect to their use in peptide drug therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaBOLVVLuwhLVg90H21EOLACvtfcHk0lg8aR_5-S5rVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Gjtb3P&md5=1b7acc892ab2ee8a7473fac86d93c141</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.4155%2Ffmc.12.76&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.12.76%26sid%3Dliteratum%253Aachs%26aulast%3DAhrens%26aufirst%3DV.%2BM.%26aulast%3DBellmann-Sickert%26aufirst%3DK.%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26atitle%3DPeptides%2520and%2520peptide%2520conjugates%253A%2520therapeutics%2520on%2520the%2520upward%2520path%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2012%26volume%3D4%26spage%3D1567%26epage%3D1586%26doi%3D10.4155%2Ffmc.12.76" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mäde, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Els-Heindl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span></span> <span> </span><span class="NLM_article-title">Automated solid-phase peptide synthesis to obtain therapeutic peptides</span>. <i>Beilstein J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1197</span>– <span class="NLM_lpage">1212</span>, <span class="refDoi"> DOI: 10.3762/bjoc.10.118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.3762%2Fbjoc.10.118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=24991269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A280%3ADC%252BC2cfovFCnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=1197-1212&author=V.+M%C3%A4deauthor=S.+Els-Heindlauthor=A.+G.+Beck-Sickinger&title=Automated+solid-phase+peptide+synthesis+to+obtain+therapeutic+peptides&doi=10.3762%2Fbjoc.10.118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Automated solid-phase peptide synthesis to obtain therapeutic peptides</span></div><div class="casAuthors">Made Veronika; Els-Heindl Sylvia; Beck-Sickinger Annette G</div><div class="citationInfo"><span class="NLM_cas:title">Beilstein journal of organic chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1197-212</span>
        ISSN:<span class="NLM_cas:issn">1860-5397</span>.
    </div><div class="casAbstract">The great versatility and the inherent high affinities of peptides for their respective targets have led to tremendous progress for therapeutic applications in the last years.  In order to increase the drugability of these frequently unstable and rapidly cleared molecules, chemical modifications are of great interest.  Automated solid-phase peptide synthesis (SPPS) offers a suitable technology to produce chemically engineered peptides.  This review concentrates on the application of SPPS by Fmoc/t-Bu protecting-group strategy, which is most commonly used.  Critical issues and suggestions for the synthesis are covered.  The development of automated methods from conventional to essentially improved microwave-assisted instruments is discussed.  In order to improve pharmacokinetic properties of peptides, lipidation and PEGylation are described as covalent conjugation methods, which can be applied by a combination of automated and manual synthesis approaches.  The synthesis and application of SPPS is described for neuropeptide Y receptor analogs as an example for bioactive hormones.  The applied strategies represent innovative and potent methods for the development of novel peptide drug candidates that can be manufactured with optimized automated synthesis technologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQDzQldX7Z4YinGiHuhFGv8fW6udTcc2eZLb7JuARfCILntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfovFCnsA%253D%253D&md5=2cc3d20221e88f69c35f3ec1713f3d92</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.3762%2Fbjoc.10.118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3762%252Fbjoc.10.118%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25A4de%26aufirst%3DV.%26aulast%3DEls-Heindl%26aufirst%3DS.%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26atitle%3DAutomated%2520solid-phase%2520peptide%2520synthesis%2520to%2520obtain%2520therapeutic%2520peptides%26jtitle%3DBeilstein%2520J.%2520Org.%2520Chem.%26date%3D2014%26volume%3D10%26spage%3D1197%26epage%3D1212%26doi%3D10.3762%2Fbjoc.10.118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engel, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schally, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rieger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hönig, A.</span></span> <span> </span><span class="NLM_article-title">Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">652</span>– <span class="NLM_lpage">658</span>, <span class="refDoi"> DOI: 10.1021/mp0700514</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp0700514" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpt1GitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2007&pages=652-658&author=J.+B.+Engelauthor=A.+V.+Schallyauthor=J.+Dietlauthor=L.+Riegerauthor=A.+H%C3%B6nig&title=Targeted+therapy+of+breast+and+gynecological+cancers+with+cytotoxic+analogues+of+peptide+hormones&doi=10.1021%2Fmp0700514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Therapy of Breast and Gynecological Cancers with Cytotoxic Analogues of Peptide Hormones</span></div><div class="casAuthors">Engel, Joerg B.; Schally, Andrew V.; Dietl, Johannes; Rieger, Lorenz; Hoenig, Arnd</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">652-658</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review and discussion.  Gynecol. cancers such as breast, ovarian, and endometrial carcinoma express receptors for LH-releasing hormone (LHRH), bombesin/gastrin-releasing peptide (BN/GRP), and somatostatin (SST).  These tumors are therefore suitable candidates for targeted therapy with cytotoxic hybrid mols. consisting of a cytotoxic radical and a peptide hormone analog as a carrier.  These compds. have been shown to be more active and less toxic in vivo than nontargeted chemotherapy in models of various human cancers which express the resp. receptors.  The current review summarizes exptl. and clin. findings with cytotoxic peptide hormone analogs of LHRH (AN-152 [AEZS 108], AN-207), BN/GRP (AN-215), and SST (AN-238) in breast, ovarian, and endometrial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAD9SM0sGXh7Vg90H21EOLACvtfcHk0liEw0JalWZ_lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpt1GitL4%253D&md5=c1bcab69c621c220bd473316ec09d95a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fmp0700514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp0700514%26sid%3Dliteratum%253Aachs%26aulast%3DEngel%26aufirst%3DJ.%2BB.%26aulast%3DSchally%26aufirst%3DA.%2BV.%26aulast%3DDietl%26aufirst%3DJ.%26aulast%3DRieger%26aufirst%3DL.%26aulast%3DH%25C3%25B6nig%26aufirst%3DA.%26atitle%3DTargeted%2520therapy%2520of%2520breast%2520and%2520gynecological%2520cancers%2520with%2520cytotoxic%2520analogues%2520of%2520peptide%2520hormones%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2007%26volume%3D4%26spage%3D652%26epage%3D658%26doi%3D10.1021%2Fmp0700514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okarvi, S. M.</span></span> <span> </span><span class="NLM_article-title">Peptide-based radiopharmaceuticals and cytotoxic conjugates: potential tools against cancer</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1016/j.ctrv.2007.07.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1016%2Fj.ctrv.2007.07.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=17870245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVKht7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2008&pages=13-26&author=S.+M.+Okarvi&title=Peptide-based+radiopharmaceuticals+and+cytotoxic+conjugates%3A+potential+tools+against+cancer&doi=10.1016%2Fj.ctrv.2007.07.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide-based radiopharmaceuticals and cytotoxic conjugates: Potential tools against cancer</span></div><div class="casAuthors">Okarvi, S. M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-26</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Summary: A hope for the diagnosis and treatment of cancer is the development of new tumor-specific peptide-based radiopharmaceuticals.  The overexpression of many peptide receptors on human tumors makes such receptors an attractive potential target for diagnostic imaging and radiotherapy with specifically designed radiolabeled peptides.  The use of solid-phase peptide synthesis, and the availability of a wide range of bifunctional chelating agents for the convenient radiolabeling of bioactive peptides with different radionuclides have produced a wide variety of medicinally useful peptide radiopharmaceuticals.  A few of these peptides, such as somatostatin, bombesin, cholecystokinin/gastrin, neurotensin and vasoactive intestinal peptide are currently under investigation for their possible clin. applications in nuclear oncol.  This article presents the recent development in radiolabeled small peptides, with major emphasis on somatostatin and bombesin analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnoWW9VaE3gbVg90H21EOLACvtfcHk0liEw0JalWZ_lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVKht7Y%253D&md5=f6c0694ef7afcf01fd010705928fedec</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2007.07.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2007.07.017%26sid%3Dliteratum%253Aachs%26aulast%3DOkarvi%26aufirst%3DS.%2BM.%26atitle%3DPeptide-based%2520radiopharmaceuticals%2520and%2520cytotoxic%2520conjugates%253A%2520potential%2520tools%2520against%2520cancer%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2008%26volume%3D34%26spage%3D13%26epage%3D26%26doi%3D10.1016%2Fj.ctrv.2007.07.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tatemoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlquist, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutt, V.</span></span> <span> </span><span class="NLM_article-title">Neuropeptide Y--a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>296</i></span>,  <span class="NLM_fpage">659</span>– <span class="NLM_lpage">660</span>, <span class="refDoi"> DOI: 10.1038/296659a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1038%2F296659a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=6896083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADyaL38XlsFKlt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=296&publication_year=1982&pages=659-660&author=K.+Tatemotoauthor=M.+Carlquistauthor=V.+Mutt&title=Neuropeptide+Y%2D%2Da+novel+brain+peptide+with+structural+similarities+to+peptide+YY+and+pancreatic+polypeptide&doi=10.1038%2F296659a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Neuropeptide Y.  A novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide</span></div><div class="casAuthors">Tatemoto, Kazuhiko; Carlquist, Mats; Mutt, Viktor</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">296</span>
        (<span class="NLM_cas:issue">5858</span>),
    <span class="NLM_cas:pages">659-61</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">A peptide amide thought to be peptide YY was isolated from exts. of porcine brain.  However, the peptide, although having distinct structural and biol. similarities to both peptide YY and pancreatic polypeptide, was shown to be a novel peptide which was designated neuropeptide Y.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUAmzxRfV_5rVg90H21EOLACvtfcHk0lju9rjNi1yZwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XlsFKlt78%253D&md5=a012588ed43cc6a6de7afb974b703e4b</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2F296659a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F296659a0%26sid%3Dliteratum%253Aachs%26aulast%3DTatemoto%26aufirst%3DK.%26aulast%3DCarlquist%26aufirst%3DM.%26aulast%3DMutt%26aufirst%3DV.%26atitle%3DNeuropeptide%2520Y--a%2520novel%2520brain%2520peptide%2520with%2520structural%2520similarities%2520to%2520peptide%2520YY%2520and%2520pancreatic%2520polypeptide%26jtitle%3DNature%26date%3D1982%26volume%3D296%26spage%3D659%26epage%3D660%26doi%3D10.1038%2F296659a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larhammar, D.</span></span> <span> </span><span class="NLM_article-title">Evolution of neuropeptide Y, peptide YY and pancreatic polypeptide</span>. <i>Regul. Pept.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1016/0167-0115(95)00169-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1016%2F0167-0115%2895%2900169-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=8738876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADyaK28XjtFWit7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=1996&pages=1-11&author=D.+Larhammar&title=Evolution+of+neuropeptide+Y%2C+peptide+YY+and+pancreatic+polypeptide&doi=10.1016%2F0167-0115%2895%2900169-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Evolution of neuropeptide Y, peptide YY and pancreatic polypeptide</span></div><div class="casAuthors">Larhammar, Dan</div><div class="citationInfo"><span class="NLM_cas:title">Regulatory Peptides</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-11</span>CODEN:
                <span class="NLM_cas:coden">REPPDY</span>;
        ISSN:<span class="NLM_cas:issn">0167-0115</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review, with 104 refs., on the evolution of the title peptides in vertebrates and invertebrates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOOam8F5YOF7Vg90H21EOLACvtfcHk0lju9rjNi1yZwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjtFWit7g%253D&md5=39c1e52b9dc19fbfaea51904839f1228</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2F0167-0115%2895%2900169-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0167-0115%252895%252900169-7%26sid%3Dliteratum%253Aachs%26aulast%3DLarhammar%26aufirst%3DD.%26atitle%3DEvolution%2520of%2520neuropeptide%2520Y%252C%2520peptide%2520YY%2520and%2520pancreatic%2520polypeptide%26jtitle%3DRegul.%2520Pept.%26date%3D1996%26volume%3D62%26spage%3D1%26epage%3D11%26doi%3D10.1016%2F0167-0115%2895%2900169-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michel, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doods, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herzog, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larhammar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quirion, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westfall, T.</span></span> <span> </span><span class="NLM_article-title">XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">143</span>– <span class="NLM_lpage">150</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=9549761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADyaK1cXitlylsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1998&pages=143-150&author=M.+C.+Michelauthor=A.+G.+Beck-Sickingerauthor=H.+Coxauthor=H.+N.+Doodsauthor=H.+Herzogauthor=D.+Larhammarauthor=R.+Quirionauthor=T.+Schwartzauthor=T.+Westfall&title=XVI.+International+Union+of+Pharmacology+recommendations+for+the+nomenclature+of+neuropeptide+Y%2C+peptide+YY%2C+and+pancreatic+polypeptide+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">XVI. International union of pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors</span></div><div class="casAuthors">Michel, Martin C.; Beck-Sickinger, Annette; Cox, Helen; Doods, Henri N.; Herzog, Herbert; Larhammar, Dan; Quirion, Remi; Schwartz, Thue; Westfall, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">143-150</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">A review with ∼80 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_xqi5KSXmjLVg90H21EOLACvtfcHk0lju9rjNi1yZwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXitlylsrc%253D&md5=a7fef0f0217b7cef340130fb94989b7a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMichel%26aufirst%3DM.%2BC.%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26aulast%3DCox%26aufirst%3DH.%26aulast%3DDoods%26aufirst%3DH.%2BN.%26aulast%3DHerzog%26aufirst%3DH.%26aulast%3DLarhammar%26aufirst%3DD.%26aulast%3DQuirion%26aufirst%3DR.%26aulast%3DSchwartz%26aufirst%3DT.%26aulast%3DWestfall%26aufirst%3DT.%26atitle%3DXVI.%2520International%2520Union%2520of%2520Pharmacology%2520recommendations%2520for%2520the%2520nomenclature%2520of%2520neuropeptide%2520Y%252C%2520peptide%2520YY%252C%2520and%2520pancreatic%2520polypeptide%2520receptors%26jtitle%3DPharmacol.%2520Rev.%26date%3D1998%26volume%3D50%26spage%3D143%26epage%3D150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stichel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span></span> <span> </span><span class="NLM_article-title">Molecular recognition of the NPY hormone family by their receptors</span>. <i>Nutrition</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">907</span>– <span class="NLM_lpage">917</span>, <span class="refDoi"> DOI: 10.1016/j.nut.2008.06.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1016%2Fj.nut.2008.06.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=18725086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVent7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2008&pages=907-917&author=D.+Lindnerauthor=J.+Stichelauthor=A.+G.+Beck-Sickinger&title=Molecular+recognition+of+the+NPY+hormone+family+by+their+receptors&doi=10.1016%2Fj.nut.2008.06.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular recognition of the NPY hormone family by their receptors</span></div><div class="casAuthors">Lindner, Diana; Stichel, Jan; Beck-Sickinger, Annette G.</div><div class="citationInfo"><span class="NLM_cas:title">Nutrition (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">907-917</span>CODEN:
                <span class="NLM_cas:coden">NUTRER</span>;
        ISSN:<span class="NLM_cas:issn">0899-9007</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Many G-protein-coupled receptors belong to families of different receptor subtypes, which are recognized by a variety of distinct ligands.  We summarize the current state of the art of the multireceptor/multiligand system of the so-called Y-receptor family.  This family consists of four G-protein-coupled Y receptors in humans (hY1, hY2, hY4, and hY5) and is activated by the so-called neuropeptide Y hormone family, which consists of three native peptide ligands named neuropeptide Y, pancreatic polypeptide, and peptide YY.  We recently reported that one conserved aspartate residue in the third extracellular loop is essential for ligand binding in all four Y receptors, but binds the endogenous ligands in a different mode by interacting with different ligand arginine residues.  By combining peptide synthesis to obtain chem. modified neuropeptide Y, peptide YY, and pancreatic polypeptide analogs, receptor mutagenesis, and receptor chimeras, we could trace binding and signaling to a mol. level.  The data on the variation of the ligands and an overview of the currently known mutagenesis data are summarized and specific models for the binding mode of the three ligands in all four receptors are provided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXmabT3Bi7p7Vg90H21EOLACvtfcHk0lju9rjNi1yZwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVent7vM&md5=f4a221a59d63a3d5ffaea5e3ece25d89</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.nut.2008.06.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nut.2008.06.025%26sid%3Dliteratum%253Aachs%26aulast%3DLindner%26aufirst%3DD.%26aulast%3DStichel%26aufirst%3DJ.%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26atitle%3DMolecular%2520recognition%2520of%2520the%2520NPY%2520hormone%2520family%2520by%2520their%2520receptors%26jtitle%3DNutrition%26date%3D2008%26volume%3D24%26spage%3D907%26epage%3D917%26doi%3D10.1016%2Fj.nut.2008.06.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Böhme, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stichel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walther, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mörl, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span></span> <span> </span><span class="NLM_article-title">Agonist induced receptor internalization of neuropeptide Y receptor subtypes depends on third intracellular loop and C-terminus</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1740</span>– <span class="NLM_lpage">1749</span>, <span class="refDoi"> DOI: 10.1016/j.cellsig.2008.05.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1016%2Fj.cellsig.2008.05.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=18598760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A280%3ADC%252BD1crjtFSltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2008&pages=1740-1749&author=I.+B%C3%B6hmeauthor=J.+Stichelauthor=C.+Waltherauthor=K.+M%C3%B6rlauthor=A.+G.+Beck-Sickinger&title=Agonist+induced+receptor+internalization+of+neuropeptide+Y+receptor+subtypes+depends+on+third+intracellular+loop+and+C-terminus&doi=10.1016%2Fj.cellsig.2008.05.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Agonist induced receptor internalization of neuropeptide Y receptor subtypes depends on third intracellular loop and C-terminus</span></div><div class="casAuthors">Bohme Ilka; Stichel Jan; Walther Cornelia; Morl Karin; Beck-Sickinger Annette G</div><div class="citationInfo"><span class="NLM_cas:title">Cellular signalling</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1740-9</span>
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    </div><div class="casAbstract">Agonist stimulation of G-protein coupled receptors (GPCRs) results in the redistribution of the receptor from the cell surface into intracellular compartments through the process of endocytosis.  Monitoring ligand-mediated internalization of GPCRs in living cells has become experimentally accessible by applying fluorescent reagents and fluorescence microscopy.  By using cell lines that transiently, stably or endogenously express the human Y receptor (hYR) subtypes hY(1)R, hY(2)R, hY(4)R and hY(5)R and differently fluorescently tagged receptor proteins we were able to unravel further details concerning the internalization behavior of this multi-receptor/multi-ligand system.  For the first time we could show that also the hY(2)R is internalized with a rate which is comparable to the hY(1)R and the hY(4)R.  In contrast, the hY(5)R was internalized much slower and the rate remained unaffected by co-expression with other hYR subtypes.  Furthermore receptor subtype co-expressing cells and selectively binding peptides revealed a receptor subtype selective internalization.  By using novel hY(5)/hY(2) receptor chimera the receptor subtype dependent differences in hY receptor internalization could be identified on a molecular level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS1_oavs96kyXO4gDb7JggCfW6udTcc2eaO66wyK_kymrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1crjtFSltQ%253D%253D&md5=5eb7dfb86e75c35b92b95b5ee3775f39</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2008.05.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2008.05.017%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25B6hme%26aufirst%3DI.%26aulast%3DStichel%26aufirst%3DJ.%26aulast%3DWalther%26aufirst%3DC.%26aulast%3DM%25C3%25B6rl%26aufirst%3DK.%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26atitle%3DAgonist%2520induced%2520receptor%2520internalization%2520of%2520neuropeptide%2520Y%2520receptor%2520subtypes%2520depends%2520on%2520third%2520intracellular%2520loop%2520and%2520C-terminus%26jtitle%3DCell.%2520Signalling%26date%3D2008%26volume%3D20%26spage%3D1740%26epage%3D1749%26doi%3D10.1016%2Fj.cellsig.2008.05.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reubi, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gugger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waser, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaer, J. C. Y.</span></span> <span> </span><span class="NLM_article-title">Y(1)-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4636</span>– <span class="NLM_lpage">4641</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=11389101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD3MXktlWjsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=4636-4641&author=J.+C.+Reubiauthor=M.+Guggerauthor=B.+Waserauthor=J.+C.+Y.+Schaer&title=Y%281%29-mediated+effect+of+neuropeptide+Y+in+cancer%3A+breast+carcinomas+as+targets"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Y1-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets</span></div><div class="casAuthors">Reubi, Jean Claude; Gugger, Mathias; Waser, Beatrice; Schaer, Jean-Claude</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4636-4641</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Overexpression of selected peptide receptors in human tumors has been shown to represent clin. relevant targets for cancer diagnosis and therapy.  Neuropeptide Y (NPY) is a peptide neurotransmitter mediating feeding behavior and vasoconstriction.  It has never been shown to be involved in human cancer.  The authors show here, using in vitro receptor autoradiog., a NPY receptor incidence of 85% in primary human breast carcinomas and of 100% in lymph node metastases of receptor-pos. primaries, predominantly as Y1 subtype, whereas non-neoplastic human breast expressed Y2 preferentially.  Y1 mRNA was detected in Y1-expressing tumors by in situ hybridization, whereas Y2 mRNA was found in normal breast tissue.  The strong predominance of Y1 in breast carcinomas compared with Y2 in normal breast suggests that neoplastic transformation can switch the NPY receptor expression from Y2 to Y1 subtype.  Moreover, in Y1-expressing human SK-N-MC tumor cells, an NPY-induced, dose-dependent inhibition of tumor cell growth of >40% was obsd., suggesting a functional role of NPY in cancer, mediated by Y1.  NPY should therefore be added to the list of small regulatory peptides related to cancer.  The high incidence of Y1 in in situ, invasive, and metastatic breast cancers allows for the possibility to target them for diagnosis and therapy with NPY analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNp9iNJjyGQrVg90H21EOLACvtfcHk0lgRWirq3Zaf9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXktlWjsbo%253D&md5=cef7c485884a8e9c937aade3cfd45567</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DReubi%26aufirst%3DJ.%2BC.%26aulast%3DGugger%26aufirst%3DM.%26aulast%3DWaser%26aufirst%3DB.%26aulast%3DSchaer%26aufirst%3DJ.%2BC.%2BY.%26atitle%3DY%25281%2529-mediated%2520effect%2520of%2520neuropeptide%2520Y%2520in%2520cancer%253A%2520breast%2520carcinomas%2520as%2520targets%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D4636%26epage%3D4641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Körner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reubi, J. C.</span></span> <span> </span><span class="NLM_article-title">NPY receptors in human cancer</span>. <i>Peptides</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">419</span>– <span class="NLM_lpage">425</span>, <span class="refDoi"> DOI: 10.1016/j.peptides.2006.08.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1016%2Fj.peptides.2006.08.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=17223228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252FnsFyjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2007&pages=419-425&author=M.+K%C3%B6rnerauthor=J.+C.+Reubi&title=NPY+receptors+in+human+cancer&doi=10.1016%2Fj.peptides.2006.08.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">NPY receptors in human cancer: a review of current knowledge</span></div><div class="casAuthors">Korner Meike; Reubi Jean Claude</div><div class="citationInfo"><span class="NLM_cas:title">Peptides</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">419-25</span>
        ISSN:<span class="NLM_cas:issn">0196-9781</span>.
    </div><div class="casAbstract">Many peptide hormone receptors are over-expressed in human cancer, permitting an in vivo targeting of tumors for diagnostic and therapeutic purposes.  NPY receptors are novel and promising candidates in this field.  Using in vitro receptor autoradiography, Y1 and Y2 receptors have been found to be expressed in breast carcinomas, adrenal gland and related tumors, renal cell carcinomas, and ovarian cancers in both tumor cells and tumor-associated blood vessels.  Pathophysiologically, tumoral NPY receptors may be activated by endogenous NPY released from intratumoral nerve fibers or tumor cells themselves, and mediate NPY effects on tumor cell proliferation and tumoral blood supply.  Clinically, tumoral NPY receptors may be targeted with NPY analogs coupled with adequate radionuclides or cytotoxic agents for a scintigraphic tumor imaging and/or tumor therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQKRlaq_gfxtNyzdcP07UmufW6udTcc2eaO66wyK_kymrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252FnsFyjtA%253D%253D&md5=c9ee2ef8072c56a93aa0336d7826733f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.peptides.2006.08.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.peptides.2006.08.037%26sid%3Dliteratum%253Aachs%26aulast%3DK%25C3%25B6rner%26aufirst%3DM.%26aulast%3DReubi%26aufirst%3DJ.%2BC.%26atitle%3DNPY%2520receptors%2520in%2520human%2520cancer%26jtitle%3DPeptides%26date%3D2007%26volume%3D28%26spage%3D419%26epage%3D425%26doi%3D10.1016%2Fj.peptides.2006.08.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Söll, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinger, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundell, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larhammer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span></span> <span> </span><span class="NLM_article-title">Novel analogues of neuropeptide Y with a preference for the Y1-receptor</span>. <i>Eur. J. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>268</i></span>,  <span class="NLM_fpage">2828</span>– <span class="NLM_lpage">2837</span>, <span class="refDoi"> DOI: 10.1046/j.1432-1327.2001.02161.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1046%2Fj.1432-1327.2001.02161.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=11358498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD3MXktVSktrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=2001&pages=2828-2837&author=R.+M.+S%C3%B6llauthor=M.+C.+Dingerauthor=I.+Lundellauthor=D.+Larhammerauthor=A.+G.+Beck-Sickinger&title=Novel+analogues+of+neuropeptide+Y+with+a+preference+for+the+Y1-receptor&doi=10.1046%2Fj.1432-1327.2001.02161.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Novel analogues of neuropeptide Y with a preference for the Y1-receptor</span></div><div class="casAuthors">Soll, Richard M.; Dinger, Michaela C.; Lundell, Ingrid; Larhammer, Dan; Beck-Sickinger, Annette G.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">268</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2828-2837</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">Neuropeptide Y (NPY) is one of the most abundant neuropeptides in the mammalian brain and acts in humans via at least three receptor subtypes: Y1, Y2, and Y5.  Whereas selective agonists and antagonists are known for the Y2- and Y5-receptors, the Y1-receptor still lacks a highly selective agonist.  This work presents the first NPY-based analogs with Y1-receptor preference and agonistic properties.  Furthermore, the importance of specific amino acids of NPY for binding to the Y-receptor subtypes is presented.  Amongst the analogs tested, [Phe 7,Pro 34]pNPY (where pNPY is porcine neuropeptide Y) showed the most significant Y1-receptor preference (> 1: 3000-fold), with subnanomolar affinity to the Y1-receptor, and Ki values of ≈ 30 nM for the Y2- and Y5-subtype, resp.  Variations of position 6, esp. [Arg 6,Pro 34]pNPY and variations within positions 20-23 of NPY were found to result in further analogs with significant Y1-receptor preference (1: 400-1: 2000).  In contrast, cyclo S-S [Cys 20,Cys 24]pNPY was found to be a highly selective ligand at the Y2-receptor, binding only threefold less efficiently than NPY.  Analogs contg. variations of positions 31 and 32 showed highly reduced affinity to the Y1-receptor, while binding to the Y5-receptor was affected less.  Inhibition of cAMP-accumulation of selected peptides with replacements within position 20-23 of NPY showed preserved agonistic properties.  The NPY analogs tested give insights into ligand-receptor interaction of NPY at the Y1-, Y2- and Y5-receptor and contribute to the authors' understanding of subtype selectivity.  Furthermore, the Y1-receptor-preferring peptides are novel tools that will provide insight into the physiol. role of the Y1-receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtVDMFg8Gy5bVg90H21EOLACvtfcHk0lgsz2gx79ui-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXktVSktrc%253D&md5=f1f262c1527c76ba3f43a7b8d84a2b41</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1046%2Fj.1432-1327.2001.02161.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1432-1327.2001.02161.x%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25B6ll%26aufirst%3DR.%2BM.%26aulast%3DDinger%26aufirst%3DM.%2BC.%26aulast%3DLundell%26aufirst%3DI.%26aulast%3DLarhammer%26aufirst%3DD.%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26atitle%3DNovel%2520analogues%2520of%2520neuropeptide%2520Y%2520with%2520a%2520preference%2520for%2520the%2520Y1-receptor%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D2001%26volume%3D268%26spage%3D2828%26epage%3D2837%26doi%3D10.1046%2Fj.1432-1327.2001.02161.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Böhme, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span></span> <span> </span><span class="NLM_article-title">Controlling toxicity of Peptide-drug conjugates by different chemical linker structures</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">804</span>– <span class="NLM_lpage">814</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201402514</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1002%2Fcmdc.201402514" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=25914147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A280%3ADC%252BC2MjnvFartA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=804-814&author=D.+B%C3%B6hmeauthor=A.+G.+Beck-Sickinger&title=Controlling+toxicity+of+Peptide-drug+conjugates+by+different+chemical+linker+structures&doi=10.1002%2Fcmdc.201402514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Controlling toxicity of Peptide-drug conjugates by different chemical linker structures</span></div><div class="casAuthors">Bohme David; Beck-Sickinger Annette G</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">804-14</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The side effects of chemotherapy can be overcome by linking toxic agents to tumor-targeting peptides with cleavable linkers.  Herein, this concept is demonstrated by addressing the human Y1 receptor (hY1 R), overexpressed in breast tumors, with analogues of the hY1 R-preferring [F(7) ,P(34) ]NPY.  First, carboxytetramethylrhodamine was connected to [F(7) ,P(34) ]NPY by an amide, ester, disulfide, or enzymatic linkage.  Live imaging revealed hY1 R-mediated delivery and allowed visualization of time-dependent intracellular release.  Next, the fluorophore was replaced by the toxic agent methotrexate (MTX).  In addition to linkage through the amide, ester, disulfide bond, or enzymatic cleavage site, a novel disulfide/ester linker was designed and coupled to [F(7) ,P(34) ]NPY by solid-phase peptide synthesis.  Internalization studies showed hY1 R subtype selective uptake, and cell viability experiments demonstrated hY1 R-mediated toxicity that was clearly dependent on the linkage type.  Fast release profiles for fluorophore-[F(7) ,P(34) ]NPY analogues correlated with high toxicities of MTX conjugates carrying the same linker types and emphasize the relevance of new structures connecting the toxophore and the carrier.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT2bukcAgyF4-RS7coPn-RtfW6udTcc2ebWgWC6ujZDKbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjnvFartA%253D%253D&md5=f2a894f2cd215e9bc28c7bda041e03ae</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201402514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201402514%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25B6hme%26aufirst%3DD.%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26atitle%3DControlling%2520toxicity%2520of%2520Peptide-drug%2520conjugates%2520by%2520different%2520chemical%2520linker%2520structures%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D804%26epage%3D814%26doi%3D10.1002%2Fcmdc.201402514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maschauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwert, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prante, O.</span></span> <span> </span><span class="NLM_article-title">Synthesis and in vitro and in vivo evaluation of an (18)F-labeled neuropeptide Y analogue for imaging of breast cancer by PET</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1121</span>– <span class="NLM_lpage">1130</span>, <span class="refDoi"> DOI: 10.1021/mp500601z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp500601z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFensLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=1121-1130&author=S.+Hofmannauthor=S.+Maschauerauthor=T.+Kuwertauthor=A.+G.+Beck-Sickingerauthor=O.+Prante&title=Synthesis+and+in+vitro+and+in+vivo+evaluation+of+an+%2818%29F-labeled+neuropeptide+Y+analogue+for+imaging+of+breast+cancer+by+PET&doi=10.1021%2Fmp500601z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and in Vitro and in Vivo Evaluation of an 18F-Labeled Neuropeptide Y Analogue for Imaging of Breast Cancer by PET</span></div><div class="casAuthors">Hofmann, Sven; Maschauer, Simone; Kuwert, Torsten; Beck-Sickinger, Annette G.; Prante, Olaf</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1121-1130</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Imaging of Y1R expression in breast cancer is still a challenging task.  Herein, we report a suitable 18F-labeled high-mol.-wt. glycopeptide for imaging of peripheral neuropeptide Y (NPY) Y1 receptor (Y1R)-pos. tumors by preclin. small-animal positron emission tomog. (PET).  The Y1R-preferring NPY [F7,P34]NPY analog was functionalized with an alkyne-bearing propargylglycine (Pra) in position 4.  The corresponding fluoroglycosylated (FGlc) peptide analog [Pra4(FGlc),F7,P34]NPY and its 18F-labeled analog were synthesized by click chem.-based fluoroglycosylation.  The radiosynthesis was performed by 18F-fluoroglycosylation starting from the 2-triflate of the β-mannosylazide and the alkyne peptide [Pra4,F7,P34]NPY.  The radiosynthesis of the18F-labeled analog was optimized using a min. amt. of peptide precursor (40 nmol), proceeding with an overall radiochem. yield of 20-25% (nondecay cor.) in a total synthesis time of 75 min with specific activities of 40-70 GBq/μmol.  In comparison to NPY and [F7,P34]NPY, in vitro Y1R and Y2R activation studies with the cold [Pra4(FGlc),F7,P34]NPY on stably transfected COS-7 cells displayed a high potency for the induction of Y1R-specific inositol accumulation (pEC50 = 8.5 ± 0.1), whereas the potency at Y2R was significantly decreased.  Internalization studies on stably transfected HEK293 cells confirmed a strong glycopeptide-mediated Y1R internalization and a substantial Y1R subtype selectivity over Y2R.  In vitro autoradiog. with Y1R-pos. MCF-7 tumor tissue slices indicated high specific binding of the 18F-labeled glycopeptide, when binding was reduced by 95% ([Pra4,F7,P34]NPY) and by 86% (BIBP3226 Y1R antagonist) in competition studies.  Biodistribution and small-animal PET studies on MCF-7 breast tumor-bearing nude mice revealed radiotracer uptake in the MCF-7 tumor of 1.8%ID/g at 20 min p.i. and 0.7%ID/g at 120 min p.i. (n = 3-4), increasing tumor-to-blood ratios from 1.2 to 2.4, and a tumor retention of 76 ± 4% (n = 4; 45-90 min p.i.).  PET imaging studies with MCF-7 tumor-bearing nude mice demonstrated uptake of the 18F-labeled glycopeptide in the tumor region at 60 min p.i., whereas only negligible tumor uptake was obsd. in animals injected with a nonbinding 18F-labeled glycopeptide pendant as a measure of nonspecific binding.  In conclusion, PET imaging expts. with the 18F-labeled NPY glycopeptide revealed Y1R-specific binding uptake in MCF-7 tumors in vivo together with decreased kidney uptake compared to DOTA-derivs. of this peptide.  We consider this glycopeptide to be a potent lead peptide for the design of improved 18F-glycopeptides with shorter amino acid sequences that would further facilitate PET imaging studies of Y1R-pos. breast tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCDblWANo0ZLVg90H21EOLACvtfcHk0lgsz2gx79ui-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFensLs%253D&md5=51b3662355d59694cb4b09a3cfb9653e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fmp500601z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp500601z%26sid%3Dliteratum%253Aachs%26aulast%3DHofmann%26aufirst%3DS.%26aulast%3DMaschauer%26aufirst%3DS.%26aulast%3DKuwert%26aufirst%3DT.%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26aulast%3DPrante%26aufirst%3DO.%26atitle%3DSynthesis%2520and%2520in%2520vitro%2520and%2520in%2520vivo%2520evaluation%2520of%2520an%2520%252818%2529F-labeled%2520neuropeptide%2520Y%2520analogue%2520for%2520imaging%2520of%2520breast%2520cancer%2520by%2520PET%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2015%26volume%3D12%26spage%3D1121%26epage%3D1130%26doi%3D10.1021%2Fmp500601z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, I. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwanziger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böhme, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naseer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyder, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span></span> <span> </span><span class="NLM_article-title">Breast-cancer diagnosis by neuropeptide Y analogues: from synthesis to clinical application</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">1155</span>– <span class="NLM_lpage">1158</span>, <span class="refDoi"> DOI: 10.1002/anie.200905008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1002%2Fanie.200905008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVGktLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=1155-1158&author=I.+U.+Khanauthor=D.+Zwanzigerauthor=I.+B%C3%B6hmeauthor=M.+Javedauthor=H.+Naseerauthor=S.+W.+Hyderauthor=A.+G.+Beck-Sickinger&title=Breast-cancer+diagnosis+by+neuropeptide+Y+analogues%3A+from+synthesis+to+clinical+application&doi=10.1002%2Fanie.200905008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Breast Cancer Diagnosis by Neuropeptide Y Analogues: From Synthesis to Clinical Application</span></div><div class="casAuthors">Khan, Irfan U.; Zwanziger, Denise; Boehme, Ilka; Javed, Muhammad; Naseer, Hamid; Hyder, Syed W.; Beck-Sickinger, Annette G.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1155-1158, S1155/1-S1155/6</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Synthesis and clin. application of radiolabeled neuropeptide Y analogs for breast cancer imaging and diagnosis are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovlr3pffrSGrVg90H21EOLACvtfcHk0lh5pZ_ciQZokw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVGktLk%253D&md5=2770c359dbab5b8680520fa0f9a75009</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fanie.200905008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200905008%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DI.%2BU.%26aulast%3DZwanziger%26aufirst%3DD.%26aulast%3DB%25C3%25B6hme%26aufirst%3DI.%26aulast%3DJaved%26aufirst%3DM.%26aulast%3DNaseer%26aufirst%3DH.%26aulast%3DHyder%26aufirst%3DS.%2BW.%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26atitle%3DBreast-cancer%2520diagnosis%2520by%2520neuropeptide%2520Y%2520analogues%253A%2520from%2520synthesis%2520to%2520clinical%2520application%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2010%26volume%3D49%26spage%3D1155%26epage%3D1158%26doi%3D10.1002%2Fanie.200905008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hawthorne, M. F.</span></span> <span> </span><span class="NLM_article-title">The role of chemistry in the development of boron neutron capture therapy of cancer</span>. <i>Angew. Chem., Int. Ed. Engl.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">950</span>– <span class="NLM_lpage">984</span>, <span class="refDoi"> DOI: 10.1002/anie.199309501</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1002%2Fanie.199309501" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1993&pages=950-984&author=M.+F.+Hawthorne&title=The+role+of+chemistry+in+the+development+of+boron+neutron+capture+therapy+of+cancer&doi=10.1002%2Fanie.199309501"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2Fanie.199309501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.199309501%26sid%3Dliteratum%253Aachs%26aulast%3DHawthorne%26aufirst%3DM.%2BF.%26atitle%3DThe%2520role%2520of%2520chemistry%2520in%2520the%2520development%2520of%2520boron%2520neutron%2520capture%2520therapy%2520of%2520cancer%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%2520Engl.%26date%3D1993%26volume%3D32%26spage%3D950%26epage%3D984%26doi%3D10.1002%2Fanie.199309501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soloway, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tjarks, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnum, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, F.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Codogni, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J. G.</span></span> <span> </span><span class="NLM_article-title">The chemistry of neutron capture therapy</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">1515</span>– <span class="NLM_lpage">1562</span>, <span class="refDoi"> DOI: 10.1021/cr941195u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr941195u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADyaK1cXjtlygtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=1998&pages=1515-1562&author=A.+H.+Solowayauthor=W.+Tjarksauthor=B.+A.+Barnumauthor=F.-G.+Rongauthor=R.+F.+Barthauthor=I.+M.+Codogniauthor=J.+G.+Wilson&title=The+chemistry+of+neutron+capture+therapy&doi=10.1021%2Fcr941195u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The Chemistry of Neutron Capture Therapy</span></div><div class="casAuthors">Soloway, Albert H.; Tjarks, Werner; Barnum, Beverly A.; Rong, Feng-Guang; Barth, Rolf F.; Codogni, Iwona M.; Wilson, J. Gerald</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1515-1562</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with 633 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQlar2oXrwMrVg90H21EOLACvtfcHk0lh5pZ_ciQZokw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjtlygtL8%253D&md5=52bcd4d4e2f37833d76092e9a1867b3c</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fcr941195u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr941195u%26sid%3Dliteratum%253Aachs%26aulast%3DSoloway%26aufirst%3DA.%2BH.%26aulast%3DTjarks%26aufirst%3DW.%26aulast%3DBarnum%26aufirst%3DB.%2BA.%26aulast%3DRong%26aufirst%3DF.-G.%26aulast%3DBarth%26aufirst%3DR.%2BF.%26aulast%3DCodogni%26aufirst%3DI.%2BM.%26aulast%3DWilson%26aufirst%3DJ.%2BG.%26atitle%3DThe%2520chemistry%2520of%2520neutron%2520capture%2520therapy%26jtitle%3DChem.%2520Rev.%26date%3D1998%26volume%3D98%26spage%3D1515%26epage%3D1562%26doi%3D10.1021%2Fcr941195u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlsson, J.</span></span> <span> </span><span class="NLM_article-title">Radiation dose heterogeneity in receptor and antigen mediated boron neutron capture therapy</span>. <i>Radiother. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">75</span>, <span class="refDoi"> DOI: 10.1016/0167-8140(94)90414-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1016%2F0167-8140%2894%2990414-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=8041899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADyaK2cXlsFahtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1994&pages=61-75&author=T.+Hartmanauthor=J.+Carlsson&title=Radiation+dose+heterogeneity+in+receptor+and+antigen+mediated+boron+neutron+capture+therapy&doi=10.1016%2F0167-8140%2894%2990414-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Radiation dose heterogeneity in receptor and antigen mediated boron neutron capture therapy</span></div><div class="casAuthors">Hartman, Torjoern; Carlsson, Joergen</div><div class="citationInfo"><span class="NLM_cas:title">Radiotherapy and Oncology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">61-75</span>CODEN:
                <span class="NLM_cas:coden">RAONDT</span>;
        ISSN:<span class="NLM_cas:issn">0167-8140</span>.
    </div><div class="casAbstract">Boron neutron capture therapy, BNCT, might be a valuable tumor therapeutical modality for the treatment of cells that are difficult to handle with conventional methods such as surgery or external radiotherapy.  The principle is that tumor assocd. 10B atoms capture thermal neutrons and thereby forms high-LET helium and lithium ions as reaction products.  An interesting development is to conjugate 10B atoms to macromols. that bind to tumor cells with over-expressed receptors or specific antigens.  The targeting macromols. might be receptor-ligands, antibodies or antibody-fragments contg. 10B.  The present study deals with the limitations of such an approach.  One problem is the background dose from capture of neutrons in physiol. occurring elements, esp. nitrogen.  The authors showed, with computer simulations, that the background specific energy (the stochastic analogy of dose) in the cell nuclei, due to captures in nitrogen, had a wide spread and could be rather high, up to 3 Gy in some cells, when relevant neutron fluences were applied.  The maximal amt. of 10B that can be delivered to single tumor cells due to receptor-ligand, receptor-antibody or antigen-antibody mediated binding is probably in the range 108-1010 atoms/cell.  The authors' calcns. showed that the tumor cells had to contain about 109 10B/cell to give a therapeutically interesting dose to the nuclei of the targeted cells.  The doses were highest when the boron was in the cell nucleus.  There was also a wide spread of specific energy absorbed by the nuclei after neutron capture in 10B.  When, for example, 108 10B/nucleus were applied the specific energy to the analyzed nuclei varied from 0 Gy up to about 7 Gy.  These variations were due to the stochastic nature of the capture processes.  Some helium or lithium ion tracks passed through the center of the cell nuclei delivering a lot of energy, some passed through only a smaller part delivering small amts. of energy and sometimes the nuclei escaped without any hits at all.  The results were obtained when relevant neutron fluences (2-5 × 1012 n/cm2) were applied.  Increased neutron fluences gave higher doses both due to capture in boron and in nitrogen but in order to improve the ratio between the dose to targeted tumor cells and the dose to normal cells, the no. of 10B atoms in the targeted cells had to be increased and/or the boron placed in the cell nuclei.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe3TsTs0ii1LVg90H21EOLACvtfcHk0lh5pZ_ciQZokw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlsFahtLg%253D&md5=230b2bbb5e63ac80548443023944812f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2F0167-8140%2894%2990414-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0167-8140%252894%252990414-6%26sid%3Dliteratum%253Aachs%26aulast%3DHartman%26aufirst%3DT.%26aulast%3DCarlsson%26aufirst%3DJ.%26atitle%3DRadiation%2520dose%2520heterogeneity%2520in%2520receptor%2520and%2520antigen%2520mediated%2520boron%2520neutron%2520capture%2520therapy%26jtitle%3DRadiother.%2520Oncol.%26date%3D1994%26volume%3D31%26spage%3D61%26epage%3D75%26doi%3D10.1016%2F0167-8140%2894%2990414-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barth, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coderre, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vicente, M. G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blue, T. E.</span></span> <span> </span><span class="NLM_article-title">Boron neutron capture therapy of cancer: current status and future prospects</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">3987</span>– <span class="NLM_lpage">4002</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-05-0035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1158%2F1078-0432.CCR-05-0035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=15930333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Gksr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=3987-4002&author=R.+F.+Barthauthor=J.+A.+Coderreauthor=M.+G.+H.+Vicenteauthor=T.+E.+Blue&title=Boron+neutron+capture+therapy+of+cancer%3A+current+status+and+future+prospects&doi=10.1158%2F1078-0432.CCR-05-0035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Boron Neutron Capture Therapy of Cancer: Current Status and Future Prospects</span></div><div class="casAuthors">Barth, Rolf F.; Coderre, Jeffrey A.; Vicente, M. Graca H.; Blue, Thomas E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3987-4002</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Background: Boron neutron capture therapy (BNCT) is based on the nuclear reaction that occurs when boron-10 is irradiated with low-energy thermal neutrons to yield high linear energy transfer α particles and recoiling lithium-7 nuclei.  Clin. interest in BNCT has focused primarily on the treatment of high-grade gliomas and either cutaneous primaries or cerebral metastases of melanoma, most recently, head and neck and liver cancer.  Neutron sources for BNCT currently are limited to nuclear reactors and these are available in the United States, Japan, several European countries, and Argentina.  Accelerators also can be used to produce epithermal neutrons and these are being developed in several countries, but none are currently being used for BNCT.  Boron Delivery Agents: Two boron drugs have been used clin., sodium borocaptate (Na2B12H11SH) and a dihydroxyboryl deriv. of phenylalanine called boronophenylalanine.  The major challenge in the development of boron delivery agents has been the requirement for selective tumor targeting to achieve boron concns. (∼20 μg/g tumor) sufficient to deliver therapeutic doses of radiation to the tumor with minimal normal tissue toxicity.  Over the past 20 years, other classes of boron-contg. compds. have been designed and synthesized that include boron-contg. amino acids, biochem. precursors of nucleic acids, DNA-binding mols., and porphyrin derivs.  High mol. wt. delivery agents include monoclonal antibodies and their fragments, which can recognize a tumor-assocd. epitope, such as epidermal growth factor, and liposomes.  However, it is unlikely that any single agent will target all or even most of the tumor cells, and most likely, combinations of agents will be required and their delivery will have to be optimized.  Clin. Trials: Current or recently completed clin. trials have been carried out in Japan, Europe, and the United States.  The vast majority of patients have had high-grade gliomas.  Treatment has consisted first of "debulking" surgery to remove as much of the tumor as possible, followed by BNCT at varying times after surgery.  Sodium borocaptate and boronophenylalanine administered i.v. have been used as the boron delivery agents.  The best survival data from these studies are at least comparable with those obtained by current std. therapy for glioblastoma multiforme, and the safety of the procedure has been established.  Conclusions: Crit. issues that must be addressed include the need for more selective and effective boron delivery agents, the development of methods to provide semiquant. ests. of tumor boron content before treatment, improvements in clin. implementation of BNCT, and a need for randomized clin. trials with an unequivocal demonstration of therapeutic efficacy.  If these issues are adequately addressed, then BNCT could move forward as a treatment modality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6ZX4_Ygd317Vg90H21EOLACvtfcHk0li7lvLqtZp0ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Gksr4%253D&md5=377a149d1c9c994ebe7b9655e18726b2</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-0035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-0035%26sid%3Dliteratum%253Aachs%26aulast%3DBarth%26aufirst%3DR.%2BF.%26aulast%3DCoderre%26aufirst%3DJ.%2BA.%26aulast%3DVicente%26aufirst%3DM.%2BG.%2BH.%26aulast%3DBlue%26aufirst%3DT.%2BE.%26atitle%3DBoron%2520neutron%2520capture%2520therapy%2520of%2520cancer%253A%2520current%2520status%2520and%2520future%2520prospects%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D3987%26epage%3D4002%26doi%3D10.1158%2F1078-0432.CCR-05-0035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barth, R. F.</span></span> <span> </span><span class="NLM_article-title">Boron neutron capture therapy at the crossroads: challenges and opportunities</span>. <i>Appl. Radiat. Isot.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">S3</span>– <span class="NLM_lpage">S6</span>, <span class="refDoi"> DOI: 10.1016/j.apradiso.2009.03.102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1016%2Fj.apradiso.2009.03.102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=19467879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnt1Wqurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2009&pages=S3-S6&author=R.+F.+Barth&title=Boron+neutron+capture+therapy+at+the+crossroads%3A+challenges+and+opportunities&doi=10.1016%2Fj.apradiso.2009.03.102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Boron neutron capture therapy at the crossroads: Challenges and opportunities</span></div><div class="casAuthors">Barth, Rolf F.</div><div class="citationInfo"><span class="NLM_cas:title">Applied Radiation and Isotopes</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">7-8S</span>),
    <span class="NLM_cas:pages">S3-S6</span>CODEN:
                <span class="NLM_cas:coden">ARISEF</span>;
        ISSN:<span class="NLM_cas:issn">0969-8043</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Over the past 25 years research on boron neutron capture therapy (BNCT) has progressed relatively slowly but steadily with the greatest progress in the field of clin. studies.  These specifically have included the use of BNCT to treat a variety of malignancies other than high grade gliomas and melanomas.  However, there are a no. of key areas where little, if any, significant progress has been made.  First and foremost among these has been the lack of new boron delivery agents.  Improvement in drug delivery and the development of the best dosing paradigms for both boronophenylalanine (BPA) and sodium borocaptate (BSH) are of major importance and these still have not been optimized.  Dosimetry for BNCT is still imprecise and is based on treating to normal tissue tolerance, based on blood boron values, rather than any real-time information on the boron content of the residual tumor that is to be irradiated.  Another major problem has been the total dependence on nuclear reactors as neutron sources for BNCT.  However, this will change in the near future when a clin. useful accelerator comes into use in 2009.  Like it or not, in order to gain the credibility of a broad community of physicians who treat brain tumor patients, there will have to be a randomized clin. trial.  Finally, BNCT will have to compete with new therapeutic approaches that are less costly and more effective for the treatment of brain tumors.  These challenges notwithstanding, BNCT can fill an important niche for those malignancies, whether primary or recurrent, for which there is currently no effective therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9aFSQ_rvvkbVg90H21EOLACvtfcHk0li7lvLqtZp0ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnt1Wqurw%253D&md5=9d2a2e07cb0af5bf8e91fbf42b9eea51</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.apradiso.2009.03.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apradiso.2009.03.102%26sid%3Dliteratum%253Aachs%26aulast%3DBarth%26aufirst%3DR.%2BF.%26atitle%3DBoron%2520neutron%2520capture%2520therapy%2520at%2520the%2520crossroads%253A%2520challenges%2520and%2520opportunities%26jtitle%3DAppl.%2520Radiat.%2520Isot.%26date%3D2009%26volume%3D67%26spage%3DS3%26epage%3DS6%26doi%3D10.1016%2Fj.apradiso.2009.03.102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barth, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vicente, M. G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harling, O. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiger, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binns, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aihara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawabata, S.</span></span> <span> </span><span class="NLM_article-title">Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer</span>. <i>Radiat. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">146</span>, <span class="refDoi"> DOI: 10.1186/1748-717X-7-146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1186%2F1748-717X-7-146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=22929110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A280%3ADC%252BC38bhvFyntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=146&author=R.+F.+Barthauthor=M.+G.+H.+Vicenteauthor=O.+K.+Harlingauthor=W.+S.+Kigerauthor=K.+J.+Rileyauthor=P.+J.+Binnsauthor=F.+M.+Wagnerauthor=M.+Suzukiauthor=T.+Aiharaauthor=I.+Katoauthor=S.+Kawabata&title=Current+status+of+boron+neutron+capture+therapy+of+high+grade+gliomas+and+recurrent+head+and+neck+cancer&doi=10.1186%2F1748-717X-7-146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer</span></div><div class="casAuthors">Barth Rolf F; Vicente M Graca H; Harling Otto K; Kiger W S 3rd; Riley Kent J; Binns Peter J; Wagner Franz M; Suzuki Minoru; Aihara Teruhito; Kato Itsuro; Kawabata Shinji</div><div class="citationInfo"><span class="NLM_cas:title">Radiation oncology (London, England)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">146</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Boron neutron capture therapy (BNCT) is a biochemically targeted radiotherapy based on the nuclear capture and fission reactions that occur when non-radioactive boron-10, which is a constituent of natural elemental boron, is irradiated with low energy thermal neutrons to yield high linear energy transfer alpha particles and recoiling lithium-7 nuclei.  Clinical interest in BNCT has focused primarily on the treatment of high grade gliomas, recurrent cancers of the head and neck region and either primary or metastatic melanoma.  Neutron sources for BNCT currently have been limited to specially modified nuclear reactors, which are or until the recent Japanese natural disaster, were available in Japan, United States, Finland and several other European countries, Argentina and Taiwan.  Accelerators producing epithermal neutron beams also could be used for BNCT and these are being developed in several countries.  It is anticipated that the first Japanese accelerator will be available for therapeutic use in 2013.  The major hurdle for the design and synthesis of boron delivery agents has been the requirement for selective tumor targeting to achieve boron concentrations in the range of 20 μg/g.  This would be sufficient to deliver therapeutic doses of radiation with minimal normal tissue toxicity.  Two boron drugs have been used clinically, a dihydroxyboryl derivative of phenylalanine, referred to as boronophenylalanine or "BPA", and sodium borocaptate or "BSH" (Na2B12H11SH).  In this report we will provide an overview of other boron delivery agents that currently are under evaluation, neutron sources in use or under development for BNCT, clinical dosimetry, treatment planning, and finally a summary of previous and on-going clinical studies for high grade gliomas and recurrent tumors of the head and neck region.  Promising results have been obtained with both groups of patients but these outcomes must be more rigorously evaluated in larger, possibly randomized clinical trials.  Finally, we will summarize the critical issues that must be addressed if BNCT is to become a more widely established clinical modality for the treatment of those malignancies for which there currently are no good treatment options.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSmgtNvZmceJgxyojvcjibhfW6udTcc2ebd8FVJGg_fm7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38bhvFyntw%253D%253D&md5=67fe6387a90e9ec7aa293340f54e92fa</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1186%2F1748-717X-7-146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1748-717X-7-146%26sid%3Dliteratum%253Aachs%26aulast%3DBarth%26aufirst%3DR.%2BF.%26aulast%3DVicente%26aufirst%3DM.%2BG.%2BH.%26aulast%3DHarling%26aufirst%3DO.%2BK.%26aulast%3DKiger%26aufirst%3DW.%2BS.%26aulast%3DRiley%26aufirst%3DK.%2BJ.%26aulast%3DBinns%26aufirst%3DP.%2BJ.%26aulast%3DWagner%26aufirst%3DF.%2BM.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DAihara%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DI.%26aulast%3DKawabata%26aufirst%3DS.%26atitle%3DCurrent%2520status%2520of%2520boron%2520neutron%2520capture%2520therapy%2520of%2520high%2520grade%2520gliomas%2520and%2520recurrent%2520head%2520and%2520neck%2520cancer%26jtitle%3DRadiat.%2520Oncol.%26date%3D2012%26volume%3D7%26spage%3D146%26doi%3D10.1186%2F1748-717X-7-146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reedy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lennarz, W. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis of aromatic boronic acids. Aldehydo boronic acids and a boronic acid analog of tyrosine 1</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1958</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">835</span>– <span class="NLM_lpage">838</span>, <span class="refDoi"> DOI: 10.1021/ja01537a021</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja01537a021" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADyaG1cXmtV2lsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=1958&pages=835-838&author=H.+R.+Snyderauthor=A.+J.+Reedyauthor=W.+J.+Lennarz&title=Synthesis+of+aromatic+boronic+acids.+Aldehydo+boronic+acids+and+a+boronic+acid+analog+of+tyrosine+1&doi=10.1021%2Fja01537a021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of aromatic boronic acids. Aldehydo boronic acids and a boronic acid analog of tyrosine</span></div><div class="casAuthors">Snyder, H. R.; Reedy, Albert J.; Lennarz, Wm. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1958</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">835-8</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">ο-MeC6H4B(OH)2 (I) (5 g.) and 100 cc. CCl4 treated with stirring with about 5 cc. soln. of 6 g. dry Br in 50 cc. CCl4 while being illuminated with a 200-w. light bulb, the mixt. treated after an induction period of 5-15 min. with the remainder of the Br soln. in portions of about 5 cc. during about 15 min. and evapd., and the residue recrystd. from CHCl3 yielded 7.4 g. ο-BrCH2C6H4B(OH)2 (II), m. 139-46°.  p-MeC6H4B(OH)2 (III) (5 g.) gave similarly 7.2 g. p-BrCH2C6H4B(OH)2 (IV), m. 138-44°.  III (5 g.), 150 cc. dry CHCl3, 650 mg. Bz2O2, and 6.5 g. N-bromosuccinimide (V) refluxed 3 hrs. while being illuminated with a 200-w. light bulb, the mixt. refluxed 1 hr. with 7 g. hexamethylenetetramine in 75 cc. dry CHCl3, the hot soln. decanted, the residue extd. with 40 cc. HCl of pH 4, the aq. soln. freed of a few drops CHCl3, refluxed 1 hr., poured into a beaker, treated immediately with 10 cc. concd. HCl, and cooled, and the cryst. product recrystd. from H2O yielded 1.5 g. p-OHCC6H4B(OH)2 (VI).0.5H2O, m. 230-40°, which dried 24 hrs. at room temp. and 1 mm. gave VI; a sample dried 1 hr. at 80°/1 mm. gave the anhydride.  I (1 g.), 40 cc. dry CCl4, 2.6 g. V, and 260 mg. Bz2O2 refluxed 2.5 hrs. while being illuminated by a 200-w. bulb, filtered, and extd. with 15% aq. KOH, the alk. ext. acidified after 15 min., kept 2 hrs., and extd. with Et2O, and the ext. evapd. gave 370 mg. ο-OHCC6H4B(OH)2 (VII), m. 118-20°.  VI (500 mg.), 200 mg. MeNO2, and 4 cc. EtOH treated slowly below 10° with 274 mg. NaOH in 4 cc. H2O, stirred 15 min. at 10°, clarified with aq. NaOH, cooled to 5°, and added to 2 cc. concd. HCl in 3 cc. H2O at 0° yielded 455 mg. p-O2NCH:CHC6H4B(OH)2, light yellow, m. 289-90° (decompn.) (33% EtOH).  VII was recovered unchanged from a similar run.  VI (1 g.), 15 cc. Me2CO, 5 cc. H2O, and 5 cc. 10% aq. NaOH kept below 30° by cooling with tap water and then 4 hrs. at room temp. and filtered, the residue dissolved in 10 cc. H2O and acidified, the ppt. filtered, and the residues recrystd. from aq. EtOH gave 1.05 g. p-AcCH:CHC6H4B(OH)2, m. 205-12°.  VII was recovered unchanged from a similar run.  VI (1 g.), 3.5 g. KCN, and 7 cc. H2O treated slowly at 10° with 0.57 cc. concd. H2SO4 in 1.73 cc. H2O, filtered, acidified with 10% HCl, kept 10 min. at 10°, and the product isolated with Et2O gave p-NC(HO)CHC6H4B(OH)2, which softened at about 65° and appeared to undergo several changes before completely m. 104°.  VI treated with N2H4.H2O gave the azine of VI, m. 295° (aq. HCONMe2).  VI oxidized with KMnO4 at room temp. yielded 86% p-HO2CC6H4B(OH)2, m. 219-20°.  VI in EtOH hydrogenated over PtO2 gave a gelatinous solid which could not be purified.  VI treated with 10 or 20% aq. NaOH at room temp. to reflux temp. from 45 min. to 12 hrs. was recovered unchanged; similar results were obtained in the attempted benzoin condensation during 40-90 min. and in the attempted condensations with BzH, p-Me2NC6H4CHO, and p-O2NC6H4CHO.  VII (600 mg.) refluxed 2 hrs. with 5 cc. deoxygenated 20% aq. NaOH under N yielded 300 mg. BzOH.  VII (500 mg.) and 360 mg. NH2OH.HCl in 20 cc. hot H2O adjusted with NaOH to pH 7, refluxed 15 min., cooled, acidified with concd. HCl, and refrigerated 2 days gave 420 mg. p-HON:CHC6H4B(OH)2, m. 150-5°.  I (5 g.) treated in CCl4 in the usual manner with 6 g. Br and extd. with 15% aq. KOH, the ext. kept 1 hr. at room temp., acidified with 15% HCl, and filtered, the filtrate concd. to 50 cc., and the product isolated with Et2O gave 3.5 g. ο-C6H4.CH2.O.BOH (VIII), m. 96-8° (H2O).  I (25 g.), 32.5 g. V, 3.25 g. Bz2O2, and 350 cc. dry CHCl3 refluxed 3 hrs., treated with 30 g. hexamethylenetetramine in 200 cc. CHCl3, refluxed 15 min., and decanted, the residue dissolved in 100 cc. aq. HCl of pH 4, and the aq. soln. refluxed 1 hr. gave 5.2 g. IX, m. 308-9° (HCONMe2).  IX in 10% HCl treated with NaNO2 effervesced and gave VIII.  AcNHCH(CO2Et)2 (28.8 g.) added to 3.16 g. Na in 300 cc. abs. EtOH with stirring, the mixt. treated with stirring with 19.7 g. VI, refluxed 11 hrs. with stirring, cooled to room temp., treated with 12 cc. 3N HCl, and filtered, the filtrate evapd., and the residual semisolid crystd. from about 600 cc. 33% EtOH yielded 21.7 g. p-(EtO2C)2C(NHAc)CH2C6H4B(OH)2 (X), m. 220-3°.  X (21.7 g.) and 180 cc. 5% aq. NaOH refluxed 3.75 hrs. with stirring, cooled, treated slowly with 90 cc. 3NN HCl, refluxed 1 hr., and evapd. in vacuo, and the residue crystd. from the min. amt. of H2O yielded 13.5 g. p-HO2CCH(NHAc)C6H4B(OH)2 (XI), m. 168-70°.  XI (13.5 g.) and 16 g. NaOH in 250 cc. H2O refluxed 9 hrs. with stirring, acidified with 25 cc. concd. HCl, adjusted to pH 6.2 with NH4OH, concd. to 100 cc. in vacuo, and refrigerated overnight yielded 8.3 g. p-HO2CCH(NH2)CH2C6H4B(OH)2 (XII), m. 285-90° (decompn.).  XII (0.1-0.2 g.) treated with 3 cc. N HCl and slowly evapd. to dryness yielded XII.HCl, m. 200-3°.  XII (0.5 g.) in 20 cc. 5% aq. NaOH refluxed 48 hrs. in a Cu flask, filtered hot, adjusted to pH 3 with HCl and then to pH 5.7 with NH4OH, and filtered, the filtrate evapd. to near dryness in vacuo, the residue treated with 10 cc. H2O, and the remaining solid filtered off gave a mixt., m. 235-40°, of XII and PhCH2CH(NH2)CO2H which chromatographed with 4:1:5 BuOH-AcOH-H2O (descending) showed the Rf values 0.46 and 0.69, resp.  XII in excess aq. NaOH titrated with 0.1N HCl gave a titration curve similar in shape to that of a normal amino acid.  The boronic acid function has a pKa of the same magnitude as the ammonium ion; on the basic side of the titration curve 2 equivs. acid were required for neutralization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo50pif1I7F2bVg90H21EOLACvtfcHk0lirK82AK8okvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaG1cXmtV2lsw%253D%253D&md5=95318dbe3031236608bed3b91c3bdf2a</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fja01537a021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja01537a021%26sid%3Dliteratum%253Aachs%26aulast%3DSnyder%26aufirst%3DH.%2BR.%26aulast%3DReedy%26aufirst%3DA.%2BJ.%26aulast%3DLennarz%26aufirst%3DW.%2BJ.%26atitle%3DSynthesis%2520of%2520aromatic%2520boronic%2520acids.%2520Aldehydo%2520boronic%2520acids%2520and%2520a%2520boronic%2520acid%2520analog%2520of%2520tyrosine%25201%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1958%26volume%3D80%26spage%3D835%26epage%3D838%26doi%3D10.1021%2Fja01537a021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soloway, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. A.</span></span> <span> </span><span class="NLM_article-title">Penetration of brain and brain tumor. VII. Tumor-binding sulfhydryl boron compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1967</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">714</span>– <span class="NLM_lpage">717</span>, <span class="refDoi"> DOI: 10.1021/jm00316a042</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00316a042" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADyaF2sXksFalurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1967&pages=714-717&author=A.+H.+Solowayauthor=H.+Hatanakaauthor=M.+A.+Davis&title=Penetration+of+brain+and+brain+tumor.+VII.+Tumor-binding+sulfhydryl+boron+compounds&doi=10.1021%2Fjm00316a042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Penetration of brain and brain tumor.  VII.  Tumor-binding sulfhydryl boron compounds</span></div><div class="casAuthors">Soloway, Albert H.; Hatanaka, Hiroshi; Davis, Michael Allan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1967</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">714-17</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">cf. CA 62: 10964d.  The discovery of a class of B compds. contg. the sulfhydryl group, which become fixed to tumor tissue and to serum proteins, is presented.  A comparison is made between the toxicity and tissue-binding properties of B12H122- and B12H11SH2-.  There are definite indications that SH groups on such anions are potent nucleophils.  Toxicity studies of this latter anion in rabbits are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1onOfKKUZ-LVg90H21EOLACvtfcHk0lirK82AK8okvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2sXksFalurY%253D&md5=ab337fa146d6a39900e661c2edbf6ce5</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm00316a042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00316a042%26sid%3Dliteratum%253Aachs%26aulast%3DSoloway%26aufirst%3DA.%2BH.%26aulast%3DHatanaka%26aufirst%3DH.%26aulast%3DDavis%26aufirst%3DM.%2BA.%26atitle%3DPenetration%2520of%2520brain%2520and%2520brain%2520tumor.%2520VII.%2520Tumor-binding%2520sulfhydryl%2520boron%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1967%26volume%3D10%26spage%3D714%26epage%3D717%26doi%3D10.1021%2Fjm00316a042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luderer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Puente, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azab, A. K.</span></span> <span> </span><span class="NLM_article-title">Advancements in tumor targeting strategies for boron neutron capture therapy</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">2824</span>– <span class="NLM_lpage">2836</span>, <span class="refDoi"> DOI: 10.1007/s11095-015-1718-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1007%2Fs11095-015-1718-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=26033767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsVyktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2015&pages=2824-2836&author=M.+J.+Ludererauthor=P.+de+la+Puenteauthor=A.+K.+Azab&title=Advancements+in+tumor+targeting+strategies+for+boron+neutron+capture+therapy&doi=10.1007%2Fs11095-015-1718-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Advancements in Tumor Targeting Strategies for Boron Neutron Capture Therapy</span></div><div class="casAuthors">Luderer, Micah John; de la Puente, Pilar; Azab, Abdel Kareem</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2824-2836</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Boron neutron capture therapy (BNCT) is a promising cancer therapy modality that utilizes the nuclear capture reaction of epithermal neutrons by boron-10 resulting in a localized nuclear fission reaction and subsequent cell death.  Since cellular destruction is limited to approx. the diam. of a single cell, primarily only cells in the neutron field with significant boron accumulation will be damaged.  However, the emergence of BNCT as a prominent therapy has in large part been hindered by a paucity of tumor selective boron contg. agents.  While L-boronophenylalanine and sodium borocaptate are the most commonly investigated clin. agents, new agents are desperately needed due to their suboptimal tumor selectivity.  This review will highlight the various strategies to improve tumor boron delivery including: nucleoside and carbohydrate analogs, unnatural amino acids, porphyrins, antibody-dendrimer conjugates, cationic polymers, cell-membrane penetrating peptides, liposomes and nanoparticles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR6dU5mkUizrVg90H21EOLACvtfcHk0lirK82AK8okvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsVyktb8%253D&md5=32c8e328650a1147d2535204bc64af5b</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs11095-015-1718-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-015-1718-y%26sid%3Dliteratum%253Aachs%26aulast%3DLuderer%26aufirst%3DM.%2BJ.%26aulast%3Dde%2Bla%2BPuente%26aufirst%3DP.%26aulast%3DAzab%26aufirst%3DA.%2BK.%26atitle%3DAdvancements%2520in%2520tumor%2520targeting%2520strategies%2520for%2520boron%2520neutron%2520capture%2520therapy%26jtitle%3DPharm.%2520Res.%26date%3D2015%26volume%3D32%26spage%3D2824%26epage%3D2836%26doi%3D10.1007%2Fs11095-015-1718-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahrens, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadlbauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hey-Hawkins, E.</span></span> <span> </span><span class="NLM_article-title">Incorporation of ortho-carbaboranyl-Nε-modified L-lysine into neuropeptide Y receptor Y1- and Y2-selective analogues</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2368</span>– <span class="NLM_lpage">2377</span>, <span class="refDoi"> DOI: 10.1021/jm101514m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101514m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtFeksLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2368-2377&author=V.+M.+Ahrensauthor=R.+Frankauthor=S.+Stadlbauerauthor=A.+G.+Beck-Sickingerauthor=E.+Hey-Hawkins&title=Incorporation+of+ortho-carbaboranyl-N%CE%B5-modified+L-lysine+into+neuropeptide+Y+receptor+Y1-+and+Y2-selective+analogues&doi=10.1021%2Fjm101514m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Incorporation of ortho-Carbaboranyl-Nε-Modified L-Lysine into Neuropeptide Y Receptor Y1- and Y2-Selective Analogues</span></div><div class="casAuthors">Ahrens, Verena M.; Frank, Rene; Stadlbauer, Sven; Beck-Sickinger, Annette G.; Hey-Hawkins, Evamarie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2368-2377</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nontoxic ortho-carbaborane is one of the most promising structure for boron neutron capture therapy (BNCT).  For directed uptake of ortho-carbaborane by tumor cells, receptor-subtype selective neuropeptide Y (NPY) and its derivs. were modified with ortho-carbaborane.  The deriv. [F7, P34]-NPY has been shown to be a breast cancer selective ligand that binds to the Y1-receptor subtype, whereas [Ahx(5-24)]-NPY selectively addresses Y2-receptor subtypes that are found in neuroblastoma cells.  Ortho-carbaboranylpropionic acid was synthesized and linked to the ε-amino group of Nα-Fmoc protected L-lysine.  The characterization of the compds. was performed by NMR, IR, and MS studies.  The carbaborane-modified amino acid was incorporated into NPY, [F7, P34]-NPY, and [Ahx(5-24)]-NPY by an optimized solid-phase peptide synthesis using Fmoc protection.  Binding studies and IP accumulation assays confirmed nanomolar affinity and activity of the modified analogs despite of the large carbaborane cluster.  Internalization studies revealed excellent and receptor subtype specific uptake of the conjugates into resp. cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLcru9u9v-B7Vg90H21EOLACvtfcHk0lirK82AK8okvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtFeksLY%253D&md5=383ef862554b036f8289144487d0eda3</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm101514m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101514m%26sid%3Dliteratum%253Aachs%26aulast%3DAhrens%26aufirst%3DV.%2BM.%26aulast%3DFrank%26aufirst%3DR.%26aulast%3DStadlbauer%26aufirst%3DS.%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26aulast%3DHey-Hawkins%26aufirst%3DE.%26atitle%3DIncorporation%2520of%2520ortho-carbaboranyl-N%25CE%25B5-modified%2520L-lysine%2520into%2520neuropeptide%2520Y%2520receptor%2520Y1-%2520and%2520Y2-selective%2520analogues%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2368%26epage%3D2377%26doi%3D10.1021%2Fjm101514m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahrens, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehnke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schütz, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hampel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iffland, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bings, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hey-Hawkins, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span></span> <span> </span><span class="NLM_article-title">Receptor-mediated uptake of boron-rich neuropeptide y analogues for boron neutron capture therapy</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">164</span>– <span class="NLM_lpage">172</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201402368</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1002%2Fcmdc.201402368" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=25338544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFamtr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=164-172&author=V.+M.+Ahrensauthor=R.+Frankauthor=S.+Boehnkeauthor=C.+L.+Sch%C3%BCtzauthor=G.+Hampelauthor=D.+S.+Ifflandauthor=N.+H.+Bingsauthor=E.+Hey-Hawkinsauthor=A.+G.+Beck-Sickinger&title=Receptor-mediated+uptake+of+boron-rich+neuropeptide+y+analogues+for+boron+neutron+capture+therapy&doi=10.1002%2Fcmdc.201402368"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor-Mediated Uptake of Boron-Rich Neuropeptide Y Analogues for Boron Neutron Capture Therapy</span></div><div class="casAuthors">Ahrens, Verena M.; Frank, Rene; Boehnke, Solveig; Schuetz, Christian L.; Hampel, Gabriele; Iffland, Dorothee S.; Bings, Nicolas H.; Hey-Hawkins, Evamarie; Beck-Sickinger, Annette G.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">164-172</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Peptidic ligands selectively targeting distinct G protein-coupled receptors that are highly expressed in tumor tissue represent a promising approach in drug delivery.  Receptor-preferring analogs of neuropeptide Y (NPY) bind and activate the human Y1 receptor subtype (hY1 receptor), which is found in 90 % of breast cancer tissue and in all breast-cancer-derived metastases.  Herein, novel highly boron-loaded Y1-receptor-preferring peptide analogs are described as smart shuttle systems for carbaboranes as 10B-contg. moieties.  Various positions in the peptide were screened for their susceptibility to carbaborane modification, and the most promising positions were chosen to create a multi-carbaborane peptide contg. 30 boron atoms per peptide with excellent activation and internalization patterns at the hY1 receptor.  Boron uptake studies by inductively coupled plasma mass spectrometry revealed successful uptake of the multi-carbaborane peptide into hY1-receptor-expressing cells, exceeding the required amt. of 109 boron atoms per cell.  This result demonstrates that the NPY/hY receptor system can act as an effective transport system for boron-contg. moieties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjhrquUuNmmrVg90H21EOLACvtfcHk0ljHNxV3fGiSjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFamtr3I&md5=01ba090bce18667db1893b3be84399a8</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201402368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201402368%26sid%3Dliteratum%253Aachs%26aulast%3DAhrens%26aufirst%3DV.%2BM.%26aulast%3DFrank%26aufirst%3DR.%26aulast%3DBoehnke%26aufirst%3DS.%26aulast%3DSch%25C3%25BCtz%26aufirst%3DC.%2BL.%26aulast%3DHampel%26aufirst%3DG.%26aulast%3DIffland%26aufirst%3DD.%2BS.%26aulast%3DBings%26aufirst%3DN.%2BH.%26aulast%3DHey-Hawkins%26aufirst%3DE.%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26atitle%3DReceptor-mediated%2520uptake%2520of%2520boron-rich%2520neuropeptide%2520y%2520analogues%2520for%2520boron%2520neutron%2520capture%2520therapy%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D164%26epage%3D172%26doi%3D10.1002%2Fcmdc.201402368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Worm, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Els-Heindl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kellert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhnert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saretz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koebberling, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riedl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hey-Hawkins, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span></span> <span> </span><span class="NLM_article-title">A stable meta-carborane enables the generation of boron-rich peptide agonists targeting the ghrelin receptor</span>. <i>J. Pept. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>, <span class="NLM_elocation-id">e3119</span> <span class="refDoi"> DOI: 10.1002/psc.3119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1002%2Fpsc.3119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=30168238" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&author=D.+J.+Wormauthor=S.+Els-Heindlauthor=M.+Kellertauthor=R.+Kuhnertauthor=S.+Saretzauthor=J.+Koebberlingauthor=B.+Riedlauthor=E.+Hey-Hawkinsauthor=A.+G.+Beck-Sickinger&title=A+stable+meta-carborane+enables+the+generation+of+boron-rich+peptide+agonists+targeting+the+ghrelin+receptor&doi=10.1002%2Fpsc.3119"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fpsc.3119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsc.3119%26sid%3Dliteratum%253Aachs%26aulast%3DWorm%26aufirst%3DD.%2BJ.%26aulast%3DEls-Heindl%26aufirst%3DS.%26aulast%3DKellert%26aufirst%3DM.%26aulast%3DKuhnert%26aufirst%3DR.%26aulast%3DSaretz%26aufirst%3DS.%26aulast%3DKoebberling%26aufirst%3DJ.%26aulast%3DRiedl%26aufirst%3DB.%26aulast%3DHey-Hawkins%26aufirst%3DE.%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26atitle%3DA%2520stable%2520meta-carborane%2520enables%2520the%2520generation%2520of%2520boron-rich%2520peptide%2520agonists%2520targeting%2520the%2520ghrelin%2520receptor%26jtitle%3DJ.%2520Pept.%2520Sci.%26date%3D2018%26volume%3D24%26doi%3D10.1002%2Fpsc.3119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Plešek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heřmánek, S.</span></span> <span> </span><span class="NLM_article-title">Experimental evaluation of charge distribution on particular skeletal atoms in icosahedral carboranes by means of HS-derivatives</span>. <i>Collect. Czech. Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">24</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1135/cccc19790024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1135%2Fcccc19790024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADyaE1MXhs1OrsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1979&pages=24-33&author=J.+Ple%C5%A1ekauthor=S.+He%C5%99m%C3%A1nek&title=Experimental+evaluation+of+charge+distribution+on+particular+skeletal+atoms+in+icosahedral+carboranes+by+means+of+HS-derivatives&doi=10.1135%2Fcccc19790024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental evaluation of charge distribution on particular skeletal atoms in icosahedral carboranes by means of mercapto derivatives</span></div><div class="casAuthors">Plesek, Jaromir; Hermanek, Stanislav</div><div class="citationInfo"><span class="NLM_cas:title">Collection of Czechoslovak Chemical Communications</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">24-33</span>CODEN:
                <span class="NLM_cas:coden">CCCCAK</span>;
        ISSN:<span class="NLM_cas:issn">0366-547X</span>.
    </div><div class="casAbstract">The icosahedral skeleton is capable of conjugative interactions with HS groups and all groups of +M character.  The M interaction with the HS is approx. the same in all positions and is similar to that in PhSH.  The LFER for the pKa of the HS-isomer with the group charge (ε) on BH or CH is obsd.  The ε ranges between -0.10 (9-o) and +0.156 (1-o) and is correlated with dipole moment and chem. reactivity.  The pKa of 8 mercaptodicarba-closo-dodecaboranes (1-o, 8-o, 9-o, 1-m, 4-m, 9-m, 1-p, 2-p) and pKa values of 5 of their -SCH2CO2H derivs. are detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfgnoTaAZmg7Vg90H21EOLACvtfcHk0ljHNxV3fGiSjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXhs1OrsLg%253D&md5=62b133600c9ab222476aa52dd3e46d53</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1135%2Fcccc19790024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1135%252Fcccc19790024%26sid%3Dliteratum%253Aachs%26aulast%3DPle%25C5%25A1ek%26aufirst%3DJ.%26aulast%3DHe%25C5%2599m%25C3%25A1nek%26aufirst%3DS.%26atitle%3DExperimental%2520evaluation%2520of%2520charge%2520distribution%2520on%2520particular%2520skeletal%2520atoms%2520in%2520icosahedral%2520carboranes%2520by%2520means%2520of%2520HS-derivatives%26jtitle%3DCollect.%2520Czech.%2520Chem.%2520Commun.%26date%3D1979%26volume%3D44%26spage%3D24%26epage%3D33%26doi%3D10.1135%2Fcccc19790024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kellert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Worm, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoppenz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sárosi, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lönnecke, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riedl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koebberling, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hey-Hawkins, E.</span></span> <span> </span><span class="NLM_article-title">Modular triazine-based carborane-containing carboxylic acids - synthesis and characterisation of potential boron neutron capture therapy agents made of readily accessible building blocks</span>. <i>Dalton Trans</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">10834</span>– <span class="NLM_lpage">10844</span>, <span class="refDoi"> DOI: 10.1039/C9DT02130B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1039%2FC9DT02130B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=31246208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFyisL7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2019&pages=10834-10844&author=M.+Kellertauthor=D.+J.+Wormauthor=P.+Hoppenzauthor=M.+B.+S%C3%A1rosiauthor=P.+L%C3%B6nneckeauthor=B.+Riedlauthor=J.+Koebberlingauthor=A.+G.+Beck-Sickingerauthor=E.+Hey-Hawkins&title=Modular+triazine-based+carborane-containing+carboxylic+acids+-+synthesis+and+characterisation+of+potential+boron+neutron+capture+therapy+agents+made+of+readily+accessible+building+blocks&doi=10.1039%2FC9DT02130B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Modular triazine-based carborane-containing carboxylic acids - synthesis and characterisation of potential boron neutron capture therapy agents made of readily accessible building blocks</span></div><div class="casAuthors">Kellert, Martin; Worm, Dennis J.; Hoppenz, Paul; Sarosi, Menyhart B.; Loennecke, Peter; Riedl, Bernd; Koebberling, Johannes; Beck-Sickinger, Annette G.; Hey-Hawkins, Evamarie</div><div class="citationInfo"><span class="NLM_cas:title">Dalton Transactions</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">10834-10844</span>CODEN:
                <span class="NLM_cas:coden">DTARAF</span>;
        ISSN:<span class="NLM_cas:issn">1477-9226</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Triazine-bridged carborane-aminocarboxylate and peptide conjugates were prepd. as prospective BNCT agents.  Based on a modular combination of s-triazine, the well-known 9-mercapto-1,7-dicarba-closo-dodecaborane(12) and com. available carboxylic acids, namely thioglycolic acid, glycine, and Nα-Boc-L-lysine, several carboxylic acid derivs. were synthesized and fully characterized.  The thioglycolic acid deriv. was introduced into a peptide hormone by solid phase peptide synthesis.  High activity and selective internalization into peptide receptor-expressing cells was obsd.  With a very high boron content of twenty boron atoms, these derivs. are interesting as selective Boron Neutron Capture Therapy (BNCT) agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0sjdC_QKaw7Vg90H21EOLACvtfcHk0liijDq6cX91Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFyisL7P&md5=0c14505635d92b01f8d4f3e24e3c0692</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1039%2FC9DT02130B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9DT02130B%26sid%3Dliteratum%253Aachs%26aulast%3DKellert%26aufirst%3DM.%26aulast%3DWorm%26aufirst%3DD.%2BJ.%26aulast%3DHoppenz%26aufirst%3DP.%26aulast%3DS%25C3%25A1rosi%26aufirst%3DM.%2BB.%26aulast%3DL%25C3%25B6nnecke%26aufirst%3DP.%26aulast%3DRiedl%26aufirst%3DB.%26aulast%3DKoebberling%26aufirst%3DJ.%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26aulast%3DHey-Hawkins%26aufirst%3DE.%26atitle%3DModular%2520triazine-based%2520carborane-containing%2520carboxylic%2520acids%2520-%2520synthesis%2520and%2520characterisation%2520of%2520potential%2520boron%2520neutron%2520capture%2520therapy%2520agents%2520made%2520of%2520readily%2520accessible%2520building%2520blocks%26jtitle%3DDalton%2520Trans%26date%3D2019%26volume%3D48%26spage%3D10834%26epage%3D10844%26doi%3D10.1039%2FC9DT02130B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kerns, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, G. T.</span></span> <span> </span><span class="NLM_article-title">In vitro solubility assays in drug discovery</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">879</span>– <span class="NLM_lpage">885</span>, <span class="refDoi"> DOI: 10.2174/138920008786485100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.2174%2F138920008786485100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=18991584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivF2nsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=879-885&author=E.+H.+Kernsauthor=L.+Diauthor=G.+T.+Carter&title=In+vitro+solubility+assays+in+drug+discovery&doi=10.2174%2F138920008786485100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro solubility assays in drug discovery</span></div><div class="casAuthors">Kerns, Edward H.; Di, Li; Carter, Guy T.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">879-885</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The soly. of a compd. depends on its structure and soln. conditions.  Structure dets. the lipophilicity, hydrogen bonding, mol. vol., crystal energy and ionizability, which det. soly.  Soln. conditions are affected by pH, cosolvents, additives, ionic strength, time and temp.  Many drug discovery expts. are conducted under "kinetic" soly. conditions.  In drug discovery, soly. has a major impact on bioassays, formulation for in vivo dosing, and intestinal absorption.  A good goal for the soly. of drug discovery compds. is >60 ug/mL.  Equil. soly. assays can be conducted in moderate throughput, by incubating excess solid with buffer and agitating for several days, prior to filtration and HPLC quantitation.  Kinetic soly. assays are performed in high throughput with shorter incubation times and high throughput analyses using plate readers.  The most frequently used of these are the nephelometric assay and direct UV assay, which begin by adding a small vol. of DMSO stock soln. of each test compd. to buffer.  In nephelometry, this soln. is serially dild. across a microtiter plate and undissolved particles are detected via light scattering.  In direct UV, undissolved particles are sepd. by filtration, after which the dissolved material is quantitated using UV absorption.  Equil. soly. is useful for preformulation.  Kinetic soly. is useful for rapid compd. assessment, guiding optimization via structure modification, and diagnosing bioassays.  It is often useful to customize soly. expts. using conditions that answer specific research questions of drug discovery teams, such as compd. selection and vehicle development for pharmacol. and PK studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1Pe5z4JU_6LVg90H21EOLACvtfcHk0liijDq6cX91Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivF2nsb8%253D&md5=416cf5bfde2278eac1ba2c67feb1f62e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.2174%2F138920008786485100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920008786485100%26sid%3Dliteratum%253Aachs%26aulast%3DKerns%26aufirst%3DE.%2BH.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DCarter%26aufirst%3DG.%2BT.%26atitle%3DIn%2520vitro%2520solubility%2520assays%2520in%2520drug%2520discovery%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2008%26volume%3D9%26spage%3D879%26epage%3D885%26doi%3D10.2174%2F138920008786485100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kreiner, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergueiro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cartelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castell, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asoia, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padulo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suárez Sandín, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igarzabal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erhardt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercuri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valda, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minsky, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debray, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somacal, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capoulat, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrera, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Grosso, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagetti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anzorena, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canepa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Real, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tacca, H.</span></span> <span> </span><span class="NLM_article-title">Present status of accelerator-based BNCT</span>. <i>Rep. Pract. Oncol. Radiother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">101</span>, <span class="refDoi"> DOI: 10.1016/j.rpor.2014.11.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1016%2Fj.rpor.2014.11.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=26933390" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A280%3ADC%252BC28jmtFOrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=95-101&author=A.+J.+Kreinerauthor=J.+Bergueiroauthor=D.+Cartelliauthor=M.+Baldoauthor=W.+Castellauthor=J.+G.+Asoiaauthor=J.+Paduloauthor=J.+C.+Su%C3%A1rez+Sand%C3%ADnauthor=M.+Igarzabalauthor=J.+Erhardtauthor=D.+Mercuriauthor=A.+A.+Valdaauthor=D.+M.+Minskyauthor=M.+E.+Debrayauthor=H.+R.+Somacalauthor=M.+E.+Capoulatauthor=M.+S.+Herreraauthor=M.+F.+Del+Grossoauthor=L.+Gagettiauthor=M.+S.+Anzorenaauthor=N.+Canepaauthor=N.+Realauthor=M.+Gunauthor=H.+Tacca&title=Present+status+of+accelerator-based+BNCT&doi=10.1016%2Fj.rpor.2014.11.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Present status of Accelerator-Based BNCT</span></div><div class="casAuthors">Kreiner Andres Juan; Cartelli Daniel; Minsky Daniel M; Capoulat Maria Eugenia; Herrera Maria S; Gagetti Leonardo; Bergueiro Javier; Baldo Matias; Castell Walter; Asoia Javier Gomez; Padulo Javier; Suarez Sandin Juan Carlos; Igarzabal Marcelo; Erhardt Julian; Mercuri Daniel; Anzorena Manuel Suarez; Canepa Nicolas; Real Nicolas; Valda Alejandro A; Debray Mario E; Somacal Hector R; Del Grosso Mariela F; Gun Marcelo; Tacca Hernan</div><div class="citationInfo"><span class="NLM_cas:title">Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">95-101</span>
        ISSN:<span class="NLM_cas:issn">1507-1367</span>.
    </div><div class="casAbstract">AIM:  This work aims at giving an updated report of the worldwide status of Accelerator-Based BNCT (AB-BNCT).  BACKGROUND:  There is a generalized perception that the availability of accelerators installed in hospitals, as neutron sources, may be crucial for the advancement of BNCT.  Accordingly, in recent years a significant effort has started to develop such machines.  MATERIALS AND METHODS:  A variety of possible charged-particle induced nuclear reactions and the characteristics of the resulting neutron spectra are discussed along with the worldwide activity in suitable accelerator development.  RESULTS:  Endothermic (7)Li(p,n)(7)Be and (9)Be(p,n)(9)B and exothermic (9)Be(d,n)(10)B are compared.  In addition to having much better thermo-mechanical properties than Li, Be as a target leads to stable products.  This is a significant advantage for a hospital-based facility. (9)Be(p,n)(9)B needs at least 4-5 MeV bombarding energy to have a sufficient yield, while (9)Be(d,n)(10)B can be utilized at about 1.4 MeV, implying the smallest possible accelerator.  This reaction operating with a thin target can produce a sufficiently soft spectrum to be viable for AB-BNCT.  The machines considered are electrostatic single ended or tandem accelerators or radiofrequency quadrupoles plus drift tube Linacs.  CONCLUSIONS:  (7)Li(p,n)(7)Be provides one of the best solutions for the production of epithermal neutron beams for deep-seated tumors.  However, a Li-based target poses significant technological challenges.  Hence, Be has been considered as an alternative target, both in combination with (p,n) and (d,n) reactions. (9)Be(d,n)(10)B at 1.4 MeV, with a thin target has been shown to be a realistic option for the treatment of deep-seated lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSiRzYlOIIH2Ny3lHz94U-GfW6udTcc2eY_TLddGbLdHrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jmtFOrsQ%253D%253D&md5=e934e8e2a0d54a06bee775cf8de1e880</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.rpor.2014.11.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rpor.2014.11.004%26sid%3Dliteratum%253Aachs%26aulast%3DKreiner%26aufirst%3DA.%2BJ.%26aulast%3DBergueiro%26aufirst%3DJ.%26aulast%3DCartelli%26aufirst%3DD.%26aulast%3DBaldo%26aufirst%3DM.%26aulast%3DCastell%26aufirst%3DW.%26aulast%3DAsoia%26aufirst%3DJ.%2BG.%26aulast%3DPadulo%26aufirst%3DJ.%26aulast%3DSu%25C3%25A1rez%2BSand%25C3%25ADn%26aufirst%3DJ.%2BC.%26aulast%3DIgarzabal%26aufirst%3DM.%26aulast%3DErhardt%26aufirst%3DJ.%26aulast%3DMercuri%26aufirst%3DD.%26aulast%3DValda%26aufirst%3DA.%2BA.%26aulast%3DMinsky%26aufirst%3DD.%2BM.%26aulast%3DDebray%26aufirst%3DM.%2BE.%26aulast%3DSomacal%26aufirst%3DH.%2BR.%26aulast%3DCapoulat%26aufirst%3DM.%2BE.%26aulast%3DHerrera%26aufirst%3DM.%2BS.%26aulast%3DDel%2BGrosso%26aufirst%3DM.%2BF.%26aulast%3DGagetti%26aufirst%3DL.%26aulast%3DAnzorena%26aufirst%3DM.%2BS.%26aulast%3DCanepa%26aufirst%3DN.%26aulast%3DReal%26aufirst%3DN.%26aulast%3DGun%26aufirst%3DM.%26aulast%3DTacca%26aufirst%3DH.%26atitle%3DPresent%2520status%2520of%2520accelerator-based%2520BNCT%26jtitle%3DRep.%2520Pract.%2520Oncol.%2520Radiother.%26date%3D2016%26volume%3D21%26spage%3D95%26epage%3D101%26doi%3D10.1016%2Fj.rpor.2014.11.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barth, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span> <span> </span><span class="NLM_article-title">A realistic appraisal of boron neutron capture therapy as a cancer treatment modality</span>. <i>Cancer Commun. (Lond).</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1186/s40880-018-0280-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1186%2Fs40880-018-0280-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=29914575" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A280%3ADC%252BC1MbosFamuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=36-43&author=R.+F.+Barthauthor=Z.+Zhangauthor=T.+Liu&title=A+realistic+appraisal+of+boron+neutron+capture+therapy+as+a+cancer+treatment+modality&doi=10.1186%2Fs40880-018-0280-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">A realistic appraisal of boron neutron capture therapy as a cancer treatment modality</span></div><div class="casAuthors">Barth Rolf F; Zhang Zizhu; Liu Tong</div><div class="citationInfo"><span class="NLM_cas:title">Cancer communications (London, England)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Boron neutron capture therapy (BNCT) is a binary therapeutic modality based on the nuclear capture and fission reactions that occur when the stable isotope boron-10 is irradiated with neutrons to produce high-energy alpha particles and recoiling lithium-7 nuclei.  In this Commentary we will focus on a number of papers that were presented at a Symposium entitled "Current Clinical Status of Boron Neutron Capture Therapy and Paths to the Future", which was held in September 2017 at the China National Convention Center in Beijing.  Results were presented by clinicians from Japan, Finland, the United States, the China mainland and Taiwan, China who have been working in the multiple disciplines that are required for carrying out clinical BNCT.  The main focus was on the treatment of patients with malignant brain tumors, recurrent tumors of the head and neck region, and cutaneous melanomas.  The results obtained in treating these patients were reported in detail and, although most of the patients with brain tumors and head and neck cancer were not cured, there was evidence of some clinical efficacy.  Although there are a number of problems that must be addressed, further clinical studies to evaluate the efficacy of BNCT are warranted.  First, despite considerable effort by numerous investigators over the past 40 years, there still are only two boron-containing drugs in clinical use, L-boronophenylalanine (BPA) and sodium borocaptate (BSH).  Therefore, until new and more effective boron delivery agents are developed, efforts should be directed to improving the dosing and delivery of BPA and BSH.  Second, due to a variety of reasons, nuclear reactor-based BNCT has ended except for its use in the China mainland and Taiwan.  Therefore, the future of BNCT depends upon the results of the ongoing Phase II clinical trials that are being carried out in Japan and the soon to be initiated trials that will be carried out in Finland.  If the results obtained from these clinical trials are sufficiently promising, then BNCT will have a clear path to the future, especially for patients with the therapeutically challenging malignancies that in the past have been treated with reactor-based BNCT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR-_cHN3uno-8K3uFsUIZtkfW6udTcc2eYWRvPPq4lGsLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MbosFamuw%253D%253D&md5=aaf7960e10efcae0cbdcaa5113ba2bda</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1186%2Fs40880-018-0280-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40880-018-0280-5%26sid%3Dliteratum%253Aachs%26aulast%3DBarth%26aufirst%3DR.%2BF.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DT.%26atitle%3DA%2520realistic%2520appraisal%2520of%2520boron%2520neutron%2520capture%2520therapy%2520as%2520a%2520cancer%2520treatment%2520modality%26jtitle%3DCancer%2520Commun.%2520%2528Lond%2529.%26date%3D2018%26volume%3D38%26spage%3D36%26epage%3D43%26doi%3D10.1186%2Fs40880-018-0280-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barth, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span> <span> </span><span class="NLM_article-title">Boron delivery agents for neutron capture therapy of cancer</span>. <i>Cancer Commun. (Lond).</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">35</span>, <span class="refDoi"> DOI: 10.1186/s40880-018-0299-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1186%2Fs40880-018-0299-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=29914561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A280%3ADC%252BC1MbosFantw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=35&author=R.+F.+Barthauthor=P.+Miauthor=W.+Yang&title=Boron+delivery+agents+for+neutron+capture+therapy+of+cancer&doi=10.1186%2Fs40880-018-0299-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Boron delivery agents for neutron capture therapy of cancer</span></div><div class="casAuthors">Barth Rolf F; Yang Weilian; Mi Peng; Yang Weilian</div><div class="citationInfo"><span class="NLM_cas:title">Cancer communications (London, England)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">35</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Boron neutron capture therapy (BNCT) is a binary radiotherapeutic modality based on the nuclear capture and fission reactions that occur when the stable isotope, boron-10, is irradiated with neutrons to produce high energy alpha particles.  This review will focus on tumor-targeting boron delivery agents that are an essential component of this binary system.  Two low molecular weight boron-containing drugs currently are being used clinically, boronophenylalanine (BPA) and sodium borocaptate (BSH).  Although they are far from being ideal, their therapeutic efficacy has been demonstrated in patients with high grade gliomas, recurrent tumors of the head and neck region, and a much smaller number with cutaneous and extra-cutaneous melanomas.  Because of their limitations, great effort has been expended over the past 40 years to develop new boron delivery agents that have more favorable biodistribution and uptake for clinical use.  These include boron-containing porphyrins, amino acids, polyamines, nucleosides, peptides, monoclonal antibodies, liposomes, nanoparticles of various types, boron cluster compounds and co-polymers.  Currently, however, none of these have reached the stage where there is enough convincing data to warrant clinical biodistribution studies.  Therefore, at present the best way to further improve the clinical efficacy of BNCT would be to optimize the dosing paradigms and delivery of BPA and BSH, either alone or in combination, with the hope that future research will identify new and better boron delivery agents for clinical use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR-_cHN3uno-8NIRw0GKUoEfW6udTcc2eYWRvPPq4lGsLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MbosFantw%253D%253D&md5=4580caac6fbe21e1487ca8bb897f96ed</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1186%2Fs40880-018-0299-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40880-018-0299-7%26sid%3Dliteratum%253Aachs%26aulast%3DBarth%26aufirst%3DR.%2BF.%26aulast%3DMi%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DW.%26atitle%3DBoron%2520delivery%2520agents%2520for%2520neutron%2520capture%2520therapy%2520of%2520cancer%26jtitle%3DCancer%2520Commun.%2520%2528Lond%2529.%26date%3D2018%26volume%3D38%26spage%3D35%26doi%3D10.1186%2Fs40880-018-0299-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Körner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waser, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reubi, J. C.</span></span> <span> </span><span class="NLM_article-title">High expression of neuropeptide Y1 receptors in ewing sarcoma tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">5043</span>– <span class="NLM_lpage">5049</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-4551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1158%2F1078-0432.CCR-07-4551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=18698022" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A280%3ADC%252BD1crhsVyhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=5043-5049&author=M.+K%C3%B6rnerauthor=B.+Waserauthor=J.+C.+Reubi&title=High+expression+of+neuropeptide+Y1+receptors+in+ewing+sarcoma+tumors&doi=10.1158%2F1078-0432.CCR-07-4551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">High expression of neuropeptide Y1 receptors in ewing sarcoma tumors</span></div><div class="casAuthors">Korner Meike; Waser Beatrice; Reubi Jean Claude</div><div class="citationInfo"><span class="NLM_cas:title">Clinical cancer research : an official journal of the American Association for Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5043-9</span>
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    </div><div class="casAbstract">PURPOSE:  Peptide receptors are frequently overexpressed in human tumors, allowing receptor-targeted scintigraphic imaging and therapy with radiolabeled peptide analogues.  Neuropeptide Y (NPY) receptors are new candidates for these applications, based on their high expression in specific cancers.  Because NPY receptors are expressed in selected sarcoma cell lines and because novel treatment options are needed for sarcomas, this study assessed the NPY receptor in primary human sarcomas.  EXPERIMENTAL DESIGN:  Tumor tissues of 88 cases, including Ewing sarcoma family of tumors (ESFT), synovial sarcomas, osteosarcomas, chondrosarcomas, liposarcomas, angiosarcomas, rhabdomyosarcomas, leiomyosarcomas, and desmoid tumors, were investigated for NPY receptor protein with in vitro receptor autoradiography using (125)I-labeled NPY receptor ligands and for NPY receptor mRNA expression with in situ hybridization.  RESULTS:  ESFT expressed the NPY receptor subtype Y1 on tumor cells in remarkably high incidence (84%) and density (mean, 5,314 dpm/mg tissue).  Likewise, synovial sarcomas expressed Y1 on tumor cells in high density (mean, 7,497 dpm/mg; incidence, 40%).  The remaining tumors expressed NPY receptor subtypes Y1 or Y2 at lower levels.  Moreover, many of the sarcomas showed Y1 expression on intratumoral blood vessels.  In situ hybridization for Y1 mRNA confirmed the autoradiography results.  CONCLUSIONS:  NPY receptors are novel molecular markers for human sarcomas.  Y1 may inhibit growth of specific sarcomas, as previously shown in an in vivo mouse model of human ESFT.  The high Y1 expression on tumor cells of ESFT and synovial sarcomas and on blood vessels in many other sarcomas represents an attractive basis for an in vivo tumor targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTuDvMZ7pFzitLIORRPd5lbfW6udTcc2eYWRvPPq4lGsLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1crhsVyhuw%253D%253D&md5=969fda27f4733e5d578f339933be4c74</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-4551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-4551%26sid%3Dliteratum%253Aachs%26aulast%3DK%25C3%25B6rner%26aufirst%3DM.%26aulast%3DWaser%26aufirst%3DB.%26aulast%3DReubi%26aufirst%3DJ.%2BC.%26atitle%3DHigh%2520expression%2520of%2520neuropeptide%2520Y1%2520receptors%2520in%2520ewing%2520sarcoma%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D5043%26epage%3D5049%26doi%3D10.1158%2F1078-0432.CCR-07-4551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gabel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairchild, R. G.</span></span> <span> </span><span class="NLM_article-title">The Monte Carlo simulation of the biological effect of the 10B(n, alpha)7Li reaction in cells and tissue and its implication for boron neutron capture therapy</span>. <i>Radiat. Res.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">14</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.2307/3577018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.2307%2F3577018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=3602351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADyaL2sXkslenur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=1987&pages=14-25&author=D.+Gabelauthor=S.+Fosterauthor=R.+G.+Fairchild&title=The+Monte+Carlo+simulation+of+the+biological+effect+of+the+10B%28n%2C+alpha%297Li+reaction+in+cells+and+tissue+and+its+implication+for+boron+neutron+capture+therapy&doi=10.2307%2F3577018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">The Monte Carlo simulation of the biological effect on the 10B(n,α)7Li reaction in cells and tissue and its implication for boron neutron capture therapy</span></div><div class="casAuthors">Gabel, Detlef; Foster, Sheila; Fairchild, Ralph G.</div><div class="citationInfo"><span class="NLM_cas:title">Radiation Research</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">14-25</span>CODEN:
                <span class="NLM_cas:coden">RAREAE</span>;
        ISSN:<span class="NLM_cas:issn">0033-7587</span>.
    </div><div class="casAbstract">The energy deposition in the nucleus of cells exposed to the 10B(n,α)7Li neutron capture reaction has been calcd. and compared to the measured biol. effect of this reaction.  It was found that a considerable distribution of hit sizes to the nucleus occurs.  The comparison of hit size frequency with the obsd. survival indicates that not every hit, independent of its size, can lead to cell death.  This implies the existence of a hit size effectiveness function.  The anal. shows that the location of B relative to the radiation-sensitive vol. of the cell is of great importance and that av. dose values alone are of limited use for predicting the biol. effect of this reaction.  B accumulating in the cell nucleus is much more efficient in cell killing than the same amt. of B uniformly distributed; its presence in one cell, however, has little effect on its neighboring cells in a tissue.  When B is present on the cell surface of a tissue (as presumably delivered by antibodies), its cell-killing effect is greatly reduced compared to that in uniform distribution.  However, in this case much of the dose to one cell comes from neutron capture reactions occurring on the surface of its neighbor cells.  These data have implications for the choice of B carriers in neutron capture therapy.  The math. anal. carried out here is similar to that proposed recently for low-level exposure effects of radiation, taking mutation and/or carcinogenesis as biol. effects.  The results here show that high-level exposure to high linear energy transfer particles (resulting in cell killing) should be treated in an analogous manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwl3Ha5xw3WrVg90H21EOLACvtfcHk0limVo6ModBMQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXkslenur4%253D&md5=eab28332c0b0ae59f05978c0c9cbf740</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.2307%2F3577018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2307%252F3577018%26sid%3Dliteratum%253Aachs%26aulast%3DGabel%26aufirst%3DD.%26aulast%3DFoster%26aufirst%3DS.%26aulast%3DFairchild%26aufirst%3DR.%2BG.%26atitle%3DThe%2520Monte%2520Carlo%2520simulation%2520of%2520the%2520biological%2520effect%2520of%2520the%252010B%2528n%252C%2520alpha%25297Li%2520reaction%2520in%2520cells%2520and%2520tissue%2520and%2520its%2520implication%2520for%2520boron%2520neutron%2520capture%2520therapy%26jtitle%3DRadiat.%2520Res.%26date%3D1987%26volume%3D111%26spage%3D14%26epage%3D25%26doi%3D10.2307%2F3577018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schirrmacher, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirrmacher, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trautman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rösch, F.</span></span> <span> </span><span class="NLM_article-title">Synthesis of a Tyr3-octreotate conjugated closo-carborane [HC<sub>2</sub>B<sub>10</sub>H<sub>10</sub>]</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">9143</span>– <span class="NLM_lpage">9145</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2003.10.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1016%2Fj.tetlet.2003.10.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovF2ltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2003&pages=9143-9145&author=E.+Schirrmacherauthor=R.+Schirrmacherauthor=C.+Beckauthor=W.+Mierauthor=N.+Trautmanauthor=F.+R%C3%B6sch&title=Synthesis+of+a+Tyr3-octreotate+conjugated+closo-carborane+%5BHC2B10H10%5D&doi=10.1016%2Fj.tetlet.2003.10.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of a Tyr3-octreotate conjugated closo-carborane [HC2B10H10]: a potential compound for boron neutron capture therapy</span></div><div class="casAuthors">Schirrmacher, Esther; Schirrmacher, Ralf; Beck, Carmen; Mier, Walter; Trautman, Norbert; Rosch, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">9143-9145</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A novel Tyr3-octreotate conjugated closo-carborane as a potential compd. for boron neutron capture therapy was obtained via Fmoc (Fmoc = 9-fluorenylmethyloxycarbonyl) solid phase peptide synthesis.  The boron cluster [C2B10H11] was introduced through the reaction of 6,9-bis(acetonitrile)decaborane and 5-hexynoic acid yielding a new closo-carborane conjugated carboxylic acid which was coupled subsequently with solid phase conjugated Tyr3-octreotate.  The final boron-contg. peptide was purified by preparative reverse phase HPLC and structural identity was proved applying MALDI-TOF mass spectrometry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDfu1KH0IpB7Vg90H21EOLACvtfcHk0limVo6ModBMQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovF2ltL8%253D&md5=9d175eab88f70e88d89bfe9ed622283c</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2003.10.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2003.10.048%26sid%3Dliteratum%253Aachs%26aulast%3DSchirrmacher%26aufirst%3DE.%26aulast%3DSchirrmacher%26aufirst%3DR.%26aulast%3DBeck%26aufirst%3DC.%26aulast%3DMier%26aufirst%3DW.%26aulast%3DTrautman%26aufirst%3DN.%26aulast%3DR%25C3%25B6sch%26aufirst%3DF.%26atitle%3DSynthesis%2520of%2520a%2520Tyr3-octreotate%2520conjugated%2520closo-carborane%2520%255BHC2B10H10%255D%26jtitle%3DTetrahedron%2520Lett.%26date%3D2003%26volume%3D44%26spage%3D9143%26epage%3D9145%26doi%3D10.1016%2Fj.tetlet.2003.10.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberkorn, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenhut, M.</span></span> <span> </span><span class="NLM_article-title">Conjugation of the closo-borane mercaptoundecahydrododecaborate (BSH) to a tumour selective peptide</span>. <i>Z. Anorg. Allg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>630</i></span>,  <span class="NLM_fpage">1258</span>– <span class="NLM_lpage">1262</span>, <span class="refDoi"> DOI: 10.1002/zaac.200400064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1002%2Fzaac.200400064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmsFSntLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=630&publication_year=2004&pages=1258-1262&author=W.+Mierauthor=D.+Gabelauthor=U.+Haberkornauthor=M.+Eisenhut&title=Conjugation+of+the+closo-borane+mercaptoundecahydrododecaborate+%28BSH%29+to+a+tumour+selective+peptide&doi=10.1002%2Fzaac.200400064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Conjugation of the closo-borane mercaptoundecahydrododecaborate (BSH) to a tumor selective peptide</span></div><div class="casAuthors">Mier, Walter; Gabel, Detlef; Haberkorn, Uwe; Eisenhut, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Zeitschrift fuer Anorganische und Allgemeine Chemie</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">630</span>
        (<span class="NLM_cas:issue">8-9</span>),
    <span class="NLM_cas:pages">1258-1262</span>CODEN:
                <span class="NLM_cas:coden">ZAACAB</span>;
        ISSN:<span class="NLM_cas:issn">0044-2313</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The non-toxic disodium mercaptoundecahydrododecaborate (BSH) is one of the most promising agents known for boron-neutron-capture therapy (BNCT).  In order to enhance the intratumoral concn. of the boron cluster by receptor mediated endocytosis, a synthetic method for the conjugation of borane clusters to peptides was developed.  A Michael addn. was performed to link BSH to the thiol reactive maleimido modified Tyr3-octreotate.  Tyr3-octreotate, synthesized by Fmoc-solid phase peptide synthesis, is a selective ligand for somatostatin receptors.  The modified boron cluster was obtained in 68% yield after purifn.  Characterization of the BSH conjugate was performed with HPLC, MALDI-TOF and electrospray mass spectrometry.  The BSH-Tyr3-octreotate conjugate is considered to target receptor-pos. tumors which might further improve the potential of BNCT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAA1G3yAX4-LVg90H21EOLACvtfcHk0limVo6ModBMQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmsFSntLc%253D&md5=5c264f0453cbdcbcc757fa5450dcfb09</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1002%2Fzaac.200400064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fzaac.200400064%26sid%3Dliteratum%253Aachs%26aulast%3DMier%26aufirst%3DW.%26aulast%3DGabel%26aufirst%3DD.%26aulast%3DHaberkorn%26aufirst%3DU.%26aulast%3DEisenhut%26aufirst%3DM.%26atitle%3DConjugation%2520of%2520the%2520closo-borane%2520mercaptoundecahydrododecaborate%2520%2528BSH%2529%2520to%2520a%2520tumour%2520selective%2520peptide%26jtitle%3DZ.%2520Anorg.%2520Allg.%2520Chem.%26date%3D2004%26volume%3D630%26spage%3D1258%26epage%3D1262%26doi%3D10.1002%2Fzaac.200400064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Betzel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waser, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reubi, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roesch, F.</span></span> <span> </span><span class="NLM_article-title">closo-borane conjugated regulatory peptides retain high biological affinity: synthesis of closo-borane conjugated Tyr(3)-octreotate derivatives for BNCT</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1796</span>– <span class="NLM_lpage">1802</span>, <span class="refDoi"> DOI: 10.1021/bc800101h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc800101h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVShtLjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2008&pages=1796-1802&author=T.+Betzelauthor=T.+Hessauthor=B.+Waserauthor=J.+C.+Reubiauthor=F.+Roesch&title=closo-borane+conjugated+regulatory+peptides+retain+high+biological+affinity%3A+synthesis+of+closo-borane+conjugated+Tyr%283%29-octreotate+derivatives+for+BNCT&doi=10.1021%2Fbc800101h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">closo-Borane Conjugated Regulatory Peptides Retain High Biological Affinity: Synthesis of closo-Borane Conjugated Tyr3-Octreotate Derivatives for BNCT</span></div><div class="casAuthors">Betzel, Thomas; Hess, Tobias; Waser, Beatrice; Reubi, Jean-C.; Roesch, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1796-1802</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Despite the improvements in cancer therapy during the past years, high-grade gliomas and many other types of cancer are still extremely resistant to current forms of therapy.  Boron neutron capture therapy (BNCT) provides a promising way to destroy cancer cells without damaging healthy tissue.  However, BNCT in practice is still limited due to the lack of boron-contg. compds. that selectively deliver boron to cancer cells.  Since many neuroendocrine tumors show an overexpression of the somatostatin receptor, it was our aim to synthesize compds. that contain a large no. of boron atoms and still show high affinity toward this transmembrane receptor.  The synthetic peptide Tyr3-octreotate (TATE) was chosen as a high-affinity and internalizing tumor targeting vector (TTV).  Novel boron cluster compds., contg. 10 or 20 boron atoms, were coupled to the N-terminus of TATE.  The obtained affinity data demonstrate that the use of a spacer between TATE and the closo-borane moiety is the option to avoid a loss of biol. affinity of closo-borane conjugated TATE.  For the first time, it was shown that closo-borane conjugated regulatory peptides retain high biol. affinity and selectivity toward their transmembrane tumor receptors.  The results obtained and the improvement of spacer and boron building block chem. may stimulate new directions for BNCT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrB-TrLFb3XmbVg90H21EOLACvtfcHk0lixsLw37BsHww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVShtLjL&md5=91b9559936a84427015dad982c2276c1</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fbc800101h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc800101h%26sid%3Dliteratum%253Aachs%26aulast%3DBetzel%26aufirst%3DT.%26aulast%3DHess%26aufirst%3DT.%26aulast%3DWaser%26aufirst%3DB.%26aulast%3DReubi%26aufirst%3DJ.%2BC.%26aulast%3DRoesch%26aufirst%3DF.%26atitle%3Dcloso-borane%2520conjugated%2520regulatory%2520peptides%2520retain%2520high%2520biological%2520affinity%253A%2520synthesis%2520of%2520closo-borane%2520conjugated%2520Tyr%25283%2529-octreotate%2520derivatives%2520for%2520BNCT%26jtitle%3DBioconjugate%2520Chem.%26date%3D2008%26volume%3D19%26spage%3D1796%26epage%3D1802%26doi%3D10.1021%2Fbc800101h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Valliant, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guenther, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaffer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sogbein, O. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephenson, K. A.</span></span> <span> </span><span class="NLM_article-title">The medicinal chemistry of carboranes</span>. <i>Coord. Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>232</i></span>,  <span class="NLM_fpage">173</span>– <span class="NLM_lpage">230</span>, <span class="refDoi"> DOI: 10.1016/S0010-8545(02)00087-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1016%2FS0010-8545%2802%2900087-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD38XntF2kur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=232&publication_year=2002&pages=173-230&author=J.+F.+Valliantauthor=K.+J.+Guentherauthor=A.+S.+Kingauthor=P.+Morelauthor=P.+Schafferauthor=O.+O.+Sogbeinauthor=K.+A.+Stephenson&title=The+medicinal+chemistry+of+carboranes&doi=10.1016%2FS0010-8545%2802%2900087-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The medicinal chemistry of carboranes</span></div><div class="casAuthors">Valliant, John F.; Guenther, Katharina J.; King, Arienne S.; Morel, Pierre; Schaffer, Paul; Sogbein, Oyebola O.; Stephenson, Karin A.</div><div class="citationInfo"><span class="NLM_cas:title">Coordination Chemistry Reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">232</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">173-230</span>CODEN:
                <span class="NLM_cas:coden">CCHRAM</span>;
        ISSN:<span class="NLM_cas:issn">0010-8545</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  The medicinal chem. of dicarba-closo-dodecaboranes (otherwise referred to as carboranes) has traditionally centered on their use in B neutron capture therapy (BNCT).  More recently, work has begun to exploit the unique chem. and phys. properties of carboranes for the prepn. of novel inorg. pharmaceuticals and biol. probes.  This review is designed to highlight some of the recent work concerning medicinal carborane chem. including the synthesis and testing of new BNCT agents, use of carboranes in medical imaging, and use of carboranes as pharmacophores.  Following this review, as an appendix, is an illustrated summary of reactions involving carboranes reported in literature since 1992.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNW7Buyv6o17Vg90H21EOLACvtfcHk0lixsLw37BsHww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntF2kur8%253D&md5=52e3a1bb3de706088f181207d6a3e377</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2FS0010-8545%2802%2900087-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0010-8545%252802%252900087-5%26sid%3Dliteratum%253Aachs%26aulast%3DValliant%26aufirst%3DJ.%2BF.%26aulast%3DGuenther%26aufirst%3DK.%2BJ.%26aulast%3DKing%26aufirst%3DA.%2BS.%26aulast%3DMorel%26aufirst%3DP.%26aulast%3DSchaffer%26aufirst%3DP.%26aulast%3DSogbein%26aufirst%3DO.%2BO.%26aulast%3DStephenson%26aufirst%3DK.%2BA.%26atitle%3DThe%2520medicinal%2520chemistry%2520of%2520carboranes%26jtitle%3DCoord.%2520Chem.%2520Rev.%26date%3D2002%26volume%3D232%26spage%3D173%26epage%3D230%26doi%3D10.1016%2FS0010-8545%2802%2900087-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scholz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hey-Hawkins, E.</span></span> <span> </span><span class="NLM_article-title">Carbaboranes as pharmacophores: properties, synthesis, and application strategies</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">7035</span>– <span class="NLM_lpage">7062</span>, <span class="refDoi"> DOI: 10.1021/cr200038x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr200038x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptlSltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2011&pages=7035-7062&author=M.+Scholzauthor=E.+Hey-Hawkins&title=Carbaboranes+as+pharmacophores%3A+properties%2C+synthesis%2C+and+application+strategies&doi=10.1021%2Fcr200038x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Carbaboranes as Pharmacophores: Properties, Synthesis, and Application Strategies</span></div><div class="casAuthors">Scholz, Matthias; Hey-Hawkins, Evamarie</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">7035-7062</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Geometry and electronic structure make carbaboranes unique artificial pharmacophores that are inert to catabolism, because corresponding enzymes are not known.  Most frequently, carbaboranes are used as hydrophobic pharmacophores to address hydrophobic binding sites of biol. targets.  The icosahedral cluster with its very versatile chem. allows attachment of all org. substituents that are necessary in drug design in mostly high-yielding syntheses.  The orthogonality of the reactions at the carbonatoms to those at the boron atoms renders regioselective substitutions easily possible.  The extraordinary electronic structure makes the carbaboranes yet more than just scaffolds.  This is expressed byhydrogen and dihydrogen bonds with CH or BH vertices and by the influence on adjacent substituents.  The inductive effects at different cluster positions fine-tune adjacent functionalities, which is particularly useful to adjust a pharmacophoric entity to a biol. target.  The option to increase the size by modifying multiple boron vertices makes the cluster addnl. superior to classical org. fragments such as benzene and adamantane.  The deboronation reaction allows formation of charged cluster species and thus modification of the soly.  This option is very pronounced for ortho-carbaborane, which also clearly differs from the other two isomers in pharmacol. behavior and should therefore be regarded as functional group.  The carbaboranyl-Ph arrangement in general turned out to be a very good scaffold to address different targets by addn. of particular substituents.  All these aspects make carbaboranes unique and yet underrepresented pharmacophores, which will hopefully change in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqngRuxXCYl9LVg90H21EOLACvtfcHk0lixsLw37BsHww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptlSltb8%253D&md5=46592230e62a115fb669620da5540bab</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fcr200038x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr200038x%26sid%3Dliteratum%253Aachs%26aulast%3DScholz%26aufirst%3DM.%26aulast%3DHey-Hawkins%26aufirst%3DE.%26atitle%3DCarbaboranes%2520as%2520pharmacophores%253A%2520properties%252C%2520synthesis%252C%2520and%2520application%2520strategies%26jtitle%3DChem.%2520Rev.%26date%3D2011%26volume%3D111%26spage%3D7035%26epage%3D7062%26doi%3D10.1021%2Fcr200038x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieland, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittneben, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willim, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolf, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, G.</span></span> <span> </span><span class="NLM_article-title">Complete L-alanine scan of neuropeptide Y reveals ligands binding to Y1 and Y2 receptors with distinguished conformations</span>. <i>Eur. J. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>225</i></span>,  <span class="NLM_fpage">947</span>– <span class="NLM_lpage">958</span>, <span class="refDoi"> DOI: 10.1111/j.1432-1033.1994.0947b.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1111%2Fj.1432-1033.1994.0947b.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=7957231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADyaK2cXmsVKmtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=225&publication_year=1994&pages=947-958&author=A.+G.+Beck-Sickingerauthor=H.+A.+Wielandauthor=H.+Wittnebenauthor=K.+D.+Willimauthor=K.+Rudolfauthor=G.+Jung&title=Complete+L-alanine+scan+of+neuropeptide+Y+reveals+ligands+binding+to+Y1+and+Y2+receptors+with+distinguished+conformations&doi=10.1111%2Fj.1432-1033.1994.0947b.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Complete L-alanine scan of neuropeptide Y reveals ligands binding to Y1 and Y2 receptors with distinguished conformations</span></div><div class="casAuthors">Beck-Sickinger, Annette G.; Wieland, Heike A.; Wittneben, Helmut; Willim, Klaus-Dieter; Rudolf, Klaus; Jung, Guenther</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">225</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">947-58</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    </div><div class="casAbstract">The synthesis of more than fifty 36-residue oligopeptide analogs of neuropeptide Y (NPY) and their affinity to human Y1 and Y2 receptors is described.  Each amino acid of the natural sequence was replaced by L-alanine, the four alanine residues at position 12, 14, 18 and 23 were replaced by glycine.  Addnl. residues were exchanged to closely related ones to characterize the prerequisites for binding.  A combination of automated single and multiple peptide synthesis using fluoren-9-ylmethoxycarbonyl/tert-butoxy strategy was applied.  The purified peptides were characterized by electrospray mass spectrometry, anal. HPLC and amino acid anal.  Binding was investigated by displacement of 125I-labeled neuropeptide Y from human neuroblastoma cell lines SK-N-MC and SMS-KAN. PhenylalanineABS: whereas Pro2 and the integrity of the neuropeptide Y loop is important for the binding to the Y1 receptor, exchanges within the C-terminal helix affect the affinity to the Y2 receptor.  The C-terminal pentapeptide amide is important for both receptors and probably represents the binding site.  However, Arg33 and Arg35 may not be exchanged by L-alanine in the Y1 system, whereas Arg35 and Tyr36 are the most susceptible residues in the Y2 system.  To distinguish between conformational effects and direct hormone/receptor interaction via the side chains of neuropeptide Y, circular dichroic studies of the alanine-contg. peptides were performed and structure affinity relationships are discussed.  Comparing the affinities of the neuropeptide Y analogs to Y1 and Y2 receptors significant differences were found for the two binding sites, which suggests a different active conformation of neuropeptide Y at the two subtypes of receptors.  Using mol. dynamics calcns., two distinct conformations were identified which are in good agreement with the data obtained by structure/affinity investigations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCypHQPmEPgLVg90H21EOLACvtfcHk0lhv0cT_6ANyXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmsVKmtbk%253D&md5=617d86a9c13fdca96b2e38d87d94705d</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1111%2Fj.1432-1033.1994.0947b.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1432-1033.1994.0947b.x%26sid%3Dliteratum%253Aachs%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26aulast%3DWieland%26aufirst%3DH.%2BA.%26aulast%3DWittneben%26aufirst%3DH.%26aulast%3DWillim%26aufirst%3DK.%2BD.%26aulast%3DRudolf%26aufirst%3DK.%26aulast%3DJung%26aufirst%3DG.%26atitle%3DComplete%2520L-alanine%2520scan%2520of%2520neuropeptide%2520Y%2520reveals%2520ligands%2520binding%2520to%2520Y1%2520and%2520Y2%2520receptors%2520with%2520distinguished%2520conformations%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D1994%26volume%3D225%26spage%3D947%26epage%3D958%26doi%3D10.1111%2Fj.1432-1033.1994.0947b.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Svantesson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettersson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olin, Å.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markides, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjöberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallec, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shono, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toftlund, H.</span></span> <span> </span><span class="NLM_article-title">A kinetic study of the self-degradation of o-carboranylalanine to nido-carboranylalanine in solution</span>. <i>Acta Chem. Scand.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">731</span>– <span class="NLM_lpage">736</span>, <span class="refDoi"> DOI: 10.3891/acta.chem.scand.53-0731</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.3891%2Facta.chem.scand.53-0731" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADyaK1MXmtVaqt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1999&pages=731-736&author=E.+Svantessonauthor=J.+Petterssonauthor=%C3%85.+Olinauthor=K.+Markidesauthor=S.+Sj%C3%B6bergauthor=A.+Tallecauthor=T.+Shonoauthor=H.+Toftlund&title=A+kinetic+study+of+the+self-degradation+of+o-carboranylalanine+to+nido-carboranylalanine+in+solution&doi=10.3891%2Facta.chem.scand.53-0731"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">A kinetic study of the self-degradation of o-carboranylalanine to nido-carboranylalanine in solution</span></div><div class="casAuthors">Svantesson, Eva; Pettersson, Jean; Olin, Ake; Markides, Karin; Sjoberg, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Acta Chemica Scandinavica</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">731-736</span>CODEN:
                <span class="NLM_cas:coden">ACHSE7</span>;
        ISSN:<span class="NLM_cas:issn">0904-213X</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard International Publishers Ltd.</span>)
        </div><div class="casAbstract">The spontaneous degrdn. of racemic o-carboranylalanine [3-(1,2-dicarba-closo-dodecaboran(12)-1-yl)-2-aminopropanoic acid], a carborane analog of the amino acid phenylalanine, to the corresponding diastereomeric, racemic pairs of nido-carboranylalanine [contg. the dodecahydro-7,8-dicarba-nido-undecaborate(1-) cage] was studied in buffered water-MeOH soln. at three temps.  The parent compd. and the two diastereomeric reaction products were sepd. off-line by liq. chromatog.  The reaction is 1st order with respect to o-carboranylalanine.  The rate is pH dependent with a broad max. around pH 5, where the zwitterion form predominates.  Rate consts. and activation parameters for the formation of the two nido-compds. were detd.  The activation entropies close to zero (0 and 3 J K-1 mol-1, resp.) show that the loss of one B atom from o-carboranylalanine is a unimol. process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot9g5Jr-ONhbVg90H21EOLACvtfcHk0lhv0cT_6ANyXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmtVaqt7Y%253D&md5=749ca5620e7c62e9459e6db0f2b5bc54</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.3891%2Facta.chem.scand.53-0731&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3891%252Facta.chem.scand.53-0731%26sid%3Dliteratum%253Aachs%26aulast%3DSvantesson%26aufirst%3DE.%26aulast%3DPettersson%26aufirst%3DJ.%26aulast%3DOlin%26aufirst%3D%25C3%2585.%26aulast%3DMarkides%26aufirst%3DK.%26aulast%3DSj%25C3%25B6berg%26aufirst%3DS.%26aulast%3DTallec%26aufirst%3DA.%26aulast%3DShono%26aufirst%3DT.%26aulast%3DToftlund%26aufirst%3DH.%26atitle%3DA%2520kinetic%2520study%2520of%2520the%2520self-degradation%2520of%2520o-carboranylalanine%2520to%2520nido-carboranylalanine%2520in%2520solution%26jtitle%3DActa%2520Chem.%2520Scand.%26date%3D1999%26volume%3D53%26spage%3D731%26epage%3D736%26doi%3D10.3891%2Facta.chem.scand.53-0731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Azev, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slepukhina, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabel, D.</span></span> <span> </span><span class="NLM_article-title">Synthesis of boron-containing heterocyclic compounds</span>. <i>Appl. Radiat. Isot.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1107</span>– <span class="NLM_lpage">1110</span>, <span class="refDoi"> DOI: 10.1016/j.apradiso.2004.05.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1016%2Fj.apradiso.2004.05.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=15308200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD2cXms1yhur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2004&pages=1107-1110&author=Y.+Azevauthor=I.+Slepukhinaauthor=D.+Gabel&title=Synthesis+of+boron-containing+heterocyclic+compounds&doi=10.1016%2Fj.apradiso.2004.05.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of boron-containing heterocyclic compounds</span></div><div class="casAuthors">Azev, Yuri; Slepukhina, Irina; Gabel, Detlef</div><div class="citationInfo"><span class="NLM_cas:title">Applied Radiation and Isotopes</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1107-1110</span>CODEN:
                <span class="NLM_cas:coden">ARISEF</span>;
        ISSN:<span class="NLM_cas:issn">0969-8043</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The synthesis of B-contg. 1,3,5-triazines and 1,2,4-triazines is described.  Derivs. of 1,3,5-triazine contg. the o-carborane cluster were obtained by reacting the corresponding propargyl derivs. with B10H14.  Derivs. of 1,2,4-triazine contg. the B12H122- cluster were obtained by nucleophilic substitution of alkylsulfone derivs. with B12H11SH2-.  They were isolated in their ring-protonated form.  Reaction of RNH2-B8H11NH-R with sterically demanding heterocycles failed, either for steric or for soly. reasons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMcG86aY1aArVg90H21EOLACvtfcHk0lhv0cT_6ANyXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXms1yhur8%253D&md5=b60a4fa42a4bab37ec9e388dac1c8050</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.apradiso.2004.05.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apradiso.2004.05.002%26sid%3Dliteratum%253Aachs%26aulast%3DAzev%26aufirst%3DY.%26aulast%3DSlepukhina%26aufirst%3DI.%26aulast%3DGabel%26aufirst%3DD.%26atitle%3DSynthesis%2520of%2520boron-containing%2520heterocyclic%2520compounds%26jtitle%3DAppl.%2520Radiat.%2520Isot.%26date%3D2004%26volume%3D61%26spage%3D1107%26epage%3D1110%26doi%3D10.1016%2Fj.apradiso.2004.05.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.-D.</span></span> <span> </span><span class="NLM_article-title">Synthesis and characterization of o-carboranylthiolate substituted 1,3,5-triazines</span>. <i>Bull. Korean Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">697</span>– <span class="NLM_lpage">700</span>, <span class="refDoi"> DOI: 10.5012/bkcs.2008.29.3.697</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.5012%2Fbkcs.2008.29.3.697" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlt1Ois74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2008&pages=697-700&author=C.-H.+Leeauthor=G.+F.+Jinauthor=H.-S.+Kimauthor=H.+Nakamuraauthor=J.-D.+Lee&title=Synthesis+and+characterization+of+o-carboranylthiolate+substituted+1%2C3%2C5-triazines&doi=10.5012%2Fbkcs.2008.29.3.697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and characterization of o-carboranylthiolate substituted 1,3,5-triazines</span></div><div class="casAuthors">Lee, Chai-Ho; Jin, Guo Fan; Kim, Hyo-Suk; Nakamura, Hiroyuki; Lee, Jong-Dae</div><div class="citationInfo"><span class="NLM_cas:title">Bulletin of the Korean Chemical Society</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">697-700</span>CODEN:
                <span class="NLM_cas:coden">BKCSDE</span>;
        ISSN:<span class="NLM_cas:issn">0253-2964</span>.
    
            (<span class="NLM_cas:orgname">Korean Chemical Society</span>)
        </div><div class="casAbstract">Ortho-carboranyl 1,3,5-triazin-2-yl thioethers were prepd. from appropriate Li thiolates and chlorotriazines.  The products are moderately stable in air and decomp. slowly on contact with light and moisture.  Unexpectedly, toxicity was not improved, but boron uptake in B-16 melanoma cells increased.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCH4WeCcw_IbVg90H21EOLACvtfcHk0li_dqBcPzR0DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlt1Ois74%253D&md5=babd13772edafbb38cd676e4bb7eb8e0</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.5012%2Fbkcs.2008.29.3.697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5012%252Fbkcs.2008.29.3.697%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.-H.%26aulast%3DJin%26aufirst%3DG.%2BF.%26aulast%3DKim%26aufirst%3DH.-S.%26aulast%3DNakamura%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DJ.-D.%26atitle%3DSynthesis%2520and%2520characterization%2520of%2520o-carboranylthiolate%2520substituted%25201%252C3%252C5-triazines%26jtitle%3DBull.%2520Korean%2520Chem.%2520Soc.%26date%3D2008%26volume%3D29%26spage%3D697%26epage%3D700%26doi%3D10.5012%2Fbkcs.2008.29.3.697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockwell, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knobler, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawthorne, M. F.</span></span> <span> </span><span class="NLM_article-title">Synthesis and characterization of water-soluble boron-substituted ortho-carborane derivatives</span>. <i>C. R. Acad. Sci., Ser. IIc: Chim.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">223</span>– <span class="NLM_lpage">229</span>, <span class="refDoi"> DOI: 10.1016/S1387-1609(00)00132-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1016%2FS1387-1609%2800%2900132-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlvFOqsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2000&pages=223-229&author=W.+Chenauthor=M.+Diazauthor=J.+J.+Rockwellauthor=C.+B.+Knoblerauthor=M.+F.+Hawthorne&title=Synthesis+and+characterization+of+water-soluble+boron-substituted+ortho-carborane+derivatives&doi=10.1016%2FS1387-1609%2800%2900132-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and characterization of water-soluble boron-substituted ortho-carborane derivatives</span></div><div class="casAuthors">Chen, Weilin; Diaz, Martin; Rockwell, Juston J.; Knobler, Carolyn B.; Hawthorne, M. Frederick</div><div class="citationInfo"><span class="NLM_cas:title">Comptes Rendus de l'Academie des Sciences, Serie IIc: Chimie</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">223-229</span>CODEN:
                <span class="NLM_cas:coden">CASCFN</span>;
        ISSN:<span class="NLM_cas:issn">1387-1609</span>.
    
            (<span class="NLM_cas:orgname">Editions Scientifiques et Medicales Elsevier</span>)
        </div><div class="casAbstract">The synthesis of water-sol., boron-substituted carborane derivs. was achieved by treatment of boron-substituted bromoalkyl carborane derivs. with trimethylphosphine to yield the corresponding phosphonium salts.  These new carborane salts exhibit soly. in both aq. and polar org. media.  The synthesis and characterization of the first water-sol., boron-substituted carborane species, closo-9,12-(CH2CH2CH2P(CH3)3+Br-)2-1,2-C2B10H10, 4, and closo-3-[CH2CH2CH2P(CH3)3+B r-]-1,2-C2B10H11, 5 is reported.  The crystal structure of 5 is reported.  Addnl., another method of prepg. mono- and difunctionalized water-sol. phosphonium salts of B3-substituted carborane derivs. was developed.  This method produces both the monophosphonium salt, closo-3-[CH2CH(CH2I)CH2P(CH3)3+ I-]-1,2-C2B10H11 and the diphosphonium salt, closo-3-[CH2CH(CH2P(CH3)3+I-)2]-1,2-C2B10H11.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlQBRd4fWiobVg90H21EOLACvtfcHk0li_dqBcPzR0DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlvFOqsbg%253D&md5=f94414345d6496a2326937c8848e06c1</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2FS1387-1609%2800%2900132-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1387-1609%252800%252900132-8%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DW.%26aulast%3DDiaz%26aufirst%3DM.%26aulast%3DRockwell%26aufirst%3DJ.%2BJ.%26aulast%3DKnobler%26aufirst%3DC.%2BB.%26aulast%3DHawthorne%26aufirst%3DM.%2BF.%26atitle%3DSynthesis%2520and%2520characterization%2520of%2520water-soluble%2520boron-substituted%2520ortho-carborane%2520derivatives%26jtitle%3DC.%2520R.%2520Acad.%2520Sci.%252C%2520Ser.%2520IIc%253A%2520Chim.%26date%3D2000%26volume%3D3%26spage%3D223%26epage%3D229%26doi%3D10.1016%2FS1387-1609%2800%2900132-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nemoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, Y.</span></span> <span> </span><span class="NLM_article-title">Polyols of a cascade type as a water-solubilizing element of carborane derivatives for boron neutron capture therapy</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">435</span>– <span class="NLM_lpage">435</span>, <span class="refDoi"> DOI: 10.1021/jo00028a010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00028a010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADyaK38XktVylsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1992&pages=435-435&author=H.+Nemotoauthor=J.+G.+Wilsonauthor=H.+Nakamuraauthor=Y.+Yamamoto&title=Polyols+of+a+cascade+type+as+a+water-solubilizing+element+of+carborane+derivatives+for+boron+neutron+capture+therapy&doi=10.1021%2Fjo00028a010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Polyols of a cascade type as a water-solubilizing element of carborane derivatives for boron neutron capture therapy</span></div><div class="casAuthors">Nemoto, Hisao; Wilson, J. Gerald; Nakamura, Hiroyuki; Yamamoto, Yoshinori</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">435</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">The reaction of epichlorohydrin with benzyl alc. in the presence of Bu4NI, KOH, and water gave 88% 1,3-dibenzyloxy-2-propanol.  The reaction of this alc. with epichlorohydrin under the same conditions produced 88% 1,3-bis[2-(1,3-dibenzylglyceryl]glycerol (I).  Debenzylation of I in the presence of Pd(OH)2 gave the corresponding tetraol (II).  Accordingly, the repeated use of this reaction sequence affords polyols of a cascade type in high yield.  A carborane attached to tetraol (II) was dissolved in water in a concn. of 5.44 M.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpomkj-CROvrbVg90H21EOLACvtfcHk0li_dqBcPzR0DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XktVylsQ%253D%253D&md5=ebaa346621d961409a73b79f1da8a391</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjo00028a010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00028a010%26sid%3Dliteratum%253Aachs%26aulast%3DNemoto%26aufirst%3DH.%26aulast%3DWilson%26aufirst%3DJ.%2BG.%26aulast%3DNakamura%26aufirst%3DH.%26aulast%3DYamamoto%26aufirst%3DY.%26atitle%3DPolyols%2520of%2520a%2520cascade%2520type%2520as%2520a%2520water-solubilizing%2520element%2520of%2520carborane%2520derivatives%2520for%2520boron%2520neutron%2520capture%2520therapy%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1992%26volume%3D57%26spage%3D435%26epage%3D435%26doi%3D10.1021%2Fjo00028a010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serino, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawthorne, M. F.</span></span> <span> </span><span class="NLM_article-title">Hydrophilically augmented glycosyl carborane derivatives for incorporation in antibody conjugation reagents</span>. <i>Organometallics</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2519</span>– <span class="NLM_lpage">2524</span>, <span class="refDoi"> DOI: 10.1021/om00102a015</span> </span><div class="citationLinks">[<a href="/doi/10.1021/om00102a015" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADyaL1cXmtlWnsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1988&pages=2519-2524&author=J.+L.+Maurerauthor=A.+J.+Serinoauthor=M.+F.+Hawthorne&title=Hydrophilically+augmented+glycosyl+carborane+derivatives+for+incorporation+in+antibody+conjugation+reagents&doi=10.1021%2Fom00102a015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Hydrophilically augmented glycosyl carborane derivatives for incorporation in antibody conjugation reagents</span></div><div class="casAuthors">Maurer, Julie L.; Serino, Anthony J.; Hawthrone, M. Frederick</div><div class="citationInfo"><span class="NLM_cas:title">Organometallics</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2519-24</span>CODEN:
                <span class="NLM_cas:coden">ORGND7</span>;
        ISSN:<span class="NLM_cas:issn">0276-7333</span>.
    </div><div class="casAbstract">The synthesis of a series of O-glycosyl carboranes is described.  The reactions of hydroxyalkyl carboranes and esterified carbohydrates, in the presence of a Lesis acid catalyst, proved to be stereoselective.  Reactions of these carboranes with tri-O-acetyl-D-glucal or di-O-acetyl-D-xylal and a catalytic amt. of BF3.OEt2 favored the formation of α anomers, while the β anomer was the major product of the SnCl4-catalyzed reaction involving hydroxymethyl carborane and 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose.  The 1H and 13C NMR spectra of 1-[(4,6-di-O-acetyl-2,3-dideoxy-α-D-erythro-hex-2-enopyranosyl)methyl]-1,2-dicarba-closo-dodecaborane (I) were analyzed by using several one-dimensional and two-dimensional techniques; the chem. shifts and coupling interactions of all atoms were unequivocally assigned.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdlArPJCvjobVg90H21EOLACvtfcHk0li_dqBcPzR0DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXmtlWnsrc%253D&md5=1ccbf34904faf2e5242aeb45befb64fc</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fom00102a015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fom00102a015%26sid%3Dliteratum%253Aachs%26aulast%3DMaurer%26aufirst%3DJ.%2BL.%26aulast%3DSerino%26aufirst%3DA.%2BJ.%26aulast%3DHawthorne%26aufirst%3DM.%2BF.%26atitle%3DHydrophilically%2520augmented%2520glycosyl%2520carborane%2520derivatives%2520for%2520incorporation%2520in%2520antibody%2520conjugation%2520reagents%26jtitle%3DOrganometallics%26date%3D1988%26volume%3D7%26spage%3D2519%26epage%3D2524%26doi%3D10.1021%2Fom00102a015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tietze, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bothe, U.</span></span> <span> </span><span class="NLM_article-title">Ortho-carboranyl glycosides of glucose, mannose, maltose and lactose for cancer treatment by boron neutron-capture therapy</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1179</span>– <span class="NLM_lpage">1183</span>, <span class="refDoi"> DOI: 10.1002/(SICI)1521-3765(19980710)4:7<1179::AID-CHEM1179>3.0.CO;2-F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1002%2F%28SICI%291521-3765%2819980710%294%3A7%3C1179%3A%3AAID-CHEM1179%3E3.0.CO%3B2-F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADyaK1cXkvVamu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1998&pages=1179-1183&author=L.+F.+Tietzeauthor=U.+Bothe&title=Ortho-carboranyl+glycosides+of+glucose%2C+mannose%2C+maltose+and+lactose+for+cancer+treatment+by+boron+neutron-capture+therapy&doi=10.1002%2F%28SICI%291521-3765%2819980710%294%3A7%3C1179%3A%3AAID-CHEM1179%3E3.0.CO%3B2-F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Ortho-carboranyl glycosides of glucose, mannose, maltose and lactose for cancer treatment by boron neutron-capture therapy</span></div><div class="casAuthors">Tietze, Lutz F.; Bothe, Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1179-1183</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH</span>)
        </div><div class="casAbstract">Glycosidation of alkynols HO (CH2)n C≡CH using the trichloroacetimidate method led to the alkynyl glycosides (I; R = Ac, R1 = CH2C≡CH), I [R = Ac, (CH2)4C≡CH], (II; R = Ac, R1 = CH2CH2C≡CH), (III; R = Ac, R1 = CH2C≡CH), and IV (R = Ac, R1 = CH2C≡CH) in 53-68% yield, which by reaction with decaborane (B10H14) afforded the protected peracetylated ortho-carboranyl glycosides I (R = Ac, R1 = Q, n = 2), I (R = Ac, R1 = Q1, n = 4), II (R = Ac, R1 = Q, n = 2), III (R = Ac, R1 = Q, n = 1), and IV (R = Ac, R1 = Q, n = 1) in 43-61% yield.  Base-catalyzed solvolysis gave the unprotected glycosides I (R = H, R1 = Q, n = 2), I (R = H, R1 = Q1, n = 4), II (R = H, R1 = Q, n = 2), III (R = H, R1 = Q, n = 1), and IV (R = H, R1 = Q, n = 1) in 71-97% yield.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQvmRlCEiIV7Vg90H21EOLACvtfcHk0lhZ6i_lQMReCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXkvVamu70%253D&md5=b08ed4f66379a95fe43ecac22df77f0e</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291521-3765%2819980710%294%3A7%3C1179%3A%3AAID-CHEM1179%3E3.0.CO%3B2-F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291521-3765%252819980710%25294%253A7%253C1179%253A%253AAID-CHEM1179%253E3.0.CO%253B2-F%26sid%3Dliteratum%253Aachs%26aulast%3DTietze%26aufirst%3DL.%2BF.%26aulast%3DBothe%26aufirst%3DU.%26atitle%3DOrtho-carboranyl%2520glycosides%2520of%2520glucose%252C%2520mannose%252C%2520maltose%2520and%2520lactose%2520for%2520cancer%2520treatment%2520by%2520boron%2520neutron-capture%2520therapy%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D1998%26volume%3D4%26spage%3D1179%26epage%3D1183%26doi%3D10.1002%2F%28SICI%291521-3765%2819980710%294%3A7%3C1179%3A%3AAID-CHEM1179%3E3.0.CO%3B2-F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frank, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hey-Hawkins, E.</span></span> <span> </span><span class="NLM_article-title">A convenient route towards deoxygalactosyl-functionalised <i>ortho</i>-carbaborane</span>. <i>J. Organomet. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>798</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1016/j.jorganchem.2015.08.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1016%2Fj.jorganchem.2015.08.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCnu7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=798&publication_year=2015&pages=46-50&author=R.+Frankauthor=E.+Hey-Hawkins&title=A+convenient+route+towards+deoxygalactosyl-functionalised+ortho-carbaborane&doi=10.1016%2Fj.jorganchem.2015.08.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">A convenient route towards deoxygalactosyl-functionalised ortho-carbaborane: Synthesis of a building block for peptide conjugation</span></div><div class="casAuthors">Frank, Rene; Hey-Hawkins, Evamarie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organometallic Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">798</span>
        (<span class="NLM_cas:issue">Part_1</span>),
    <span class="NLM_cas:pages">46-50</span>CODEN:
                <span class="NLM_cas:coden">JORCAI</span>;
        ISSN:<span class="NLM_cas:issn">0022-328X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In the treatment of cancer, boron neutron capture therapy (BNCT) is a mild and promising alternative to established harsh therapeutic methods such as chemo- and radiation therapy.  However, successful BNCT procedures strongly depend on efficient, tumor-selective boron-delivery systems, and recently we have demonstrated that the breast tumor-selective peptide [F7,P34]-NPY is a promising boron-shuttle system after conjugation with three ortho-carbaborane clusters (1,2-closo-C2B10H10).  The extreme hydrophobicity of the latter, however, causes problems in medicinal applications in vivo.  Therefore, we have elaborated a synthetic protocol towards a deoxygalactosyl-modified (and thus more hydrophilic) building block that can readily be conjugated with the shuttle peptide.  A key intermediate, i.e., ortho-carbaborane functionalised with a bis-isopropylidene-protected deoxygalactosyl moiety, was synthesized by both a silyl protection strategy (which is generally recommended for monosubstitution) and direct reaction of metalated ortho-carbaborane in acceptable yield.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOwwzC6b-GD7Vg90H21EOLACvtfcHk0lhZ6i_lQMReCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCnu7jP&md5=4d73743345c43564c7c4703e2c8ea7ad</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.jorganchem.2015.08.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jorganchem.2015.08.011%26sid%3Dliteratum%253Aachs%26aulast%3DFrank%26aufirst%3DR.%26aulast%3DHey-Hawkins%26aufirst%3DE.%26atitle%3DA%2520convenient%2520route%2520towards%2520deoxygalactosyl-functionalised%2520ortho-carbaborane%26jtitle%3DJ.%2520Organomet.%2520Chem.%26date%3D2015%26volume%3D798%26spage%3D46%26epage%3D50%26doi%3D10.1016%2Fj.jorganchem.2015.08.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frank, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahrens, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehnke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hey-Hawkins, E.</span></span> <span> </span><span class="NLM_article-title">Charge-compensated metallacarborane building blocks for conjugation with peptides</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">308</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1002/cbic.201500569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1002%2Fcbic.201500569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=26662708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BC28Xoslaluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=308-317&author=R.+Frankauthor=V.+M.+Ahrensauthor=S.+Boehnkeauthor=A.+G.+Beck-Sickingerauthor=E.+Hey-Hawkins&title=Charge-compensated+metallacarborane+building+blocks+for+conjugation+with+peptides&doi=10.1002%2Fcbic.201500569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Charge-Compensated Metallacarborane Building Blocks for Conjugation with Peptides</span></div><div class="casAuthors">Frank, Rene; Ahrens, Verena M.; Boehnke, Solveig; Beck-Sickinger, Annette G.; Hey-Hawkins, Evamarie</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">308-317</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The cobalt bis(dicarbollide) complex [commo-3,3'-Co(1,2-C2B9H11)2]- has captured much attention in biochem. and medical contexts, in particular for the treatment of tumors by boron neutron capture therapy (BNCT).  Derivs. of cobalt bis(dicarbollide) are commonly prepd. through ring-opening reactions of cyclic oxonium ions, so the corresponding products are usually charged.  Furthermore, attempts to incorporate cobalt bis(dicarbollide) into peptides are rare, despite obvious potential advantages.  Here the synthesis of an imidazolium-based charge-compensated cobalt bis(dicarbollide) building block, which allows addnl. modifications with moieties of biochem. relevance, such as monosaccharides, is reported.  Furthermore, conjugates of these building blocks with the Y1-receptor-selective deriv. of neuropeptide Y ([F7,P34]-NPY) retained excellent response to hY1 receptors found to be overexpressed in breast tumors and metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_KAeTOOESOrVg90H21EOLACvtfcHk0lhZ6i_lQMReCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xoslaluw%253D%253D&md5=40a3b207f40db23164ae8bdc9e7c37ea</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201500569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201500569%26sid%3Dliteratum%253Aachs%26aulast%3DFrank%26aufirst%3DR.%26aulast%3DAhrens%26aufirst%3DV.%2BM.%26aulast%3DBoehnke%26aufirst%3DS.%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26aulast%3DHey-Hawkins%26aufirst%3DE.%26atitle%3DCharge-compensated%2520metallacarborane%2520building%2520blocks%2520for%2520conjugation%2520with%2520peptides%26jtitle%3DChemBioChem%26date%3D2016%26volume%3D17%26spage%3D308%26epage%3D317%26doi%3D10.1002%2Fcbic.201500569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kögler, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wifling, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernhardt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plank, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Littmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larhammar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huster, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meiler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buschauer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span> <span> </span><span class="NLM_article-title">Structural basis of ligand binding modes at the neuropeptide Y Y1 receptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>556</i></span>,  <span class="NLM_fpage">520</span>– <span class="NLM_lpage">524</span>, <span class="refDoi"> DOI: 10.1038/s41586-018-0046-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1038%2Fs41586-018-0046-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=29670288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosVCgur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=556&publication_year=2018&pages=520-524&author=Z.+Yangauthor=S.+Hanauthor=M.+Kellerauthor=A.+Kaiserauthor=B.+J.+Benderauthor=M.+Bosseauthor=K.+Burkertauthor=L.+M.+K%C3%B6glerauthor=D.+Wiflingauthor=G.+Bernhardtauthor=N.+Plankauthor=T.+Littmannauthor=P.+Schmidtauthor=C.+Yiauthor=B.+Liauthor=S.+Yeauthor=R.+Zhangauthor=B.+Xuauthor=D.+Larhammarauthor=R.+C.+Stevensauthor=D.+Husterauthor=J.+Meilerauthor=Q.+Zhaoauthor=A.+G.+Beck-Sickingerauthor=A.+Buschauerauthor=B.+Wu&title=Structural+basis+of+ligand+binding+modes+at+the+neuropeptide+Y+Y1+receptor&doi=10.1038%2Fs41586-018-0046-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of ligand binding modes at the neuropeptide Y Y1 receptor</span></div><div class="casAuthors">Yang, Zhenlin; Han, Shuo; Keller, Max; Kaiser, Anette; Bender, Brian J.; Bosse, Mathias; Burkert, Kerstin; Kogler, Lisa M.; Wifling, David; Bernhardt, Guenther; Plank, Nicole; Littmann, Timo; Schmidt, Peter; Yi, Cuiying; Li, Beibei; Ye, Sheng; Zhang, Rongguang; Xu, Bo; Larhammar, Dan; Stevens, Raymond C.; Huster, Daniel; Meiler, Jens; Zhao, Qiang; Beck-Sickinger, Annette G.; Buschauer, Armin; Wu, Beili</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">556</span>
        (<span class="NLM_cas:issue">7702</span>),
    <span class="NLM_cas:pages">520-524</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Neuropeptide Y (NPY) receptors belong to the G-protein-coupled receptor superfamily and have important roles in food intake, anxiety and cancer biol.1,2.  The NPY-Y receptor system has emerged as one of the most complex networks with three peptide ligands (NPY, peptide YY and pancreatic polypeptide) binding to four receptors in most mammals, namely the Y1, Y2, Y4 and Y5 receptors, with different affinity and selectivity3.  NPY is the most powerful stimulant of food intake and this effect is primarily mediated by the Y1 receptor (Y1R)4.  A no. of peptides and small-mol. compds. have been characterized as Y1R antagonists and have shown clin. potential in the treatment of obesity4, tumor1 and bone loss5.  However, their clin. usage has been hampered by low potency and selectivity, poor brain penetration ability or lack of oral bioavailability6.  Here we report crystal structures of the human Y1R bound to the two selective antagonists UR-MK299 and BMS-193885 at 2.7 and 3.0 Å resoln., resp.  The structures combined with mutagenesis studies reveal the binding modes of Y1R to several structurally diverse antagonists and the determinants of ligand selectivity.  The Y1R structure and mol. docking of the endogenous agonist NPY, together with NMR, photo-crosslinking and functional studies, provide insights into the binding behavior of the agonist and for the first time, to our knowledge, det. the interaction of its N terminus with the receptor.  These insights into Y1R can enable structure-based drug discovery that targets NPY receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr584bBD3wdnbVg90H21EOLACvtfcHk0lgEY0UajD_cIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosVCgur8%253D&md5=79289fb85d5f65b94fbf873ec4ea31f3</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fs41586-018-0046-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-018-0046-x%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DKeller%26aufirst%3DM.%26aulast%3DKaiser%26aufirst%3DA.%26aulast%3DBender%26aufirst%3DB.%2BJ.%26aulast%3DBosse%26aufirst%3DM.%26aulast%3DBurkert%26aufirst%3DK.%26aulast%3DK%25C3%25B6gler%26aufirst%3DL.%2BM.%26aulast%3DWifling%26aufirst%3DD.%26aulast%3DBernhardt%26aufirst%3DG.%26aulast%3DPlank%26aufirst%3DN.%26aulast%3DLittmann%26aufirst%3DT.%26aulast%3DSchmidt%26aufirst%3DP.%26aulast%3DYi%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DYe%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DLarhammar%26aufirst%3DD.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DHuster%26aufirst%3DD.%26aulast%3DMeiler%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26aulast%3DBuschauer%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DB.%26atitle%3DStructural%2520basis%2520of%2520ligand%2520binding%2520modes%2520at%2520the%2520neuropeptide%2520Y%2520Y1%2520receptor%26jtitle%3DNature%26date%3D2018%26volume%3D556%26spage%3D520%26epage%3D524%26doi%3D10.1038%2Fs41586-018-0046-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zellmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheidt, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meiler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huster, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, P.</span></span> <span> </span><span class="NLM_article-title">Unwinding of the C-terminal residues of neuropeptide Y is critical for Y<sub>2</sub> receptor binding and activation</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7446</span>– <span class="NLM_lpage">7449</span>, <span class="refDoi"> DOI: 10.1002/anie.201411688</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1002%2Fanie.201411688" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnsFCmtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=7446-7449&author=A.+Kaiserauthor=P.+M%C3%BCllerauthor=T.+Zellmannauthor=H.+A.+Scheidtauthor=L.+Thomasauthor=M.+Bosseauthor=R.+Meierauthor=J.+Meilerauthor=D.+Husterauthor=A.+G.+Beck-Sickingerauthor=P.+Schmidt&title=Unwinding+of+the+C-terminal+residues+of+neuropeptide+Y+is+critical+for+Y2+receptor+binding+and+activation&doi=10.1002%2Fanie.201411688"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Unwinding of the C-Terminal Residues of Neuropeptide Y is critical for Y2 Receptor Binding and Activation</span></div><div class="casAuthors">Kaiser, Anette; Mueller, Paul; Zellmann, Tristan; Scheidt, Holger A.; Thomas, Lars; Bosse, Mathias; Meier, Rene; Meiler, Jens; Huster, Daniel; Beck-Sickinger, Annette G.; Schmidt, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">7446-7449</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Despite recent breakthroughs in the structural characterization of G-protein-coupled receptors (GPCRs), there is only sparse data on how GPCRs recognize larger peptide ligands.  NMR spectroscopy, mol. modeling, and double-cycle mutagenesis studies were integrated to obtain a structural model of the peptide hormone neuropeptide Y (NPY) bound to its human G-protein-coupled Y2 receptor (Y2R).  Solid-state NMR measurements of specific isotope-labeled NPY in complex with in vitro folded Y2R reconstituted into phospholipid bicelles provided the bioactive structure of the peptide.  Guided by soln. NMR expts., it could be shown that the ligand is tethered to the second extracellular loop by hydrophobic contacts.  The C-terminal α-helix of NPY, which is formed in a membrane environment in the absence of the receptor, is unwound starting at T32 to provide optimal contacts in a deep binding pocket within the transmembrane bundle of the Y2R.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLkPseIiGmvrVg90H21EOLACvtfcHk0lgEY0UajD_cIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnsFCmtrY%253D&md5=327c142cca18a18959057f45dc3b2f96</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1002%2Fanie.201411688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201411688%26sid%3Dliteratum%253Aachs%26aulast%3DKaiser%26aufirst%3DA.%26aulast%3DM%25C3%25BCller%26aufirst%3DP.%26aulast%3DZellmann%26aufirst%3DT.%26aulast%3DScheidt%26aufirst%3DH.%2BA.%26aulast%3DThomas%26aufirst%3DL.%26aulast%3DBosse%26aufirst%3DM.%26aulast%3DMeier%26aufirst%3DR.%26aulast%3DMeiler%26aufirst%3DJ.%26aulast%3DHuster%26aufirst%3DD.%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26aulast%3DSchmidt%26aufirst%3DP.%26atitle%3DUnwinding%2520of%2520the%2520C-terminal%2520residues%2520of%2520neuropeptide%2520Y%2520is%2520critical%2520for%2520Y2%2520receptor%2520binding%2520and%2520activation%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D7446%26epage%3D7449%26doi%3D10.1002%2Fanie.201411688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moradi, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussein, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varamini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simerska, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toth, I.</span></span> <span> </span><span class="NLM_article-title">Glycosylation, an effective synthetic strategy to improve the bioavailability of therapeutic peptides</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2492</span>– <span class="NLM_lpage">2500</span>, <span class="refDoi"> DOI: 10.1039/C5SC04392A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1039%2FC5SC04392A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=28660018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1Krsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=2492-2500&author=S.+V.+Moradiauthor=W.+M.+Husseinauthor=P.+Varaminiauthor=P.+Simerskaauthor=I.+Toth&title=Glycosylation%2C+an+effective+synthetic+strategy+to+improve+the+bioavailability+of+therapeutic+peptides&doi=10.1039%2FC5SC04392A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Glycosylation, an effective synthetic strategy to improve the bioavailability of therapeutic peptides</span></div><div class="casAuthors">Moradi, Shayli Varasteh; Hussein, Waleed M.; Varamini, Pegah; Simerska, Pavla; Toth, Istvan</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2492-2500</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Glycosylation of peptides is a promising strategy for modulating the physicochem. properties of peptide drugs and for improving their absorption through biol. membranes.  This review highlights various methods for the synthesis of glycoconjugates and recent progress in the development of glycosylated peptide therapeutics.  Furthermore, the impacts of glycosylation in overcoming the existing barriers that restrict oral and brain delivery of peptides are described herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3OH1jtMuZibVg90H21EOLACvtfcHk0lgEY0UajD_cIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1Krsb0%253D&md5=4b48b4aaf751cfc2dda015123aa3aad3</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1039%2FC5SC04392A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5SC04392A%26sid%3Dliteratum%253Aachs%26aulast%3DMoradi%26aufirst%3DS.%2BV.%26aulast%3DHussein%26aufirst%3DW.%2BM.%26aulast%3DVaramini%26aufirst%3DP.%26aulast%3DSimerska%26aufirst%3DP.%26aulast%3DToth%26aufirst%3DI.%26atitle%3DGlycosylation%252C%2520an%2520effective%2520synthetic%2520strategy%2520to%2520improve%2520the%2520bioavailability%2520of%2520therapeutic%2520peptides%26jtitle%3DChem.%2520Sci.%26date%3D2016%26volume%3D7%26spage%3D2492%26epage%3D2500%26doi%3D10.1039%2FC5SC04392A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Capala, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendayan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauzon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soloway, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenstermaker, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlsson, J.</span></span> <span> </span><span class="NLM_article-title">Boronated epidermal growth factor as a potential targeting agent for boron neutron capture therapy of brain tumors</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1021/bc950077q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc950077q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADyaK28XivVartA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1996&pages=7-15&author=J.+Capalaauthor=R.+F.+Barthauthor=M.+Bendayanauthor=M.+Lauzonauthor=D.+M.+Adamsauthor=A.+H.+Solowayauthor=R.+A.+Fenstermakerauthor=J.+Carlsson&title=Boronated+epidermal+growth+factor+as+a+potential+targeting+agent+for+boron+neutron+capture+therapy+of+brain+tumors&doi=10.1021%2Fbc950077q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Boronated Epidermal Growth Factor as a Potential Targeting Agent for Boron Neutron Capture Therapy of Brain Tumors</span></div><div class="casAuthors">Capala, Jacek; Barth, Rolf F.; Bendayan, Moise; Lauzon, Michel; Adams, Dianne M.; Soloway, Albert H.; Fenstermaker, Robert A.; Carlsson, Jorgen</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-15</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">For boron neutron capture therapy (BNCT) to be successful, a large no. (∼109) of 10B atoms must be delivered to each cancer cell to sustain a lethal 10B(n, α)7Li reaction.  The majority of high grade gliomas express an amplified epidermal growth factor receptor (EGFR) gene, and increased nos. of EGFR are found on the cell surface.  If a sufficiently large no. of 10B atoms could be attached to EGF, the resulting bioconjugates might be useful for targeting brain tumors.  To accomplish this, we have boronated a fourth-generation starburst dendrimer (SD) using an isocyanato polyhedral borane, Na(CH3)3NB10H8NCO.  For conjugation, reactive thiol groups were introduced into the boronated SD using N-succinimidyl 3-(2-pyridyldithio)propionate (SPDP), and EGF was derivatized with m-maleimidobenzoyl-N-hydroxysulfosuccinimide ester (sMBS).  Subsequent reaction of thiol groups of derivatized BSD with maleimide groups of derivatized EGF produced stable BSD-EGF bioconjugates contg. ∼960 atoms of boron per mol. of EGF with KA of 8.55 × 107 M-1 compared to 9.1 × 108 M-1 for native EGF.  As detd. by electron spectroscopic imaging, the BSD-EGF initially was bound to the cell surface membrane and then was endocytosed, which resulted in accumulation of boron in lysosomes.  The favorable in vitro properties of these bioconjugates suggest that they may be useful for the in vivo targeting of EGFR pos. brain tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGri6nQyYtW3mrVg90H21EOLACvtfcHk0lhz3BqhKerpbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XivVartA%253D%253D&md5=664262af1d849d8580bc006070a05812</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fbc950077q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc950077q%26sid%3Dliteratum%253Aachs%26aulast%3DCapala%26aufirst%3DJ.%26aulast%3DBarth%26aufirst%3DR.%2BF.%26aulast%3DBendayan%26aufirst%3DM.%26aulast%3DLauzon%26aufirst%3DM.%26aulast%3DAdams%26aufirst%3DD.%2BM.%26aulast%3DSoloway%26aufirst%3DA.%2BH.%26aulast%3DFenstermaker%26aufirst%3DR.%2BA.%26aulast%3DCarlsson%26aufirst%3DJ.%26atitle%3DBoronated%2520epidermal%2520growth%2520factor%2520as%2520a%2520potential%2520targeting%2520agent%2520for%2520boron%2520neutron%2520capture%2520therapy%2520of%2520brain%2520tumors%26jtitle%3DBioconjugate%2520Chem.%26date%3D1996%26volume%3D7%26spage%3D7%26epage%3D15%26doi%3D10.1021%2Fbc950077q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tjarks, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciesielski, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenstermaker, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wikstrand, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binns, P. J.</span></span> <span> </span><span class="NLM_article-title">Convection enhanced delivery of boronated EGF as a molecular targeting agent for neutron capture therapy of brain tumors</span>. <i>J. Neuro-Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">355</span>– <span class="NLM_lpage">365</span>, <span class="refDoi"> DOI: 10.1007/s11060-009-9945-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1007%2Fs11060-009-9945-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=19588228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlKitbvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2009&pages=355-365&author=W.+Yangauthor=R.+F.+Barthauthor=G.+Wuauthor=T.+Huoauthor=W.+Tjarksauthor=M.+J.+Ciesielskiauthor=R.+A.+Fenstermakerauthor=B.+D.+Rossauthor=C.+J.+Wikstrandauthor=K.+J.+Rileyauthor=P.+J.+Binns&title=Convection+enhanced+delivery+of+boronated+EGF+as+a+molecular+targeting+agent+for+neutron+capture+therapy+of+brain+tumors&doi=10.1007%2Fs11060-009-9945-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Convection enhanced delivery of boronated EGF as a molecular targeting agent for neutron capture therapy of brain tumors</span></div><div class="casAuthors">Yang, Weilian; Barth, Rolf F.; Wu, Gong; Huo, Tian-Yao; Tjarks, Werner; Ciesielski, Michael; Fenstermaker, Robert A.; Ross, Brain D.; Wikstrand, Carol J.; Riley, Kent J.; Binns, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuro-Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">355-365</span>CODEN:
                <span class="NLM_cas:coden">JNODD2</span>;
        ISSN:<span class="NLM_cas:issn">0167-594X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">In the present study, we have evaluated a boronated dendrimer-epidermal growth factor (BD-EGF) bioconjugate as a mol. targeting agent for boron neutron capture therapy (BNCT) of the human EGFR gene-transfected F98 rat glioma, designated F98EGFR.  EGF was chem. linked to a heavily boronated polyamidoamine dendrimer (BD) by means of the heterobifunctional reagent, mMBS.  Biodistribution studies were carried out at 6 h and 24 h following intratumoral (i.t.) injection or intracerebral (i.c.) convection enhanced delivery (CED) of 125I-labeled or unlabeled BD-EGF (40 μg 10B/10 μg EGF) to F98 glioma bearing rats.  At 24 h. there was 43% more radioactivity in EGFR(+) tumors following CED compared to i.t. injection, and a doubling of the tumor boron concn. (22.3 μg/g vs. 11.7 μg/g).  CED of BD-EGF resulted in a 7.2× increase in the vol. of distribution within the infused cerebral hemisphere and a 1.9× increase in tumor uptake of BD-EGF compared with i.t. injection.  Based on these favorable biodistribution data, BNCT was carried out at the Massachusetts Institute of Technol. nuclear reactor 14 days following i.c. tumor implantation and 24 h. after CED of BD-EGF.  These animals had a MST of 54.1 ± 4.7 days compared to 43.0 ± 2.8 days following i.t. injection.  Rats that received BD-EGF by CED in combination with i.v. boronophenylalanine (BPA), which has been used in both exptl. and clin. studies, had a MST of 86.0 ± 28.1 days compared to 39.8 ± 1.6 days for i.v.  BPA alone (P < 0.01), 30.9 ± 1.4 days for irradiated controls and 25.1 ± 1.0 days for untreated controls (overall P < 0.0001).  These data have demonstrated that the efficacy of BNCT was significantly increased (P < 0.006), following i.c CED of BD-EGF compared to i.t injection, and that the survival data were equiv. to those previously reported by us using the boronated anti-human-EGF mAb, C225 (cetuximab).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNNOK5mLSWf7Vg90H21EOLACvtfcHk0lhz3BqhKerpbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlKitbvP&md5=c02d1b5492bf577a8820837589f887ff</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1007%2Fs11060-009-9945-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11060-009-9945-x%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DW.%26aulast%3DBarth%26aufirst%3DR.%2BF.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DHuo%26aufirst%3DT.%26aulast%3DTjarks%26aufirst%3DW.%26aulast%3DCiesielski%26aufirst%3DM.%2BJ.%26aulast%3DFenstermaker%26aufirst%3DR.%2BA.%26aulast%3DRoss%26aufirst%3DB.%2BD.%26aulast%3DWikstrand%26aufirst%3DC.%2BJ.%26aulast%3DRiley%26aufirst%3DK.%2BJ.%26aulast%3DBinns%26aufirst%3DP.%2BJ.%26atitle%3DConvection%2520enhanced%2520delivery%2520of%2520boronated%2520EGF%2520as%2520a%2520molecular%2520targeting%2520agent%2520for%2520neutron%2520capture%2520therapy%2520of%2520brain%2520tumors%26jtitle%3DJ.%2520Neuro-Oncol.%26date%3D2009%26volume%3D95%26spage%3D355%26epage%3D365%26doi%3D10.1007%2Fs11060-009-9945-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tjarks, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciesielski, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenstermaker, R. A.</span></span> <span> </span><span class="NLM_article-title">Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab (IMC-C225) and its evaluation as a potential delivery agent for neutron capture therapy</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">194</span>, <span class="refDoi"> DOI: 10.1021/bc0341674</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc0341674" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD3sXps1WgtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2004&pages=185-194&author=G.+Wuauthor=R.+F.+Barthauthor=W.+Yangauthor=M.+Chatterjeeauthor=W.+Tjarksauthor=M.+J.+Ciesielskiauthor=R.+A.+Fenstermaker&title=Site-specific+conjugation+of+boron-containing+dendrimers+to+anti-EGF+receptor+monoclonal+antibody+cetuximab+%28IMC-C225%29+and+its+evaluation+as+a+potential+delivery+agent+for+neutron+capture+therapy&doi=10.1021%2Fbc0341674"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Site-Specific Conjugation of Boron-Containing Dendrimers to Anti-EGF Receptor Monoclonal Antibody Cetuximab (IMC-C225) and Its Evaluation as a Potential Delivery Agent for Neutron Capture Therapy</span></div><div class="casAuthors">Wu, Gong; Barth, Rolf F.; Yang, Weilian; Chatterjee, Madhumita; Tjarks, Werner; Ciesielski, Michael J.; Fenstermaker, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">185-194</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The gene encoding EGFR often is amplified in human gliomas, and the receptor itself has been considered as a potential target for the specific delivery of therapeutic agents to brain tumors.  The purpose of the present study was to investigate the use of the chimeric MoAb cetuximab (IMC-C225), which is directed against EGFR and EGFRvIII, as a boron delivery agent for neutron capture therapy (NCT) of brain tumors.  As detd. by 125I-cetuximab radioligand binding assays, F98 rat glioma cells, which had been transfected with the gene encoding EGFR (F98EGFR), expressed 1.60 ± 0.13 × 105 receptor sites/cell with a Ka = 1.64 ± 0.32 × 108 M-1.  F98 cells transfected with the gene encoding a mutant form of EGFR, designated the F98EGFRvIII glioma, expressed 1.07 ± 0.10 × 105 receptor sites/cell with a Ka = 2.18 ± 0.54 × 109 M-1 compared to background levels expressed on F98 wild-type cells (F98WT).  A heavily boronated, fifth generation polyamidoamine (PAMAM or "starburst") dendrimer, G5-B1100, was linked to oligosaccharide moieties, which were distant from antigen binding sites of cetuximab, by means of the heterobifunctional reagents N-succinimidyl 3-(2-pyridyldithio)propionate (SPDP) and N-(k-maleimidoundecanoic acid) hydrazide (KMUH).  The resulting bioconjugate, designated C225-G5-B1100, was sepd. from the unconjugated dendrimer using a Sephacryl S-300 column.  On the basis of the relative concn. ratios of boron and protein, there were ∼1100 boron atoms per mol. of cetuximab with only a slight redn. of Ka.  The localization of C225-G5-B1100 or G5-B1100 in rats bearing intracerebral implants of either F98EGFR or F98WT gliomas was detd. 24 h following direct intratumoral (i.t.) injection at which time 92.3 ± 23.3 μg B/g tumor was localized in F98EGFR gliomas vs. 36.5 ± 18.8 μg B/g tumor in F98WT gliomas and 13.4 ± 6.1 μg in normal brain.  In contrast, only 6.7 ± 3.6 μg B/g tumor of G5-B1100 was localized in F98EGFR gliomas following i.t.  Injection, thereby demonstrating specific mol. targeting of EGFR.  Based on these data, BNCT studies will be initiated in F98EGFR glioma bearing rats to evaluate C225-G5-B1100 for the treatment of intracerebral brain tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt3633MwPsB7Vg90H21EOLACvtfcHk0lg-DGV0wIxNdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXps1WgtLg%253D&md5=d1de41c2c82d0a2e0179394b0c6ce758</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Fbc0341674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc0341674%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DG.%26aulast%3DBarth%26aufirst%3DR.%2BF.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DChatterjee%26aufirst%3DM.%26aulast%3DTjarks%26aufirst%3DW.%26aulast%3DCiesielski%26aufirst%3DM.%2BJ.%26aulast%3DFenstermaker%26aufirst%3DR.%2BA.%26atitle%3DSite-specific%2520conjugation%2520of%2520boron-containing%2520dendrimers%2520to%2520anti-EGF%2520receptor%2520monoclonal%2520antibody%2520cetuximab%2520%2528IMC-C225%2529%2520and%2520its%2520evaluation%2520as%2520a%2520potential%2520delivery%2520agent%2520for%2520neutron%2520capture%2520therapy%26jtitle%3DBioconjugate%2520Chem.%26date%3D2004%26volume%3D15%26spage%3D185%26epage%3D194%26doi%3D10.1021%2Fbc0341674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawabata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sferra, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandyopadhyaya, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tjarks, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferketich, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moeschberger, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binns, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coderre, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciesielski, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenstermaker, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wikstrand, C. J.</span></span> <span> </span><span class="NLM_article-title">Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">3792</span>– <span class="NLM_lpage">3802</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-06-0141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1158%2F1078-0432.CCR-06-0141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=16778107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvVSltrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=3792-3802&author=W.+Yangauthor=R.+F.+Barthauthor=G.+Wuauthor=S.+Kawabataauthor=T.+J.+Sferraauthor=A.+K.+Bandyopadhyayaauthor=W.+Tjarksauthor=A.+K.+Ferketichauthor=M.+L.+Moeschbergerauthor=P.+J.+Binnsauthor=K.+J.+Rileyauthor=J.+A.+Coderreauthor=M.+J.+Ciesielskiauthor=R.+A.+Fenstermakerauthor=C.+J.+Wikstrand&title=Molecular+targeting+and+treatment+of+EGFRvIII-positive+gliomas+using+boronated+monoclonal+antibody+L8A4&doi=10.1158%2F1078-0432.CCR-06-0141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Targeting and Treatment of EGFRvIII-Positive Gliomas Using Boronated Monoclonal Antibody L8A4</span></div><div class="casAuthors">Yang, Weilian; Barth, Rolf F.; Wu, Gong; Kawabata, Shinji; Sferra, Thomas J.; Bandyopadhyaya, Achintya K.; Tjarks, Werner; Ferketich, Amy K.; Moeschberger, Melvin L.; Binns, Peter J.; Riley, Kent J.; Coderre, Jeffrey A.; Ciesielski, Michael J.; Fenstermaker, Robert A.; Wikstrand, Carol J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3792-3802</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: The purpose of the present study was to evaluate a boronated EGFRvIII-specific monoclonal antibody, L8A4, for boron neutron capture therapy (BNCT) of the receptor-pos. rat glioma, F98npEGFRvIII.  Exptl. Design: A heavily boronated polyamido amine (PAMAM) dendrimer (BD) was chem. linked to L8A4 by two heterobifunctional reagents, N-succinimidyl 3-(2-pyridyldithio)propionate and N-(k-maleimidoundecanoic acid)hydrazide.  For in vivo studies, F98 wild-type receptor-neg. or EGFRvIII human gene-transfected receptor-pos. F98npEGFRvIII glioma cells were implanted i.c. into the brains of Fischer rats.  Biodistribution studies were initiated 14 days later.  Animals received [125I]BD-L8A4 by either convection enhanced delivery (CED) or direct i.t. injection and were euthanized 6, 12, 24, or 48 h later.  RESULTS: At 6 h, equiv. amts. of the bioconjugate were detected in receptor-pos. and receptor-neg. tumors, but by 24 h the amts. retained by receptor-pos. gliomas were 60.1% following CED and 43.7% following i.t. injection compared with 14.6% ID/g by receptor-neg. tumors.  Boron concns. in normal brain, blood, liver, kidneys, and spleen all were at nondetectable levels (<0.5 μg/g) at the corresponding times.  Based on these favorable biodistribution data, BNCT studies were initiated at the Massachusetts Institute of Technol. Research Reactor-II.  Rats received BD-L8A4 (∼40 μg 10B/∼750 μg protein) by CED either alone or in combination with i.v. boronophenylalanine (BPA; 500 mg/kg).  BNCT was carried out 24 h after administration of the bioconjugate and 2.5 h after i.v. injection of BPA for those animals that received both agents.  Rats that received BD-L8A4 by CED in combination with i.v.  BPA had a mean ± SE survival time of 85.5 ± 15.5 days with 20% long-term survivors (>6 mo) and those that received BD-L8A4 alone had a mean ± SE survival time of 70.4 ± 11.1 days with 10% long-term survivors compared with 40.1 ± 2.2 days for i.v.  BPA and 30.3 ± 1.6 and 26.3 ± 1.1 days for irradiated and untreated controls, resp.  CONCLUSIONS: These data convincingly show the therapeutic efficacy of mol. targeting of EGFRvIII using either boronated monoclonal antibody L8A4 alone or in combination with BPA and should provide a platform for the future development of combinations of high and low mol. wt. delivery agents for BNCT of brain tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtL7HONgZyY7Vg90H21EOLACvtfcHk0lg-DGV0wIxNdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvVSltrc%253D&md5=8162846f8b388e7a56c74747546be928</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-0141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-0141%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DW.%26aulast%3DBarth%26aufirst%3DR.%2BF.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DKawabata%26aufirst%3DS.%26aulast%3DSferra%26aufirst%3DT.%2BJ.%26aulast%3DBandyopadhyaya%26aufirst%3DA.%2BK.%26aulast%3DTjarks%26aufirst%3DW.%26aulast%3DFerketich%26aufirst%3DA.%2BK.%26aulast%3DMoeschberger%26aufirst%3DM.%2BL.%26aulast%3DBinns%26aufirst%3DP.%2BJ.%26aulast%3DRiley%26aufirst%3DK.%2BJ.%26aulast%3DCoderre%26aufirst%3DJ.%2BA.%26aulast%3DCiesielski%26aufirst%3DM.%2BJ.%26aulast%3DFenstermaker%26aufirst%3DR.%2BA.%26aulast%3DWikstrand%26aufirst%3DC.%2BJ.%26atitle%3DMolecular%2520targeting%2520and%2520treatment%2520of%2520EGFRvIII-positive%2520gliomas%2520using%2520boronated%2520monoclonal%2520antibody%2520L8A4%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D3792%26epage%3D3802%26doi%3D10.1158%2F1078-0432.CCR-06-0141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawabata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swindall, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandyopadhyaya, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tjarks, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khorsandi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blue, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferketich, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christoforidis, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sferra, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binns, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciesielski, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenstermaker, R. A.</span></span> <span> </span><span class="NLM_article-title">Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1260</span>– <span class="NLM_lpage">1268</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-06-2399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1158%2F1078-0432.CCR-06-2399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=17317838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvF2htrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=1260-1268&author=G.+Wuauthor=W.+Yangauthor=R.+F.+Barthauthor=S.+Kawabataauthor=M.+R.+Swindallauthor=A.+K.+Bandyopadhyayaauthor=W.+Tjarksauthor=B.+Khorsandiauthor=T.+E.+Blueauthor=A.+K.+Ferketichauthor=M.+Yangauthor=G.+A.+Christoforidisauthor=T.+J.+Sferraauthor=P.+J.+Binnsauthor=K.+J.+Rileyauthor=M.+J.+Ciesielskiauthor=R.+A.+Fenstermaker&title=Molecular+targeting+and+treatment+of+an+epidermal+growth+factor+receptor-positive+glioma+using+boronated+cetuximab&doi=10.1158%2F1078-0432.CCR-06-2399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Targeting and Treatment of an Epidermal Growth Factor Receptor-Positive Glioma Using Boronated Cetuximab</span></div><div class="casAuthors">Wu, Gong; Yang, Weilian; Barth, Rolf F.; Kawabata, Shinji; Swindall, Michele; Bandyopadhyaya, Achintya K.; Tjarks, Werner; Khorsandi, Behrooz; Blue, Thomas E.; Ferketich, Amy K.; Yang, Ming; Christoforidis, Gregory A.; Sferra, Thomas J.; Binns, Peter J.; Riley, Kent J.; Ciesielski, Michael J.; Fenstermaker, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1260-1268</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The purpose of the present study was to evaluate the anti-epidermal growth factor monoclonal antibody (mAb) cetuximab (IMC-C225) as a delivery agent for boron neutron capture therapy (BNCT) of a human epidermal growth factor receptor (EGFR) gene-transfected rat glioma, designated as F98EGFR.  Exptl. Design: A heavily boronated polyamidoamine dendrimer was chem. linked to cetuximab by means of the heterobifunctional reagents N-succinimidyl 3-(2-pyridyldithio)-propionate and N-(k-maleimido undecanoic acid)-hydrazide.  The bioconjugate, designated as BD-C225, was specifically taken up by F98EGFR glioma cells in vitro compared with receptor-neg. F98 wild-type cells (41.8 vs. 9.1 μg/g).  For in vivo biodistribution studies, F98EGFR cells were implanted stereotactically into the brains of Fischer rats, and 14 days later, BD-C225 was given intracerebrally by either convection enhanced delivery (CED) or direct intratumoral (i.t.) injection.  Results: The amt. of boron retained by F98EGFR gliomas 24 h following CED or i.t. injection was 77.2 and 50.8 μg/g, resp., with normal brain and blood boron values <0.05 μg/g.  Boron neutron capture therapy was carried out at the Massachusetts Institute of Technol. Research Reactor 24 h after CED of BD-C225, either alone or in combination with i.v. boronophenylalanine (BPA).  The corresponding mean survival times (MST) were 54.5 and 70.9 days (P = 0.017), resp., with one long-term survivor (more than 180 days).  In contrast, the MSTs of irradiated and untreated controls, resp., were 30.3 and 26.3 days.  In a second study, the combination of BD-C225 and BPA plus sodium borocaptate, given by either i.v. or intracarotid injection, was evaluated and the MSTs were equiv. to that obtained with BD-C225 plus i.v. BPA.  Conclusions: The survival data obtained with BD-C225 are comparable with those recently reported by us using boronated mAb L8A4 as the delivery agent.  This mAb recognizes the mutant receptor, EGFRvIII.  Taken together, these data convincingly show the therapeutic efficacy of mol. targeting of EGFR using a boronated mAb either alone or in combination with BPA and provide a platform for the future development of combinations of high and low mol. wt. delivery agents for BNCT of brain tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotddR9_NdN-bVg90H21EOLACvtfcHk0lg-DGV0wIxNdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvF2htrw%253D&md5=0a032c37c254ec3a650466df33b3c7a9</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-2399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-2399%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DBarth%26aufirst%3DR.%2BF.%26aulast%3DKawabata%26aufirst%3DS.%26aulast%3DSwindall%26aufirst%3DM.%2BR.%26aulast%3DBandyopadhyaya%26aufirst%3DA.%2BK.%26aulast%3DTjarks%26aufirst%3DW.%26aulast%3DKhorsandi%26aufirst%3DB.%26aulast%3DBlue%26aufirst%3DT.%2BE.%26aulast%3DFerketich%26aufirst%3DA.%2BK.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DChristoforidis%26aufirst%3DG.%2BA.%26aulast%3DSferra%26aufirst%3DT.%2BJ.%26aulast%3DBinns%26aufirst%3DP.%2BJ.%26aulast%3DRiley%26aufirst%3DK.%2BJ.%26aulast%3DCiesielski%26aufirst%3DM.%2BJ.%26aulast%3DFenstermaker%26aufirst%3DR.%2BA.%26atitle%3DMolecular%2520targeting%2520and%2520treatment%2520of%2520an%2520epidermal%2520growth%2520factor%2520receptor-positive%2520glioma%2520using%2520boronated%2520cetuximab%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D1260%26epage%3D1268%26doi%3D10.1158%2F1078-0432.CCR-06-2399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swindall, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandyopadhyaya, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tjarks, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tordoff, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moeschberger, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sferra, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binns, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciesielski, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenstermaker, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wikstrand, C. J.</span></span> <span> </span><span class="NLM_article-title">Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">883</span>– <span class="NLM_lpage">891</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-1968</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1158%2F1078-0432.CCR-07-1968" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=18245552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFyktLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=883-891&author=W.+Yangauthor=G.+Wuauthor=R.+F.+Barthauthor=M.+R.+Swindallauthor=A.+K.+Bandyopadhyayaauthor=W.+Tjarksauthor=K.+Tordoffauthor=M.+L.+Moeschbergerauthor=T.+J.+Sferraauthor=P.+J.+Binnsauthor=K.+J.+Rileyauthor=M.+J.+Ciesielskiauthor=R.+A.+Fenstermakerauthor=C.+J.+Wikstrand&title=Molecular+targeting+and+treatment+of+composite+EGFR+and+EGFRvIII-positive+gliomas+using+boronated+monoclonal+antibodies&doi=10.1158%2F1078-0432.CCR-07-1968"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Targeting and Treatment of Composite EGFR and EGFRvIII-Positive Gliomas Using Boronated Monoclonal Antibodies</span></div><div class="casAuthors">Yang, Weilian; Wu, Gong; Barth, Rolf F.; Swindall, Michele R.; Bandyopadhyaya, Achintya K.; Tjarks, Werner; Tordoff, Kevin; Moeschberger, Melvin; Sferra, Thomas J.; Binns, Peter J.; Riley, Kent J.; Ciesielski, Michael J.; Fenstermaker, Robert A.; Wikstrand, Carol J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">883-891</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: The purpose of the present study was to evaluate the anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb), cetuximab, (IMC-C225) and the anti-EGFRvIII mAb, L8A4, used in combination as delivery agents for boron neutron capture therapy (BNCT) of a rat glioma composed of a mixt. of cells expressing either wild-type (F98EGFR) or mutant receptors(F98npEGFRvIII).  Exptl. Design: A heavily boronated polyamidoamine dendrimer (BD) was linked by heterobifunctional reagents to produce the boronated mAbs, BD-C225 and BD-L8A4.  For in vivo biodistribution and therapy studies, a mixt. of tumor cells were implanted intracerebrally into Fischer rats.  Biodistribution studies were carried out by administering 125I-labeled bioconjugates via convection-enhanced delivery (CED), and for therapy studies, nonradiolabeled bioconjugates were used for BNCT.  This was carried out 14 days after tumor implantation and 24 h after CED at the Massachusetts Institute of Technol. nuclear reactor.  RESULTS: Following CED of a mixt. of 125I-BD-C225 and 125I-BD-L8A4 to rats bearing composite tumors, 61.4% of the injected dose per g (ID/g) was localized in the tumor compared with 30.8% ID/g for 125I-BD-L8A4 and 34.7% ID/g for 125I-BD-C225 alone.  The corresponding calcd. tumor boron values were 24.4 μg/g for rats that received both mAbs, and 12.3 and 13.8 μg/g, resp., for BD-L8A4 or BD-C225 alone.  The mean survival time of animals bearing composite tumors, which received both mAbs, was 55 days (P < 0.0001) compared with 36 days for BD-L8A4 and 38 days for BD-C225 alone, which were not significantly different from irradiated controls.  CONCLUSIONS: Both EGFRvIII and wild-type EGFR tumor cell populations must be targeted using a combination of BD-cetuximab and BD-L8A4.  Although in vitro C225 recognized both receptors, in vivo it was incapable of delivering the requisite amt. of 10B for BNCT of EGFRvIII-expressing gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrARkzcnXBdabVg90H21EOLACvtfcHk0lhTmiSB7qlS8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFyktLs%253D&md5=7ba4e2739edba61248b514b16be23822</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-1968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-1968%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DBarth%26aufirst%3DR.%2BF.%26aulast%3DSwindall%26aufirst%3DM.%2BR.%26aulast%3DBandyopadhyaya%26aufirst%3DA.%2BK.%26aulast%3DTjarks%26aufirst%3DW.%26aulast%3DTordoff%26aufirst%3DK.%26aulast%3DMoeschberger%26aufirst%3DM.%2BL.%26aulast%3DSferra%26aufirst%3DT.%2BJ.%26aulast%3DBinns%26aufirst%3DP.%2BJ.%26aulast%3DRiley%26aufirst%3DK.%2BJ.%26aulast%3DCiesielski%26aufirst%3DM.%2BJ.%26aulast%3DFenstermaker%26aufirst%3DR.%2BA.%26aulast%3DWikstrand%26aufirst%3DC.%2BJ.%26atitle%3DMolecular%2520targeting%2520and%2520treatment%2520of%2520composite%2520EGFR%2520and%2520EGFRvIII-positive%2520gliomas%2520using%2520boronated%2520monoclonal%2520antibodies%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D883%26epage%3D891%26doi%3D10.1158%2F1078-0432.CCR-07-1968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tjarks, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binns, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, K.</span></span> <span> </span><span class="NLM_article-title">Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents</span>. <i>Appl. Radiat. Isot.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">S328</span>– <span class="NLM_lpage">S331</span>, <span class="refDoi"> DOI: 10.1016/j.apradiso.2009.03.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1016%2Fj.apradiso.2009.03.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=19467880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnt1Wqu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2009&pages=S328-S331&author=W.+Yangauthor=R.+F.+Barthauthor=G.+Wuauthor=W.+Tjarksauthor=P.+Binnsauthor=K.+Riley&title=Boron+neutron+capture+therapy+of+EGFR+or+EGFRvIII+positive+gliomas+using+either+boronated+monoclonal+antibodies+or+epidermal+growth+factor+as+molecular+targeting+agents&doi=10.1016%2Fj.apradiso.2009.03.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents</span></div><div class="casAuthors">Yang, W.; Barth, R. F.; Wu, G.; Tjarks, W.; Binns, P.; Riley, K.</div><div class="citationInfo"><span class="NLM_cas:title">Applied Radiation and Isotopes</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">7-8S</span>),
    <span class="NLM_cas:pages">S328-S331</span>CODEN:
                <span class="NLM_cas:coden">ARISEF</span>;
        ISSN:<span class="NLM_cas:issn">0969-8043</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In the present report we have summarized studies carried out over the past five years on mol. targeting of the epidermal growth factor receptor (EGFR) and its mutant isoform, EFGRvIII, for BNCT of genetically engineered F98 rat gliomas, expressing either wildtype (F98EGFR) or mutant receptors (F98npEGFRvIII).  EGF or the monoclonal antibodies (mAbs), cetuximab (IMC-C225) and L8A4, which recognize wildtype EGFR and EGFRvIII, resp., were heavily boronated using polyamidoamine (PAMAM) dendrimers (BD) linked to the targeting vehicles by means of heterobifunctional reagents.  Boronated EGF or mAbs, alone or in combination with i.v. boronophenylalanine (BPA), were administered intracerebrally (i.c.) by either intratumoral (i.t.) injection or convection enhanced delivery (CED) to rats bearing F98 gliomas following which BNCT was initiated.  The best survival data were obtained in rats bearing F98npEGFRvIII gliomas that had received CED of BD-L8A4 either alone or in combination with i.v. boronophenylalanine (BPA).  Studies carried out in rats bearing composite tumors (F98EGFR/F98npEGFRvIII) demonstrated that it was essential to target both tumor cell populations in order to obtain an optimal therapeutic effect.  Based on these observations, we have concluded that EGFR targeting vehicles are useful, but not stand-alone boron delivery agents due to the heterogeneity of receptor expression in brain tumors.  They could, however, be quite useful in combination with the two drugs that currently are being used clin., BPA and sodium borocaptate (BSH) for BNCT of either brain tumors or head and neck cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeZD6OF-L4-rVg90H21EOLACvtfcHk0lhTmiSB7qlS8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnt1Wqu78%253D&md5=c50903c1448205084a83521a84772cad</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.apradiso.2009.03.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apradiso.2009.03.030%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DW.%26aulast%3DBarth%26aufirst%3DR.%2BF.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DTjarks%26aufirst%3DW.%26aulast%3DBinns%26aufirst%3DP.%26aulast%3DRiley%26aufirst%3DK.%26atitle%3DBoron%2520neutron%2520capture%2520therapy%2520of%2520EGFR%2520or%2520EGFRvIII%2520positive%2520gliomas%2520using%2520either%2520boronated%2520monoclonal%2520antibodies%2520or%2520epidermal%2520growth%2520factor%2520as%2520molecular%2520targeting%2520agents%26jtitle%3DAppl.%2520Radiat.%2520Isot.%26date%3D2009%26volume%3D67%26spage%3DS328%26epage%3DS331%26doi%3D10.1016%2Fj.apradiso.2009.03.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michiue, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakurai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitamatsu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirota, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawabata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiki, T.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohmori, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomizawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyatake, S.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ono, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsui, H.</span></span> <span> </span><span class="NLM_article-title">The acceleration of boron neutron capture therapy using multi-linked mercaptoundecahydrododecaborate (BSH) fused cell-penetrating peptide</span>. <i>Biomaterials</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">3396</span>– <span class="NLM_lpage">3405</span>, <span class="refDoi"> DOI: 10.1016/j.biomaterials.2013.12.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1016%2Fj.biomaterials.2013.12.055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=24452095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVyjs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=3396-3405&author=H.+Michiueauthor=Y.+Sakuraiauthor=N.+Kondoauthor=M.+Kitamatsuauthor=F.+Binauthor=K.+Nakajimaauthor=Y.+Hirotaauthor=S.+Kawabataauthor=T.-i.+Nishikiauthor=I.+Ohmoriauthor=K.+Tomizawaauthor=S.-i.+Miyatakeauthor=K.+Onoauthor=H.+Matsui&title=The+acceleration+of+boron+neutron+capture+therapy+using+multi-linked+mercaptoundecahydrododecaborate+%28BSH%29+fused+cell-penetrating+peptide&doi=10.1016%2Fj.biomaterials.2013.12.055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">The acceleration of boron neutron capture therapy using multi-linked mercaptoundecahydrododecaborate (BSH) fused cell-penetrating peptide</span></div><div class="casAuthors">Michiue, Hiroyuki; Sakurai, Yoshinori; Kondo, Natsuko; Kitamatsu, Mizuki; Bin, Feng; Nakajima, Kiichiro; Hirota, Yuki; Kawabata, Shinji; Nishiki, Tei-ichi; Ohmori, Iori; Tomizawa, Kazuhito; Miyatake, Shin-ichi; Ono, Koji; Matsui, Hideki</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3396-3405</span>CODEN:
                <span class="NLM_cas:coden">BIMADU</span>;
        ISSN:<span class="NLM_cas:issn">0142-9612</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">New anti-cancer therapy with boron neutron capture therapy (BNCT) is based on the nuclear reaction of boron-10 with neutron irradn.  The median survival of BNCT patients with glioblastoma was almost twice as long as those receiving std. therapy in a Japanese BNCT clin. trial.  In this clin. trial, two boron compds., BPA (boronophenylalanine) and BSH (sodium borocaptate), were used for BNCT.  BPA is taken up into cells through amino acid transporters that are expressed highly in almost all malignant cells, but BSH cannot pass through the cell membrane and remains outside the cell.  We simulated the energy transfer against the nucleus at different locations of boron from outside the cell to the nuclear region with neutron irradn. and concluded that there was a marked difference between inside and outside the cell in boron localization.  To overcome this disadvantage of BSH in BNCT, we used a cell-penetrating peptide system for transduction of BSH.  CPP (cell-membrane penetrating peptide) is very common peptide domains that transduce many physiol. active substances into cells in vitro and in vivo.  BSH-fused CPPs can penetrate the cell membrane and localize inside a cell.  To increase the boron ratio in one BSH-peptide mol., 8BSH fused to 11R with a dendritic lysine structure was synthesized and administrated to malignant glioma cells and a brain tumor mouse model.  8BSH-11R localized at the cell nucleus and showed a very high boron value in ICP results.  With neutron irradn., the 8BSH-11R administrated group showed a significant cancer killing effect compared to the 100 times higher concn. of BSH-administrated group.  We concluded that BSH-fused CPPs were one of the most improved and potential boron compds. in the next-stage BNCT trial and 8BSH-11R may be applied in the clin. setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtp_1ZZM5M8bVg90H21EOLACvtfcHk0liKi-1qwq3XuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVyjs74%253D&md5=cd2c4799cd7e8ba8806cdbafaf7f482b</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.biomaterials.2013.12.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biomaterials.2013.12.055%26sid%3Dliteratum%253Aachs%26aulast%3DMichiue%26aufirst%3DH.%26aulast%3DSakurai%26aufirst%3DY.%26aulast%3DKondo%26aufirst%3DN.%26aulast%3DKitamatsu%26aufirst%3DM.%26aulast%3DBin%26aufirst%3DF.%26aulast%3DNakajima%26aufirst%3DK.%26aulast%3DHirota%26aufirst%3DY.%26aulast%3DKawabata%26aufirst%3DS.%26aulast%3DNishiki%26aufirst%3DT.-i.%26aulast%3DOhmori%26aufirst%3DI.%26aulast%3DTomizawa%26aufirst%3DK.%26aulast%3DMiyatake%26aufirst%3DS.-i.%26aulast%3DOno%26aufirst%3DK.%26aulast%3DMatsui%26aufirst%3DH.%26atitle%3DThe%2520acceleration%2520of%2520boron%2520neutron%2520capture%2520therapy%2520using%2520multi-linked%2520mercaptoundecahydrododecaborate%2520%2528BSH%2529%2520fused%2520cell-penetrating%2520peptide%26jtitle%3DBiomaterials%26date%3D2014%26volume%3D35%26spage%3D3396%26epage%3D3405%26doi%3D10.1016%2Fj.biomaterials.2013.12.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, N.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, X.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">A survey on “Trojan Horse” peptides: opportunities, issues and controlled entry to “Troy”</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>194</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1016/j.jconrel.2014.08.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1016%2Fj.jconrel.2014.08.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=25151981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVCisr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=2014&pages=53-70&author=N.-Q.+Shiauthor=X.-R.+Qiauthor=B.+Xiangauthor=Y.+Zhang&title=A+survey+on+%E2%80%9CTrojan+Horse%E2%80%9D+peptides%3A+opportunities%2C+issues+and+controlled+entry+to+%E2%80%9CTroy%E2%80%9D&doi=10.1016%2Fj.jconrel.2014.08.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">A survey on "Trojan Horse" peptides: Opportunities, issues and controlled entry to "Troy"</span></div><div class="casAuthors">Shi, Nian-Qiu; Qi, Xian-Rong; Xiang, Bai; Zhang, Yong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">194</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">53-70</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Cell-penetrating peptides (CPPs), often vividly termed as the "Trojan Horse" peptides, have attracted considerable interest for the intracellular delivery of a wide range of cargoes, such as small mols., peptides, proteins, nucleic acids, contrast agents, nanocarriers and so on.  Some preclin. and clin. developments of CPP conjugates demonstrate their promise as therapeutic agents for drug discovery.  There is increasing evidence to suggest that CPPs have the potential to cross several bio-barriers (e.g., blood-brain barriers, intestinal mucosa, nasal mucosa and skin barriers).  Despite revolutionary process in many aspects, there are a lot of basic issues unclear for these entities, such as internalization mechanisms, translocation efficiency, translocation kinetics, metabolic degrdn., toxicity, side effect, distribution and non-specificity.  Among them, non-specificity remains a major drawback for the in vivo application of CPPs in the targeted delivery of cargoes.  So far, diverse organelle-specific CPPs or controlled delivery strategies have emerged and improved their specificity.  In this review, we will look at the opportunities of CPPs in clin. development, bio-barriers penetration and nanocarriers delivery.  Then, a series of basic problems of CPPs will be discussed.  Finally, this paper will highlight the use of various controlled strategies in the organelle-specific delivery and targeted delivery of CPPs.  The purpose of this review will be to emphasize most influential advance in this field and present a fundamental understanding for challenges and utilizations of CPPs.  This will accelerate their translation as efficient vectors from the in vitro setting into the clinic arena, and retrieve the entry art to "Troy".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokzu6wAt-y2rVg90H21EOLACvtfcHk0liKi-1qwq3XuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVCisr7O&md5=149b9e4bfc80e0eb9a19b0531bc32d62</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2014.08.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2014.08.014%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DN.-Q.%26aulast%3DQi%26aufirst%3DX.-R.%26aulast%3DXiang%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DA%2520survey%2520on%2520%25E2%2580%259CTrojan%2520Horse%25E2%2580%259D%2520peptides%253A%2520opportunities%252C%2520issues%2520and%2520controlled%2520entry%2520to%2520%25E2%2580%259CTroy%25E2%2580%259D%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2014%26volume%3D194%26spage%3D53%26epage%3D70%26doi%3D10.1016%2Fj.jconrel.2014.08.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span>; <span class="NLM_string-name">Els-Heindl, S.</span>; <span class="NLM_string-name">Worm, D. J.</span>; <span class="NLM_string-name">Hey-Hawkins, E.</span>; <span class="NLM_string-name">Kellert, M.</span>; <span class="NLM_string-name">Kuhnert, R.</span>; <span class="NLM_string-name">Saretz, S.</span>; <span class="NLM_string-name">Riedl, B.</span>; <span class="NLM_string-name">Bierer, D.</span>; <span class="NLM_string-name">Koebberling, J.</span>; <span class="NLM_string-name">Griebenow, N.</span></span> <span> </span><span class="NLM_article-title">Saccharide Functionalised Carborane Conjugates of Human Peptide Y</span>. Patent 	<span class="NLM_patent">WO 2019/115609</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=A.+G.+Beck-Sickinger&author=S.+Els-Heindl&author=D.+J.+Worm&author=E.+Hey-Hawkins&author=M.+Kellert&author=R.+Kuhnert&author=S.+Saretz&author=B.+Riedl&author=D.+Bierer&author=J.+Koebberling&author=N.+Griebenow&title=Saccharide+Functionalised+Carborane+Conjugates+of+Human+Peptide+Y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26atitle%3DSaccharide%2520Functionalised%2520Carborane%2520Conjugates%2520of%2520Human%2520Peptide%2520Y%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span>; <span class="NLM_string-name">Els-Heindl, S.</span>; <span class="NLM_string-name">Wolf, P.</span>; <span class="NLM_string-name">Hey-Hawkins, E.</span>; <span class="NLM_string-name">Kellert, M.</span>; <span class="NLM_string-name">Kuhnert, R.</span>; <span class="NLM_string-name">Saretz, S.</span>; <span class="NLM_string-name">Riedl, B.</span>; <span class="NLM_string-name">Bierer, D.</span>; <span class="NLM_string-name">Koebberling, J.</span>; <span class="NLM_string-name">Griebenow, N.</span></span> <span> </span><span class="NLM_article-title">Peptidic Melanocortin 1 Receptor Agonist - Saccharirde Functionalised Carbaborane Conjugates</span>. Patent <span class="NLM_patent">WO 2019/115614 A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=A.+G.+Beck-Sickinger&author=S.+Els-Heindl&author=P.+Wolf&author=E.+Hey-Hawkins&author=M.+Kellert&author=R.+Kuhnert&author=S.+Saretz&author=B.+Riedl&author=D.+Bierer&author=J.+Koebberling&author=N.+Griebenow&title=Peptidic+Melanocortin+1+Receptor+Agonist+-+Saccharirde+Functionalised+Carbaborane+Conjugates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26atitle%3DPeptidic%2520Melanocortin%25201%2520Receptor%2520Agonist%2520-%2520Saccharirde%2520Functionalised%2520Carbaborane%2520Conjugates%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span>; <span class="NLM_string-name">Els-Heindl, S.</span>; <span class="NLM_string-name">Hoppenz, P.</span>; <span class="NLM_string-name">Hey-Hawkins, E.</span>; <span class="NLM_string-name">Kellert, M.</span>; <span class="NLM_string-name">Kuhnert, R.</span>; <span class="NLM_string-name">Saretz, S.</span>; <span class="NLM_string-name">Riedl, B.</span>; <span class="NLM_string-name">Bierer, D.</span>; <span class="NLM_string-name">Koebberling, J.</span>; <span class="NLM_string-name">Griebenow, N.</span></span> <span> </span><span class="NLM_article-title">Peptidic BB2 Receptor Agonist - Saccharirde Functionalised Carbaborane Conjugates</span>. Patent <span class="NLM_patent">WO 2019/115611</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=A.+G.+Beck-Sickinger&author=S.+Els-Heindl&author=P.+Hoppenz&author=E.+Hey-Hawkins&author=M.+Kellert&author=R.+Kuhnert&author=S.+Saretz&author=B.+Riedl&author=D.+Bierer&author=J.+Koebberling&author=N.+Griebenow&title=Peptidic+BB2+Receptor+Agonist+-+Saccharirde+Functionalised+Carbaborane+Conjugates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26atitle%3DPeptidic%2520BB2%2520Receptor%2520Agonist%2520-%2520Saccharirde%2520Functionalised%2520Carbaborane%2520Conjugates%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span>; <span class="NLM_string-name">Els-Heindl, S.</span>; <span class="NLM_string-name">Worm, D. J.</span>; <span class="NLM_string-name">Hey-Hawkins, E.</span>; <span class="NLM_string-name">Kellert, M.</span>; <span class="NLM_string-name">Kuhnert, R.</span>; <span class="NLM_string-name">Saretz, S.</span>; <span class="NLM_string-name">Riedl, B.</span>; <span class="NLM_string-name">Bierer, D.</span>; <span class="NLM_string-name">Koebberling, J.</span>; <span class="NLM_string-name">Griebenow, N.</span></span> <span> </span><span class="NLM_article-title">Carborane-Modified Ghrelin Receptor Agonists for BNCT</span>. <span class="NLM_patent">WO 2019/115624</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=A.+G.+Beck-Sickinger&author=S.+Els-Heindl&author=D.+J.+Worm&author=E.+Hey-Hawkins&author=M.+Kellert&author=R.+Kuhnert&author=S.+Saretz&author=B.+Riedl&author=D.+Bierer&author=J.+Koebberling&author=N.+Griebenow&title=Carborane-Modified+Ghrelin+Receptor+Agonists+for+BNCT"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26atitle%3DCarborane-Modified%2520Ghrelin%2520Receptor%2520Agonists%2520for%2520BNCT%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hey-Hawkins, E.</span>; <span class="NLM_string-name">Beck-Sickinger, A. G.</span>; <span class="NLM_string-name">Kellert, M.</span>; <span class="NLM_string-name">Kuhnert, R.</span>; <span class="NLM_string-name">Saretz, S.</span>; <span class="NLM_string-name">Riedl, B.</span>; <span class="NLM_string-name">Bierer, D.</span>; <span class="NLM_string-name">Koebberling, J.</span>; <span class="NLM_string-name">Griebenow, N.</span></span> <span> </span><span class="NLM_article-title">Novel 1,7-Dicarba-Closo-Dodecarborane(12) (Meta-Carbaborane)-derived Carboxylic Acids Suitable for Peptide Modification for Application in Boron Neutron Capture Therapy (BNCT)</span>. Patent 	<span class="NLM_patent">WO 2019/115616</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=E.+Hey-Hawkins&author=A.+G.+Beck-Sickinger&author=M.+Kellert&author=R.+Kuhnert&author=S.+Saretz&author=B.+Riedl&author=D.+Bierer&author=J.+Koebberling&author=N.+Griebenow&title=Novel+1%2C7-Dicarba-Closo-Dodecarborane%2812%29+%28Meta-Carbaborane%29-derived+Carboxylic+Acids+Suitable+for+Peptide+Modification+for+Application+in+Boron+Neutron+Capture+Therapy+%28BNCT%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHey-Hawkins%26aufirst%3DE.%26atitle%3DNovel%25201%252C7-Dicarba-Closo-Dodecarborane%252812%2529%2520%2528Meta-Carbaborane%2529-derived%2520Carboxylic%2520Acids%2520Suitable%2520for%2520Peptide%2520Modification%2520for%2520Application%2520in%2520Boron%2520Neutron%2520Capture%2520Therapy%2520%2528BNCT%2529%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harris, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabral de Menezes, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodfellow, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granger, P.</span></span> <span> </span><span class="NLM_article-title">NMR nomenclature: nuclear spin properties and conventions for chemical shifts. IUPAC recommendations 2001</span>. <i>Solid State Nucl. Magn. Reson.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">458</span>– <span class="NLM_lpage">483</span>, <span class="refDoi"> DOI: 10.1006/snmr.2002.0063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1006%2Fsnmr.2002.0063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=12637147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD38XpslWltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2002&pages=458-483&author=R.+K.+Harrisauthor=E.+D.+Beckerauthor=S.+M.+Cabral+de+Menezesauthor=R.+Goodfellowauthor=P.+Granger&title=NMR+nomenclature%3A+nuclear+spin+properties+and+conventions+for+chemical+shifts.+IUPAC+recommendations+2001&doi=10.1006%2Fsnmr.2002.0063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">NMR nomenclature: Nuclear spin properties and conventions for chemical shifts. IUPAC recommendations 2001</span></div><div class="casAuthors">Harris, Robin K.; Becker, Edwin D.; Cabral de Menezes, Sonia M.; Goodfellow, Robin; Granger, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Solid State Nuclear Magnetic Resonance</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">458-483</span>CODEN:
                <span class="NLM_cas:coden">SSNRE4</span>;
        ISSN:<span class="NLM_cas:issn">0926-2040</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">A unified scale is recommended for reporting the NMR chem. shifts of all nuclei relative to the 1H resonance of tetramethylsilane.  The unified scale is designed to provide a precise ratio, Ξ, of the resonance frequency of a given nuclide to that of the primary ref., the 1H resonance of tetramethylsilane (TMS) in dil. soln. (vol. fraction, φ<1%) in CHCl3.  Referencing procedures are discussed, including matters of practical application of the unified scale.  Special attention is paid to recommended ref. samples, and values of Ξ for secondary refs. on the unified scale are listed, many of which are the results of new measurements.  Some earlier recommendations relating to the reporting of chem. shifts are endorsed.  The chem. shift, δ, is redefined to avoid previous ambiguities but to leave practical usage unchanged.  Relations between the unified scale and recently published recommendations for referencing in aq. solns. (for specific use in biochem. work) are discussed, as well as the special effects of working in the solid state with magic-angle spinning.  In all, nine new recommendations relating to chem. shifts are made.  Standardized nuclear spin data are also presented in tabular form for the stable (and some unstable) isotopes of all elements with nonzero quantum nos.  The information given includes quantum nos., isotopic abundances, magnetic moments, magnetogyric ratios, and receptivities, together with quadrupole moments and line-width factors (appropriate).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp7V_2u85ZU7Vg90H21EOLACvtfcHk0lgdvpf4XzcEdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpslWltrw%253D&md5=0bf22f16d4c932a54075c9619edca00c</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1006%2Fsnmr.2002.0063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fsnmr.2002.0063%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DR.%2BK.%26aulast%3DBecker%26aufirst%3DE.%2BD.%26aulast%3DCabral%2Bde%2BMenezes%26aufirst%3DS.%2BM.%26aulast%3DGoodfellow%26aufirst%3DR.%26aulast%3DGranger%26aufirst%3DP.%26atitle%3DNMR%2520nomenclature%253A%2520nuclear%2520spin%2520properties%2520and%2520conventions%2520for%2520chemical%2520shifts.%2520IUPAC%2520recommendations%25202001%26jtitle%3DSolid%2520State%2520Nucl.%2520Magn.%2520Reson.%26date%3D2002%26volume%3D22%26spage%3D458%26epage%3D483%26doi%3D10.1006%2Fsnmr.2002.0063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frank, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehnke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hey-Hawkins, E.</span></span> <span> </span><span class="NLM_article-title">From ortho-carbaborane-9-thiol towards new building blocks</span>. <i>Polyhedron</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.1016/j.poly.2012.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1016%2Fj.poly.2012.03.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BC38Xls1ens7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2012&pages=9-13&author=R.+Frankauthor=S.+Boehnkeauthor=A.+Alievauthor=E.+Hey-Hawkins&title=From+ortho-carbaborane-9-thiol+towards+new+building+blocks&doi=10.1016%2Fj.poly.2012.03.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">From ortho-carbaborane-9-thiol towards new building blocks</span></div><div class="casAuthors">Frank, Rene; Boehnke, Solveig; Aliev, Almaz; Hey-Hawkins, Evamarie</div><div class="citationInfo"><span class="NLM_cas:title">Polyhedron</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-13</span>CODEN:
                <span class="NLM_cas:coden">PLYHDE</span>;
        ISSN:<span class="NLM_cas:issn">0277-5387</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The potential of 1,2-dicarba-closo-dodecaborane(12)-9-thiol, 9-HS-1,2-closo-C2B10H11, for the design of novel building blocks is highlighted by two examples envisioned for incorporation into tumor-selective peptides for B neutron capture therapy (BNCT).  By employing a t-Bu protection strategy the synthesis of a bis-galactosyl-substituted ortho-carbaborane carboxylic acid was elaborated, and the procedure is suggested as a general approach towards carbaboranes with three substituents.  Also, a simple route to a tris(ortho-carbaborane) building block starting from pentaerythritol is illustrated.  All compds. were synthesized in moderate to high yields and identified by 1H, 11B, and 13C NMR spectroscopy, IR spectroscopy, mass spectrometry, and in one case by x-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpas1kN2Q88C7Vg90H21EOLACvtfcHk0lgdvpf4XzcEdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xls1ens7s%253D&md5=6537ba24c3ab602771c943e9a9af159e</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.poly.2012.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.poly.2012.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DFrank%26aufirst%3DR.%26aulast%3DBoehnke%26aufirst%3DS.%26aulast%3DAliev%26aufirst%3DA.%26aulast%3DHey-Hawkins%26aufirst%3DE.%26atitle%3DFrom%2520ortho-carbaborane-9-thiol%2520towards%2520new%2520building%2520blocks%26jtitle%3DPolyhedron%26date%3D2012%26volume%3D39%26spage%3D9%26epage%3D13%26doi%3D10.1016%2Fj.poly.2012.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crudden, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sateesh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, R.</span></span> <span> </span><span class="NLM_article-title">Mercaptopropyl-modified mesoporous silica: a remarkable support for the preparation of a reusable, heterogeneous palladium catalyst for coupling reactions</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">10045</span>– <span class="NLM_lpage">10050</span>, <span class="refDoi"> DOI: 10.1021/ja0430954</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja0430954" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltlyrtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2005&pages=10045-10050&author=C.+M.+Cruddenauthor=M.+Sateeshauthor=R.+Lewis&title=Mercaptopropyl-modified+mesoporous+silica%3A+a+remarkable+support+for+the+preparation+of+a+reusable%2C+heterogeneous+palladium+catalyst+for+coupling+reactions&doi=10.1021%2Fja0430954"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Mercaptopropyl-Modified Mesoporous Silica: A Remarkable Support for the Preparation of a Reusable, Heterogeneous Palladium Catalyst for Coupling Reactions</span></div><div class="casAuthors">Crudden, Cathleen M.; Sateesh, Mutyala; Lewis, Roxanne</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">10045-10050</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The functionalization of SBA-15 with mercaptopropyl trimethoxysilane leads to a material capable of absorbing Pd from org. and aq. solns.  The resulting Pd-loaded material acts as a catalyst for the Suzuki-Miyaura and Mizoroki-Heck coupling reactions.  Leaching studies show that the filtrate contains as little as 3 ppb Pd after reaction.  (Amino)propyl-modified silica is an effective scavenger, and catalyst for the Mizoroki-Heck reaction, but leaching is significant (35 ppm), illustrating the importance of the thiol ligand to retain Pd on the surface.  Heterogeneity tests such as hot filtration expts. and three-phase tests show that the reaction is occurring predominantly via surface-bound Pd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCU0hOOyLilbVg90H21EOLACvtfcHk0lgdvpf4XzcEdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltlyrtrc%253D&md5=8cf722caf4d68a99633bf560794579bd</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Fja0430954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja0430954%26sid%3Dliteratum%253Aachs%26aulast%3DCrudden%26aufirst%3DC.%2BM.%26aulast%3DSateesh%26aufirst%3DM.%26aulast%3DLewis%26aufirst%3DR.%26atitle%3DMercaptopropyl-modified%2520mesoporous%2520silica%253A%2520a%2520remarkable%2520support%2520for%2520the%2520preparation%2520of%2520a%2520reusable%252C%2520heterogeneous%2520palladium%2520catalyst%2520for%2520coupling%2520reactions%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2005%26volume%3D127%26spage%3D10045%26epage%3D10050%26doi%3D10.1021%2Fja0430954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hey-Hawkins, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, P.</span></span> <span> </span><span class="NLM_article-title">Manipulating Y receptor subtype activation of short neuropeptide Y analogs by introducing carbaboranes</span>. <i>Neuropeptides</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1016/j.npep.2012.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1016%2Fj.npep.2012.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=23352609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFCqsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2013&pages=59-66&author=S.+Hofmannauthor=R.+Frankauthor=E.+Hey-Hawkinsauthor=A.+G.+Beck-Sickingerauthor=P.+Schmidt&title=Manipulating+Y+receptor+subtype+activation+of+short+neuropeptide+Y+analogs+by+introducing+carbaboranes&doi=10.1016%2Fj.npep.2012.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Manipulating Y receptor subtype activation of short neuropeptide Y analogs by introducing carbaboranes</span></div><div class="casAuthors">Hofmann, S.; Frank, R.; Hey-Hawkins, E.; Beck-Sickinger, A. G.; Schmidt, P.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropeptides (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">59-66</span>CODEN:
                <span class="NLM_cas:coden">NRPPDD</span>;
        ISSN:<span class="NLM_cas:issn">0143-4179</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Short selective neuropeptide Y (NPY) analogs are highly attractive because of their facile synthesis.  Based on the reduced-size NPY analog [Pro30, Nle31, Bpa32, Leu34]NPY 28-36 position 32 was identified as a key position to alter the preferential activation pattern of the human neuropeptide Y receptors (hYRs).  By replacing benzoylphenylalanine (Bpa) by a biphenylalanine (Bip) the photostability was first improved while the biol. activity was maintained.  SAR-studies showed that both arom. rings have a high influence on the preferential hYR subtype activation.  Interestingly, replacement of Bpa32 by a strongly hydrophobic moiety changed the hYR subtype preference of the analog.  Whereas the parent compd. is able to activate the human neuropeptide Y1 receptor (hY1R) subtype, the introduction of an Nε-ortho-carbaboranyl propionic acid modified lysine resulted in a loss of activity at the hY1R but in an increased activity at both the hY2R and the hY4R.  However, subsequent receptor internalization studies with this novel analog revealed that receptor internalization can neither be triggered at the hY2R nor at the hY4R suggesting a biased ligand.  Surprisingly, investigations by 1H NMR spectroscopy revealed structural changes in the side chains of residues Pro30 and Leu34 which nicely correlates with the shift from hY1R/hY4R to hY2R/hY4R activation preference.  Thus, position 32 has been identified to switch the bioactive conformation and subsequently influences receptor subtype activation behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvP9VxxSzNyrVg90H21EOLACvtfcHk0liRUjDmXgStyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFCqsbw%253D&md5=bc298e83582804b6cad8c2000a99b172</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.npep.2012.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.npep.2012.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DHofmann%26aufirst%3DS.%26aulast%3DFrank%26aufirst%3DR.%26aulast%3DHey-Hawkins%26aufirst%3DE.%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26aulast%3DSchmidt%26aufirst%3DP.%26atitle%3DManipulating%2520Y%2520receptor%2520subtype%2520activation%2520of%2520short%2520neuropeptide%2520Y%2520analogs%2520by%2520introducing%2520carbaboranes%26jtitle%3DNeuropeptides%26date%3D2013%26volume%3D47%26spage%3D59%26epage%3D66%26doi%3D10.1016%2Fj.npep.2012.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wanka, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babilon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mörl, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck-Sickinger, A. G.</span></span> <span> </span><span class="NLM_article-title">Different mode of arrestin-3 binding at the human Y1 and Y2 receptor</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.1016/j.cellsig.2018.06.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=10.1016%2Fj.cellsig.2018.06.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=29944985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht12mu77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2018&pages=58-71&author=L.+Wankaauthor=S.+Babilonauthor=A.+Kaiserauthor=K.+M%C3%B6rlauthor=A.+G.+Beck-Sickinger&title=Different+mode+of+arrestin-3+binding+at+the+human+Y1+and+Y2+receptor&doi=10.1016%2Fj.cellsig.2018.06.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Different mode of arrestin-3 binding at the human Y1 and Y2 receptor</span></div><div class="casAuthors">Wanka, Lizzy; Babilon, Stefanie; Kaiser, Anette; Moerl, Karin; Beck-Sickinger, Annette G.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">58-71</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">GPCR internalization, which is induced by arrestin recruitment, is an important mechanism for the regulation of signaling and receptor quantity at the cell surface.  In this study, differences in the mechanism of arrestin-3 (arr-3) recruitment to the neuropeptide Y1 and Y2 receptor were identified.  These receptors play an essential role in the regulation of feeding, energy homeostasis and cancer.  The Y1R displays high affinity to arr-3, which induces rapid internalization of the arrestin/receptor complex.  In contrast, the Y2R has a lower affinity for arr-3.  Internalization is induced by arrestin binding, but arr-3 is released from the receptor and remains at the membrane while the receptor internalizes.  Moreover, the deletion of the finger loop region of arr-3 reduces its agonist-dependent recruitment to the Y2R significantly, but not to the Y1R suggesting different binding conformations.  For the first time, the formation of a supercomplex consisting of Y receptor, Gα0 protein and arrestin was studied by BRET-assay.  We demonstrated that the Y1R is able to bind Gα0 protein as well as arr-3 simultaneously and internalizes as a supercomplex.  For the Y2R no supercomplex formation was obsd.  By substituting the C-terminus or specific residues within the intracellular loop 1 and 2 of the receptors, the arr-3 recruitment of the Y1R and Y2R can be switched.  Thus, we shed light on the specific spatio-temporal distribution of Gα0 protein and arrestin in response to Y1 vs. Y2 receptor activation and identified the mol. determinants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYuyxWeG-A7bVg90H21EOLACvtfcHk0liRUjDmXgStyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht12mu77N&md5=b52c1ea5cb54ae0d8fe0d4840e4ac4c3</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2018.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2018.06.010%26sid%3Dliteratum%253Aachs%26aulast%3DWanka%26aufirst%3DL.%26aulast%3DBabilon%26aufirst%3DS.%26aulast%3DKaiser%26aufirst%3DA.%26aulast%3DM%25C3%25B6rl%26aufirst%3DK.%26aulast%3DBeck-Sickinger%26aufirst%3DA.%2BG.%26atitle%3DDifferent%2520mode%2520of%2520arrestin-3%2520binding%2520at%2520the%2520human%2520Y1%2520and%2520Y2%2520receptor%26jtitle%3DCell.%2520Signalling%26date%3D2018%26volume%3D50%26spage%3D58%26epage%3D71%26doi%3D10.1016%2Fj.cellsig.2018.06.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i35"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01136">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_33015"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b01136">10.1021/acs.jmedchem.9b01136</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Structural Characterisation of synthesized building blocks; structures of synthesized peptide conjugates; RP-HPLC pure analytics of all synthesized peptide conjugates; biological characterization of conjugates <b>10</b>, <b>11</b>, <b>12</b>, and <b>14</b>; reversed phase chromatograms of the kinetic solubility assay; receptor activation properties of conjugate <b>22</b>; analytical characterization of synthesized peptides (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01136/suppl_file/jm9b01136_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01136/suppl_file/jm9b01136_si_001.pdf">jm9b01136_si_001.pdf (1.94 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b01136&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b01136%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-5" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b01136" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677addeea8081995","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
